

24675 SEARCH REQUEST FORM

Requestor's

Name:

GAMZEL / 1844

Serial

Number:

08/819669

Date:

9/12/00

Phone:

302 3997

Art Unit:

3000

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

SEQ + SEQ INTERFERENCE
SEARCH

SEQ ID NO: 26 x2

8

30-9/12-39-43

MP2 - 9/12 -

173 ✓
174 ✓
176 ✓
177 ✓
181 ✓
182 ✓

REQUEST

IN

THUR

STAFF USE ONLY

Date completed:

9/13/00

Searcher:

u

Terminal time:

25

Elapsed time:

x 10

CPU time:

x 10

Total time:

x 10

Number of Searches:

x 10

Number of Databases:

x 10

Search Site

STIC

CM-I

Pre-S

Type of Search

N.A. Sequence

A.A. Sequence

Structure

Bibliographic

Vendors

IG

STN

Dialog

APS

Geninfo

SDC

DARC/Questel

Other

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2000, 01:18:33 : Search time 2504.47 Seconds
(without alignments)
9990.683 Million cell updates/sec

Title: US-08-819-669E-8
Perfect score: 5674

Sequence: 1 CCGGGGCGACCACTGCATC.....TAATGATCTGGTGGATCC 5674

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 5247842 seqs, 2204914090 residues

Total number of hits satisfying chosen parameters: 10495684

Minimum DB seq length: 0

Maximum DB seq length: 20000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

EST :

1: em_est1:
2: em_est2:
3: em_est3:
4: em_est4:
5: em_est5:
6: em_est6:
7: em_est7:
8: em_est8:
9: em_est9:
10: em_est10:
11: em_est11:
12: em_est12:
13: em_est13:
14: em_est14:
15: em_est15:
16: em_est16:
17: em_est17:
18: em_est18:
19: em_est19:
20: gb_est1:
21: gb_est2:
22: gb_est3:
23: gb_est4:
24: gb_est5:
25: gb_est6:
26: gb_est7:
27: gb_est8:
28: gb_est9:
29: gb_est10:
30: gb_est11:
31: gb_est12:
32: gb_est13:
33: gb_est14:
34: gb_est15:
35: gb_est16:
36: gb_est17:
37: gb_est18:
38: gb_est19:
39: gb_est20:
40: gb_est21:
41: gb_est22:
42: gb_est23:
43: gb_est24:

44: gb_est25:
45: gb_est26:
46: gb_est27:
47: gb_est28:
48: gb_est29:
49: em_est20:
50: em_est21:
51: em_est22:
52: gb_est30:
53: gb_est31:
54: gb_est32:
55: em_est23:
56: em_est24:
57: em_est25:
58: em_est26:
59: gb_est33:
60: gb_est34:
61: gb_est35:
62: gb_est36:
63: gb_est37:
64: gb_est38:
65: em_est27:
66: em_est28:
67: em_est29:
68: em_est30:
69: gb_est39:
70: gb_est40:
71: gb_est41:
72: gb_est42:
73: gb_est43:
74: gb_est44:
75: em_est31:
76: em_est32:
77: em_est33:
78: em_est34:
79: gb_est45:
80: gb_est46:
81: gb_est47:
82: em_est35:
83: em_est36:
84: em_est37:
85: gb_est48:
86: gb_est49:
87: gb_est50:
88: gb_est51:
89: gb_est52:
90: gb_est53:
91: gb_est54:
92: gb_est55:
93: gb_est56:
94: gb_est57:
95: gb_est58:
96: gb_est59:
97: em_gss1:
98: em_gss2:
99: em_gss3:
100: em_gss4:
101: gb_gss5:
102: gb_gss6:
103: em_gss5:
104: em_gss6:
105: gb_gss7:
106: gb_gss8:
107: gb_gss9:
108: em_gss7:
109: em_gss8:
110: gb_gss11:
111: gb_gss10:
112: em_gss9:
113: em_gss10:
114: em_gss11:
115: em_gss12:
116: gb_gss12:

117: 9b_gss13:*

118: 9b_gss14:*

119: 9b_gss15:*

120: 9b_gss16:*

121: 9b_gss17:*

122: 9b_gss18:*

123: 9b_gss19:*

124: em_gss13:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, *and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Match %	Score	Length	ID	Description
C 1	427.4	7.5	859	44	AI798898 we94a11.x
C 2	413	7.3	414	63	AI103876 xd47e12.x
C 3	392.6	6.9	728	44	AI805537 tx86c10.x
C 4	375.4	6.6	670	72	AI438674 xt02b04.x
C 5	349.6	6.2	533	71	AI383186 PM3-HT034
C 6	331	5.8	578	47	AI044464 DPF2434H
C 7	328.2	5.8	599	47	AI044465 DPF2434H
C 8	286	5.0	464	79	AI673548 bs5509.y
C 9	285	5.0	504	47	AI044429 DPF2434F
C 10	275.2	4.9	493	45	AI863022 wmd5d10.x
C 11	272.6	4.8	511	69	AI245614 2822978.3
C 12	270.6	4.8	481	33	AA995045 ou53602.s
C 13	270.6	4.8	495	69	AI94089 xnl12a03.x
C 14	260.2	4.6	521	70	AI250219 2822505.3
C 15	257.8	4.5	459	36	AI222439 qh04h04.x
C 16	251.2	4.4	451	44	AI805352 tx85c10.x
C 17	247.6	4.4	430	79	AI628104 h98402.x
C 18	246.4	4.3	415	36	AI200443 qf93807.x
C 19	243.4	4.3	519	69	AI245872 2822978.5
C 20	242.8	4.3	534	70	AI247017 2822505.5
C 21	242.8	4.3	394	32	AA857809 o103h03.s
C 22	240.2	3.9	457	80	AI731700 ba55b09.x
C 23	218.6	3.8	566	39	AI394145 t960807.x
C 24	215.4	3.8	780	40	AI479347 tm27408.x
C 25	212.4	3.7	638	70	AI273455 xt39h01.x
C 26	212.2	3.7	638	70	AI248864 2820966.3
C 27	206.8	3.6	514	79	AI664428 h111h03.x
C 28	205.2	3.6	399	69	AI193638 xnl18f07.x
C 29	201	3.5	488	44	AI830281 wj95b10.x
C 30	193.8	3.4	478	63	AI103946 xd62h08.x
C 31	193.2	3.4	467	35	AI142010 oc21e08.x
C 32	188.8	3.3	459	93	AQ017378 CIT-HSP-2
C 33	188.4	3.3	597	70	AI249285 2820966.5
C 34	181.6	3.2	338	88	AI954607 wq34a12.x
C 35	181.6	3.2	630	46	AI954607 wq34a12.x
C 36	178.6	3.1	256	89	T29724 EST92093.Hu
C 37	176.4	3.1	457	119	AZ070771 RPCI-23-4
C 38	175	3.1	387	88	R06042 ye89f02.r1
C 39	166	2.9	486	30	AA704513 xj23a12.s
C 40	163.2	2.9	293	89	T29746 EST92986.Hu
C 41	163.2	2.9	345	71	AA356066 38053.MAR
C 42	159	2.8	324	71	AA905896 o188a05.s
C 43	157.2	2.8	467	34	AI032153 os76e10.s
C 44	155.4	2.7	441	88	R23773 yh34b02.r1
C 45	150.6	2.7	523	116	AQ838224 HS-4729.A

ALIGNMENTS

RESULT 1
 AI798898/c 869 bp mRNA EST 18-DEC-1999
 LOCUS we94a11.x1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone
 DEFINITION IMAGE:2348732.3, similar to SW:MAG2_HUMAN P43356

MELANOMA-ASSOCIATED ANTIGEN 2 ; mRNA sequence.

ACCESSION AI798898
 VERSION AI798898.1 GI:5364370
 KEYWORDS EST.
 SOURCE human.

ORGANISM

Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE

1 (Bases 1 to 869)
 NCI-CCAP http://www.ncbi.nlm.nih.gov/ncicgap.

AUTHORS

National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index

JOURNAL

Unpublished (1997)

COMMENT

On Apr 7, 1998 this sequence version replaced gi:3036723.

CONTACT

Contact: Robert Strausberg, Ph.D.

TELEPHONE

Tel: (301) 496-1550

EMAIL

Email: Robert_Strausberg@nih.gov

NOTES

This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.llnl.gov) for further information.

INSERT LENGTH

Insert Length: 933 Std Error: 0.00

SEQ PRIMER

Seq primer: -40UP from Gibco

HIGH QUALITY

High quality sequence stop: 466.

FEATURES

1..869

SOURCE

/organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone_image="IMAGE:2348732"
 /clone_lib="Soares_NFL_T_GBC_S1"
 /lab_host="DH10B"

NOTES

/note="Organ: pooled; Vector: pT73D-Pac (Pharmacia) with
 a modified polylinker; Site1: Not I; Site2: Eco RI;
 Equal amounts of plasmid DNA from three normalized
 libraries (fetal lung NbHL19W, testis NHT, and B-cell
 NCI-CCAP SCB1) were mixed, and ss circles were made in
 vitro. Following HAP purification, this DNA was used as
 tracer in a subtractive hybridization reaction. The driver
 was PCR-amplified cDNAs from pools of 5,000 clones made
 from the same 3 libraries. The pools consisted of
 I.M.A.G.E. clones 297480-302087, 682632-687239,
 724008-728711, and 729096-731399. Subtraction by Bento
 Soares and M. Fatima Bonaldo.
 251 a 206 c 169 g 239 t 4 others

BASE COUNT

251 a 206 c 169 g 239 t 4 others

ORIGIN

251 a 206 c 169 g 239 t 4 others

QUERY MATCH

Query Match 7.58; Score 427.4; DB 44; Length 869;

BEST LOCAL SIMILARITY

Best Local Similarity 75.43; Pred. No. 4.5e-96;

MATCHES

Matches 669; Conservative 0; Mismatches 185; Indels 33; Gaps 10;

QY

QY 4484 ATTGCAATGAGGGGGGGGGCTCTCTCCTCAGGAGGAAATCTGGGAGGAGCTAGTGTGATG 4543

DB

DB 869 ATCGCAATAGAGGGGGGGCTGTGCCCCCTGAGCAGCAGCATCTGGAAGNAGCTAGTAAGTTG 810

QY

QY 4544 GAGGTGTATGATGGGAGGAGCAGTGCCTATGGGGAGCCAGGAGCT-GCTCACCA 4602

DB

DB 809 NAGGTGT-TGAGGGAAGAAAGTAGTGTCTTCGCATCCAGAAAGCTAGTCTATGCA 751

QY

QY 4603 AGATTGTGTCAGGAAAGTAGTACCTGGATGACGAGTGGCGGACAGTATCCCGCACGC 4662

DB

DB 750 TGAATCTGTGACAGTACTACTACCTGAAAGTTCGGCAGGGTCCGAGCAGTATCTCTCATC 691

QY

QY 4663 TATGATGTTCTGTGGGTCCCAAGGCCCTCTGCAACACAGCTATGTGAAGTCCCTTGA 4722

DB

DB 690 CTCGATGTTCTGTAGTCCCGAGGGCCATTTGTAACCAAGCTATGTGAAGTCTGCAC 531

QY

QY 4723 TATGTGATCAAGGTGATGCAAGAGTTCGCTTTTCTTCCATCCCTCGGTGAAGCAGCT 4782

DB

DB 630 CATACACTAAAGATCGGTGAAGACCCCTCACATTTCTTACCCACCCCTGATGAACGGCT 571

QY

QY 4783 TTGACAGAGGAGGAGGAGGAGTCTGAGCATGATGTGACCCCAAGCCAGTGGGAGGGGG 4842

DB

DB 570 TTGACAGAGGAGGAGGAGTCTGAGTCTGACACATGTTGACACCCAGCCAGTGGGAGGGGG 513

```

QY 4843 ACTGGCCAGTCACCTTCCAGGCGCGTCCACGACGCTCCCTGCTGCTGACATG 4902
DB 510 TCTGGCCAGTGCACCTTCCAGGCGCCCATCCATAGCTTCCACTGCTGCTGATATG 451
QY 4903 AGGCCCAATCTT--CACTCTCAAGAGAGCGGTCTAGTCTTCTCAGTAGTCTTCTTTC 4960
DB 450 AGGCCCAATCTGCTCTTCAAGAGAGAGCAGTACGACATCTTACGAGTCTTCTGCTTC 391
QY 4961 TATGGGTGACCTGGAGATTTATCTTGTCTCTTCTTGGAAATGCTCAAAATGTTTTTT 5020
DB 390 TCTGGATGACCTTGGAGATTTATCTTGTCTCTTCTTGGAAATGCTCAAAATG-TTCTTT 332
QY 5021 TAAGGATGGTGAATGAATTCAGCATCCCAAGTTTATGAATGACAGCAGTCACAC--AG 5078
DB 331 TAACAAATGGTGGATGAATTCAGCATCCCAAGTTTATGAATGCGAGTAGTCACACATAG 272
QY 5079 TCTCTGTATATAGTTTAAGGTAAGAGTCTTGTCTTCTTATTCAGATGGGAATCCATT 5138
DB 271 TCTCTGTATATAGTTTAAGGTAAGAGTCTTGTCTTCTTATTCAGATGGGAATCCATT 212
QY 5139 CTATTTTGTGAATG--GGATAATAACAGCAGTGGAAATAGTACTTAGAAATGT----GA 5192
DB 211 CCATTTTGTGAGTGTGCATATATACAGCAGTGGAAATAGTACTTAGAAATGT----GA 152
QY 5193 AAAATGAGCAGTAATAATAGATGAGATAAAGAACTAAAGAAATTAAGAGATAGTCAATCT 5252
DB 151 CGAATTAGCAGTAAATAATACATACACAGGAAC-----TCAAAGATAGTTAATCT 100
QY 5253 TGCCCTATACCTCAGTCTATCTGTAAATTTTAAAGATATATCATACCTGGATTTCC 5312
DB 99 TGCCCTATACCTCAGTCTATCTGTAAATTTTAAAGATATATCATACCTGGATTTCC 5312
QY 5313 TTGGCTTCTTGGAGATGTAAGAGAAATTAATCTGAATAAGAAAT 5359
DB 51 TTAGATCTCTGAGATGCAAAAGAAATTAATCTAGTAGGTAAT 5

RESULT 2
AW103876/c 414 bp mRNA EST 20-OCT-1999
LOCUS xd47e12.x1 NCI_CGAP_Ov23 Homo sapiens cDNA clone IMAGE:2596942 3',
DEFINITION mRNA sequence.
ACCESSION AW103876
VERSION AW103876.1 GI:6074611
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE 1 (bases 1 to 414)
JOURNAL NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
COMMENT National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert.Strausberg@nih.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
Emmert-Buck, M.D., Ph.D.
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www.bio.llnl.gov/dbp/image/image.html
Seq primer: -40UP from Gibco
High quality sequence stop: 399.
Location/Qualifiers
1. . 414
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2596942"
/clone_lib="NCI_CGAP_Ov23"

```

```

/tissue_type="tumor, 5 pooled (see description)"
/lab_host="DH10B"
/Note="Organ: ovary; Vector: pCMV-SPORT6; Site: 1; Salt;
Site: 2; NotI: Cloned unidirectionally. Primer: Oligo dr.
Average insert size 1.35 kb. Tumor types include: mixed
Mullerian tumor, papillary serous, clear cell, spindle
cell. All are primary tumors, metastasis positive. Life
Technologies catalog #: 11534-013"
BASE COUNT 149 a 84 c 46 g 134 t 1 others
ORIGIN

Query Match 7.3%; Score 413; DB 53; Length 414;
Best Local Similarity 99.8%; Pred. No. 1.5e-92;
Matches 413; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4942 CAGTAGAGTCTTCTGCTCTATTTGGGTGACCTGGAGATTTATCTTCTCTTTGGAA 5061
DB 414 CAGTAGAGTCTTCTGCTCTATTTGGGTGACCTGGAGATTTATCTTCTCTTTGGAA 355
QY 5002 TTCTTCAAAATGTTTTTTTAAGGGATGGTTGAATGAATTCAGCATCCCAAGTTTAA 5061
DB 354 TTCTTCAAAATGTTTTTTTAAGGGATGGTTGAATGAATTCAGCATCCCAAGTTTAA 295
QY 5062 TGACAGCAGTCACACAGTCTGCTATATAGTTTAAGGGTAAGAGTCTTCTGTTTATTC 5121
DB 294 TGACAGCAGTCACACAGTCTGCTATATAGTTTAAGGGTAAGAGTCTTCTGTTTATTC 235
QY 5122 AGATTGGGAATCCATCTCTATTTTGTGAATGGGATATAACAGCAGTGGAAATAGTACT 5181
DB 234 AGATTGGGAATCCATCTCTATTTTGTGAATGGGATATAACAGCAGTGGAAATAGTACT 175
QY 5182 TAGAAATGTGAATAGCAGCAGTAATAAGATAGATGAATAAGAACTAAAGAAATTAAGAA 5241
DB 174 TAGAAATGTGAATAGCAGCAGTAATAAGATAGATGAATAAGAACTAAAGAAATTAAGAA 115
QY 5242 TAGTCAATCTTGTCTTATACCTCAGTCTATTTCTGTAATTTTAAAGATATATGATA 5301
DB 114 TAGTCAATCTTGTCTTATACCTCAGTCTATTTCTGTAATTTTAAAGATATATGATA 55
QY 5302 CCTGGATTTCTTGGCTCTTGTGAGATGTAAGAGAAATTAATCTGAATAAAG 5355
DB 54 CCTGGATTTCTTGGCTCTTGTGAGATGTAAGAGAAATTAATCTGAATAAAG 1

RESULT 3
AW105537/c 728 bp mRNA EST 16-DEC-1999
LOCUS tx86c10.x1 NCI_CGAP_Ov4 Homo sapiens cDNA clone IMAGE:2276466 3',
DEFINITION similar to SW:MAG4_HUMAN P43358 MELANOMA-ASSOCIATED ANTIGEN 4',
ACCESSION AW105537
VERSION AW105537.1 GI:5392103
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE 1 (bases 1 to 728)
JOURNAL NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
COMMENT National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Unpublished (1997)
On May 11, 1999 this sequence version replaced gi:4776345.
Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert.Strausberg@nih.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
Emmert-Buck, M.D., Ph.D.
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be

```


Site 2: SmaI; A mini-library was made by cloning products derived from ORESTES PCR (U.S. Letters Patent application No. 196,716 - Ludwig Institute for Cancer Research) profiles into the pUC 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions.

BASE COUNT 117 a 112 c 175 g 129 t

Query Match 6.2%; Score 349.6; DB 71; Length 533;
Best Local Similarity 84.0%; Pred. No. 1.2e-76;
Matches 445; Conservative 0; Mismatches 74; Indels 11; Gaps 4;

QY 4484 ATTGCAATGGAGGGCGCCATGCTCTCTGAGGAGGAAATCTGGGAGGAGCTGAGTGTGATG 4543
DB 6 ATTCAATGGAGGGCTGACAGCCCTCTGAGGAGGAAATCTGGGAGGAGCTGGGTGTGATG 65
QY 4544 GAGGTGTATGATGGGAGGAGGACACAGTGCCTATGGGAGCCAGCAAGCTGCTCACCAG 4603
DB 66 GGGGTGTATGATGGGAGGAGGACACAGTGCCTATGGGAGCCAGCAAGCTGCTCACCAG 125
QY 4604 GATTTGGTTCAGGAAAGTACCTGGAGTA - CGGAGGTGCGGAGCAGTATCCCCACGC 4662
DB 126 GATTTGGTTCAGGAAAGTACCTGGAGTA - CGGAGGTGCGGAGCAGTATCCCCACGC 185
QY 4663 TATGAGTCTCTGGGTCGAGGCGCTGCTGAGGAGGAGTATGAAAGTCTGAG 4722
DB 186 TATGAGTCTCTGGGTCGAGGCGCTGCTGAGGAGGAGTATGAAAGTCTGAG 245
QY 4723 TATGATCAAGTTCAGTGCAGAGTTCGCTTTTCTTCCATCCCTGCGTGAACAGCT 4782
DB 246 CATTTGGTTCAGGAGTCAATGCAAGAGTTCGCTTACCCATCCCTGCGTGAACAGCT 305
QY 4783 TTGAGAGGAGGAGGAGGAGTCTGAGCATGAGTTGCAGCCAGCCAGTGGAGGG - 4840
DB 306 TTGTTAGAGGAGGAGGAGGAGTCTGAGCATGAGTTGCAGCCAGCCAGTGGAGGG 365
QY 4841 --GGAGTCTGGGTCGAGTGCAGCTTCCAGGCGCGCTCCAGCAGCTTCCCTGCTGTGA 4898
DB 366 CAGGGCTGGGCGCAGTGCATCAACA - GCCCTGTCAGCAGCTTCCCTGCTGTGA 423
QY 4899 CATGAGGCCATCTTCACTC --- TGAAGAGAGCGGTGAGTGTCTCAGTAGTAGTTT 4954
DB 424 CATGAGGCCATCTTCACTC --- TGAAGAGAGCGGTGAGTGTCTCAGTAGTAGTTT 483
QY 4955 CTGTTCTATTGGTGCAGTTCGAGATTATCTTTGTTCTCTTTTGAATTG 5004
DB 484 CTAATTGGTTGATGACTGGAGATTATCTCTGTTTCCCTTACAATTG 533

RESULT 6
AL044464
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

AL044464
578 bp mRNA
EST
Homo sapiens
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 578)
Ansoerge, W., Benes, V., Krieger, S., Mewes, H.W., Gassenhuber, J. and
Wiemann, S.
EST (Ansoerge, Benes, et al.)
Unpublished (1999)
Contact: Ansoerge W
MPS
Am Klopferspitz 18a D-82152 Martinsried, Germany
This is the 5' sequence of the clone insert
Clone from S. Wiemann, Molecular Genome Analysis, German Cancer

Db 481 CCTTGCTCGTGTACATGAGGCCATCTCTCACTCTGTTGAAGAAATAGTCACTGTT 422
QY 4940 CTAGTAGTAGTTCCTGTTCTATTTGGGTCACCTGAGATTTATCTTCTCTTTTGG 4999
DB 421 CTAGTAGTGGGTTCTATTTGTTGATGACTGGAGATTATCTCTGTTCTTTTAC 362
QY 5000 AATTGTTCAATGTTTCTTTTAAAGGATGGTTGAATGAACCTTCAGCATCCCAAGTTTATG 5059
DB 361 AATTGTTGAATG - TTCTTTTAAATGATGGTTGAATTAACCTTCAGCATCCCAAGTTTATG 303
QY 5060 AATGACAGCAGTACACAGTCTGTATATAGTTTAAAGGTAAGAGTCTGTGTTTAT 5119
DB 302 AATCGTAGTTAAGCTATATTCCTGTTAAATATAGTTTAAAGGTAAGAGTCTGTGTTTAT 243
QY 5120 TCAGATTGGGAAATCCATCTTATTTTGTGAATGGG --- ATAATACAGCAGTGGAAATA 5176
DB 242 TCAGATTGGGAAATCCCTTCTATTTTGTGAATTTGGACATAATAACAGCAGTGGAGTAA 183
QY 5177 GTACTTAGAATGTGAATAATGACAGTAAATAGATGAGTAAGAACTAAGAAATTA 5236
DB 182 GTATTTAGAAGTGT --- AATTCACCGTGAATAGGTGAGT --- AAATTA 138
QY 5237 AGAGATGATCAATTTCTGCTTATACCTCAGTCTATTTCTGTAATAATTT - TTAAGATATA 5295
DB 137 AAGATACCTTAATTTCCGCTCTATGCTCAGTCTATTTCTGTAATAATTTAAGATATA 78
QY 5296 TGCATACCTGATTTCTGCTGCTTTTGAAGATGTAAGAGAAATTAATCTGAATAAG 5355
DB 77 TGCATACCTGATTTCTGCTGCTTTCTGCTGCT --- GTGAATGTAAGAGAAATTAATCTGAATAAT 21
QY 5356 AATCTTCTCTGTTCA 5370
DB 20 AATCTTCTCTGTTAA 6

RESULT 5
AW383186
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

AW383186
533 bp mRNA
EST
Homo sapiens
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 533)
HCGP <http://www.ludwig.org.br/ORESTES>.
The FAPESP/LICR Human Cancer Genome Project
Unpublished (1999)
On Jun 15, 1998 this sequence version replaced gi:3224202.
Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil
Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the FAPESP/LICR Human Cancer Genome
Project. This entry can be seen in the following URL
([FEATURES
source
Location/Qualifiers
1..533
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="HT0344"
/dev_stage="Adult"
/note="Organ: head_neck; Vector: puc18; Site: 1: SmaI;](http://www.ludwig.org.br/scripts/gethtml2.pl?tl=PM3&t2=PM3&t3=PM3&t4=PM3&t5=PM3&t6=PM3&t7=PM3&t8=PM3&t9=PM3&t10=PM3&t11=PM3&t12=PM3&t13=PM3&t14=PM3&t15=PM3&t16=PM3&t17=PM3&t18=PM3&t19=PM3&t20=PM3&t21=PM3&t22=PM3&t23=PM3&t24=PM3&t25=PM3&t26=PM3&t27=PM3&t28=PM3&t29=PM3&t30=PM3&t31=PM3&t32=PM3&t33=PM3&t34=PM3&t35=PM3&t36=PM3&t37=PM3&t38=PM3&t39=PM3&t40=PM3&t41=PM3&t42=PM3&t43=PM3&t44=PM3&t45=PM3&t46=PM3&t47=PM3&t48=PM3&t49=PM3&t50=PM3&t51=PM3&t52=PM3&t53=PM3&t54=PM3&t55=PM3&t56=PM3&t57=PM3&t58=PM3&t59=PM3&t60=PM3&t61=PM3&t62=PM3&t63=PM3&t64=PM3&t65=PM3&t66=PM3&t67=PM3&t68=PM3&t69=PM3&t70=PM3&t71=PM3&t72=PM3&t73=PM3&t74=PM3&t75=PM3&t76=PM3&t77=PM3&t78=PM3&t79=PM3&t80=PM3&t81=PM3&t82=PM3&t83=PM3&t84=PM3&t85=PM3&t86=PM3&t87=PM3&t88=PM3&t89=PM3&t90=PM3&t91=PM3&t92=PM3&t93=PM3&t94=PM3&t95=PM3&t96=PM3&t97=PM3&t98=PM3&t99=PM3&t100=PM3&t101=PM3&t102=PM3&t103=PM3&t104=PM3&t105=PM3&t106=PM3&t107=PM3&t108=PM3&t109=PM3&t110=PM3&t111=PM3&t112=PM3&t113=PM3&t114=PM3&t115=PM3&t116=PM3&t117=PM3&t118=PM3&t119=PM3&t120=PM3&t121=PM3&t122=PM3&t123=PM3&t124=PM3&t125=PM3&t126=PM3&t127=PM3&t128=PM3&t129=PM3&t130=PM3&t131=PM3&t132=PM3&t133=PM3&t134=PM3&t135=PM3&t136=PM3&t137=PM3&t138=PM3&t139=PM3&t140=PM3&t141=PM3&t142=PM3&t143=PM3&t144=PM3&t145=PM3&t146=PM3&t147=PM3&t148=PM3&t149=PM3&t150=PM3&t151=PM3&t152=PM3&t153=PM3&t154=PM3&t155=PM3&t156=PM3&t157=PM3&t158=PM3&t159=PM3&t160=PM3&t161=PM3&t162=PM3&t163=PM3&t164=PM3&t165=PM3&t166=PM3&t167=PM3&t168=PM3&t169=PM3&t170=PM3&t171=PM3&t172=PM3&t173=PM3&t174=PM3&t175=PM3&t176=PM3&t177=PM3&t178=PM3&t179=PM3&t180=PM3&t181=PM3&t182=PM3&t183=PM3&t184=PM3&t185=PM3&t186=PM3&t187=PM3&t188=PM3&t189=PM3&t190=PM3&t191=PM3&t192=PM3&t193=PM3&t194=PM3&t195=PM3&t196=PM3&t197=PM3&t198=PM3&t199=PM3&t200=PM3&t201=PM3&t202=PM3&t203=PM3&t204=PM3&t205=PM3&t206=PM3&t207=PM3&t208=PM3&t209=PM3&t210=PM3&t211=PM3&t212=PM3&t213=PM3&t214=PM3&t215=PM3&t216=PM3&t217=PM3&t218=PM3&t219=PM3&t220=PM3&t221=PM3&t222=PM3&t223=PM3&t224=PM3&t225=PM3&t226=PM3&t227=PM3&t228=PM3&t229=PM3&t230=PM3&t231=PM3&t232=PM3&t233=PM3&t234=PM3&t235=PM3&t236=PM3&t237=PM3&t238=PM3&t239=PM3&t240=PM3&t241=PM3&t242=PM3&t243=PM3&t244=PM3&t245=PM3&t246=PM3&t247=PM3&t248=PM3&t249=PM3&t250=PM3&t251=PM3&t252=PM3&t253=PM3&t254=PM3&t255=PM3&t256=PM3&t257=PM3&t258=PM3&t259=PM3&t260=PM3&t261=PM3&t262=PM3&t263=PM3&t264=PM3&t265=PM3&t266=PM3&t267=PM3&t268=PM3&t269=PM3&t270=PM3&t271=PM3&t272=PM3&t273=PM3&t274=PM3&t275=PM3&t276=PM3&t277=PM3&t278=PM3&t279=PM3&t280=PM3&t281=PM3&t282=PM3&t283=PM3&t284=PM3&t285=PM3&t286=PM3&t287=PM3&t288=PM3&t289=PM3&t290=PM3&t291=PM3&t292=PM3&t293=PM3&t294=PM3&t295=PM3&t296=PM3&t297=PM3&t298=PM3&t299=PM3&t300=PM3&t301=PM3&t302=PM3&t303=PM3&t304=PM3&t305=PM3&t306=PM3&t307=PM3&t308=PM3&t309=PM3&t310=PM3&t311=PM3&t312=PM3&t313=PM3&t314=PM3&t315=PM3&t316=PM3&t317=PM3&t318=PM3&t319=PM3&t320=PM3&t321=PM3&t322=PM3&t323=PM3&t324=PM3&t325=PM3&t326=PM3&t327=PM3&t328=PM3&t329=PM3&t330=PM3&t331=PM3&t332=PM3&t333=PM3&t334=PM3&t335=PM3&t336=PM3&t337=PM3&t338=PM3&t339=PM3&t340=PM3&t341=PM3&t342=PM3&t343=PM3&t344=PM3&t345=PM3&t346=PM3&t347=PM3&t348=PM3&t349=PM3&t350=PM3&t351=PM3&t352=PM3&t353=PM3&t354=PM3&t355=PM3&t356=PM3&t357=PM3&t358=PM3&t359=PM3&t360=PM3&t361=PM3&t362=PM3&t363=PM3&t364=PM3&t365=PM3&t366=PM3&t367=PM3&t368=PM3&t369=PM3&t370=PM3&t371=PM3&t372=PM3&t373=PM3&t374=PM3&t375=PM3&t376=PM3&t377=PM3&t378=PM3&t379=PM3&t380=PM3&t381=PM3&t382=PM3&t383=PM3&t384=PM3&t385=PM3&t386=PM3&t387=PM3&t388=PM3&t389=PM3&t390=PM3&t391=PM3&t392=PM3&t393=PM3&t394=PM3&t395=PM3&t396=PM3&t397=PM3&t398=PM3&t399=PM3&t400=PM3&t401=PM3&t402=PM3&t403=PM3&t404=PM3&t405=PM3&t406=PM3&t407=PM3&t408=PM3&t409=PM3&t410=PM3&t411=PM3&t412=PM3&t413=PM3&t414=PM3&t415=PM3&t416=PM3&t417=PM3&t418=PM3&t419=PM3&t420=PM3&t421=PM3&t422=PM3&t423=PM3&t424=PM3&t425=PM3&t426=PM3&t427=PM3&t428=PM3&t429=PM3&t430=PM3&t431=PM3&t432=PM3&t433=PM3&t434=PM3&t435=PM3&t436=PM3&t437=PM3&t438=PM3&t439=PM3&t440=PM3&t441=PM3&t442=PM3&t443=PM3&t444=PM3&t445=PM3&t446=PM3&t447=PM3&t448=PM3&t449=PM3&t450=PM3&t451=PM3&t452=PM3&t453=PM3&t454=PM3&t455=PM3&t456=PM3&t457=PM3&t458=PM3&t459=PM3&t460=PM3&t461=PM3&t462=PM3&t463=PM3&t464=PM3&t465=PM3&t466=PM3&t467=PM3&t468=PM3&t469=PM3&t470=PM3&t471=PM3&t472=PM3&t473=PM3&t474=PM3&t475=PM3&t476=PM3&t477=PM3&t478=PM3&t479=PM3&t480=PM3&t481=PM3&t482=PM3&t483=PM3&t484=PM3&t485=PM3&t486=PM3&t487=PM3&t488=PM3&t489=PM3&t490=PM3&t491=PM3&t492=PM3&t493=PM3&t494=PM3&t495=PM3&t496=PM3&t497=PM3&t498=PM3&t499=PM3&t500=PM3&t501=PM3&t502=PM3&t503=PM3&t504=PM3&t505=PM3&t506=PM3&t507=PM3&t508=PM3&t509=PM3&t510=PM3&t511=PM3&t512=PM3&t513=PM3&t514=PM3&t515=PM3&t516=PM3&t517=PM3&t518=PM3&t519=PM3&t520=PM3&t521=PM3&t522=PM3&t523=PM3&t524=PM3&t525=PM3&t526=PM3&t527=PM3&t528=PM3&t529=PM3&t530=PM3&t531=PM3&t532=PM3&t533=PM3&t534=PM3&t535=PM3&t536=PM3&t537=PM3&t538=PM3&t539=PM3&t540=PM3&t541=PM3&t542=PM3&t543=PM3&t544=PM3&t545=PM3&t546=PM3&t547=PM3&t548=PM3&t549=PM3&t550=PM3&t551=PM3&t552=PM3&t553=PM3&t554=PM3&t555=PM3&t556=PM3&t557=PM3&t558=PM3&t559=PM3&t560=PM3&t561=PM3&t562=PM3&t563=PM3&t564=PM3&t565=PM3&t566=PM3&t567=PM3&t568=PM3&t569=PM3&t570=PM3&t571=PM3&t572=PM3&t573=PM3&t574=PM3&t575=PM3&t576=PM3&t577=PM3&t578=PM3&t579=PM3&t580=PM3&t581=PM3&t582=PM3&t583=PM3&t584=PM3&t585=PM3&t586=PM3&t587=PM3&t588=PM3&t589=PM3&t590=PM3&t591=PM3&t592=PM3&t593=PM3&t594=PM3&t595=PM3&t596=PM3&t597=PM3&t598=PM3&t599=PM3&t600=PM3&t601=PM3&t602=PM3&t603=PM3&t604=PM3&t605=PM3&t606=PM3&t607=PM3&t608=PM3&t609=PM3&t610=PM3&t611=PM3&t612=PM3&t613=PM3&t614=PM3&t615=PM3&t616=PM3&t617=PM3&t618=PM3&t619=PM3&t620=PM3&t621=PM3&t622=PM3&t623=PM3&t624=PM3&t625=PM3&t626=PM3&t627=PM3&t628=PM3&t629=PM3&t630=PM3&t631=PM3&t632=PM3&t633=PM3&t634=PM3&t635=PM3&t636=PM3&t637=PM3&t638=PM3&t639=PM3&t640=PM3&t641=PM3&t642=PM3&t643=PM3&t644=PM3&t645=PM3&t646=PM3&t647=PM3&t648=PM3&t649=PM3&t650=PM3&t651=PM3&t652=PM3&t653=PM3&t654=PM3&t655=PM3&t656=PM3&t657=PM3&t658=PM3&t659=PM3&t660=PM3&t661=PM3&t662=PM3&t663=PM3&t664=PM3&t665=PM3&t666=PM3&t667=PM3&t668=PM3&t669=PM3&t670=PM3&t671=PM3&t672=PM3&t673=PM3&t674=PM3&t675=PM3&t676=PM3&t677=PM3&t678=PM3&t679=PM3&t680=PM3&t681=PM3&t682=PM3&t683=PM3&t684=PM3&t685=PM3&t686=PM3&t687=PM3&t688=PM3&t689=PM3&t690=PM3&t691=PM3&t692=PM3&t693=PM3&t694=PM3&t695=PM3&t696=PM3&t697=PM3&t698=PM3&t699=PM3&t700=PM3&t701=PM3&t702=PM3&t703=PM3&t704=PM3&t705=PM3&t706=PM3&t707=PM3&t708=PM3&t709=PM3&t710=PM3&t711=PM3&t712=PM3&t713=PM3&t714=PM3&t715=PM3&t716=PM3&t717=PM3&t718=PM3&t719=PM3&t720=PM3&t721=PM3&t722=PM3&t723=PM3&t724=PM3&t725=PM3&t726=PM3&t727=PM3&t728=PM3&t729=PM3&t730=PM3&t731=PM3&t732=PM3&t733=PM3&t734=PM3&t735=PM3&t736=PM3&t737=PM3&t738=PM3&t739=PM3&t740=PM3&t741=PM3&t742=PM3&t743=PM3&t744=PM3&t745=PM3&t746=PM3&t747=PM3&t748=PM3&t749=PM3&t750=PM3&t751=PM3&t752=PM3&t753=PM3&t754=PM3&t755=PM3&t756=PM3&t757=PM3&t758=PM3&t759=PM3&t760=PM3&t761=PM3&t762=PM3&t763=PM3&t764=PM3&t765=PM3&t766=PM3&t767=PM3&t768=PM3&t769=PM3&t770=PM3&t771=PM3&t772=PM3&t773=PM3&t774=PM3&t775=PM3&t776=PM3&t777=PM3&t778=PM3&t779=PM3&t780=PM3&t781=PM3&t782=PM3&t783=PM3&t784=PM3&t785=PM3&t786=PM3&t787=PM3&t788=PM3&t789=PM3&t790=PM3&t791=PM3&t792=PM3&t793=PM3&t794=PM3&t795=PM3&t796=PM3&t797=PM3&t798=PM3&t799=PM3&t800=PM3&t801=PM3&t802=PM3&t803=PM3&t804=PM3&t805=PM3&t806=PM3&t807=PM3&t808=PM3&t809=PM3&t810=PM3&t811=PM3&t812=PM3&t813=PM3&t814=PM3&t815=PM3&t816=PM3&t817=PM3&t818=PM3&t819=PM3&t820=PM3&t821=PM3&t822=PM3&t823=PM3&t824=PM3&t825=PM3&t826=PM3&t827=PM3&t828=PM3&t829=PM3&t830=PM3&t831=PM3&t832=PM3&t833=PM3&t834=PM3&t835=PM3&t836=PM3&t837=PM3&t838=PM3&t839=PM3&t840=PM3&t841=PM3&t842=PM3&t843=PM3&t844=PM3&t845=PM3&t846=PM3&t847=PM3&t848=PM3&t849=PM3&t850=PM3&t851=PM3&t852=PM3&t853=PM3&t854=PM3&t855=PM3&t856=PM3&t857=PM3&t858=PM3&t859=PM3&t860=PM3&t861=PM3&t862=PM3&t863=PM3&t864=PM3&t865=PM3&t866=PM3&t867=PM3&t868=PM3&t869=PM3&t870=PM3&t871=PM3&t872=PM3&t873=PM3&t874=PM3&t875=PM3&t876=PM3&t877=PM3&t878=PM3&t879=PM3&t880=PM3&t881=PM3&t882=PM3&t883=PM3&t884=PM3&t885=PM3&t886=PM3&t887=PM3&t888=PM3&t889=PM3&t890=PM3&t891=PM3&t892=PM3&t893=PM3&t894=PM3&t895=PM3&t896=PM3&t897=PM3&t898=PM3&t899=PM3&t900=PM3&t901=PM3&t902=PM3&t903=PM3&t904=PM3&t905=PM3&t906=PM3&t907=PM3&t908=PM3&t909=PM3&t910=PM3&t911=PM3&t912=PM3&t913=PM3&t914=PM3&t915=PM3&t916=PM3&t917=PM3&t918=PM3&t919=PM3&t920=PM3&t921=PM3&t922=PM3&t923=PM3&t924=PM3&t925=PM3&t926=PM3&t927=PM3&t928=PM3&t929=PM3&t930=PM3&t931=PM3&t932=PM3&t933=PM3&t934=PM3&t935=PM3&t936=PM3&t937=PM3&t938=PM3&t939=PM3&t940=PM3&t941=PM3&t942=PM3&t943=PM3&t944=PM3&t945=PM3&t946=PM3&t947=PM3&t948=PM3&t949=PM3&t950=PM3&t951=PM3&t952=PM3&t953=PM3&t954=PM3&t955=PM3&t956=PM3&t957=PM3&t958=PM3&t959=PM3&t960=PM3&t961=PM3&t962=PM3&t963=PM3&t964=PM3&t965=PM3&t966=PM3&t967=PM3&t968=PM3&t969=PM3&t970=PM3&t971=PM3&t972=PM3&t973=PM3&t974=PM3&t975=PM3&t976=PM3&t977=PM3&t978=PM3&t979=PM3&t980=PM3&t981=PM3&t982=PM3&t983=PM3&t984=PM3&t985=PM3&t986=PM3&t987=PM3&t988=PM3&t989=PM3&t990=PM3&t991=PM3&t992=PM3&t993=PM3&t994=PM3&t995=PM3&t996=PM3&t997=PM3&t998=PM3&t999=PM3&t1000=PM3</p></div><div data-bbox=)


```

Db 1 CCAAGATTGGGTGAGGAAACTACCTGGAGTANGCGGAGTACCGGACGATTCCTGC 60
Qy 4659 AGCGTATGAGTTCCTGTGGGTGCTCAAGGGCCCTGGCTGAAACACGAGCTATGTGAAGTCCT 4718
Db 61 GCGCTATGAGTTCCTGTGGGTGCTCAAGGGCTCTGGCTGANACGAGCTATGTGAAGTCCT 120
Qy 4719 TCAGTATGATCAAGGTGAGTGCAGAGTTCGCTTTTCTCCATCCCTGCGTGAAGC 4778
Db 121 GGAGCATGTGGTCAAGGTCAATGCAAGAGTTCGCAATCCCTACCCATCCCTGCNCGAAGC 180
Qy 4779 ACCTTTGAGAGGAGGAGGAGGAGTCTGAGCATGATTCGAGCCAGGCGAGTGGGAG 4838
Db 181 ACCTTTGAGAGGAGGAGGAGTCTGAGCATGATTCGAGCCAGGCGTGTGGGGA 240
Qy 4839 GG----GGACCTGGCCAGTGCACCTTCAGGGCCCGTCCAGCAGCTCCCTGCTCGT 4894
Db 241 GGGGAGGGCTGGGCGAGTGCATCTAACAA--GCCCTGTGCAGCAGCTTCCTTCCCTCGT 298
Qy 4895 GTGACATGAGGCGCAATTCCTCACTCTGAAGAGAGGGGTCACT-----GTCTCAGTAGT 4948
Db 299 GTACATGAGGCGCAATTCCTCACTCTGTTGAAGAAATAGTCAAGTGTCTTAAGTAGT 358
Qy 4949 AGGTTCTGCTTATATGGG--TGACGTGAGATTTATCTTTGCTCTCTTTTGAATTTGTC 5007
Db 359 GGGTTCTATTTTGTGGGAGTGGAGATTTATCTCTGTTTCTTTTACAAATTTGTG 418
Qy 5008 AAATGTTTTTTTTTAAGGATGTTGAATGAACTTCAGATCCCAAGTTTATGAATGACAG 5067
Db 419 AAATG--TTCCCTTTTAATGATGGTGTGAATTAACCTTCAGATCCCAAGTTTATGAATCGTAN 477
Qy 5068 CAGTCACACAGTTCCTGTGTATATAGTT 5094
Db 478 TTAACGTATATGCTGTTAATATAATT 504

```

```

RESULT 10
AW245614/c 493 bp mRNA EST 07-MAR-2000
LOCUS
DEFINITION
  wm45d10.x1 NCI_CGAP_Ut4 Homo sapiens cDNA clone IMAGE:2438899 3',
  mRNA sequence.
ACCESSION
  AW245614
VERSION
  AW245614.1 GI:5527129
KEYWORDS
  EST.
SOURCE
  Human.
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 (bases 1 to 493)
  NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
  National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
  Tumor Gene Index
  Unpublished (1997)
  On Oct 30, 1998 this sequence version replaced gi:3815061.
  Contact: Robert Strausberg, Ph.D.
  Tel: (301) 496-1550
  Email: Robert.Strausberg@nih.gov
  Tissue Procurement: Christopher Moskalko, M.D., Ph.D., Michael R.
  Emmert-Buck, M.D., Ph.D.
  cDNA Library Preparation: Life Technologies, Inc.
  DNA Sequencing by: Greg Lennon, Ph.D.
  Clone distribution: Washington University Genome Sequencing Center
  found through the I.M.A.G.E. Consortium/LLNL at:
  www.bio.llnl.gov/bbrp/image/image.html
  Insert Length: 1787 Std Error: 0.00
  Seq primer: -400P from Gibco
  High quality sequence stop: 395.
  Location/Qualifiers
    1. .493
      /organism="Homo sapiens"
      /db_xref="taxon:9606"
      /clone="IMAGE:2438899"

```

```

/clone_lib="NCI_CGAP_Ut4"
/tissue_type="serous papillary carcinoma, high grade, 2
  pooled tumors"
/lab_host="DH10B"
/notes="Organ: uterus; Vector: pCMV-SPORT6; Site: 1: SalI;
  Site 2: NotI; Cloned unidirectionally. Primer: Oligo dt.
  Average insert size 1.48 kb. Life Technologies catalog #:
  11542-016"
BASE COUNT 184 a 92 c 66 g 151 t
ORIGIN
  Query Match 4.9%; Score 275.2; DB 45; Length 493;
  Best Local Similarity 82.0%; Pred. No. 4.8e-58;
  Matches 410; Conservative 0; Mismatches 63; Indels 27; Gaps 7;
Qy 4879 GCTTCCCTGCTGTCGATGAGCGCCCATCTCTCACTC-----TGAAGAGAGCGGTCA 4934
Db 493 GCTTCCCTGCTGTCGATGAGCGCCCATCTCTCACTC-----TGAAGAGAAATAGTCA 434
Qy 4935 GTGTTCTCAGTAGTAGTTCCTCTATGTTGGTGGATGACTTGGAGATTTATCTCTGTTCTCT 4994
Db 433 GTGTTCTCAGTAGTGGGTTCTATTTTGGTGGATGACTTGGAGATTTATCTCTGTTCTCT 374
Qy 4995 TTTGGAAATGTTCAATGTTTTTTTAAAGGATGTTGAATGAACCTCAGCATCCCAAGT 5054
Db 373 TTTACAAATGTTGAAATG-TTCCTTTAATGATGGTGAATTAACCTCAGCATCCCAAGT 315
Qy 5055 TTATGATGACAGCAGTCACACAGTCTCTGTATATAGTTTAAAGGTAAGAGCTCTGTGT 5114
Db 314 TTATGATGACAGTACGTTACGTTATGCTGTTAATATAGTTTAAAGGTAAGAGCTCTGTGT 255
Qy 5115 TTTATTCAGATTTGGAAATGCTATCTATTTTGAATGGG---ATAATACAGCAGTGG 5171
Db 254 TTTATTCAGATTTGGAAATGCTATCTATTTTGAATGGG---ATAATACAGCAGTGG 195
Qy 5172 AATAAGTACTTAGAAATGTGAAATAGCAGCAGTAAATAGATGAGATGAGATGAGTAAAGA 5231
Db 194 AATAAGTACTTAGAAATGTGAAATAGCAGCAGTAAATAGATGAGATGAGTAAAGA 150
Qy 5232 AATAAGATGATGATCAATTCCTGCTTATACCTCAGTCTATTCGTGTAATTTT-TTAAAG 5290
Db 149 AATAAGATGATGATCAATTCCTGCTTATACCTCAGTCTATTCGTGTAATTTT-TTAAAG 90
Qy 5291 ATATATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 5350
Db 89 ATATATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 33
Qy 5351 TAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 5370
Db 32 TAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 13

```

```

RESULT 11
AW245614/c 511 bp mRNA EST 07-JAN-2000
LOCUS
DEFINITION
  2822978.3prime NIH_MGC_7 Homo sapiens cDNA clone IMAGE:2822978 3',
  mRNA sequence.
ACCESSION
  AW245614
VERSION
  AW245614.1 GI:6588607
KEYWORDS
  EST.
SOURCE
  Human.
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 (bases 1 to 511)
  NIH-MGC http://www.ncbi.nlm.nih.gov/MGC/.
  National Institutes of Health, Mammalian Gene Collection (MGC)
  Unpublished (1999)
  Other_ESTs: 2822978.5prime
  Contact: Robert Strausberg, Ph.D.
  Tel: (301) 496-1550
  Email: Robert.Strausberg@nih.gov

```

QY	5331	TAAGGAAATTTAAATCTGAATAAGAATT	5359
Dd	39	CACCGAATTTAAATCTGAGTAAATAATT	11

RESULT	12		
AA995045/c			
LOCUS			
DEFINITION			
	AA995045	481 bp	mRNA
	cu5se02.s1 NCI_CGAP_Br2 Homo sapiens		EST
			cdna clone IMAGE:1631546
			' ,
			27-AUG-1998
ACCESSION	AA995045		
VERSION	AA995045.1	GI:3181534	
KEYWORDS	EST.		
SOURCE	human.		

ORGANISM	Homo sapiens Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1. (bases 1 to 481)
AUTHORS	NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap .
TITLE	National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
JOURNAL	Unpublished (1997)
COMMENT	On May 18, 1998 this sequence version replaced gi:3138536. Contact: Robert Strausberg, Ph.D.

Tel: (301) 496-1550
 Email: Robert.Strausberg@nih.gov
 Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R. Emmert-Buck, M.D., Ph.D.
 cDNA Library Preparation: M. Bento Soares, Ph.D.
 cDNA Library Arrayed by: Greg Lennon, Ph.D.
 DNA Sequencing by: Washington University Genome Sequencing Center
 Clone distribution: NCI-CCGAP clone distribution information can
 be found through the I.A.G.E. Consortium/LLNL at:
www.bio.llnl.gov/dbbrp/image/image.html
 Insert Length: 1718 Std Error: 0.00
 Seq primer: -40m13 fwd. ET from Amersham
 High quality sequence stop: 446.

FEATURES	Source
Location/Qualifiers	1.481
/organism="Homo sapiens"	
/db_xref="taxon:9606"	
/clone="IMAGE:1631546"	
/clone_lib="NCI_CGAP_Br2"	
/sex="female", pooled"	
/tissue_type="breast"	
/lab_host="DH10B"	
/note="Vector: pT73D-Pac (Pharmacia) with a modified polylinker: 1st strand cDNA was prepared from pooled breast tumor tissue, and was then primed with a Not I - oligo(dT) primer. Double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT73 vector. This library is the normalized version of NCI_CGAP_Br1.1. Library was constructed by Bento Soares and M. Fatima Bonaldo."	
BASE COUNT	165 a 91 c 154 t
ORIGIN	

	Query Match	4.98;	Score	270.6;	DB	33;	Length	481;
	Best Local Similarity	84.68;	Pred.	No.	6.8e-57;			
	Matches	402;	Conservative	0;	Mismatches	54;	Indels	19; Gaps
Qy	4902	GAGGCCATCTTCACATC - TGAAGAGAGCGGTCAGTGTCTCTCAGTAGTAGTGTTTCGTT	4959					

.....

Db 362 TTAACGGATGGTTGAATGAGCGTCAGCATCCAGGTTTATGAATGACAGTAGTCACACATA 303
 QY 5078 GTTCTGTGTATAGTATTAAGCGTGAAGAGTCTGTGTATTTATTCAGATGGGAATCCAT 5137
 Db 302 GTGCGTTTATATAGTTTAGGAGTGAAGTCTGTGTATTTATTCAGATGGGAATCCAT 243
 QY 5138 TCTATTTTGTGAATGGG--ATAAATACAGCAGTGGGATAAGTA---CTTAGAATGTG 5191
 Db 242 TCCATTTTGTGAATGTGACATAATATAGCAGTGGGAAAGATATTCCTTAAATTTGTG 183
 QY 5192 A-AAATGACGAGTAAATAGATGAGATAAAGAACTAAAGAAATTAAGAGATAGTCAAT 5250
 Db 182 AGCGAATAGCAATAACATACATGAGAT---AACTCAAGAAATCAAAAGATAGTTGATT 127
 QY 5251 CTTCGCTTATACCTCAGTCTATCTGTAAATTTTAAAGATATATGATACCTGGATT 5310
 Db 126 CTTCGCTTACCTCAATCTATCTGTAAAT---TAAACAATATGCAAAACAGGATTT 70
 QY 5311 CTTTGGCTCTTTTGAATGTGAAGAGAAATTAATCTGAATAAGAAATCTTCCT 5365
 Db 69 CTTTGAATCTTTTGAATGTGAAGAGAAATTAATCTGAATAAGAAATCTTCCT 15

RESULT 13
 LOCUS AW194089/c
 DEFINITION xm12a03.x1 NCI_CGAP_Ut4 Homo sapiens cDNA clone IMAGE:2683948 3', mRNA sequence.
 ACCESSION AW194089
 VERSION AW194089.1 GI:6472822
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 495)
 AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
 TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
 JOURNAL Unpublished (1997)
 COMMENT On Oct 30, 1998 this sequence version replaced gi:3817926.
 Contact: Robert Strausberg, Ph.D.
 Tel: (301) 496-1550
 Email: Robert.Strausberg@nih.gov
 Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R. Emmert-Buck, M.D., Ph.D.
 cDNA Library Preparation: Life Technologies, Inc.
 cDNA Library Arrayed by: Greg Lennon, Ph.D.
 DNA Sequencing by: Washington University Genome Sequencing Center
 Clone distribution: NCI-CGAP
 found through the I.M.A.G.E. Consortium/LLNL at: www-bio.llnl.gov/bbrp/image/image.html

Possible reversed clone: polyT not found
 Seq primer: -40UP from Gibco
 High quality sequence stop: 408.
 Location/Qualifiers
 1. .495
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:2683948"
 /clone_lib="NCI_CGAP_Ut4"
 /tissue_type="serous papillary carcinoma, high grade, 2 pooled tumors"
 /lab_host="DH10B"
 /note="Organ: uterus; Vector: pCMV-SPORT6; Site_1: SalI; Site_2: NotI; Cloned unidirectionally. Primer: Oligo dt. Average insert size 1.48 kb. Life Technologies catalog #: 11542-016"
 186 a 95 c 68 g 146 t


FEATURES

Source

Query Match 4.8%; Score 270.6; DB 69; Length 495;
 Best Local Similarity 81.9%; Pred. No. 6.8e-57;
 Matches 417; Conservative 0; Mismatches 64; Indels 28; Gaps 8;
 QY 4871 GTCCAGCAGCTTCCCGCCCTCGTGTGACATGAGGCCATCTCTCACTC---TGAAGAG 4926
 Db 494 GTGCAGCAGCTTCCCTGCGCTCGTGTACATGAGGCCATCTCTCACTCCTGTTGAAGAA 435
 QY 4927 AGCGGTGAGTGTCTCAGTAGTAGTCTTCTGTCTATTTGGTGTGACCTTGGAGATTAATCTT 4986
 Db 434 AATAGTCAGTGTCTTCTAGTAGTGGTCTTCTATTTTGTGTGATGACTTGGAGATTTATCTC 375
 QY 4987 TGTCTCTCTTTTGGAAATGTTCAAAATGTTTTTTTTTAAGGATGGTTGAATCAACTTCAGC 5046
 Db 374 TGTTCCTCTTTTACAAATGTTGAATG-TTCTTTTATGATGATGGTGAATTAACCTCAGC 316
 QY 5047 ATCCAAGTTT-ATGAATGACAGCAGTCACACAGTCTCTGTATATATAGTTTAAAGGTAAGA 5105
 Db 315 ATCCAAGTTTAAATGATCGTAGTTAAGGTATATTCGTGTTAATATAGTTTAGGAGTAAGA 256
 QY 5106 GTCTTGTGTTTATTCAGATGGGAATCCATCTCTATTTTGTGAATGGG---ATAATAA 5162
 Db 255 GTCTTGTGTTTATTCAGATGGGAATCCGTTCTATTTTGTGAATGGGACATATAA 196
 QY 5163 CAGCAGTGGAAATAGTACTTAGAAATGTGAAATGAGCAGTAAATAGATGAGATAAG 5222
 Db 195 CAGCAGTGGAGTAGTATTAGAGTGTG---AATTCACCGTGAATAGGTGAGAT---- 141
 QY 5223 AACTAAGAAATTAAGAGATAGTCAATCTTCCTTATACCTCAGTCTATTTCTGTAAT 5282
 Db 142 -----AAATTAAGAGTACTTAATTCGCGCTTATGCTCAGTCTATTTCTGTAAT 91
 QY 5283 TT-TTAAGATATATGATACCTGAGTTTCCTTGGCTTCTTTGAGAATGAAGAATAAT 5341
 Db 90 TTAATAAATATATATGATACCTGAGTTTCCTTGGCTTC---GTGAATGAAGAATAAT 34
 QY 5342 AACTTGAATGAAGAATAATCTCTGTTCA 5370
 Db 33 AACTTGAATGAATGAATCTCTTCTGTTAA 5
 RESULT 14
 LOCUS AW250219/c
 DEFINITION AW250219 521 bp mRNA EST 07-JAN-2000
 ACCESSION AW250219
 VERSION AW250219.1 GI:6593212
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 521)
 AUTHORS NIH-MGC http://www.ncbi.nlm.nih.gov/MGC/.
 TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
 JOURNAL Unpublished (1999)
 COMMENT On Jun 15, 1998 this sequence version replaced gi:3222620.
 Other ESTs: 2822505.5prime
 Contact: Robert Strausberg, Ph.D.
 Email: Robert.Strausberg@nih.gov
 Tissue Procurement: DCTD/DTF CDNA Library Preparation: Ling Hong/Rubin Laboratory CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL) DNA Sequencing by: Berkeley MGC sequencing project
 Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www-bio.llnl.gov/bbrp/image/image.html
 Scores: PERED from University of Washington Genome Center. Vector Trimming: cross_match from University of Washington Genome Center. PHRAP suite. Poly-T Identification: patMatch.pl from Berkeley Drosophila Genome Project. University of Washington Genome Center: http://www.genome.washington.edu Polyadenylation: Based upon the

QY 5338 AATTAAATCTGAATAAAGAAATTCTTCTCTCTCA 5370
| | | | | | | | | | | | | | | | | | | | | | | |
Db 47 AATTAAATCTGAATAAAGAAATTCTTCTCTCTCA 15

Search completed: September 13, 2000, 02:38:16
Job time: 4783 sec



Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPSrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Wed Sep 13 07:14:42 2000; MasPar time 3.43 Seconds
Tabular output not generated. 40.218 Million cell updates/sec

Title: >US-08-819-669E-26
Description: (1-9) from US08819669E.pep
Perfect Score: 61
Sequence: 1 EADPTGHSY 9

Scoring table: PAM 150
Gap 15

Searched: 152433 seqs, 15329240 residues

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database: a-issued
1:5A_COMB 2:5B_COMB 3:6_COMB 4:PCT_COMB 5:backfiles1
Statistics: Mean 14.653; Variance 34.108; scale 0.430

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description	Pred. No.
1	61	100.0	9	2	US-09-036- Sequence 1, Applicatio	1.24e-01
2	61	100.0	9	2	US-08-986- Sequence 1, Applicatio	1.24e-01
3	61	100.0	9	1	US-07-938- Sequence 1, Applicatio	1.24e-01
4	61	100.0	9	1	US-08-443- Sequence 12, Applicati	1.24e-01
5	61	100.0	9	1	US-08-787- Sequence 12, Applicati	1.24e-01
6	61	100.0	9	1	US-08-073- Sequence 12, Applicati	1.24e-01
7	61	100.0	9	3	US-08-159- Sequence 12, Applicati	1.24e-01
8	61	100.0	9	3	US-08-354- Sequence 99, Applicati	1.24e-01
9	61	100.0	9	2	US-08-902- Sequence 12, Applicati	1.24e-01
10	61	100.0	9	2	US-08-142- Sequence 21, Applicati	1.24e-01
11	61	100.0	9	4	PCT-US95-0 Sequence 26, Applicati	1.24e-01
12	61	100.0	9	4	PCT-US95-0 Sequence 2, Applicatio	1.24e-01
13	61	100.0	9	1	US-08-299- Sequence 1, Applicatio	1.24e-01
14	61	100.0	9	2	US-08-498- Sequence 26, Applicatio	1.24e-01
15	61	100.0	9	3	US-08-967- Sequence 4, Applicatio	1.24e-01
16	61	100.0	9	1	US-08-186- Sequence 26, Applicatio	1.24e-01
17	61	100.0	10	3	US-08-602- Sequence 1, Applicatio	1.24e-01
18	61	100.0	10	1	US-08-796- Sequence 25, Applicati	1.24e-01
19	61	100.0	10	2	US-08-498- Sequence 25, Applicati	1.24e-01
20	61	100.0	12	2	US-08-560- Sequence 5, Applicatio	1.24e-01
21	61	100.0	12	1	US-08-190- Sequence 4, Applicatio	1.24e-01
22	61	100.0	309	1	US-08-465- Sequence 4, Applicati	1.24e-01
23	61	100.0	309	2	US-08-993- Sequence 10, Applicati	1.24e-01

24	61	100.0	309	3	US-08-845- Sequence 10, Applicati	1.24e-01
25	59	96.7	9	3	US-08-159- Sequence 1201, Applic	2.48e-01
26	57	93.4	9	3	US-08-159- Sequence 1196, Applic	4.92e-01
27	55	90.2	8	1	US-08-073- Sequence 14, Applicati	9.70e-01
28	55	90.2	8	1	US-08-443- Sequence 14, Applicati	9.70e-01
29	55	90.2	8	3	US-08-354- Sequence 8, Applicati	9.70e-01
30	55	90.2	9	2	US-08-498- Sequence 8, Applicati	9.70e-01
31	53	86.9	9	3	US-08-159- Sequence 1193, Applic	1.90e+00
32	53	86.9	9	3	US-08-159- Sequence 1198, Applic	1.90e+00
33	52	85.2	9	2	US-08-498- Sequence 1, Applicatio	2.65e+00
34	52	85.2	9	2	US-08-498- Sequence 6, Applicatio	2.65e+00
35	52	85.2	369	2	US-08-773- Sequence 4, Applicatio	2.65e+00
36	51	83.6	9	3	US-08-159- Sequence 1200, Applic	3.70e+00
37	49	80.3	8	1	US-08-073- Sequence 13, Applicati	7.15e+00
38	49	80.3	8	3	US-08-354- Sequence 13, Applicati	7.15e+00
39	49	80.3	8	1	US-08-443- Sequence 13, Applicati	7.15e+00
40	49	80.3	8	1	US-07-938- Sequence 21, Applicati	7.15e+00
41	49	80.3	9	3	US-08-159- Sequence 1195, Applic	7.15e+00
42	48	78.7	873	3	US-09-187- Sequence 6, Applicatio	9.91e+00
43	48	78.7	925	2	US-08-504- Sequence 1, Applicatio	9.91e+00
44	48	78.7	925	2	US-08-392- Sequence 1, Applicatio	9.91e+00
45	48	78.7	925	4	PCT-US94-1 Sequence 1, Applicatio	9.91e+00

ALIGNMENTS

RESULT 1
ID US-09-036-582-1 STANDARD; PRT; 9 AA.
XX AC xxxxxx

DE Sequence 1, Application US/09036582A

CC Sequence 1, Application US/09036582A

CC Patent No. 5965381

CC GENERAL INFORMATION:

CC APPLICANT: van der Bruggen, Pierre

CC APPLICANT: Cornelis, Guy R.

CC TITLE OF INVENTION: DELIVERY OF PROTEINS INTO EUKARYOTIC CELLS

CC FILE REFERENCE: 11154

CC CURRENT APPLICATION NUMBER: US/09/036,582A

CC CURRENT FILING DATE: 1998-03-06

CC NUMBER OF SEQ ID NOS: 39

CC SOFTWARE: PatentIn ver. 2.0

CC SEQ ID NO 1

CC LENGTH: 9

CC TYPE: PRT

CC ORGANISM: Human MAGS-1 peptide

CC SEQUENCE 9 AA; 976 MW; 576 CN;

Query Match 100.0%; Score 61; DB 2; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.24e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

Qy 1 EADPTGHSY 9

RESULT 2

ID US-08-986-234-1 STANDARD; PRT; 9 AA.

XX AC xxxxxx

DE Sequence 1, Application US/08986234

CC Sequence 1, Application US/08986234

CC Patent No. 5981706

CC GENERAL INFORMATION:
CC APPLICANT: Wallen, et al.
CC TITLE OF INVENTION: Methods for Synthesizing Heat Shock Protein Complexes
CC FILE REFERENCE: UNME-0008-1
CC CURRENT APPLICATION NUMBER: US/08/986,234
CC CURRENT FILING DATE: 1997-12-05
CC NUMBER OF SEQ ID NOS: 114
CC SOFTWARE: Patentin ver. 2.0
CC SEQ ID NO 1
CC LENGTH: 9
CC TYPE: PRT
CC ORGANISM: human
CC SEQUENCE 9 AA; 976 MW; 576 CN;
SQ

Query Match 100.0%; Score 61; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
| | | | | | | | |
QY 1 EADPTGHSY 9

RESULT 3
ID US-07-938-334C-1 STANDARD; PRT; 9 AA.
XX
AC xxxxxx
XX
DT
XX
XX

Sequence 1, Application US/07938334C
Patent No. 5405940
GENERAL INFORMATION:
APPLICANT: Boon, Thierry; van der Bruggen, Pierre;
APPLICANT: De Plaen, Etienne; Lurquin Christophe; Traversari, Catia
TITLE OF INVENTION: ISOLATED NONAPEPTIDES DERIVED FROM
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: Felfe & Lynch
STREET: 805 Third Avenue
CITY: New York City
STATE: New York
COUNTRY: USA
ZIP: 10022
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: Wordperfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/938,334C
FILING DATE: 31-AUG-1992
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Hanson, No. 5405940man D.
REGISTRATION NUMBER: 30,946
REFERENCE/DOCKET NUMBER: LUD 293
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 688-9200
TELEFAX: (212) 838-3884
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acid residues
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
FEATURE:
NAME/KEY: MAGE-1 derived nonapeptide
SEQUENCE 9 AA; 976 MW; 576 CN;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
| | | | | | | | |
QY 1 EADPTGHSY 9

RESULT 4
ID US-08-443-341-12 STANDARD; PRT; 9 AA.
XX
AC xxxxxx
XX
DT
XX
XX

Sequence 12, Application US/08443341
Patent No. 5695994
GENERAL INFORMATION:
APPLICANT: Boon-Falleur, Thierry
APPLICANT: van der Bruggen, Pierre
APPLICANT: De Plaen, Etienne
APPLICANT: Lurquin, Christophe
APPLICANT: Traversari, Catia
APPLICANT: Gaugler, Beatrice
APPLICANT: Van den Eynde, Benoit
TITLE OF INVENTION: ISOLATED NONAPEPTIDES DERIVED FROM
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: Felfe & Lynch
STREET: 805 Third Avenue
CITY: New York City
STATE: New York
COUNTRY: USA
ZIP: 10022
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: Wordperfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/443,341
FILING DATE: 17-MAY-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/073,103
FILING DATE: 7-JUNE-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/938,334
FILING DATE: 31-AUG-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/037,230
FILING DATE: 26-MARCH-1993
ATTORNEY/AGENT INFORMATION:
NAME: Hanson, No. 5695994man D.
REGISTRATION NUMBER: 30,946
REFERENCE/DOCKET NUMBER: LUD 5293.5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 688-9200
TELEFAX: (212) 838-3884
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE 9 AA; 976 MW; 576 CN;
SQ

Query Match 100.0%; Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 5
ID US-08-787-547-49 STANDARD; PRT; 9 AA.

AC xxxxxx

DT

DE

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 5
ID US-08-787-547-49 STANDARD; PRT; 9 AA.

AC xxxxxx

DT

DE

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 5
ID US-08-787-547-49 STANDARD; PRT; 9 AA.

AC xxxxxx

DT

DE

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 5
ID US-08-787-547-49 STANDARD; PRT; 9 AA.

AC xxxxxx

DT

DE

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 5
ID US-08-787-547-49 STANDARD; PRT; 9 AA.

AC xxxxxx

DT

DE

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 5
ID US-08-787-547-49 STANDARD; PRT; 9 AA.

AC xxxxxx

DT

DE

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 5
ID US-08-787-547-49 STANDARD; PRT; 9 AA.

AC xxxxxx

DT

DE

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 5
ID US-08-787-547-49 STANDARD; PRT; 9 AA.

AC xxxxxx

DT

DE

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

CC Patent No. 6037135

CC GENERAL INFORMATION:

CC APPLICANT: Kubo, Ralph T.

CC APPLICANT: Grey, Howard M.

CC APPLICANT: Sette, Alessandro

CC APPLICANT: Celis, Esteban

CC TITLE OF INVENTION: HLA Binding peptides and Their

CC TITLE OF INVENTION: Uses

CC NUMBER OF SEQUENCES: 1254

CC CORRESPONDENCE ADDRESS:

CC ADDRESSES: Townsend and Townsend and Crew LLP

CC STREET: Two Embarcadero Center, Eighth Floor

CC CITY: San Francisco

CC STATE: CA

CC COUNTRY: USA

CC ZIP: 94111-3834

CC COMPUTER READABLE FORM:

CC MEDIUM TYPE: Diskette

CC COMPUTER: IBM Compatible

CC OPERATING SYSTEM: DOS

CC SOFTWARE: FASTSEQ for Windows Version 2.0

CC CURRENT APPLICATION DATA:

CC APPLICATION NUMBER: US/08/159,339A

CC FILING DATE: 29-NOV-1993

CC CLASSIFICATION: 424

CC PRIOR APPLICATION DATA:

CC APPLICATION NUMBER: US 07/926,666

CC FILING DATE: 07-AUG-1992

CC APPLICATION NUMBER: US 08/027,746

CC FILING DATE: 05-MAR-1993

CC APPLICATION NUMBER: US 08/103,396

CC FILING DATE: 06-AUG-1993

CC ATTORNEY/AGENT INFORMATION:

CC NAME: Weber, Ellen Lauver

CC REGISTRATION NUMBER: 32,762

CC REFERENCE/DOCKET NUMBER: 018623-005030US

CC TELECOMMUNICATION INFORMATION:

CC TELEPHONE: (415) 576-0200

CC TELEFAX: (415) 576-0300

CC TELEX:

CC INFORMATION FOR SEQ ID NO: 99:

CC SEQUENCE CHARACTERISTICS:

CC LENGTH: 9 amino acids

CC TYPE: amino acid

CC STRANDEDNESS: single

CC TOPOLOGY: linear

CC MOLECULE TYPE: peptide

CC SEQUENCE 9 AA: 976 MW; 576 CN;

Query Match 100.0%; Score 61; DB 3; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.24e-01;

Matches 9; Conservative 0; Mismatches 0; Indel

Db 1 EADPTGHSY 9

1 EADPTGHSY 9

RESULT 8

ID US-08-354-679C-12 STANDARD; PRT; 9 AA.

XX xxxxxx

XX

XX

XX

XX

XX Sequence 12, Application US/08354679C

XX

XX Sequence 12, Application US/08354679C

CC Patent No. 6034214

CC GENERAL INFORMATION:

CC APPLICANT: Boon, Thierry; van der Bruggen, Pierre;

CC APPLICANT: De Plaen, Etienne; Lurquin Christophe;

CC TITLE OF INVENTION: ISOLATED NONAPEPTIDES DERIVED

CC	TITLE OF INVENTION:	MAGE GENES AND USES THEREOF
CC	NUMBER OF SEQUENCES:	25
CC	CORRESPONDENCE ADDRESS:	
CC	ADDRESSEE:	Felfe & Lynch
CC	STREET:	805 Third Avenue
CC	CITY:	New York City
CC	STATE:	New York
CC	COUNTRY:	USA
CC	ZIP:	10022
CC	COMPUTER READABLE FORM:	
CC	MEDIUM TYPE:	Diskette, 3.5 inch, 1.44 mb storage
CC	COMPUTER:	IBM PS/2
CC	OPERATING SYSTEM:	PC-DOS
CC	SOFTWARE:	Wordperfect
CC	CURRENT APPLICATION DATA:	
CC	APPLICATION NUMBER:	US/08/354,679C
CC	FILING DATE:	13-DECEMBER-1994
CC	CLASSIFICATION:	530
CC	PRIOR APPLICATION DATA:	
CC	APPLICATION NUMBER:	07/938,334
CC	FILING DATE:	31-AUGUST-1992
CC	ATTORNEY/AGENT INFORMATION:	
CC	NAME:	BAER, MADELINE F.
CC	REGISTRATION NUMBER:	36,437
CC	REFERENCE/DOCKET NUMBER:	LUD 5293.2
CC	TELECOMMUNICATION INFORMATION:	
CC	TELEPHONE:	(212) 688-9200
CC	TELEFAX:	(212) 838-3884
CC	INFORMATION FOR SEQ ID NO:	12:
CC	SEQUENCE CHARACTERISTICS:	
CC	LENGTH:	9 amino acids
CC	TYPE:	amino acid
CC	STRANDEDNESS:	single
CC	TOPOLOGY:	linear
CC	MOLECULE TYPE:	protein
CC	SEQUENCE	9 AA; 976 MW; 576 CN;
SQ		
	Query Match	100.0%; Score 61; DB 3; Length 9;
	Best Local Similarity	100.0%; Pred. No. 1,24e-01;
	Matches	9; Conservative 0; Mismatches 0; Indel
Db	1 EADPTGHSY	9
Qy	1 EADPTGHSY	9
RESULT	9	
ID	US-08-902-516-21	STANDARD; PRT; 9 AA.
XX		
AC	xxxxxx	
XX		
DT		
XX		
XX		
DE	Sequence 21, Application US/08902516	
XX		
CC	Sequence 21, Application US/08902516	
CC	Patent No. 5891432	
CC	GENERAL INFORMATION:	
CC	APPLICANT:	Soo Hoo, William
CC	TITLE OF INVENTION:	MEMBRANE-BOUND CYTOKINE COMPOS
CC	TITLE OF INVENTION:	COMPRISING GM-CSF AND METHODS S
CC	TITLE OF INVENTION:	RESPONSE USING SAME
CC	NUMBER OF SEQUENCES:	50
CC	CORRESPONDENCE ADDRESS:	
CC	ADDRESS:	CAMPBELL & FLORES, LLP
CC	STREET:	4370 La Jolla Village Drive, Suite 700
CC	CITY:	San Diego
CC	STATE:	California
CC	COUNTRY:	United States
CC	ZIP:	92121
CC	COMPUTER READABLE FORM:	
CC	MEDIUM TYPE:	Floppy disk
CC	COMPUTER:	IBM PC compatible

CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patent In Release #1.0, Version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/902,516
CC FILING DATE: 29-JUL-1997
CC CLASSIFICATION: 424
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Campbell, Cathryn A.
CC REGISTRATION NUMBER: 31,815
CC REFERENCE/DOCKET NUMBER: P-IM 2442
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (619)535-9001
CC TELEFAX: (619)535-8949
CC INFORMATION FOR SEQ ID NO: 21:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 9 amino acids
CC TYPE: amino acid
CC TOPOLOGY: linear
CC MOLECULE TYPE: peptide
CC SEQUENCE 9 AA; 976 MW; 576 CN;
SQ

Query Match 100.0%; Score 61; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 10
ID US-08-142-368A-26 STANDARD; PRT; 9 AA.
XX
AC xxxxxx
XX
DT
XX
XX
Sequence 26, Application US/08142368A
DE
XX
Sequence 26, Application US/08142368A
CC
Patent No. 5925729
CC
GENERAL INFORMATION:
CC APPLICANT: Boon-Falleur, Thierry; Van der Bruggen, Thierry;
CC APPLICANT: Van den Eynde, Beno t; Van Pel, Aline; De plaen, Etienne;
CC APPLICANT: Lurquin, Christophe; Chomez, Patrick; Traversari, Catia
CC TITLE OF INVENTION: Tumor Rejection Antigen Precursors, Tumor
CC TITLE OF INVENTION: Rejection Antigens and Uses Thereof
CC NUMBER OF SEQUENCES: 26
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Felfe & Lynch
CC STREET: 805 Third Avenue
CC CITY: New York City
CC STATE: New York
CC ZIP: 10022
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
CC COMPUTER: IBM
CC OPERATING SYSTEM: PC-DOS
CC SOFTWARE: wordperfect
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/142,368A
CC FILING DATE: 02-MAY-1994
CC CLASSIFICATION: 435
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: PCT/US92/04354
CC FILING DATE: 22-MAY-1992
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 07/807,043
CC FILING DATE: 12-DECEMBER-1991
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 07/764,364
CC FILING DATE: 23-SEPTEMBER-1991
CC PRIOR APPLICATION DATA:

CC APPLICATION NUMBER: 07/728,838
CC APPLICATION NUMBER: 9-JULY-1991
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 07/705,702
CC FILING DATE: 23-May-1991
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Hanson, No. 5925729man D.
CC REGISTRATION NUMBER: 30,946
CC REFERENCE/DOCKET NUMBER: LUD 5253.4-US
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (212) 688-9200
CC TELEFAX: (212) 838-3884
CC INFORMATION FOR SEQ ID NO: 26:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 9 amino acids
CC TYPE: amino acids
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC SEQUENCE 9 AA; 976 MW; 576 CN;
SQ

Query Match 100.0%; Score 61; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 11
ID PCT-US95-04975-2 STANDARD; PRT; 9 AA.
XX
AC xxxxxx
XX
DT
XX
XX
Sequence 2, Application PC/TUS9504975
DE
XX
Sequence 2, Application PC/TUS9504975
CC
GENERAL INFORMATION:
CC APPLICANT: Dyall, Rubendra
CC TITLE OF INVENTION: INDUCTION OF CYTOTOXIC T LYMPHOCYTES (CTL)USING
CC TITLE OF INVENTION: ANTIGENIC PEPTIDES AND A SUITABLE ADJUVANT
CC NUMBER OF SEQUENCES: 19
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Cooper & Dunham LLP
CC STREET: 1185 Avenue of the Americas
CC CITY: New York
CC STATE: New York
CC COUNTRY: USA
CC ZIP: 10036
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patent In Release #1.24
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: PCT/US95/04975
CC FILING DATE:
CC CLASSIFICATION:
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 08/233,496
CC FILING DATE: April 22, 1994
CC ATTORNEY/AGENT INFORMATION:
CC NAME: White Esq., John P.
CC REGISTRATION NUMBER: 28,678
CC REFERENCE/DOCKET NUMBER: 45059/JPW/MS/AMB
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: 212-278-0400
CC TELEFAX: 212-391-0525
CC INFORMATION FOR SEQ ID NO: 2:
CC SEQUENCE CHARACTERISTICS:

CC LENGTH: 9 amino acids
CC TYPE: amino acids
CC TOPOLOGY: linear
CC MOLECULE TYPE: peptide
CC HYPOTHETICAL: N
CC ANTI-SENSE: N
SQ SEQUENCE 9 AA; 976 MW; 576 CN;

Query Match 100.0%; Score 61; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
| | | | |
QY 1 EADPTGHSY 9

RESULT 12
ID PCT-US95-02121-1 STANDARD; PRT; 9 AA.
XX
AC xxxxxx
XX
XX
DT
XX
XX

DE Sequence 1, Application PC/TUS9502121

XX Sequence 1, Application PC/TUS9502121

CC GENERAL INFORMATION:

CC APPLICANT: COMPOSITIONS AND METHODS FOR ELICITING

CC TITLE OF INVENTION: CTL IMMUNITY

CC NUMBER OF SEQUENCES: 153

CC COMPUTER READABLE FORM:

CC MEDIUM TYPE: Floppy disk

CC COMPUTER: IBM PC compatible

CC OPERATING SYSTEM: PC-DOS/MS-DOS

CC SOFTWARE: Patent In Release #1.0, Version #1.25

CC CURRENT APPLICATION DATA:

CC APPLICATION NUMBER: PCT/US95/02121

CC FILING DATE: 16-FEB-1995

CC CLASSIFICATION:

CC PRIOR APPLICATION DATA:

CC APPLICATION NUMBER: US 08/197,484

CC FILING DATE: 16-FEB-1994

CC PRIOR APPLICATION DATA: US 07/935,811

CC APPLICATION NUMBER: 31,990

CC FILING DATE: 26-AUG-1992

CC APPLICATION DATA:

CC APPLICATION NUMBER: US 07/874,491

CC FILING DATE: 27-APR-1992

CC PRIOR APPLICATION DATA:

CC APPLICATION NUMBER: US 07/827,682

CC FILING DATE: 29-JAN-1992

CC APPLICATION DATA:

CC APPLICATION NUMBER: US 07/749,568

CC FILING DATE: 26-AUG-1991

CC ATTORNEY/AGENT INFORMATION:

CC NAME: Parmelee, Steven W.

CC REGISTRATION NUMBER: 31,990

CC REFERENCE/DOCKET NUMBER: 14137-26-4PC

CC TELECOMMUNICATION INFORMATION:

CC TELEPHONE: (206) 467-9600

CC TELEFAX: (415) 543-5043

CC INFORMATION FOR SEQ ID NO: 1:

CC SEQUENCE CHARACTERISTICS:

CC LENGTH: 9 amino acids

CC TYPE: amino acid

CC STRANDEDNESS: unknown

CC TOPOLOGY: unknown

CC MOLECULE TYPE: peptide

CC SEQUENCE 9 AA; 976 MW; 576 CN;

Query Match 100.0%; Score 61; DB 4; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
| | | | |
QY 1 EADPTGHSY 9

RESULT 13
ID US-08-299-849B-26 STANDARD; PRT; 9 AA.
XX
AC xxxxxx
XX
XX
DT
XX
XX

DE Sequence 26, Application US/08299849B

XX Sequence 26, Application US/08299849B

CC Patent No. 5612201

CC GENERAL INFORMATION:

CC APPLICANT: De Plaen, Etienne; Boon-Falleur, Thierry;

CC APPLICANT: Leth, Bernard; Szikora, Jean-Pierre; De Smet, Charles;

CC APPLICANT: Chomez, Patrick

CC TITLE OF INVENTION: Isolated Nucleic Acid Molecules Useful In

CC TITLE OF INVENTION: Determining Expression Of A Tumor Antigen Precursor

CC NUMBER OF SEQUENCES: 48

CC CORRESPONDENCE ADDRESS:

CC ADDRESSEE: Felfe & Lynch

CC STREET: 805 Third Avenue

CC CITY: New York City

CC STATE: New York

CC ZIP: 10022

CC COMPUTER READABLE FORM:

CC MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage

CC COMPUTER: IBM

CC OPERATING SYSTEM: PC-DOS

CC SOFTWARE: Wordperfect

CC CURRENT APPLICATION DATA:

CC APPLICATION NUMBER: US/08/299,849B

CC FILING DATE: 1-SEPTEMBER-1994

CC CLASSIFICATION: 435

CC PRIOR APPLICATION DATA:

CC APPLICATION NUMBER: 08/037,230

CC FILING DATE: 26-MARCH-1993

CC PRIOR APPLICATION DATA:

CC APPLICATION NUMBER: PCT/US92/04354

CC FILING DATE: 22-MAY-1992

CC PRIOR APPLICATION DATA:

CC APPLICATION NUMBER: 07/807,043

CC FILING DATE: 12-DECEMBER-1991

CC PRIOR APPLICATION DATA:

CC APPLICATION NUMBER: 07/764,364

CC FILING DATE: 23-SEPTEMBER-1991

CC PRIOR APPLICATION DATA:

CC APPLICATION NUMBER: 07/728,838

CC FILING DATE: 9-JULY-1991

CC PRIOR APPLICATION DATA:

CC APPLICATION NUMBER: 07/705,702

CC FILING DATE: 23-MAY-1991

CC ATTORNEY/AGENT INFORMATION:

CC NAME: Hanson, No. 5612201man D.

CC REGISTRATION NUMBER: 30,946

CC REFERENCE/DOCKET NUMBER: LOD 5355

CC TELECOMMUNICATION INFORMATION:

CC TELEPHONE: (212) 688-9200

CC TELEFAX: (212) 838-3884

CC INFORMATION FOR SEQ ID NO: 26:

CC SEQUENCE CHARACTERISTICS:

CC LENGTH: 9 amino acids

CC TYPE: amino acids

CC TOPOLOGY: linear

CC MOLECULE TYPE: protein

CC SEQUENCE 9 AA; 976 MW; 576 CN;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
| | | | |
QY 1 EADPTGHSY 9

RESULT 14
ID US-08-498-461-4 STANDARD; PRT; 9 AA.
XX
AC xxxxxx
XX
DT

Sequence 4, Application US/08498461
Patent No. 5827073
GENERAL INFORMATION:
CC APPLICANT: Idescher, Immanuel; Anjuere, Fabienne;
CC APPLICANT: Layer, Andreas; Romero, Pedro; Cerottini, Jean-Charles
CC TITLE OF INVENTION: Photoreactive Peptide Derivatives
CC NUMBER OF SEQUENCES: 16
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Felfe & Lynch
CC STREET: 805 Third Avenue
CC CITY: New York City
CC STATE: New York
CC ZIP: 10022

COMPUTER READABLE FORM:
CC MEDIUM TYPE: Diskette, 3.5 inch, 1.44 kb storage
CC COMPUTER: IBM
CC OPERATING SYSTEM: PC-DOS
CC SOFTWARE: Wordperfect
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/498.461
CC FILING DATE: 5-JULY-1995
CC CLASSIFICATION: 435
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Hanson, No. 5827073man D.
CC REGISTRATION NUMBER: 30,946
CC REFERENCE/DOCKET NUMBER: LUD 5403
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (212) 688-9200
CC TELEFAX: (212) 838-3884
CC INFORMATION FOR SEQ ID NO: 4:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 9 amino acids
CC TYPE: amino acid
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC SEQUENCE 9 AA; 976 MW; 576 CN;

Query Match 100.0%; Score 61; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
| | | | |
QY 1 EADPTGHSY 9

RESULT 15
ID US-08-967-727-26 STANDARD; PRT; 9 AA.
XX
AC xxxxxx
XX
XX
DT
XX
DE
XX

Sequence 26, Application US/08967727

Sequence 26, Application US/08967727
Patent No. 6025474
GENERAL INFORMATION:
CC APPLICANT: Gaugler, B atrice; Van den Eynde, Beno t;
CC APPLICANT: van der Bruggen, Pierre; Boon-Falleur, Thierry
CC TITLE OF INVENTION: Isolated Nucleic Acid Molecules Coding For
CC TITLE OF INVENTION: Tumor Rejection Antigen Precursor Mage-3 And Uses There
CC NUMBER OF SEQUENCES: 30
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Felfe & Lynch
CC STREET: 805 Third Avenue
CC CITY: New York City
CC STATE: New York
CC ZIP: 10022
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
CC COMPUTER: IBM
CC OPERATING SYSTEM: PC-DOS
CC SOFTWARE: Wordperfect
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/967,727
CC FILING DATE:
CC CLASSIFICATION: 435
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 08/037,230
CC FILING DATE: 26-MARCH-1993
CC APPLICATION NUMBER: PCT/US92/04354
CC FILING DATE: 22-MAY-1992
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 07/807,043
CC FILING DATE: 12-DECEMBER-1991
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 07/764,365
CC FILING DATE: 23-SEPTEMBER-1991
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 07/728,838
CC FILING DATE: 9-JULY-1991
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 07/705,702
CC FILING DATE: 23-MAY-1991
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Hanson, No. 6025474man D.
CC REGISTRATION NUMBER: 30,946
CC REFERENCE/DOCKET NUMBER: LUD 5353
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (212) 688-9200
CC TELEFAX: (212) 838-3884
CC INFORMATION FOR SEQ ID NO: 26:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 9 amino acids
CC TYPE: amino acids
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC SEQUENCE 9 AA; 976 MW; 576 CN;

Query Match 100.0%; Score 61; DB 3; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
| | | | |
QY 1 EADPTGHSY 9

RESULT 16
ID US-08-186-266-1 STANDARD; PRT; 9 AA.
XX
AC xxxxxx
XX
XX
DT
XX
DE
XX

Sequence 1, Application US/08186266

Sequence 1, Application US/08186266
Patent No. 5662907
GENERAL INFORMATION:
APPLICANT: KURO, Ralph T.
APPLICANT: GREY, Howard M.
APPLICANT: SETTE, Alessandro
APPLICANT: CELIS, Esceban
TITLE OF INVENTION: INDUCTION OF ANTI-TUMOR CYTOTOXIC
TITLE OF INVENTION: T LYMPHOCYTES IN HUMANS USING
TITLE OF INVENTION: SYNTHETIC PEPTIDE EPITOPES
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Khourie and Crew
STREET: Stuart Street Tower, One Market Plaza
CITY: San Francisco
STATE: California
COUNTRY: US
ZIP: 94105-1493
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/186,266
FILING DATE: 25-JAN-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/159,339
FILING DATE: 29-NOV-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/103,396
FILING DATE: 06-AUG-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/027,746
FILING DATE: 05-MAR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/926,666
FILING DATE: 07-AUG-1992
ATTORNEY/AGENT INFORMATION:
NAME: Bastian, Kevin L.
REGISTRATION NUMBER: 34,774
REFERENCE/DOCKET NUMBER: 14137-50-4
TELEPHONE: (415) 543-9600
TELEFAX: (415) 543-5043
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
SEQUENCE 9 AA; 976 MW; 576 CN;
Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9
RESULT 17
ID US-08-602-506A-25 STANDARD; PRT; 10 AA.
XX
AC xxxxxx
DT
DE Sequence 25, Application US/08602506A
XX Sequence 25, Application US/08602506A

Patent No. 6060257
GENERAL INFORMATION:
APPLICANT: Herman, Jean; Coulie, Pierre;
APPLICANT: Boon-Falleur, Thierry; van der Bruggen, Pierre;
APPLICANT: Luescher, Immanuel.
TITLE OF INVENTION: Tumor Rejection Antigens Presented By HLA-
TITLE OF INVENTION: B44 Molecules, And Uses Thereof
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Felfe & Lynch
STREET: 805 Third Avenue
CITY: New York City
STATE: New York
ZIP: 10022
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch, 360 kb storage
COMPUTER: IBM
OPERATING SYSTEM: PC-DOS
SOFTWARE: Wordperfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/602,506A
FILING DATE: 20-FEBRUARY-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/531,864
FILING DATE: 21-SEPTEMBER-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,636
FILING DATE: 17-JANUARY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/253,503
FILING DATE: 3-JUNE-1994
ATTORNEY/AGENT INFORMATION:
NAME: Hanson, No. 6060257man D.
REGISTRATION NUMBER: 30,946
REFERENCE/DOCKET NUMBER: LUD 5436
TELEPHONE: (212) 688-9200
TELEFAX: (212) 838-3884
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
FEATURE:
NAME/KEY: MAGE-1/HLA-B44
SEQUENCE 10 AA; 1104 MW; 684 CN;
Query Match 100.0%; Score 61; DB 3; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Db 2 EADPTGHSY 10
QY 1 EADPTGHSY 9
RESULT 18
ID US-08-796-883-25 STANDARD; PRT; 10 AA.
XX
AC xxxxxx
DT
DE Sequence 25, Application US/08796883
XX Sequence 25, Application US/08796883
Patent No. 5744353
GENERAL INFORMATION:
APPLICANT: Herman, Jean; Coulie, Pierre;
APPLICANT: Boon-Falleur, Thierry; van der Bruggen, Pierre;
APPLICANT: Luescher, Immanuel.


```

CC CLASSIFICATION: 514
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: US/08/190,411
CC FILING DATE: 01-FEBRUARY-1994
CC APPLICATION NUMBER: 037,230
CC FILING DATE: 26-MARCH-1993
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: PCT/US92/04354
CC FILING DATE: 22-MAY-1992
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 07/807,043
CC FILING DATE: 12-DECEMBER-1991
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 07/764,364
CC FILING DATE: 23-SEPTEMBER-1991
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 07/705,702
CC FILING DATE: 23-MAY-1991
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Hanson, No. 5843448man D.
CC REGISTRATION NUMBER: 30,946
CC REFERENCE/DOCKET NUMBER: LUD 5354
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (212) 688-9200
CC TELEFAX: (212) 838-3884
CC INFORMATION FOR SEQ ID NO: 4:
CC SEQUENCE CHARACTERISTICS:
CC TYPE: amino acid
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC SEQUENCE 12 AA; 1318 MW; 944 CN;

Query Match 100.0%; Score 61; DB 2; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 4 EADPTGHSY 12
QY 1 EADPTGHSY 9

RESULT 21
XX US-08-190-411A-4 STANDARD; PRT: 12 AA.
XX AC xxxxxx
XX DT
XX DE
XX SEQUENCE 4, Application US/08190411A
XX Patent No. 5541104
XX GENERAL INFORMATION:
XX APPLICANT: Chen, Yao-Tseng; Stockert, Elisabeth;
XX APPLICANT: Chen, Yachi; Garin-Chesa, Pilar; Rettig, Wolfgang J.;
XX APPLICANT: van der Bruggen, Pierre; Boon-Falleur, Thierry;
XX APPLICANT: Old, Lloyd J.
XX TITLE OF INVENTION: MONOCLONAL ANTIBODIES WHICH BIND TO
XX TITLE OF INVENTION: TUMOR REJECTION ANTIGEN PRECURSOR MAGE-1, RECOMBINANT MAGE
XX TITLE OF INVENTION: AND MAGE-1 DERIVED IMMUNOGENIC PEPTIDES
XX NUMBER OF SEQUENCES: 4
XX CORRESPONDENCE ADDRESS:
XX ADDRESSEE: Felie & Lynch
XX STREET: 805 Third Avenue
XX CITY: New York City
XX STATE: New York
XX ZIP: 10022
XX COMPUTER READABLE FORM:
XX MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage

```

```

CC COMPUTER: IBM
CC OPERATING SYSTEM: PC-DOS
CC SOFTWARE: Wordperfect
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/190,411A
CC FILING DATE: 01-FEBRUARY-1994
CC CLASSIFICATION: 436
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 037,230
CC FILING DATE: 26-MARCH-1993
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: PCT/US92/04354
CC FILING DATE: 22-MAY-1992
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 07/807,043
CC FILING DATE: 12-DECEMBER-1991
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 07/764,364
CC FILING DATE: 23-SEPTEMBER-1991
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 07/728,838
CC APPLICATION NUMBER: 9-JULY-1991
CC APPLICATION NUMBER: 07/705,702
CC FILING DATE: 23-MAY-1991
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Hanson, No. 5541104man D.
CC REGISTRATION NUMBER: 30,946
CC REFERENCE/DOCKET NUMBER: LUD 5354
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (212) 688-9200
CC TELEFAX: (212) 838-3884
CC INFORMATION FOR SEQ ID NO: 4:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 12 amino acid residues
CC TYPE: amino acid
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC SEQUENCE 12 AA; 1318 MW; 944 CN;

Query Match 100.0%; Score 61; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 4 EADPTGHSY 12
QY 1 EADPTGHSY 9

RESULT 22
XX US-08-465-167A-24 STANDARD; PRT: 309 AA.
XX AC xxxxxx
XX DT
XX DE
XX SEQUENCE 24, Application US/08465167A
XX Patent No. 5750395
XX GENERAL INFORMATION:
XX APPLICANT: Fikes, John D.
XX APPLICANT: Livingston, Brian D.
XX APPLICANT: Sette, Alessandro D.
XX APPLICANT: Sidney, John C.
XX TITLE OF INVENTION: DNA ENCODING MAGE-1 C-TERMINAL
XX TITLE OF INVENTION: IMMUNOGENIC PEPTIDES (as amended)
XX NUMBER OF SEQUENCES: 51
XX CORRESPONDENCE ADDRESS:
XX ADDRESSEE: Townsend and Crew LLP
XX STREET: Two Embarcadero Center, 8th Floor
XX CITY: San Francisco
XX STATE: CA

```


CC TYPE: amino acids
CC STRANDEDNESS: single stranded
CC TOPOLOGY: linear
SQ SEQUENCE 309 AA; 34342 MW; 512752 CN;
Query Match 100.0%; Score 61; DB 3; Length 309;
Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Db 161 EADPTGHSY 169
QY 1 EADPTGHSY 9
|||||||

Search completed: Wed Sep 13 07:14:50 2000
Job time : 8 secs.

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2000, 01:41:38 ; Search time 6530.16 seconds
(without alignments)
1550.707 Million cell updates/sec

Title: US-08-819-669E-8
Perfect score: 5674
Sequence: 1 CCGGGGACCACTGGCATC.....TAATGATCTTGGTGGATCC 5674

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 972840 seqs, 892348106 residues

Total number of hits satisfying chosen parameters: 1945680

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

GenEmbl:*

1: gb_ba1:*
2: gb_ba2:*
3: gb_om:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl1:*
9: gb_pl2:*
10: gb_pr1:*
11: gb_pr2:*
12: gb_ro:*
13: gb_sts:*
14: gb_sy:*
15: gb_un:*
16: em_fun:*
17: em_hum1:*
18: em_hum2:*
19: em_in:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl1:*
26: em_ro:*
27: em_sts:*
28: em_sy:*
29: em_un:*
30: em_vil:*
31: gb_htg1:*
32: gb_htg2:*
33: gb_in1:*
34: gb_in2:*
35: em_ba1:*
36: em_ba2:*
37: em_hum3:*
38: em_hum4:*
39: gb_pr4:*
40: gb_htg3:*
41: gb_htg4:*
42: gb_htg5:*
43: gb_htg6:*

44: gb_htg7:*
45: em_htg1:*
46: em_htg2:*
47: em_htg3:*
48: em_hum5:*
49: gb_pl3:*
50: gb_pr5:*
51: gb_htg8:*
52: gb_htg9:*
53: gb_htg10:*
54: gb_htg11:*
55: gb_htg12:*
56: gb_htg13:*
57: gb_htg14:*
58: gb_in3:*
59: gb_htg15:*
60: gb_htg16:*
61: gb_htg17:*
62: em_htg4:*
63: em_htg5:*
64: em_htg6:*
65: em_htg7:*
66: em_hum6:*
67: gb_htg18:*
68: gb_htg19:*
69: gb_htg20:*
70: gb_htg21:*
71: gb_htg22:*
72: gb_htg23:*
73: gb_htg24:*
74: gb_htg25:*
75: gb_htg26:*
76: gb_htg27:*
77: gb_htg28:*
78: gb_htg29:*
79: gb_htg30:*
80: gb_htg31:*
81: gb_vil:*
82: gb_vil2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB	ID	Description
1	5674	100.0	5674	5	AR060975	AR060975 Sequence
2	5674	100.0	5674	5	I24013	I24013 Sequence1
3	5674	100.0	5674	5	I36923	I36923 Sequence1
C	5566.2	98.1	275159	50	U82670	U82670 Homo sapien
C	5532.6	97.5	156854	48	HSU82672	U82672 Human chrom
6	2777.2	48.9	49375	39	AF134576	AF134576 Homo sapi
7	2655	46.8	11495	10	HSU10687	U10687 Human MAGE-
8	2653.2	46.8	158898	11	U82696	U82696 Homo sapien
9	2513.6	44.3	4895	10	HSU10688	U10688 Human MAGE-
10	2429.6	42.8	4736	10	HSU10690	U10690 Human MAGE-
11	2422.8	42.7	4741	10	HSU10689	U10689 Human MAGE-
12	2419	42.6	2419	5	I36922	I36922 Sequence1
13	2408	42.4	2420	5	AF007331	AF007331 Sequence
14	2408	42.4	2420	9	HUMMAG1A	M7481 Human antiq
15	2328	41.0	178515	74	AC009621	AC009621 Homo sapi
C	2307.6	40.7	37781	17	AF030261	AF030261 Homo sapi
17	2307.6	40.7	54155	37	HSAR2994	AF002994 Homo sapi
C	2307.6	40.7	302250	50	U82671	U82671 Homo sapien
19	2306	40.6	48574	37	HSAR2996	AF002996 Homo sapi
20	2306	40.6	302250	50	U82671	U82671 Homo sapien
C	2199.6	38.8	48574	37	HSAR2996	AF002996 Homo sapi
22	2117.8	37.3	4559	9	HUMMAGE2X	L18920 Human MAGE-
23	2058.8	36.3	4157	5	I36924	I36924 Sequence1
24	1945	34.3	4523	9	HUMMAGE12X	L18877 Human MAGE-

Wed Sep 13 06:09:05 2000

25	1762.6	31.1	4204	9	HSU03735	U03735	Human	MAGE-
26	1678.8	28.6	2531	5	I36928	I36928	Sequence 13	
27	1678.8	29.6	2531	5	I36929	I36929	Sequence 14	
28	1677	29.6	3871	11	HSU10691	U10691	Human	MAGE-
29	1556.6	27.4	43927	11	HSU69568	U69568	Human	XQ28
30	1555	27.4	118440	50	AC016939	U016939	Homo sapi	
31	1536.4	27.1	3680	10	HSU10692	U10692	Human	MAGE-
32	1535.2	27.1	111560	50	AC016940	U016940	Homo sapi	
33	1504.6	26.5	2305	5	I36932	I36932	Sequence 17	
34	1410.8	24.9	2226	5	I36931	I36931	Sequence 16	
35	1396.6	24.6	74299	50	AC016941	U016941	Homo sapi	
36	1353.8	23.9	73360	11	HSU66083	U66083	Human	cont1
37	1247.4	22.0	3839	10	HSU10693	U10693	Human	MAGE-
38	1226.6	21.6	2931	10	HSU10694	U10694	Human	MAGE-
39	1051	18.5	3672	10	HSU10686	U10686	Human	MAGE-
40	988.8	17.4	1640	5	I36926	I36926	Sequence 11	
41	955.8	16.8	165648	69	AC024727	U024727	Homo sapi	
42	900.2	15.9	1810	5	I36935	I36935	Sequence 20	
43	866	15.3	3510	10	HSU10685	U10685	Human	MAGE-
44	863.4	15.2	165648	69	AC024727	U024727	Homo sapi	
45	834.4	14.7	1094	5	AR052773	AR052773	Sequence	

ALIGNMENTS

[illegible]

Query Match	100.0%	Score	5674;	DB	5;	Length	5674;
Best Local Similarity	100.0%;	Pred.	No. 0;				
Matches	5674;	Conservative	0;	Mismatches	0;	Indels	0;
Gaps	0;						
QY	1	CCGGGACCACTGGCATCCTCCGCCCTACACCCCACAATCGCTCCCTTTAGCCACACC	60				
Db	1	CCGGGGCACCACTGGCATCCTCCGCCCTACACCCCACAATCGCTTTAGCCACACC	60				
QY	61	ATCCAACAATCTTACGCTCACCCCCAGCCCAAGCAGGCAGAATCGGTTCACCCCTTG	120				
Db	61	ATCCAACAATCTTACGCTCACCCCCAGCCCAAGCAGGCAGAATCGGTTCACCCCTTG	120				
QY	121	CTCTAACCCAGGGGAAGCCAGGTGCCAGATGTGACGCCACTGACTTGAGCATTAGTGG	180				
Db	121	CTCTAACCCAGGGGAAGCCAGGTGCCAGATGTGACGCCACTGACTTGAGCATTAGTGG	180				
QY	181	TTAGAGAGAAGCGAGTTTTTCGGTCTGAGGGGGCGCTTGAGATCGGTGAGGGAGACGGG	240				
Db	181	TTAGAGAGAAGCGAGTTTTTCGGTCTGAGGGGGCGCTTGAGATCGGTGAGGGAGACGGG	240				
QY	241	CCGAGCTGTGAAGGAGCAAGGTGACATGCTGAGGGAGGACTTGAGGACCCACTTACCCC	300				
Db	241	CCGAGCTGTGAAGGAGCAAGGTGACATGCTGAGGGAGGACTTGAGGACCCACTTACCCC	300				
QY	301	AGATAGAGACCCCAAATAATCCCTTCATGCGACTCTCTGSAOCCATCTGCTGTGTGACTTC	360				

Db	301	AGATAGAGGACCCCAAAATATCCCTTCATGCGAGTCCCTGGACCATCTGGTGGGACTTC	360
Qy	361	TCAGGCTGGGCCACCCCGACCCCTTGCTGCTTAAACCACTGGGGACTCGAACTCAGAG	420
Db	361	TCAGGCTGGGCCACCCCGACCCCTTGCTGCTTAAACCACTGGGGACTCGAACTCAGAG	420
Qy	421	CTCGGTGTATCAGSGAAGGGTGTCTTAGGAGAGGGCAGCGTCAGGCTCTGCCAGACAT	480
Db	421	CTCGGTGTATCAGSGAAGGGTGTCTTAGGAGAGGGCAGCGTCAGGCTCTGCCAGACAT	480
Qy	481	CATGCTCAGGATTTCTCAAGSAGGGGTGAGGGTCCCTAAGAGCCCACTCCCGTGACCCAAC	540
Db	481	CATGCTCAGGATTTCTCAAGSAGGGGTGAGGGTCCCTAAGAGCCCACTCCCGTGACCCAAC	540
Qy	541	CCCGACTCCAATGCTCACTCCCGTGACCCCAACCCCTCTTTCATTGTCTATTCACACCCCA	600
Db	541	CCCGACTCCAATGCTCACTCCCGTGACCCCAACCCCTCTTTCATTGTCTATTCACACCCCA	600
Qy	601	CCCGACATCCCGACCCCATCCCTCAACGCTGATGCCATCGGCCAGCCATTCACCCCT	660
Db	601	CCCGACATCCCGACCCCATCCCTCAACGCTGATGCCATCGGCCAGCCATTCACCCCT	660
Qy	661	CACCCACACCCACCCCGACCGCACCTCCACACCCCAACCCAGCAGCATCCGTTCCCG	720
Db	661	CACCCACACCCACCCCGACCGCACCTCCACACCCCAACCCAGCAGCATCCGTTCCCG	720
Qy	721	CCAGGAAACATCGGGTGCCGGATGTGACGCCACTGACTTGGCATTTGTGGGCAGAGA	780
Db	721	CCAGGAAACATCGGGTGCCGGATGTGACGCCACTGACTTGGCATTTGTGGGCAGAGA	780
Qy	781	GAAGCAGGTTTCCATTCTGAGGGACGGGTAGAGTTCGGCGGAAGAACCTGACCCAGG	840
Db	781	GAAGCAGGTTTCCATTCTGAGGGACGGGTAGAGTTCGGCGGAAGAACCTGACCCAGG	840
Qy	841	CTCTGTGAGGAGCAAGGTGAGAGGCTGAGGAGGACTGAGAGCCCGCCACTCCAAATA	900
Db	841	CTCTGTGAGGAGCAAGGTGAGAGGCTGAGGAGGACTGAGAGCCCGCCACTCCAAATA	900
Qy	901	GAGAGCCCAAAATATTCACGCCCCGCCCTTGCTGCCAGCCTGGCCCAACCCCGGGGAAG	960
Db	901	GAGAGCCCAAAATATTCACGCCCCGCCCTTGCTGCCAGCCTGGCCCAACCCCGGGGAAG	960
Qy	961	CGTCTCAGCCTGGCTGCCCGCAGACCCCTGCTCCAAAGCCTTGTAGAGACACCAAGTTC	1020
Db	961	CGTCTCAGCCTGGCTGCCCGCAGACCCCTGCTCCAAAGCCTTGTAGAGACACCAAGTTC	1020
Qy	1021	TTCTCCCAAGCTCTGGAATCAGAGTTGCTGTGACCAAGGCGAGGACTGGTTAGGAGAGG	1080
Db	1021	TTCTCCCAAGCTCTGGAATCAGAGTTGCTGTGACCAAGGCGAGGACTGGTTAGGAGAGG	1080
Qy	1081	GCAGGGCAGAGGCTGTGCCAGGCATCAAGATCAGCACCCCAAGAGGGAGGGCTGTGGGCC	1140
Db	1081	GCAGGGCAGAGGCTGTGCCAGGCATCAAGATCAGCACCCCAAGAGGGAGGGCTGTGGGCC	1140
Qy	1141	CCAAGACTGCACATCCCAATCCCACTCCCAACCCATTGCGATTCGCATTCGCCACCCAACC	1200
Db	1141	CCAAGACTGCACATCCCAATCCCACTCCCAACCCATTGCGATTCGCATTCGCCACCCAACC	1200
Qy	1201	CCATCTCTCAGCTACACCTCCACCCCGCATCCCTACTTCCTACTCTCGTCACTGACCAAC	1260
Db	1201	CCATCTCTCAGCTACACCTCCACCCCGCATCCCTACTTCCTACTCTCGTCACTGACCAAC	1260
Qy	1261	ACCGTCCAGCCCCAGCACCCAGCCCAAGCCCTTCTGCCACCTCAACCTCACTGCCCCCAAC	1320
Db	1261	ACCGTCCAGCCCCAGCACCCAGCCCAAGCCCTTCTGCCACCTCAACCTCACTGCCCCCAAC	1320
Qy	1321	CCCAACCTCATCTCTCATGTGCCCCACTCCCATTCGGCTCCGCCATCTGGCAGATCC	1380
Db	1321	CCCAACCTCATCTCTCATGTGCCCCACTCCCATTCGGCTCCGCCATCTGGCAGATCC	1380
Qy	1381	GGTTTGCCTCTGCTCTCAACCCAGGGAAGCCCTTGTTAGGCCCGCATGTGAACCACTGACT	1440

Db 1381 GGTGTGCCCTGTCTCAACCCAGGGAAGCCCTGGTAGGCCCGGATGTGAACCACTGACT 1440
QY 1441 TGAACCTCACAGATCTGAGAGAACCAGGTTTCATTTAATGGTCTGAGGGCGGCTTGAG 1500
Db 1441 TGAACCTCACAGATCTGAGAGAACCAGGTTTCATTTAATGGTCTGAGGGCGGCTTGAG 1500
QY 1501 ATCCACTGAGGGGAGTGGTTTTAGGCTCTGTGAGGAGGCAAGGTGAGATGCTGAGGGAGG 1560
Db 1501 ATCCACTGAGGGGAGTGGTTTTAGGCTCTGTGAGGAGGCAAGGTGAGATGCTGAGGGAGG 1560
QY 1561 ACTGAGGAGGCACACACCCAGGTAGATGGCCCCAAATGATCCAGTACCACCCCTGCTG 1620
Db 1561 ACTGAGGAGGCACACACCCAGGTAGATGGCCCCAAATGATCCAGTACCACCCCTGCTG 1620
QY 1621 CCAGCCTTGGACCAACCCGGCCAGGACAGATGCTCTCACTGGACCAACCCCGTCCCGTCC 1680
Db 1621 CCAGCCTTGGACCAACCCGGCCAGGACAGATGCTCTCACTGGACCAACCCCGTCCCGTCC 1680
QY 1681 CACTGCCACTTAAACCCACAGGCAATCTGTAGTCAATAGCTTATGTGACCGGGCAGGGTT 1740
Db 1681 CACTGCCACTTAAACCCACAGGCAATCTGTAGTCAATAGCTTATGTGACCGGGCAGGGTT 1740
QY 1741 GGTGAGGAGGAGGAGGAGGATCCAGGATCAAGTCCAGGATCCGCCGCAATAGGGTCAGG 1800
Db 1741 GGTGAGGAGGAGGAGGAGGATCCAGGATCAAGTCCAGGATCCGCCGCAATAGGGTCAGG 1800
QY 1801 ACCCTGAGGAGGAATGAGGTTTCCCAACCCACACCTGTCTCTCATCTCCCGCCACC 1860
Db 1801 ACCCTGAGGAGGAATGAGGTTTCCCAACCCACACCTGTCTCTCATCTCCCGCCACC 1860
QY 1861 CCACCTACATTCACATACCTACCCCTACCCCAACCTCATCTGTGACAGATCCCTGCTG 1920
Db 1861 CCACCTACATTCACATACCTACCCCTACCCCAACCTCATCTGTGACAGATCCCTGCTG 1920
QY 1921 TCAACCCACGAAACCCAGGGAATGGCGCCAGGCACTCGGATCTTGACCTCCCGCATCCA 1980
Db 1921 TCAACCCACGAAACCCAGGGAATGGCGCCAGGCACTCGGATCTTGACCTCCCGCATCCA 1980
QY 1981 GGGTCTGATGAGGAGAGGGCTTGAACAGGGCTCAGAGGGCTCAGGAGGAGGAGGAGGAGG 2040
Db 1981 GGGTCTGATGAGGAGAGGGCTTGAACAGGGCTCAGAGGGCTCAGGAGGAGGAGGAGGAGG 2040
QY 2041 TGCAGATGAGGGAGGCTCAGAGGAGCCAGACCCCTAGGACACCCGACCCCTGTCTGAG 2100
Db 2041 TGCAGATGAGGGAGGCTCAGAGGAGCCAGACCCCTAGGACACCCGACCCCTGTCTGAG 2100
QY 2101 ACTGAGGCTGCCACTTGTGGCTCAAGATCAGAACGATGGGAGCTCAGATTCGATGGGG 2160
Db 2101 ACTGAGGCTGCCACTTGTGGCTCAAGATCAGAACGATGGGAGCTCAGATTCGATGGGG 2160
QY 2161 GTGGACCCAGGCTGCAAGGCTTACCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGCTT 2220
Db 2161 GTGGACCCAGGCTGCAAGGCTTACCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGCTT 2220
QY 2221 GGAATCCAGATCAGTGTGGACCTCGGCCCTGAGAGGTCAGAGGTCAGGTCAGACATATG 2280
Db 2221 GGAATCCAGATCAGTGTGGACCTCGGCCCTGAGAGGTCAGAGGTCAGGTCAGACATATG 2280
QY 2281 GGGCTATTTCTGCACTTTGAGGTACAGGACAGAGCTGTGGTCTGAGAGTGGGGCC 2340
Db 2281 GGGCTATTTCTGCACTTTGAGGTACAGGACAGAGCTGTGGTCTGAGAGTGGGGCC 2340
QY 2341 TCAGGTCAACAGAGGAGGAGGTTCCAGGATCCATATGGCCCAAGATGTGCCCTTTCATG 2400
Db 2341 TCAGGTCAACAGAGGAGGAGGTTCCAGGATCCATATGGCCCAAGATGTGCCCTTTCATG 2400
QY 2401 AGGACTGGGATATCCCGGCTCAGAAGAGGAGCTCCACACAGTCTGGTGTCCCTT 2460
Db 2401 AGGACTGGGATATCCCGGCTCAGAAGAGGAGCTCCACACAGTCTGGTGTCCCTT 2460
QY 2461 TTAGTAGCTCTAGGGGAGGAGGATGGGGATGGGGATGTGTCCATTTCTCACTGTACCA 2520
Db 2461 TTAGTAGCTCTAGGGGAGGAGGATGGGGATGGGGATGTGTCCATTTCTCACTGTACCA 2520

QY 2521 CAGGCGAGGAAGTTGGGGGGGGCCCTCAGGAGATGGGGTCTTGGGTAAGAGGGGGATGCTT 2580
Db 2521 CAGGCGAGGAAGTTGGGGGGGGCCCTCAGGAGATGGGGTCTTGGGTAAGAGGGGGATGCTT 2580
QY 2581 ACTCATGTCAGGGAATTTGGGGTTGAGGAAGCACAGGCGCTTGCAGGAATAAAGATGACT 2640
Db 2581 ACTCATGTCAGGGAATTTGGGGTTGAGGAAGCACAGGCGCTTGCAGGAATAAAGATGACT 2640
QY 2641 GAGACAGACAAGGCTATTGGAATCCACACCCAGACCAAAAGGGGTGACCCCTGGACAC 2700
Db 2641 GAGACAGACAAGGCTATTGGAATCCACACCCAGACCAAAAGGGGTGACCCCTGGACAC 2700
QY 2701 TCACCCAGGATGTGGCTTCTTTTCACTCTCTGTTCCAGATCTGGGCAAGGTGAGAACCT 2760
Db 2701 TCACCCAGGATGTGGCTTCTTTTCACTCTCTGTTCCAGATCTGGGCAAGGTGAGAACCT 2760
QY 2761 CATTCACAGGGTGTACTCAGGTCAACGTAGGACCCCATCTGTCTTAAAGACAGAGCG 2820
Db 2761 CATTCACAGGGTGTACTCAGGTCAACGTAGGACCCCATCTGTCTTAAAGACAGAGCG 2820
QY 2821 GTCCAGGATCTGCCATGCGTTTCGGGTGAGGAACATGAGGAGGACTGAGGTACCCAC 2880
Db 2821 GTCCAGGATCTGCCATGCGTTTCGGGTGAGGAACATGAGGAGGACTGAGGTACCCAC 2880
QY 2881 GACCAAGACACTGAGGAGGACTGCACAGAAATCAGCCCTGCCCTGCTACCCACAGAG 2940
Db 2881 GACCAAGACACTGAGGAGGACTGCACAGAAATCAGCCCTGCCCTGCTACCCACAGAG 2940
QY 2941 AGCATGGGTGGCGCTCTGCCGAGGCTCTCCGTTATCCTGGGATCATTTGATGTGAGG 3000
Db 2941 AGCATGGGTGGCGCTCTGCCGAGGCTCTCCGTTATCCTGGGATCATTTGATGTGAGG 3000
QY 3001 ACGGGAGGCTTGTGTCTGAGAAGGCTGCGCTCAGGTCTAGTAGAGGAGCGTCCCGAGG 3060
Db 3001 ACGGGAGGCTTGTGTCTGAGAAGGCTGCGCTCAGGTCTAGTAGAGGAGCGTCCCGAGG 3060
QY 3061 CTGCCAGGATCAAGGTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 3120
Db 3061 CTGCCAGGATCAAGGTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 3120
QY 3121 GAATTTGATATCTCTGTCTGCCCTTCCCAAGGAGCTAGGACGCTGTGGCCAGATGTTT 3180
Db 3121 GAATTTGATATCTCTGTCTGCCCTTCCCAAGGAGCTAGGACGCTGTGGCCAGATGTTT 3180
QY 3181 GTCCCTCTCTGCTTCTCATTCCTTATCATGATGATGATGATGATGATGATGATGATG 3240
Db 3181 GTCCCTCTCTGCTTCTCATTCCTTATCATGATGATGATGATGATGATGATGATGATG 3240
QY 3241 ACCAGCAAAAGGCGAGGATCCAGGCCCTGCCAGGAAAAATATAAGGGCCCTCGGTGAGAA 3300
Db 3241 ACCAGCAAAAGGCGAGGATCCAGGCCCTGCCAGGAAAAATATAAGGGCCCTCGGTGAGAA 3300
QY 3301 CAGAGGGGTCTATCCACTGCATGAGAGTGGGATGTCACAGAGTCCAGGCCACCTCTCTG 3360
Db 3301 CAGAGGGGTCTATCCACTGCATGAGAGTGGGATGTCACAGAGTCCAGGCCACCTCTCTG 3360
QY 3361 GTAGCACTGAGAGGCCAGGCTGTGCTGCGTCTGACCCCTGAGGAGGAGGAGGAGGAGG 3420
Db 3361 GTAGCACTGAGAGGCCAGGCTGTGCTGCGTCTGACCCCTGAGGAGGAGGAGGAGGAGG 3420
QY 3421 CTTTCTGGAGCTCCAGGAACCCAGGAGTGGGCTTGGTCTGAGACAGTATCTCTCAGGTC 3480
Db 3421 CTTTCTGGAGCTCCAGGAACCCAGGAGTGGGCTTGGTCTGAGACAGTATCTCTCAGGTC 3480
QY 3481 ACAGACAGAGGATGACAGGCTGTGCCAGCAGTGAATTTTCCCTGATCCACACCAA 3540
Db 3481 ACAGACAGAGGATGACAGGCTGTGCCAGCAGTGAATTTTCCCTGATCCACACCAA 3540
QY 3541 GGGCCCCACCTGCCACAGGACACATAGGACTCCACAGAGTCTGGCCTCACTCCCTACTG 3600
Db 3541 GGGCCCCACCTGCCACAGGACACATAGGACTCCACAGAGTCTGGCCTCACTCCCTACTG 3600

QY 1861 CCATCACAATCCCAATACCTACCCCTACCCCAACCTCATCTTGTTCAGAAATCCCTGCTG 1920
Db 1861 CCATCACAATCCCAATACCTACCCCTACCCCAACCTCATCTTGTTCAGAAATCCCTGCTG 1920
QY 1921 TCAACCCACGAAAGCCACGCGAATGGCGGACAGCACTCGATCTTGCATCTCCCAATCCA 1980
Db 1921 TCAACCCACGAAAGCCACGCGAATGGCGGACAGCACTCGATCTTGCATCTCCCAATCCA 1980
QY 1981 GGGTCTGATGGAGGAAGGGCTTGAACAGGGCTCAGGGGACAGAGGAGGGCCCTAC 2040
Db 1981 GGGTCTGATGGAGGAAGGGCTTGAACAGGGCTCAGGGGACAGAGGAGGGCCCTAC 2040
QY 2041 TGCAGATGAGGAGGGCTCAGAGGACCCAGCACCTTAGCACACCGACCCCTGTCTGAG 2100
Db 2041 TGCAGATGAGGAGGGCTCAGAGGACCCAGCACCTTAGCACACCGACCCCTGTCTGAG 2100
QY 2101 ACTGAGGCTGCCATCTTGGCTCAAGAAATCAGAAATGAGGAGGACATGAGATGATGGGG 2160
Db 2101 ACTGAGGCTGCCATCTTGGCTCAAGAAATCAGAAATGAGGAGGACATGAGATGATGGGG 2160
QY 2161 GTGGACCCAGGCTGCAAGGCTTACCGGAGGAAGAGGAGGAGGACTCAGGGGACCTT 2220
Db 2161 GTGGACCCAGGCTGCAAGGCTTACCGGAGGAAGAGGAGGAGGACTCAGGGGACCTT 2220
QY 2221 GGAATCCAGATCAGTGTGGACCTCGGCCCTGAGAGGTCCAGGGCAGGGTCCACATATG 2280
Db 2221 GGAATCCAGATCAGTGTGGACCTCGGCCCTGAGAGGTCCAGGGCAGGGTCCACATATG 2280
QY 2281 GCCCATATTTCTGCATCTTTAGGTGACAGGACAGAGCTGTGGTCTGAGAAATGGGGCC 2340
Db 2281 GCCCATATTTCTGCATCTTTAGGTGACAGGACAGAGCTGTGGTCTGAGAAATGGGGCC 2340
QY 2341 TCAGGTCAACAGAGGAGGAGTTCAGGATCCATATATGGCCCAAGATGTGCCCTTCATG 2400
Db 2341 TCAGGTCAACAGAGGAGGAGTTCAGGATCCATATATGGCCCAAGATGTGCCCTTCATG 2400
QY 2401 AGGACTGGGATATCCCGGCTCAGAAGAGGAGCTCCACAGACTGTGCTGAGAAATGGGGCC 2460
Db 2401 AGGACTGGGATATCCCGGCTCAGAAGAGGAGCTCCACAGACTGTGCTGAGAAATGGGGCC 2460
QY 2461 TTAGTAGCTCAGGGGACAGATCAGGGATGGCGGTATGTTCATCTCAGTGTACCA 2520
Db 2461 TTAGTAGCTCAGGGGACAGATCAGGGATGGCGGTATGTTCATCTCAGTGTACCA 2520
QY 2521 CAGGAGGAATTTGGGGGCTCAGGAGATGGGGTCTGGGTAAAGGGGGATGTCT 2580
Db 2521 CAGGAGGAATTTGGGGGCTCAGGAGATGGGGTCTGGGTAAAGGGGGATGTCT 2580
QY 2581 ACTCATGTACGGGAATTTGGGGGTTGAGAGACAGCGCTGGCAGGAATAAAGATGAGT 2640
Db 2581 ACTCATGTACGGGAATTTGGGGGTTGAGAGACAGCGCTGGCAGGAATAAAGATGAGT 2640
QY 2641 GAGACAGAAAGGCTATTGGAATCCACACCCAGAAACCAAGGGGTGAGCCCTGGAGACC 2700
Db 2641 GAGACAGAAAGGCTATTGGAATCCACACCCAGAAACCAAGGGGTGAGCCCTGGAGACC 2700
QY 2701 TCACCCAGGATGTGGCTCTTTTCTCTCTGTTTCAGATCTGGGACAGGTGAGGACCT 2760
Db 2701 TCACCCAGGATGTGGCTCTTTTCTCTCTGTTTCAGATCTGGGACAGGTGAGGACCT 2760
QY 2761 CATCTCAGAGGTTGACTCAGGTCAAGTATGGGACCCCAATCTGGTCTAAAGACAGAGCG 2820
Db 2761 CATCTCAGAGGTTGACTCAGGTCAAGTATGGGACCCCAATCTGGTCTAAAGACAGAGCG 2820
QY 2821 GTCCAGGATCTGCCATGCTTGGGTGAGGAACATCAGGGAGGACTGAGGGTACCCAG 2880
Db 2821 GTCCAGGATCTGCCATGCTTGGGTGAGGAACATCAGGGAGGACTGAGGGTACCCAG 2880
QY 2881 GACCAGAACTGAGGGAGACTGCACAGAAATCAGCCCTGCCCCCTGTCTCAACCCAGAG 2940
Db 2881 GACCAGAACTGAGGGAGACTGCACAGAAATCAGCCCTGCCCCCTGTCTCAACCCAGAG 2940
QY 2941 AGCATGGGCTGGGCGCTTGGCCAGGTCCTTCCGTTTATCCTGGGATCATGTATGTCAGGG 3000

Db 2941 AGCATGGGCTGGGCGCTTGGCCAGGTCCTCCGTTATCCTGGGATCATGTATGTCAGGG 3000
QY 3001 ACGGGAGGSCCTTGGTCTGAGAAGCTCGCTCAGTTCAGTAGAGGAGCGTCCAGGCC 3060
Db 3001 ACGGGAGGSCCTTGGTCTGAGAAGCTCGCTCAGTTCAGTAGAGGAGCGTCCAGGCC 3060
QY 3061 CTGCCAGGAGTCAAGGTGAGGACCAAGGGGACCTCACCAGGACACATTAATTCCAAT 3120
Db 3061 CTGCCAGGAGTCAAGGTGAGGACCAAGGGGACCTCACCAGGACACATTAATTCCAAT 3120
QY 3121 GAATTTGATATCTCTGCTGCCCTTCCCAAGGACCTAGGCACCTGTGGCAGATGTTT 3180
Db 3121 GAATTTGATATCTCTGCTGCCCTTCCCAAGGACCTAGGCACCTGTGGCAGATGTTT 3180
QY 3181 GTCCCTCTGCTCTTCCATTCCTTATCATGATGTGACCTCTTATTTGGATTCTCAG 3240
Db 3181 GTCCCTCTGCTCTTCCATTCCTTATCATGATGTGACCTCTTATTTGGATTCTCAG 3240
QY 3241 ACCAGCAAAAGGCGAGGATCCAGGCCCTGCCAGGAAATATAAGGGCCCTCGTGAGAA 3300
Db 3241 ACCAGCAAAAGGCGAGGATCCAGGCCCTGCCAGGAAATATAAGGGCCCTCGTGAGAA 3300
QY 3301 CAGAGGGGTCTATCTCATCTGATGAGTGGGATGTACAGAGTCCAGGCCACCTCTG 3360
Db 3301 CAGAGGGGTCTATCTCATCTGATGAGTGGGATGTACAGAGTCCAGGCCACCTCTG 3360
QY 3361 GTAGCACTCAGAAAGCCAGGGCTGTGCTTGGCTGTGACCTGAGGGCCCTGCGATTCT 3420
Db 3361 GTAGCACTCAGAAAGCCAGGGCTGTGCTTGGCTGTGACCTGAGGGCCCTGCGATTCT 3420
QY 3421 CTTCTGGAGCTCCAGGAACACAGGAGTGGCTTGGTCTGAGACAGTATCCTCAGGTC 3480
Db 3421 CTTCTGGAGCTCCAGGAACACAGGAGTGGCTTGGTCTGAGACAGTATCCTCAGGTC 3480
QY 3481 ACAGACAGAGATGACAGGCTGTGCCAGCTGAATTTTGGCTGAATCACACCAA 3540
Db 3481 ACAGACAGAGATGACAGGCTGTGCCAGCTGAATTTTGGCTGAATCACACCAA 3540
QY 3541 GGCCCCACCTGCCAGGACACATAGGACTCCAGAGTCTGGCTACCTCCCTACTG 3600
Db 3541 GGCCCCACCTGCCAGGACACATAGGACTCCAGAGTCTGGCTACCTCCCTACTG 3600
QY 3601 TCAGTCTCTAGAATCGACCTCTGTGGCGGCTGTACCTGAGTACCTCTCAGTCTCT 3660
Db 3601 TCAGTCTCTAGAATCGACCTCTGTGGCGGCTGTACCTGAGTACCTCTCAGTCTCT 3660
QY 3661 CTTTCAGGTTTTCAGGGGACAGGCCAACCCAGGACAGGATTCCTGAGGCCACAGAG 3720
Db 3661 CTTTCAGGTTTTCAGGGGACAGGCCAACCCAGGACAGGATTCCTGAGGCCACAGAG 3720
QY 3721 GAGCACACAGGAGAGATCTGTAAGTAGGCTTGTAGAGTCTCAAGGTTCAAGTCTC 3780
Db 3721 GAGCACACAGGAGAGATCTGTAAGTAGGCTTGTAGAGTCTCAAGGTTCAAGTCTC 3780
QY 3781 AGTGAGGCTCTCACACACTCCCTCTCTCCAGGSCCTGTGGTCTTCATTTGCCAGCT 3840
Db 3781 AGTGAGGCTCTCACACACTCCCTCTCTCTCCAGGSCCTGTGGTCTTCATTTGCCAGCT 3840
QY 3841 CTTGCCACACATCTGCTGCTGCCCTGACAGAGTCTATCTCTTTGAGCAGAGGAG 3900
Db 3841 CTTGCCACACATCTGCTGCTGCCCTGACAGAGTCTATCTCTTTGAGCAGAGGAG 3900
QY 3901 TCTGCACTGCAAGCTGAGGAAGCCCTTTCAGGCCCAACAGAGGSCCTGGGCTGTGTG 3960
Db 3901 TCTGCACTGCAAGCTGAGGAAGCCCTTTCAGGCCCAACAGAGGSCCTGGGCTGTGTG 3960
QY 3961 TGTGAGGCTGCAACT 4020
Db 3961 TGTGAGGCTGCAACT 4020
QY 4021 CACTGCTGGTCAACAGATCTCCCGAGAGTCTCAGGAGCTCCGCTCTTCCCACTAC 4080

Db	4021	CAC	TGCTGGGTCAACAGATCTCTCCCGAGAGTCCTCCAGGGAGCCTCCGCGCTTCCCACTAC	4080	
Qy	4081	CAT	CAACTTCAC	TCGACAGAGCAACCCAGTCGAGGTTCCAGCAGCCGCTGAAGAGGAGG	4140
Db	4081	CAT	CAACTTCAC	TCGACAGAGCAACCCAGTCGAGGTTCCAGCAGCCGCTGAAGAGGAGG	4140
Qy	4141	GCC	AGCACCTCTGTATCCTCGAGTCCTTGTTCGAGCAGTAATCACTANGAAGGTGGC	4200	
Db	4141	GCC	AGCACCTCTGTATCCTCGAGTCCTTGTTCGAGCAGTAATCACTANGAAGGTGGC	4200	
Qy	4201	TGAT	TTGGTTGGTTTCTGCTCCTCAAAATATCGAGCCAGGAGCGCAGTCACAAAGGCAGA	4260	
Db	4201	TGAT	TTGGTTGGTTTCTGCTCCTCAAAATATCGAGCCAGGAGCGCAGTCACAAAGGCAGA	4260	
Qy	4261	AAT	CTGGAGAGTGTCATCAAAAATACAAAGCACATGTTTCTCTGAGATCTTCGGCAAAAGC	4320	
Db	4261	AAT	CTGGAGAGTGTCATCAAAAATACAAAGCACATGTTTCTCTGAGATCTTCGGCAAAAGC	4320	
Qy	4321	CTCT	GAGTCCTTCACGCTGGTCTTTGGCAATTCAGCTGAAGGAACGACAGCCACCGGCCA	4380	
Db	4321	CTCT	GAGTCCTTCACGCTGGTCTTTGGCAATTCAGCTGAAGGAACGACAGCCACCGGCCA	4380	
Qy	4381	CTCT	ATATGTCCTTTGCACCTGGCTAGGTCCTCCATATGATGGCCTGCTGGTGATATCA	4440	
Db	4381	CTCT	ATATGTCCTTTGCACCTGGCTAGGTCCTCCATATGATGGCCTGCTGGTGATATCA	4440	
Qy	4441	GAT	CATGCCCAACAGACAGGCTTCTTGATTAATTTCTCTGTCATGATTCGAATGGAGGCGG	4500	
Db	4441	GAT	CATGCCCAACAGACAGGCTTCTTGATTAATTTCTCTGTCATGATTCGAATGGAGGCGG	4500	
Qy	4501	CCAT	GCTCCTCGAGAGGAAATCTGGAGAGAGTGAGTGTGATGGAGGTGTATGATGGAG	4560	
Db	4501	CCAT	GCTCCTCGAGAGGAAATCTGGAGAGAGTGAGTGTGATGGAGGTGTATGATGGAG	4560	
Qy	4561	GGAC	CACAGTCCTATGGGAGCCAGGAAGCTGCTCACCAGAAATTTGGTTCAGGAAAA	4620	
Db	4561	GGAC	CACAGTCCTATGGGAGCCAGGAAGCTGCTCACCAGAAATTTGGTTCAGGAAAA	4620	
Qy	4621	GTAC	CTGGATACGGCAGGTGCGGACAGTGATCCGACACGCTATGAGTTCCTCTGGGGT	4680	
Db	4621	GTAC	CTGGATACGGCAGGTGCGGACAGTGATCCGACACGCTATGAGTTCCTCTGGGGT	4680	
Qy	4681	CCAA	GGCCCTCGCTGAAACACAGCTATGTGAAAGTCCTTGAGTATGTGATCAAGGTCAGT	4740	
Db	4681	CCAA	GGCCCTCGCTGAAACACAGCTATGTGAAAGTCCTTGAGTATGTGATCAAGGTCAGT	4740	
Qy	4741	GCA	AGAGTTCGCTTTTCTCCATCCCTCGCGGAAGCAGCTTTGAGAGAGGGAAGAG	4800	
Db	4741	GCA	AGAGTTCGCTTTTCTCCATCCCTCGCGGAAGCAGCTTTGAGAGAGGGAAGAG	4800	
Qy	4801	GGAG	CTGAGCATGAGTTGACGCCAAGGCCAGTGGGAGGGGACTGGGCCAGTCACCTT	4860	
Db	4801	GGAG	CTGAGCATGAGTTGACGCCAAGGCCAGTGGGAGGGGACTGGGCCAGTCACCTT	4860	
Qy	4861	CCAG	GGCCGGTCCAGCAGCTTCCCTCGCTGCGTGACATGAGGCCCATCTTCCTCTCT	4920	
Db	4861	CCAG	GGCCGGTCCAGCAGCTTCCCTCGCTGCGTGACATGAGGCCCATCTTCCTCTCT	4920	
Qy	4921	GAAG	GAGCGGTCAGTGTTCTCAGTAGTAGGTTTCGTTCCTATTGGGTGACTTGGAGATT	4980	
Db	4921	GAAG	GAGCGGTCAGTGTTCTCAGTAGTAGGTTTCGTTCCTATTGGGTGACTTGGAGATT	4980	
Qy	4981	TAT	CTTTGTTCTTTTGGAAATGTTCAATGCTTTTTTTTAAAGGATGGTTGAATGAAC	5040	
Db	4981	TAT	CTTTGTTCTTTTGGAAATGTTCAATGCTTTTTTTTAAAGGATGGTTGAATGAAC	5040	
Qy	5041	TTCA	GCATCCAAGTTTATGAATGACAGAGTCACACAGTCTGTGTATATAGTTTAAGGG	5100	
Db	5041	TTCA	GCATCCAAGTTTATGAATGACAGAGTCACACAGTCTGTGTATATAGTTTAAGGG	5100	
Qy	5101	TAAG	AGTCTTGTCTTTTATTCAGATGGGAAATCCATCTATTTTGTGAATTTGGGATAAT	5160	
Db	5101	TAAG	AGTCTTGTCTTTTATTCAGATGGGAAATCCATCTATTTTGTGAATTTGGGATAAT	5160	

RESULT 3

I36923

LOCUS

DEFINITION

ACCESSION
NUMBER

VERSION
REVISED

KEYWORDS
SOURCES

SOURCE
ORGANISM

.....

REFERENCE

AUTHORS

SECRET

ATTI

JOURNAL

FEATURES

Source:

Query Map

Best Local

Matches

Qy 1

...

UD

QY 121 CTCTCAACCCAGGAAAGCCAGGTGCCAGATGTGAGCCCACTGACTTGAGCAATTAGTGS 180
Db 121 CTCTCAACCCAGGAAAGCCAGGTGCCAGATGTGAGCCCACTGACTTGAGCAATTAGTGS 180
QY 181 TTAGAGAAAGCGAGGTTTTTCGTCTGAGGGGGCGCTTGAGATCGGTGAGGGAAGCGG 240
Db 181 TTAGAGAAAGCGAGGTTTTTCGTCTGAGGGGGCGCTTGAGATCGGTGAGGGAAGCGG 240
QY 241 CCAGCTCTGTAGGAGGCAAGGTGACATCTGAGGAGGACTGAGGACCCCACTTACCC 300
Db 241 CCAGCTCTGTAGGAGGCAAGGTGACATCTGAGGAGGACTGAGGACCCCACTTACCC 300
QY 301 AGATAGAGACCCCAATAATCCCTTTCATGCCAGTCCGAGGAGGACTGAGGACCCCACTTACCC 360
Db 301 AGATAGAGACCCCAATAATCCCTTTCATGCCAGTCCGAGGAGGACTGAGGACCCCACTTACCC 360
QY 361 TCAGGCTGGGCCACCCCGCCCTTGCCTTAACCACTGGGACTCGAGTTCAGAG 420
Db 361 TCAGGCTGGGCCACCCCGCCCTTGCCTTAACCACTGGGACTCGAGTTCAGAG 420
QY 421 CTCGCTGTATCAGGGAAGGCTGCTTAGGAGAGGCGAGGCTCCAGGCTTCGCCAGACAT 480
Db 421 CTCGCTGTATCAGGGAAGGCTGCTTAGGAGAGGCGAGGCTCCAGGCTTCGCCAGACAT 480
QY 481 CATGCTCAGGATTCCTAAGAGGCGTGAAGTCCCTTAAGACCCCACTCCCGTGACCCAAAC 540
Db 481 CATGCTCAGGATTCCTAAGAGGCGTGAAGTCCCTTAAGACCCCACTCCCGTGACCCAAAC 540
QY 541 CCCCACCTCCCAATGCTACTCCGCTGACCCAAACCCCTCTTCATTGTCAATCCCAACCCCA 600
Db 541 CCCCACCTCCCAATGCTACTCCGCTGACCCAAACCCCTCTTCATTGTCAATCCCAACCCCA 600
QY 601 CCCACATCCCCACCCCACTCCCTCAACCTGATGCCATCCCGCCAGCCATTCACCCCT 660
Db 601 CCCACATCCCCACCCCACTCCCTCAACCTGATGCCATCCCGCCAGCCATTCACCCCT 660
QY 661 CACCCACACCCCACTCCGCTGACCCAAACCCCTCTTCATTGTCAATCCCAACCCCA 720
Db 661 CACCCACACCCCACTCCGCTGACCCAAACCCCTCTTCATTGTCAATCCCAACCCCA 720
QY 721 CCAGGAACATCCCGGTGCCGATGTGAGCCCACTGACTTGCGCATTTGGGCGAGAGA 780
Db 721 CCAGGAACATCCCGGTGCCGATGTGAGCCCACTGACTTGCGCATTTGGGCGAGAGA 780
QY 781 GAAGCGAGTTTCCATTCTGAGGAGCGGCTGAGAGTTCGGCGAAGAACTGACCCAGG 840
Db 781 GAAGCGAGTTTCCATTCTGAGGAGCGGCTGAGAGTTCGGCGAAGAACTGACCCAGG 840
QY 841 CTCTGTAGGAGGCAAGGTGAGAGGCTGAGGAGGACTGAGGACCCCGCCACTCCAAATA 900
Db 841 CTCTGTAGGAGGCAAGGTGAGAGGCTGAGGAGGACTGAGGACCCCGCCACTCCAAATA 900
QY 901 GAGAGCCCAATAATTCAGCCCGCCCTTGCTGCCAGCCCTGGCCACCCGGGGAAGA 960
Db 901 GAGAGCCCAATAATTCAGCCCGCCCTTGCTGCCAGCCCTGGCCACCCGGGGAAGA 960
QY 961 CGTCTAGCTGGGCTGCCCGACACCCCTGCTCCAAAGCCCTTGAGAGACACAGGTTTC 1020
Db 961 CGTCTAGCTGGGCTGCCCGACACCCCTGCTCCAAAGCCCTTGAGAGACACAGGTTTC 1020
QY 1021 TTCTCCCAAGCTTGGAATCAGAGTTGTGTGACACAGGCGAGGACTGTTAGGAGAGG 1080
Db 1021 TTCTCCCAAGCTTGGAATCAGAGTTGTGTGACACAGGCGAGGACTGTTAGGAGAGG 1080
QY 1081 GCAGGACAGGCTTCGCCAGGCAATCAAGATCAGACCCCAAGAGGAGGCTGTGGGCC 1140
Db 1081 GCAGGACAGGCTTCGCCAGGCAATCAAGATCAGACCCCAAGAGGAGGCTGTGGGCC 1140
QY 1141 CCAGAGTGCATCCATCCCACTCCACCCCAATTCGATTCGCATTCGCCACCCCAACC 1200
Db 1141 CCAGAGTGCATCCATCCCACTCCACCCCAATTCGATTCGCATTCGCCACCCCAACC 1200
QY 1201 CCCATCTCTCAGCTACACCTCCACCCCACTCCCTACTCTACTCTACCTGACCCACC 1260

Db 1201 CCCATCTCTCAGCTACACCTCCACCCCACTCCCTACTCTACTCTACCTGACCCACC 1260
QY 1261 ACCCTCCAGCCCAAGCAGCCCAACCCCTTCTGCCACCTCACCCTCAGTCCGCCCAAC 1320
Db 1261 ACCCTCCAGCCCAAGCAGCCCAACCCCTTCTGCCACCTCACCCTCAGTCCGCCCAAC 1320
QY 1321 CCACCCCTCATCTCTCATGTGCCCACTCCCATCGCTCCCATCTCTGSCAATCC 1380
Db 1321 CCACCCCTCATCTCTCATGTGCCCACTCCCATCGCTCCCATCTCTGSCAATCC 1380
QY 1381 GGTTCGCCCTCTCTCAACCCAGGGAAGCCCTGTAGCCCGATGTGAACCACTGACT 1440
Db 1381 GGTTCGCCCTCTCTCAACCCAGGGAAGCCCTGTAGCCCGATGTGAACCACTGACT 1440
QY 1441 TGAACCTCAGATCTGAGAGAAGCAGGTTCAATTAATGTTCTGAGGGCGGCTTGAG 1500
Db 1441 TGAACCTCAGATCTGAGAGAAGCAGGTTCAATTAATGTTCTGAGGGCGGCTTGAG 1500
QY 1501 ATCCACTGAGGGAAGTGTGTTTAGGCTCTGTGAGGAGCAAGGTGAGATGCTGAGGGAGG 1560
Db 1501 ATCCACTGAGGGAAGTGTGTTTAGGCTCTGTGAGGAGCAAGGTGAGATGCTGAGGGAGG 1560
QY 1561 ACTGAGGAGCACACACCCAGGTAGTGGCCCAAAATGATCCAGTACACCCCTGCTG 1620
Db 1561 ACTGAGGAGCACACACCCAGGTAGTGGCCCAAAATGATCCAGTACACCCCTGCTG 1620
QY 1621 CCAGCCCTGGACACCCCGCCAGGACAGATGCTCAGTGGACACCCCGCTCCCGTCC 1680
Db 1621 CCAGCCCTGGACACCCCGCCAGGACAGATGCTCAGTGGACACCCCGCTCCCGTCC 1680
QY 1681 CACTGCCCTTAACCCACAGGCAATCTGTAGTATAGTTATGTGACGGGCGAGGTT 1740
Db 1681 CACTGCCCTTAACCCACAGGCAATCTGTAGTATAGTTATGTGACGGGCGAGGTT 1740
QY 1741 GGTGAGGAGGAGGCGCCAGGCAATCAAGTCCAGCATCCCGCCCGGCAATTAGGTCAGG 1800
Db 1741 GGTGAGGAGGAGGCGCCAGGCAATCAAGTCCAGCATCCCGCCCGGCAATTAGGTCAGG 1800
QY 1801 ACCCTGGAGGAGGACTGAGGTTCCCGCCACACCTGCTCTCTCATCTCCACCCACC 1860
Db 1801 ACCCTGGAGGAGGACTGAGGTTCCCGCCACACCTGCTCTCTCATCTCCACCCACC 1860
QY 1861 CCACTCACATTCCTACCTACCCCTACCCCAACCTCATCTTGTGAGAAATCCCTGCTG 1920
Db 1861 CCACTCACATTCCTACCTACCCCTACCCCAACCTCATCTTGTGAGAAATCCCTGCTG 1920
QY 1921 TCAACCCAGGAGCCACCGGAATGGCGCCAGGCACTCGGATCTTGAGTCCCATCCA 1980
Db 1921 TCAACCCAGGAGCCACCGGAATGGCGCCAGGCACTCGGATCTTGAGTCCCATCCA 1980
QY 1981 GGTCTGTAGGAGGGAAGGGCTTGAACAGGGCTCAGGGGAGCAGAGGAGGGCCCTAC 2040
Db 1981 GGTCTGTAGGAGGGAAGGGCTTGAACAGGGCTCAGGGGAGCAGAGGAGGGCCCTAC 2040
QY 2041 TGGAGATGAGGAGGCGCTCAGAGGACCCAGACCCCTAGGACACCCCGCTGTGAG 2100
Db 2041 TGGAGATGAGGAGGCGCTCAGAGGACCCAGACCCCTAGGACACCCCGCTGTGAG 2100
QY 2101 ACTGAGGCTGCCACTTCTGGCTCAAGATCAGAGTGGGACTCAGATTGCAATGGG 2160
Db 2101 ACTGAGGCTGCCACTTCTGGCTCAAGATCAGAGTGGGACTCAGATTGCAATGGG 2160
QY 2161 GTGGGACCCAGGCTCAAGGCTTACGGGAGGAGAGGAGGAGGACTCAGGGGACCTT 2220
Db 2161 GTGGGACCCAGGCTCAAGGCTTACGGGAGGAGAGGAGGAGGACTCAGGGGACCTT 2220
QY 2221 GGAATCCAGATCAGTGTGACCTCGGCCCTGAGAGTCCAGGGCACGGTGGCCACATAG 2280
Db 2221 GGAATCCAGATCAGTGTGACCTCGGCCCTGAGAGTCCAGGGCACGGTGGCCACATAG 2280
QY 2281 GCCATATTCTCTGATCTTTGAGGTGACAGGACAGAGTGTGGTCTGAGAGTGGGGCC 2340

Db 2281 GCCCATATTTCCCTGATCTTTGAGGTGACAGGACAGAGGTGTGGTCTGAGAAAGTGGGGC 2340
QY 2341 TCAGGTCAACAGAGGAGGAGTTCCAGGATCCATATGGCCCAAGATGTGCCCCCTTCATG 2400
Db 2341 TCAGGTCAACAGAGGAGGAGTTCCAGGATCCATATGGCCCAAGATGTGCCCCCTTCATG 2400
QY 2401 AGGACTGGGATATCCCGGCTCAGAAAGAGGAGTCCACAGACTGTGGCTGTCCCCCT 2460
Db 2401 AGGACTGGGATATCCCGGCTCAGAAAGAGGAGTCCACAGACTGTGGCTGTCCCCCT 2460
QY 2461 TTAGTACTCTAGGGGACACAGATCAGGATGGGGTATGTTCCATCTCACTTGTACCA 2520
Db 2461 TTAGTACTCTAGGGGACACAGATCAGGATGGGGTATGTTCCATCTCACTTGTACCA 2520
QY 2521 CAGCAGGAAAGTTGGGGGCCCTCAGGAGATGGGTCATGGGTAAGAGGGGGATGTCT 2580
Db 2521 CAGCAGGAAAGTTGGGGGCCCTCAGGAGATGGGTCATGGGTAAGAGGGGGATGTCT 2580
QY 2581 ACTCATGTCAAGGAATTTGGGGGTTGAGGAAGCACAGCGCTGGCAGGATAAAGATGAGT 2640
Db 2581 ACTCATGTCAAGGAATTTGGGGGTTGAGGAAGCACAGCGCTGGCAGGATAAAGATGAGT 2640
QY 2641 GAGCACAGAGGCTATTGGAATCCACACCCAGAACCAAGGGGTACGCCCTGGACACC 2700
Db 2641 GAGCACAGAGGCTATTGGAATCCACACCCAGAACCAAGGGGTACGCCCTGGACACC 2700
QY 2701 TCACCCAGGATGTGGCTTTCTTTTCACTCCTGTGTTTCAGATCTGGGGCAGGTGAGGACCT 2760
Db 2701 TCACCCAGGATGTGGCTTTCTTTTCACTCCTGTGTTTCAGATCTGGGGCAGGTGAGGACCT 2760
QY 2761 CATCTCAGAGGATGACTCAGGTCAAGTAGGAGGCCCATCTGGTCTAAAGACAGAGCG 2820
Db 2761 CATCTCAGAGGATGACTCAGGTCAAGTAGGAGGCCCATCTGGTCTAAAGACAGAGCG 2820
QY 2821 GTCCAGGATCTGCATGCGTTGCGGTGAGGAACATCAGGAGGAGTGTAGGGTACCCAG 2880
Db 2821 GTCCAGGATCTGCATGCGTTGCGGTGAGGAACATCAGGAGGAGTGTAGGGTACCCAG 2880
QY 2881 GACCAGAACACTGAGGAGTGCACAGAAATCAGCCCTGCCCTGTCTACCCAGAG 2940
Db 2881 GACCAGAACACTGAGGAGTGCACAGAAATCAGCCCTGCCCTGTCTACCCAGAG 2940
QY 2941 AGCATGGCTGGGCGCTGCGAGGTCCTTCGGTATCTCGGGATCATTTGATGTACGGG 3000
Db 2941 AGCATGGCTGGGCGCTGCGAGGTCCTTCGGTATCTCGGGATCATTTGATGTACGGG 3000
QY 3001 ACGGGGAGGCTTGGTCTGAGAGGCTGCGCTCAGSTCAGTAGGAGGAGGTCCAGGCC 3060
Db 3001 ACGGGGAGGCTTGGTCTGAGAGGCTGCGCTCAGSTCAGTAGGAGGAGGTCCAGGCC 3060
QY 3061 CTGCCAGGATCAAGGTGAGGACCAAGCGGCACCTCACCAGGACACATTAATTCAT 3120
Db 3061 CTGCCAGGATCAAGGTGAGGACCAAGCGGCACCTCACCAGGACACATTAATTCAT 3120
QY 3121 GAATTTTGTATCTCTGCTGCGCTTCCCAAGACCTTAGGAGGTCGCGCAGATGTTT 3180
Db 3121 GAATTTTGTATCTCTGCTGCGCTTCCCAAGACCTTAGGAGGTCGCGCAGATGTTT 3180
QY 3181 GTCCCTCTCTGCTCTCATTTCTTATCATGGATGTGAATCTTGAATTTCTCAG 3240
Db 3181 GTCCCTCTCTGCTCTCATTTCTTATCATGGATGTGAATCTTGAATTTCTCAG 3240
QY 3241 ACCAGAAAAGGAGGATCCAGCCCTGCGAGGAAATATAGGGCCCTGCGTGAGAA 3300
Db 3241 ACCAGAAAAGGAGGATCCAGCCCTGCGAGGAAATATAGGGCCCTGCGTGAGAA 3300
QY 3301 CAGAGGGGTATCCACTGATGAGTGGGATGTCACAGATCCAGCCACCCCTCTG 3360
Db 3301 CAGAGGGGTATCCACTGATGAGTGGGATGTCACAGATCCAGCCACCCCTCTG 3360
QY 3361 GTAGACTGAGAACCCAGGGGTGTGCTTGGGCTGTGACCCCTGAGGGCCGCTGATTCCT 3420
Db 3361 GTAGACTGAGAACCCAGGGGTGTGCTTGGGCTGTGACCCCTGAGGGCCGCTGATTCCT 3420

QY 3421 CTTCTGGAGCTCCAGGAACACAGGAGTGGCCCTTGGTCTGAGACAGTATCTCAGGTC 3480
Db 3421 CTTCTGGAGCTCCAGGAACACAGGAGTGGCCCTTGGTCTGAGACAGTATCTCAGGTC 3480
QY 3481 ACAGAGCAGAGATGCACAGGTGTGCCAGCAGTGAATGTTTGGCCCTGAATGCACACAA 3540
Db 3481 ACAGAGCAGAGATGCACAGGTGTGCCAGCAGTGAATGTTTGGCCCTGAATGCACACAA 3540
QY 3541 GGGCCCACTCCACAGGACACATAGGACTCCACAGAGTCTGGCTCACCTCCCTACTG 3600
Db 3541 GGGCCCACTCCACAGGACACATAGGACTCCACAGAGTCTGGCTCACCTCCCTACTG 3600
QY 3601 TCAGTCTCTAGATCGACCTCTGTGTGGCCGCTGTACCTGAGTACCCTCTCACTTCT 3660
Db 3601 TCAGTCTCTAGATCGACCTCTGTGTGGCCGCTGTACCTGAGTACCCTCTCACTTCT 3660
QY 3661 CTTCTAGGTTTTCAGGGGACAGCCCAACCCAGAGACAGGATTCCTGGAGGCCACAGAG 3720
Db 3661 CTTCTAGGTTTTCAGGGGACAGCCCAACCCAGAGACAGGATTCCTGGAGGCCACAGAG 3720
QY 3721 GAGCAACAAAGGAGATCTGTAAGTAGGCTTTGTTAGAGTCTCAAGGTTTCACTTCT 3780
Db 3721 GAGCAACAAAGGAGATCTGTAAGTAGGCTTTGTTAGAGTCTCAAGGTTTCACTTCT 3780
QY 3781 AGCTGAGGCTCTCACACACTCCCTCTCTCCAGGCTGTGGTCTTCATTTGCCAGCT 3840
Db 3781 AGCTGAGGCTCTCACACACTCCCTCTCTCCAGGCTGTGGTCTTCATTTGCCAGCT 3840
QY 3841 CTTGCCACACACTCCCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 3900
Db 3841 CTTGCCACACACTCCCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 3900
QY 3901 TCTGCTACTGAGGAGGAGGAGGCTTTCAGGCTTTCAGGCTTTCAGGCTTTCAGGCTTTC 3960
Db 3901 TCTGCTACTGAGGAGGAGGAGGCTTTCAGGCTTTCAGGCTTTCAGGCTTTCAGGCTTTC 3960
QY 3961 TGTGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 4020
Db 3961 TGTGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 4020
QY 4021 CACTGCTGGGTCAACAGATCTCCCGAGAGTCTTCAGGAGGCTTCCGCTTTCCTCCACTAC 4080
Db 4021 CACTGCTGGGTCAACAGATCTCCCGAGAGTCTTCAGGAGGCTTCCGCTTTCCTCCACTAC 4080
QY 4081 CATCACTTCACTCGACAGGACCAAGGCTTCCAGCAGCCTGTAAGAGGAGG 4140
Db 4081 CATCACTTCACTCGACAGGACCAAGGCTTCCAGCAGCCTGTAAGAGGAGG 4140
QY 4141 GCAAGCAGCTTCTGTATCTGAGTCTTGTTCGAGCAGTAATCAAGAGGTGCT 4200
Db 4141 GCAAGCAGCTTCTGTATCTGAGTCTTGTTCGAGCAGTAATCAAGAGGTGCT 4200
QY 4201 TGATTTGGTGGTTTCTGCTCTCAATATCGAGCCAGGAGGCTTCCAGGAGGAGG 4260
Db 4201 TGATTTGGTGGTTTCTGCTCTCAATATCGAGCCAGGAGGCTTCCAGGAGGAGG 4260
QY 4261 AATGCTGAGAGTGTCAATCAAAATTTACAGCAGTCTTTTCCTGAGATCTTCGGCAAGG 4320
Db 4261 AATGCTGAGAGTGTCAATCAAAATTTACAGCAGTCTTTTCCTGAGATCTTCGGCAAGG 4320
QY 4321 CTTCTGAGTCTTTCAGCTGCTTTCGCTTTCGCTTTCGCTTTCGCTTTCGCTTTCGCT 4380
Db 4321 CTTCTGAGTCTTTCAGCTGCTTTCGCTTTCGCTTTCGCTTTCGCTTTCGCTTTCGCT 4380
QY 4381 CTCTATGCTTTCAGCTGCTTTCGCTTTCGCTTTCGCTTTCGCTTTCGCTTTCGCTTTCGCT 4440
Db 4381 CTCTATGCTTTCAGCTGCTTTCGCTTTCGCTTTCGCTTTCGCTTTCGCTTTCGCTTTCGCT 4440
QY 4441 GATCATGCCAGACAGGCTTCTGATATTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 4500
Db 4441 GATCATGCCAGACAGGCTTCTGATATTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 4500

QY 4501 CCATGCTCCTGAGGAGAAATCTGGAGGAGCTGAGTGTGATGAGAGTGTATGATGGAG 4560
Db 4501 CCATGCTCCTGAGGAGAAATCTGGAGGAGCTGAGTGTGATGAGAGTGTATGATGGAG 4560
QY 4561 GGAGCAGTGCCTATGGGAGGCCAGGAGCTGCTACCCAGATTTGGTGCAGGAAA 4620
Db 4561 GGAGCAGTGCCTATGGGAGGCCAGGAGCTGCTACCCAGATTTGGTGCAGGAAA 4620
QY 4621 GTACCTGAGTACGCGAGTGCAGGAGTCCGCGAGTATGATGATTCCTGTTGGGT 4680
Db 4621 GTACCTGAGTACGCGAGTGCAGGAGTCCGCGAGTATGATGATTCCTGTTGGGT 4680
QY 4681 CCAAGGCGCTCGCTGAACCCAGCTATGTGAAGTCTCTGAGTATGTGATCAAGTCACT 4740
Db 4681 CCAAGGCGCTCGCTGAACCCAGCTATGTGAAGTCTCTGAGTATGTGATCAAGTCACT 4740
QY 4741 GCAGAGTTCGCTTTTCTTCCCATCCCTGCTGAACCCAGCTTTGAGAGGAGGAGAG 4800
Db 4741 GCAGAGTTCGCTTTTCTTCCCATCCCTGCTGAACCCAGCTTTGAGAGGAGGAGAG 4800
QY 4801 GGAGTCTGAGCATGAGTTGAGCCAGCCAGTGGGAGGGGACTGGGCCAGTGCACCTT 4860
Db 4801 GGAGTCTGAGCATGAGTTGAGCCAGCCAGTGGGAGGGGACTGGGCCAGTGCACCTT 4860
QY 4861 CCAGGGCGGCTCAGAGCTTCCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 4920
Db 4861 CCAGGGCGGCTCAGAGCTTCCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 4920
QY 4921 GAAGAGCGGCTCAGTGTCTCAGTGTAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCT 4980
Db 4921 GAAGAGCGGCTCAGTGTCTCAGTGTAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCT 4980
QY 4981 TATCTTTCTCTTTTGGAAATGTTCAATGTTTTTTTTTAAAGGATGTTGAATGAAC 5040
Db 4981 TATCTTTCTCTTTTGGAAATGTTCAATGTTTTTTTTTAAAGGATGTTGAATGAAC 5040
QY 5041 TTCAGCACCAGTTATGATGACAGCAGTCAACAGTCTCTGTTATATAGTTTAAAGG 5100
Db 5041 TTCAGCACCAGTTATGATGACAGCAGTCAACAGTCTCTGTTATATAGTTTAAAGG 5100
QY 5101 TAAGAGTCTTGTGTTTATTCAGATTTGGAAATCCATCTATTTTGTGAATTTGGATTAAT 5160
Db 5101 TAAGAGTCTTGTGTTTATTCAGATTTGGAAATCCATCTATTTTGTGAATTTGGATTAAT 5160
QY 5161 AACAGCAGTGAATAAGTACCTGTTGAAATGTTGAAATGAGCAGTAAATAGATGAGATAA 5220
Db 5161 AACAGCAGTGAATAAGTACCTGTTGAAATGTTGAAATGAGCAGTAAATAGATGAGATAA 5220
QY 5221 AGAATTAAGAAATTAAGAGATAGTCAATCTTCTGCTTATACCTCAGTCTATTTCTGAAA 5280
Db 5221 AGAATTAAGAAATTAAGAGATAGTCAATCTTCTGCTTATACCTCAGTCTATTTCTGAAA 5280
QY 5281 ATTTTAAAGATATGATACCTGGATTTCTTGGCTTCTTCTGCTTCTTCTGCTTCTGCTGCT 5340
Db 5281 ATTTTAAAGATATGATACCTGGATTTCTTGGCTTCTTCTGCTTCTTCTGCTTCTGCTGCT 5340
QY 5341 TAAATCTGAATAAGAAATCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 5400
Db 5341 TAAATCTGAATAAGAAATCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 5400
QY 5401 TCTGCTTTTGAAGCCCTGGTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGT 5460
Db 5401 TCTGCTTTTGAAGCCCTGGTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGT 5460
QY 5461 CCACCCATAGGCTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGTGT 5520
Db 5461 CCACCCATAGGCTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGTGTAGTGT 5520
QY 5521 TCTTAAAGATAGGAAAGTGAAGAGGGGTGAGGGGTGAGGGGTGAGGGGTGAGGGGTGAGGGGT 5580
Db 5521 TCTTAAAGATAGGAAAGTGAAGAGGGGTGAGGGGTGAGGGGTGAGGGGTGAGGGGTGAGGGGT 5580
QY 5581 GTGGAGTGTCAATGCCCTGAGCTGGGCGATTTTGGGCTTTGGGAACTGCGACCTCTCT 5640

Db 5581 GTGGAGTGTCAATGCCCTGAGCTGGGCGATTTTGGGCTTTGGGAACTGCGACCTCTCT 5640
QY 5641 GGGGAGCTGATTGTAATGATCTTGGGTGGATCC 5674
Db 5641 GGGGAGCTGATTGTAATGATCTTGGGTGGATCC 5674
RESULT 4
US2670/c 275159 bp DNA PRI 31-MAR-2000
LOCUS Homo sapiens chromosome Xq28 pSHM17 pseudogene, complete sequence;
DEFINITION (ZNF275); genes, complete cds.
ACCESSION US2670 U82672
VERSION US2670.2 GI:7274891
KEYWORDS human.
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 275159)
AUTHORS Mallon,A.M., Platzer,M., Bates,R., Gloeckner,G., Botcherby,M.,
Nordsiek,G., Strivens,M.A., Kioschis,P., Dangel,A., Cunningham,D.,
Straw,R., Weston,P., Hunter,C., Gilbert,M., Fernando,S.,
Goodall,K., Kerry,G., Greystrom,J.S., Clark,D., Goerdes,M.,
Bleischmidt,K., Rump,A., Hinemann,B., Mundy,C.R., Miller,W.,
Poustka,A., Herman,G.E., Rhodes,M., Denny,P., Rosenthal,A. and
Brown,S.D.M.
TITLE Comparative genome sequence analysis of the Bpa/Str region in mouse
and man
JOURNAL Genome Res. (2000) In press
REFERENCE 2 (bases 1631 to 52906)
AUTHORS Gloeckner,G.
JOURNAL Direct Submission
TITLE Submitted (19-DEC-1996) Genome Analysis, Institute of Molecular
Biotechnology, Beutenbergstrasse 11, Jena 07745, Germany
REFERENCE 3 (bases 1 to 275159)
AUTHORS Platzer,M. and Gloeckner,G.
JOURNAL Direct Submission
TITLE Submitted (31-DEC-1999) Genome Analysis, Institute of Molecular
Biotechnology, Beutenbergstrasse 11, Jena 07745, Germany
REMARK Sequence update by submitter
COMMENT On Mar 22, 2000 this sequence version replaced gi:2078526
gi:2286115.
This sequence is part of a larger genomic contig. The start of this
sequence is directed towards the centromere. The start of this
sequence (1..250) overlaps with the end of the neighboring sequence
deposited in GenBank Accession Number U82671.
FEATURES
Source
1..275159
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="X"
/map="Xq28"
<1..35511
Location/Qualifiers
misc_feature
1..250
/note="overlaps with the end of the sequence deposited in
GenBank Accession Number U82671"
source
1631..32310
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="RPCIP704:L1034Q12"
repeat_region
1900..2216
/clone="LK0220"
/rpt_family="THE1B"
repeat_region
complement(2590..2993)
/rpt_family="MSTA"
repeat_region
complement(2994..3093)
/rpt_family="MSTA-internal"
repeat_region
3094..3817

```

repeat_region      /rpt_family="LTR8"
                    complement(3818..5353)
repeat_region      /rpt_family="MSTA-internal"
                    complement(5354..5746)
repeat_region      /rpt_family="MSTA"
                    5946..6175
repeat_region      /rpt_family="HERVR"
                    6953..7421
repeat_region      /rpt_family="HURS-P3"
                    complement(7422..7887)
repeat_region      /rpt_family="LTR19A"
                    7888..7902
repeat_region      /rpt_family="HURS-P3"
                    complement(8146..8460)
repeat_region      /rpt_family="AluJb"
                    8603..9022
repeat_region      /rpt_family="HURS-P3"
                    9243..9437
repeat_region      /rpt_family="MSTA"
                    complement(9872..10336)
repeat_region      /rpt_family="MER41A"
                    10337..10381
repeat_region      /rpt_family="L2"
                    complement(10383..11111)
repeat_region      /rpt_family="MER41-internal"
                    complement(11113..11400)
repeat_region      /rpt_family="Alusgl"
                    complement(11401..11700)
repeat_region      /rpt_family="MER41-internal"
                    complement(11700..13089)
repeat_region      /rpt_family="MER4-internal"
                    complement(13073..13790)
repeat_region      /rpt_family="MER57-internal"
                    complement(13787..13907)
repeat_region      /rpt_family="MER57-internal"
                    complement(13903..14255)
repeat_region      /rpt_family="MER57-internal"
                    14274..15228
repeat_region      /rpt_family="L1PA5"
                    15217..18398
repeat_region      /rpt_family="L1PA5"
                    18442..18975
repeat_region      /rpt_family="L1PA15"
                    19013..19652
repeat_region      /rpt_family="LTR39"
                    19535..52906
source             /organism="Homo sapiens"
                    /db_xref="taxon:9606"
                    /clone="LK0813"
repeat_region      /rpt_family="L1M3"
                    19653..20413
repeat_region      /rpt_family="MER31-internal"
                    21078..21748
repeat_region      /rpt_family="Aluya5/8"
                    21752..21886
repeat_region      /rpt_family="MER31-internal"
                    21889..22268
repeat_region      /rpt_family="MER31-internal"
                    22269..22477
repeat_region      /rpt_family="AluJo"
                    22540..22618
repeat_region      /rpt_family="MER31-internal"
                    22756..22957
repeat_region      /rpt_family="MER31-internal"
                    22968..23269
repeat_region      /rpt_family="AluJo"
                    23285..23685
repeat_region      /rpt_family="L1M4"
                    complement(24864..25145)
repeat_region      /rpt_family="AluJb"
                    25424..25454
repeat_region      /rpt_family="(GA)n"
                    complement(25765..25894)
                    /rpt_family="MLT1H"

misc_feature       25769..26426
                    /note="DXS52; acc. no. GDB:187392"
repeat_region      25918..26172
                    /rpt_family="AluY"
repeat_region      complement(26173..26252)
                    /rpt_family="polypurine"
repeat_region      26252..26359
                    /rpt_family="(TA)n"
repeat_region      complement(26798..26907)
                    /rpt_family="MIR"
                    31846..32441
misc_feature       /note="CpG island: 64.8 %GC, O/e=0.93, #CPGS=62"
                    complement(32009..32167)
repeat_region      /rpt_family="AluJo"
                    complement(33163..33210)
repeat_region      /rpt_family="AluJo"
                    34175..34216
repeat_region      /rpt_family="MSTD"
                    34754..34823
repeat_region      /rpt_family="MSTD"
                    35068..35384
repeat_region      /rpt_family="MSTD"
                    35436..37928
repeat_region      /rpt_family="HERVL"
                    complement(38078..38402)
repeat_region      /rpt_family="AluY"
                    38510..38962
repeat_region      /rpt_family="LTR168"
                    39489..39779
repeat_region      /rpt_family="AlusX"
                    complement(40031..40384)
repeat_region      /rpt_family="L2"
                    complement(40610..40802)
repeat_region      /rpt_family="L1ME1"
                    complement(40769..40937)
repeat_region      /rpt_family="L1M4"
                    complement(41230..41395)
repeat_region      /rpt_family="L1ME"
                    41398..41663
repeat_region      /rpt_family="L2"
                    complement(41928..41993)
repeat_region      /rpt_family="MLT2FB"
                    41994..42022
repeat_region      /rpt_family="(GA)n"
                    complement(42023..42381)
repeat_region      /rpt_family="MLT2FB"
                    42155..103943
source             /organism="Homo sapiens"
                    /db_xref="taxon:9606"
                    /clone="RPC1-11:K1776"
                    complement(42824..43114)
                    /rpt_family="AluJo"
                    43685..44167
repeat_region      /rpt_family="MLT1D"
                    44916..45363
repeat_region      /rpt_family="MER41B"
                    47017..47143
repeat_region      /rpt_family="MER85"
                    complement(47268..47344)
repeat_region      /rpt_family="L2"
                    47349..47645
repeat_region      /rpt_family="AluJb"
                    48693..49693
repeat_region      /rpt_family="THE1C-internal"

Query Match       98.1%; Score 5566.2; DB 50; Length 275159;
Best Local Similarity 99.6%; Pred. No. 0;
Matches 5654; Conservative 0; Mismatches 18; Indels 7; Gaps 7;

QY 1 CCGGGGACCACTGGCATCCCTCCCTCCCTACACCCCAATCCCTCCCTTAGCCACCC 60
    |||||
DB 127368 CCGGGGACCACTGGCATCCCTCCCTCCCTACACCCCAATCCCTCCCTTAGCCACCC 127309

```


QY 61 ATCCAAACATCTTCACTGCTCACCCCGAGCCCAAGCCAGGAGCAATCCGGTTCCACCCCTG 120
D 127308 ATCCAAACATCTTCACTGCTCACCCCGAGCCCAAGCCAGGAGCAATCCGGTTCCACCCCTG 127249
QY 121 CTCTCAACCCAGGGAAGCCAGGTGCCAGATGTGACGCCACCTGACTTGAAGCAATTAGTGG 180
D 127248 CTCTCAACCCAGGGAAGCCAGGTGCCAGATGTGACGCCACCTGACTTGAAGCAATTAGTGG 127189
QY 181 TTAGAGAGACGAGGTTTTCGGTCTCAGGGGGGGCTTGAGATCGGTGAGGGAAGCGGG 240
D 127188 TTAGAGAGACGAGGTTTTCGGTCTCAGGGGGGGCTTGAGATCGGTGAGGGAAGCGGG 127129
QY 241 CCCA-GCTCTGTAAAGAGGCAAGGTGACATGCTGAGGAGGAGTCTGAGGACCCACTTACCC 299
D 127128 CCCAGGCTCTGTAAAGAGGCAAGGTGACATGCTGAGGAGGAGTCTGAGGACCCACTTACCC 127069
QY 300 CAGATAGAGGACCCCAATATCCCTTCATGCGCAGTCCCTGGACCACTGCTGGTGGACTT 359
D 127068 CAGATAGAGGACCCCAATATCCCTTCATGCGCAGTCCCTGGACCACTGCTGGTGGACTT 127009
QY 360 CTCAGGCTGGGCCACCCCGAGCCCTTGCTGTAAACCACTGGGAGCTCGAAGTCAGA 419
D 127008 CTCAGGCTGGGCCACCCCGAGCCCTTGCTGTAAACCACTGGGAGCTCTGAAGTCAG 126949
QY 420 GCTCCGTGTATAGAGGAAGGGTGTCTTAGAGAGGCGACGCTCCAGGCTCTGCCAGACA 479
D 126948 AGCTCGTGTATAGAGGAAGGGTGTCTTAGAGAGGCGACGCTCCAGGCTCTGCCAGACA 126889
QY 480 TCATGCTCAGGATCTCAAGGAGGGCTGAGGGTCCCTTAAGACCCCACTCCCGTGACCCAA 539
D 126888 TCATGCTCAGGATCTCAAGGAGGGCTGAGGGTCCCTTAAGACCCCACTCCCGTGACCCAA 126829
QY 540 CCCCACATCCAAATGCTCACTCCCGTGACCCCAACCCCTCTTCATTGTTCATTCACCCCC 599
D 126828 CCCCACATCCAAATGCTCACTCCCGTGACCCCAACCCCTCTTCATTGTTCATTCACCCCC 126769
QY 600 ACCGCACATCCCGAGCCCATCCCTCAACCTGATGCCATCGGCCAGGCATTCACCC 659
D 126768 ACCGCACATCCCGAGCCCATCCCTCAACCTGATGCCATCGGCCAGGCATTCACCC 126709
QY 660 TCACCCCGACCCCGACCCCGACCCCGCTCCACCCCGACCCCGAGGAGATCCGGTTCCC 719
D 126708 TCACCCCGACCCCGACCCCGACCCCGCTCCACCCCGACCCCGAGGAGATCCGGTTCCC 126649
QY 720 GCCAGGAACATCCGGTGGCCCGATGTGAGCCACTGACTTGGCATTTGGGGCAGAG 779
D 126648 GCCAGGAACATCCGGTGGCCCGATGTGAGCCACTGACTTGGCATTTGGGGCAGAG 126589
QY 780 AGAAGCGAGGTTTCCATTCTGAGGAGCGGCTAGAGTTCGGCCGAAGGAACTTGACCCAG 839
D 126588 AGAAGCGAGGTTTCCATTCTGAGGAGCGGCTAGAGTTCGGCCGAAGGAACTTGACCCAG 126529
QY 840 GCTCTGTAGAGCAAGGTGAGAGGTGAGGAGGACTGAGGACCCCGCACTCCCAAT 899
D 126528 GCTCTGTAGAGCAAGGTGAGAGGTGAGGAGGACTGAGGACCCCGCACTCCCAAT 126469
QY 900 AGAGAGCCCAAAATATTCACGCCCGCCCTTCTGCTGCCAGCCCTGGCCACCCCGGGGAAG 959
D 126468 AGAGAGCCCAAAATATTCACGCCCGCCCTTCTGCTGCCAGCCCTGGCCACCCCGGGGAAG 126409
QY 960 ACGTCTAGCCTGGCTGCCCGCAGACCCCTGCTCCAAAGCCCTTGAGACACACAGGTT 1019
D 126408 ACGTCTAGCCTGGCTGCCCGCAGACCCCTGCTCCAAAGCCCTTGAGACACACAGGTT 126349
QY 1020 TTCTCTCCCAAGCTCTCGAATCAGAGGTTGCTGTGACAGGCGGAGGACTGGTTAGGAGAG 1079
D 126348 TTCTCTCCCAAGCTCTCGAATCAGAGGTTGCTGTGACAGGCGGAGGACTGGTTAGGAGAG 126289
QY 1080 GCGAGGCGACAGGCTCTGCCAGGATCAAGATCAGCACCCCAAGAGGAGGCTGTGGGCC 1139
D 126288 GCGAGGCGACAGGCTCTGCCAGGATCAAGATCAGCACCCCAAGAGGAGGCTGTGGGCC 126229
QY 1140 CCCAGAGCTGCATCTCCATCCCACTCCCACTCCCACTCCCACTTCCCACTCCCACTCCCACT 1199

D 126228 CCCAGAGCTGCATCCATCCCACTCCCACTCCCACTTCCCACTTCCCACTCCCACT 126169
QY 1200 CCCCATCTCTCAGCTACACTTCACCCCGATCCCGCTACTCTACTCTCGCTGACCTGACAC 1259
D 126168 CCCCATCTCTCAGCTACACTTCACCCCGATCCCGCTACTCTACTCTCGCTGACCTGACAC 126109
QY 1260 CACCCCTCCAGCCCGAGCAGCCCGACCCCTTCTGCCACCTCAGCCCTCAGCTGCCCCCAA 1319
D 126108 CACCCCTCCAGCCCGAGCAGCCCGACCCCTTCTGCCACCTCAGCCCTCAGCTGCCCCCAA 126049
QY 1320 CCCCACCTCTCTCTCTCATGTGCCCCACTCCCATCGCTCCCCCATCTCTGGCAGATC 1379
D 126048 CCCCACCTCTCTCTCTCATGTGCCCCACTCCCATCGCTCCCCCATCTCTGGCAGATC 125989
QY 1380 CGGTTTGGCCCTGCTCTCAACCCAGGGAAGCCCTGTAGGCCCGGATGTGAAACCACTGAC 1439
D 125988 CGGTTTGGCCCTGCTCTCAACCCAGGGAAGCCCTGTAGGCCCGGATGTGAAACCACTGAC 125929
QY 1440 TTGAACCTCACAGATCTGAGAGAAGCCAGGTTTCATTTAATGTTCTGAGGGGCGGCTGA 1499
D 125928 TTGAACCTCACAGATCTGAGAGAAGCCAGGTTTCATTTAATGTTCTGAGGGGCGGCTGA 125869
QY 1500 GATCCACTGAGGGAGTGGTTTTAGGCTCTGTGAGGAGCAAGGTGAGATGCTGAGGGAG 1559
D 125868 GATCCACTGAGGGAGTGGTTTTAGGCTCTGTGAGGAGCAAGGTGAGATGCTGAGGGAG 125809
QY 1560 GACTGAGGAGCACACACCCAGGTAGATGGCCCCCAAAATGATCCAGTACCACCCCTGCT 1619
D 125808 GACTGAGGAGCACACACCCAGGTAGATGGCCCCCAAAATGATCCAGTACCACCCCTGCT 125749
QY 1620 GCCAGCCCTGGACCCCGCCAGGACAGATGCTCAGCTGGACCAACCCCGCTCCCGTC 1679
D 125748 GCCAGCCCTGGACCCCGCCAGGACAGATGCTCAGCTGGACCAACCCCGCTCCCGTC 125689
QY 1680 CCACTGCCACTTAACCCACAGGCAATCTGTAGTCAATAGCTTATGTGACCGGGGAGGGT 1739
D 125688 CCACTGCCACTTAACCCACAGGCAATCTGTAGTCAATAGCTTATGTGACCGGGGAGGGT 125629
QY 1740 TGGTCAGGAGA-GGCAGAGCCCGAGCATCAAGTCCA-CGATCCGCGCGGCAATTAGGGTC 1797
D 125628 TGGTCAGGAGAAGGGCGGCGGAGGATCAAGTCCAGGCA-CCGCGCGGCAATTAGGGTC 125569
QY 1798 AGGACCCCTGGGAGGGAACCTGAGGGTTCCCGACCCACACCTGTCTCTCATCTCCACCGCC 1857
D 125568 AGGACCCCTGGGAGGGAACCTGAGGGTTCCCGACCCACACCTGTCTCTCATCTCCACCGCC 125509
QY 1858 ACCCCACTCACATTCCTCCATACCTACCCCTACCCCTACCCCTACCTTGTGTCAGATCCCTG 1917
D 125508 ACCCCACTCACATTCCTCCATACCTACCCCTACCCCTACCCCTACCTTGTGTCAGATCCCTG 125449
QY 1918 CTGTCACCCACGGAAGCCACGGGAATGGCGCAGGCACTCGGATCTTTCAGTCTCCCAT 1977
D 125448 CTGTCACCCACGGAAGCCACGGGAATGGCGCAGGCACTCGGATCTTTCAGTCTCCCAT 125389
QY 1978 CCAGGCTCTGATGGAGGGAAGGGCTTGAACAGGGCTTCAGGGGACGAGGAGGGGCC 2037
D 125388 CCAGGCTCTGATGGAGGGAAGGGCTTGAACAGGGCTTCAGGGGACGAGGAGGGGCC 125330
QY 2038 TACTCGAGATGAGGAGGCTCAGAGGACCCAGCACCTTAGGACACCCAGCCCTGTCT 2097
D 125329 TACTCGAGATGAGGAGGCTCAGAGGACCCAGCACCTTAGGACACCCAGCCCTGTCT 125270
QY 2098 GAGACTGAGGCTGCCACTTCTGGCTCAGAGATCAGAGATCAGAGATGAGGAGTTCAGATT-GCAT 2156
D 125269 GAGACTGAGGCTGCCACTTCTGGCTCAGAGATCAGAGATCAGAGATGAGGAGTTCAGATT- 125210
QY 2157 GGGGTGGGAGCCAGGCTCGAAGGCTTACGCGAGGAAGAGGAGGAGGACTCAGGGGA 2216
D 125209 GGGGTGGGAGCCAGGCTCGAAGGCTTACGCGAGGAAGAGGAGGAGGACTCAGGGGA 125150
QY 2217 CCTTGAATCCAGATCAGTGTGGACCTCGGCCCTGAGAGGTTCCAGGGCAGGTTGGCCACA 2276
D 125150 CCTTGAATCCAGATCAGTGTGGACCTCGGCCCTGAGAGGTTCCAGGGCAGGTTGGCCACA 125100


```
QY 4437 ATCAGATCATGCCCAACAGAGGCTTCCTGATTAATTTGCTGTGTCATGATTCGAATGAGG 4496
|
|
|
Db 122930 ATCAGATCATGCCCAACAGAGGCTTCCTGATTAATTTGCTGTGTCATGATTCGAATGAGG 122871
|
|
|
QY 4497 GCGGCCATGCTCCGAGAGGAGAAATCTGGAGGAGCTGAGTGTGATGGAGGTGTATGATG 4556
|
|
|
Db 122870 GCGGCCATGCTCCGAGAGGAGAAATCTGGAGGAGCTGAGTGTGATGGAGGTGTATGATG 122811
|
|
|
QY 4557 GGAGGGAGCAGAGTGCCTATGTTGGGAGCCGAGGAGCTGTCACCCAAAGATTTGGTGCAGG 4616
|
|
|
Db 122810 GGAGGGAGCAGAGTGCCTATGTTGGGAGCCGAGGAGCTGTCACCCAAAGATTTGGTGCAGG 122751
|
|
|
QY 4617 AAAAGTACCTGGAGTA-CGGCAGGTGCGGACAGTATGCCGACGCTATGATTCCTGT 4675
|
|
|
Db 122750 AAAAGTACCTGGAGTACCGGAGGTCGGACAGTATGCCGACGCTATGATTCCTGT 122691
|
|
|
QY 4676 GGGTCCAAAGGGCCCTCGCTGAACACAGCTATGTGAAGTCCCTTGATGTATGATCAAGG 4735
|
|
|
Db 122690 GGGTCCAAAGGGCCCTCGCTGAACACAGCTATGTGAAGTCCCTTGATGTATGATCAAGG 122631
|
|
|
QY 4736 TCAGTGAAGAGTTGCGCTTTTCTTCCATCCCTGCTGAAGCAGCTTTGAGAGGAGG 4795
|
|
|
Db 122630 TCAGTGAAGAGTTGCGCTTTTCTTCCATCCCTGCTGAAGCAGCTTTGAGAGGAGG 122571
|
|
|
QY 4796 AAGAGGAGTCTGAGCATGAGTTGACGCAAGCCAGTGGAGGGGAGCTGGCCAGTGC 4855
|
|
|
Db 122570 AAGAGGAGTCTGAGCATGAGTTGACGCAAGCCAGTGGAGGGGAGCTGGCCAGTGC 122511
|
|
|
QY 4856 ACCTTCAGGCGCCGTCACAGAGCTTCCCTGCTGCTGATGACATGAGCCGATTTTC 4915
|
|
|
Db 122510 ACCTTCAGGCGCCGTCACAGAGCTTCCCTGCTGCTGATGACATGAGCCGATTTTC 122451
|
|
|
QY 4916 ACTCTGAAGAGCGGTCAGTGTCTCAGTAGTAGTTCCTGTCTATTTGGGTGACTGG 4975
|
|
|
Db 122450 ACTCTGAAGAGCGGTCAGTGTCTCAGTAGTAGTTCCTGTCTATTTGGGTGACTGG 122391
|
|
|
QY 4976 AGATTATCTTTGCTCTTTTGAAGTGTCAAAATGTTTTTTTAAAGGATGGTTGAA 5035
|
|
|
Db 122390 AGATTATCTTTGCTCTTTTGAAGTGTCAAAATGTTTTTTTAAAGGATGGTTGAA 122331
|
|
|
QY 5036 TGAACCTCAGATCCAGTTTATGAATGACAGAGTACACAGTTCCTGTATATAGTTT 5095
|
|
|
Db 122330 TGAACCTCAGATCCAGTTTATGAATGACAGAGTACACAGTTCCTGTATATAGTTT 122271
|
|
|
QY 5096 AAGGTAAAGTCTGTGTTTTATTTCAGATTGGAAATCAATTCATTTTGTGAATTTGGG 5155
|
|
|
Db 122270 AAGGTAAAGTCTGTGTTTTATTTCAGATTGGAAATCAATTCATTTTGTGAATTTGGG 122211
|
|
|
QY 5156 ATAATAACAGCAGTGGATTAAGTACTTAGAAATGTGAAATAGCAGTAAATAGATGA 5215
|
|
|
Db 122210 ATAATAACAGCAGTGGATTAAGTACTTAGAAATGTGAAATAGCAGTAAATAGATGA 122151
|
|
|
QY 5216 GATTAAGAGTAAAGAAATTAAGAGATAGTCAATTCCTGCTTATACCTCAGTCTATTCT 5275
|
|
|
Db 122150 GATTAAGAGTAAAGAAATTAAGAGATAGTCAATTCCTGCTTATACCTCAGTCTATTCT 122091
|
|
|
QY 5276 GTAAATTTTAAAGATATATGATACCTGATTTCCCTTGTGCTTCTTTGAGATGTAAAGA 5335
|
|
|
Db 122090 GTAAATTTTAAAGATATATGATACCTGATTTCCCTTGTGCTTCTTTGAGATGTAAAGA 122031
|
|
|
QY 5336 GAAATTAATCTGAATAAGAAATTTCTTCTGTTTCACTGGCTCTTTTCTTCCATGCAC 5395
|
|
|
Db 122030 GAAATTAATCTGAATAAGAAATTTCTTCTGTTTCACTGGCTCTTTTCTTCCATGCAC 121971
|
|
|
QY 5396 GAGCATCTGCTTTTGGAGGCGCTGGGTTAGTAGTGAGATGCTTAAGGTAAAGCCAGCT 5455
|
|
|
Db 121970 GAGCATCTGCTTTTGGAGGCGCTGGGTTAGTAGTGAGATGCTTAAGGTAAAGCCAGCT 121911
|
|
|
QY 5456 CATACCCACCATAGGGTCGTAGAGCTTAGAGAGTGCAGTCAACCTAATCGAGGTGGCAAG 5515
|
|
|
Db 121910 CATACCCACCATAGGGTCGTAGAGCTTAGAGAGTGCAGTCAACCTAATCGAGGTGGCAAG 121851
|
|
|
QY 5516 ATGTCTCTAAAGATGTAGGGAAAGTGAGAGAGGGGTGAGGGTGTGGGGCTCCGGGTGA 5575
|
|
|
```

```
Db 121850 ATGTCTCTAAAGATGTAGGGAAAGTGAGAGAGGGTGTGGGGTCTCCGGGTGA 121791
|
|
|
QY 5576 GAGTGTGAGTGTCAATGACCTGAGCTGGGCAATTTGGGCTTTGGGAACTGCAATTC 5635
|
|
|
Db 121790 GAGTGTGAGTGTCAATGACCTGAGCTGGGCAATTTGGGCTTTGGGAACTGCAATTC 121731
|
|
|
QY 5636 CTCTCTGGGGAGCTGATTGTAATGATCTTGGGTGATCC 5674
|
|
|
Db 121730 CTCTCTGGGGAGCTGATTGTAATGATCTTGGGTGATCC 121692
|
|
|
RESULT 5
HSU82672/c standard; DNA; HUM; 156854 BP.
XX
AC U82672;
SV U82672.1
XX
DT 14-MAY-1997 (Rel. 51, Created)
DT 02-JUL-1999 (Rel. 60, Last updated, Version 2)
XX
DE Human chromosome X clone Qc15B1, complete sequence.
XX
KW HTG.
XX
OS Homo sapiens (human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Teleostomi;
OC Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
XX
RN [1]
RP 1-156854
RA Gloeckner G., Rump A., Nordsiek G., Hinzmann B., Kioschis P., Heiss N.,
RA Foustka A., Bauer D., Drescher B., Knob A., Rosenthal A.;
RT "Sequencing and analysis of a region in Xq28 containing MAGE-1 and a
RL putative Zinc Finger Protein";
XX
RN [2]
RP 1-156854
RA Gernot G.;
RL Submitted (19-DEC-1996) to the EMBL/GenBank/DBJ databases.
XX
RL Genome Analysis, IMB, Beutenbergstr. 11, Jena 07745, Germany
XX
DR SWISS-PROT; P43355; MAG1_HUMAN.
XX
FH Key Location/Qualifiers
FH
FT source
FT 1. .156854
FT /chromosome="X"
FT /db_xref="taxon:9606"
FT /organism="Homo sapiens"
FT /map="Xq28"
FT
FT source
FT 1. .40357
FT /db_xref="taxon:9606"
FT /organism="Homo sapiens"
FT /clone="Qc15B1"
FT 1057. .1295
FT /rpt_family="Alu-Sz"
FT repeat_region
FT 2504. .2666
FT /rpt_family="MIR"
FT repeat_region
FT complement(4262. .5191)
FT mRNA
FT /gene="MAGE1"
FT /product="MAGE-1 Protein"
FT complement(4262. .5191)
FT /gene="MAGE1"
FT CDS
FT complement(4262. .5191)
FT /codon_start=1
FT /db_xref="SWISS-PROT:P43355"
FT /gene="MAGE1"
FT /product="MAGE-1 Protein"
```

```

FT /protein_id="AB54061.1"
FT /translation="MSLEQRSLHCPPEERALEAQOALGLVCVQAASSSPLVLGTLEE
FT VTAGSDPPQSPQASAPPTINFTQRPQEGSSRRSEEGPSTSCILESLFRAVITR
FT KVADLVGFLLRKAREPVTKAEMLESVKNYKHCFPEIFGKASESLQLVGDIYKQAD
FT PTGHSYLVTCGLGVDGLGDNQIMPTKGLIIVLMIAMEGGHAPPEEIIWEELSYME
FT VVDGRSAYGSPRKLLTQDLVQERYLEYRQVQSDPARYEFLWGPRLAETSYYVKLE
FT YIKVSARVRFPPSLREAAAREEEGV"
FT 9623..9892
FT /rpt_family="Alu-Sz"
FT complement(10698..10978)
FT /rpt_family="Alu-Sx"
FT complement(12218..12345)
FT /rpt_family="MER42C"
FT complement(12636..12851)
FT /rpt_family="MER42A"
FT complement(12909..13060)
FT /rpt_family="MER42A"
FT complement(13455..13825)
FT /rpt_family="MUT1A"
FT 13557..93516
FT /db_xref="taxon:9606"
FT /organism="Homo sapiens"
FT /clone="QC3H10"
FT complement(13836..13904)
FT /rpt_family="LIMC2"
FT complement(13939..14597)
FT /rpt_family="LIMD1"
FT complement(14609..14916)
FT /rpt_family="L1"
FT complement(15018..15180)
FT /rpt_family="L1"
FT 15186..15590
FT /rpt_family="MUT1B"
FT complement(15707..15927)
FT /rpt_family="L1PA7"
FT 15959..16298
FT /rpt_family="MUT2C2"
FT complement(16377..16753)
FT /rpt_family="THE1B"
FT complement(16754..18327)
FT /rpt_family="THE1BR"
FT complement(18329..18704)
FT /rpt_family="THE1B"
FT complement(18983..19802)
FT /rpt_family="L1PA2"
FT complement(19804..20131)
FT /rpt_family="L1"
FT complement(20212..20639)
FT /rpt_family="L1"
FT complement(21048..21637)
FT /rpt_family="MER11B"
FT complement(21641..21879)
FT /rpt_family="MER11A"
FT complement(21880..21960)
FT /rpt_family="MER11A"
FT complement(21970..22108)
FT /rpt_family="MER11A"
FT 24072..24198
FT /rpt_family="MUT2A1"
FT 24341..24389
FT /rpt_family="MUT2A1"
FT complement(26799..26959)
FT /rpt_family="MUT2B2"
FT complement(27010..27126)
FT /rpt_family="MUT2B2"
FT 27127..27413
FT /rpt_family="Alu-Sg"
FT complement(27433..27667)
FT /rpt_family="MUT2B2"
FT 28489..28775
FT /rpt_family="Alu-Y"
FT complement(28871..28975)
FT /rpt_family="MIR"

```

```

FT repeat_region complement(29228..29515)
FT /rpt_family="Alu-Sp"
FT repeat_region complement(29616..29942)
FT /rpt_family="L1MA10"
FT repeat_region complement(31359..31633)
FT /rpt_family="Alu-Sq"
FT repeat_region complement(32548..32808)
FT /rpt_family="L1"
FT 32809..32857
FT /rpt_family="L1"
FT repeat_region complement(34762..34995)
FT /rpt_family="MIR"
FT 35451..72634
FT /db_xref="taxon:9606"
FT /organism="Homo sapiens"
FT /clone="QC13B12"
FT 38832
FT /note="A deletion in QC13B12"
FT repeat_region complement(41850..41971)
FT /rpt_family="L1PA11"
FT repeat_region complement(42203..42617)
FT /rpt_family="L1"
FT repeat_region complement(42956..44558)
FT /rpt_family="TIGGER1"
FT 43979
FT /note="A deletion in QC13B12"
FT repeat_region complement(44611..45372)
FT /rpt_family="TIGGER1"
FT 46194..46483
FT /rpt_family="Alu-Jo"
FT repeat_region 46485..46541
FT /rpt_family="L1MA2"
FT 46772..47025
FT /rpt_family="MLT1F"
FT repeat_region 48186..48348
FT /rpt_family="MER5A"
FT complement(48811..48961)
FT /rpt_family="L1MA2"
FT repeat_region complement(48962..49219)
FT /rpt_family="L1"
FT repeat_region complement(49284..49572)
FT /rpt_family="Alu-Sbcg"
FT repeat_region complement(49578..49626)
FT /rpt_family="L1"
FT 49645..50522
FT /rpt_family="L1MA2"
FT repeat_region 51730..52541
FT /rpt_family="L1MB7"
FT 52733..52811
FT /rpt_family="L1"
FT 52814..53500
FT /rpt_family="L1PB3"
FT 63990..107000
FT /db_xref="taxon:9606"
FT /organism="Homo sapiens"
FT /clone="LL0137"
FT 64242
FT /note="A in LL0137"
FT 66361
FT /note="G in LL0137"
FT 67333
FT /note="C in LL0137"
FT 67603
FT /note="G ion LL0137"
FT 67825
FT /note="A in LL0137"
FT 68173
FT /note="A in LL0137"

```

```

Query Match 97.5%; Score 5532.6; DB 48; Length 156854;
Best Local Similarity 99.3%; Pred. No. 0;
Matches 5640; Conservative 0; Mismatches 29; Indels 10; Gaps 8;

```



```
QY 4377 GCACCTCCTATGTCCTGTGACCTGCTAGGTCCTCCTATGATGCGCTGCTGGGTGATA 4436
Db 4695 GCCACTCCTATGTCCTGTGACCTGCTAGGTCCTCCTATGATGCGCTGCTGGGTGATA 4636
QY 4437 ATCAGATCATGCCCAAGACAGGCTTCTGATTAATTTGTCCTGGTTCATGATTGCAATGAGG 4496
Db 4635 ATCAGATCATGCCCAAGACAGGCTTCTGATTAATTTGTCCTGGTTCATGATTGCAATGAGG 4576
QY 4497 CGGCCATGCTCCTGAGGAGGAATCTGGGAGGAGCTGATGATGATGGAGGTGATGATG 4556
Db 4575 CGGCCATGCTCCTGAGGAGGAATCTGGGAGGAGCTGATGATGATGGAGGTGATGATG 4516
QY 4557 GGAGGAGCAGCTGCTATGAGGAGCCCAAGGAGCTGCTACCCCAAGATTTGCTGTCAGG 4616
Db 4515 GGAGGAGCAGCTGCTATGAGGAGCCCAAGGAGCTGCTACCCCAAGATTTGCTGTCAGG 4456
QY 4617 AAAAGTACCTGGAGTA-CGGCAGGTGCGGACAGTATGATCCCGCACGCTATGATTCCTGT 4675
Db 4455 AAAAGTACCTGGAGTACCGGAGGTGCGGACAGTATGATCCCGCACGCTATGATTCCTGT 4396
QY 4676 GGGTCCCAAGGGCCCTCGCTGAACCAAGCTATGTGAAGTCCCTGAGTATGATCAAGG 4735
Db 4395 GGGTCCCAAGGGCCCTCGCTGAACCAAGCTATGTGAAGTCCCTGAGTATGATCAAGG 4336
QY 4736 TCAGTGAAGAGTTCGCTTTTCTCCATCCCTGCTGAGGAGCTTTGAGAGGAGG 4795
Db 4335 TCAGTGAAGAGTTCGCTTTTCTCCATCCCTGCTGAGGAGCTTTGAGAGGAGG 4276
QY 4796 AAGAGGAGTCTGAGCATGATGTCAGCCCAAGCCAGTGGAGGGGAGCTGGGCCAGTGC 4855
Db 4275 AAGAGGAGTCTGAGCATGATGTCAGCCCAAGCCAGTGGAGGGGAGCTGGGCCAGTGC 4216
QY 4856 ACCTTCCAGGCGCGCTCCAGCAGCTTCCCTGCTGCTGATGACATGAGCCCATCTTC 4915
Db 4215 ACCTTCCAGGCGCGCTCCAGCAGCTTCCCTGCTGCTGATGACATGAGCCCATCTTC 4156
QY 4916 ACTGTAAGAGAGGGTCACTGTCAGTACAGTACAGTTCCTGCTATGCTGGTACATGG 4975
Db 4155 ACTGTAAGAGAGGGTCACTGTCAGTACAGTACAGTTCCTGCTATGCTGGTACATGG 4096
QY 4976 AGATTTATCTTTGTCCTTTTGGAAATGTTCAAAATGTTTTTTTAAAGGATGGTTGAA 5035
Db 4095 AGATTTATCTTTGTCCTTTTGGAAATGTTCAAAATGTTTTTTTAAAGGATGGTTGAA 4036
QY 5036 TGAATTCAGCATCCCAAGTTATGAATGACAGCAGTCACACAGTTCGTGTATATAGTTT 5095
Db 4035 TGAATTCAGCATCCCAAGTTATGAATGACAGCAGTCACACAGTTCGTGTATATAGTTT 3976
QY 5096 AAGGTGAAGAGTCTGTGTTTTTATTCAGATTGGAAATCCATTCTATTTTGTGAATGGG 5155
Db 3975 AAGGTGAAGAGTCTGTGTTTTTATTCAGATTGGAAATCCATTCTATTTTGTGAATGGG 3916
QY 5156 ATAATAACAGCAGTGAATAGTACTTAGAATGTGAAAATGAGCAGTAAATAGATGA 5215
Db 3915 ATAATAACAGCAGTGAATAGTACTTAGAATGTGAAAATGAGCAGTAAATAGATGA 3856
QY 5216 GATAAAGACTAAAGAAATTAAGAGATGATCAATCTGCTGCTTATACCTCAGCTATTCT 5275
Db 3855 GATAAAGACTAAAGAAATTAAGAGATGATCAATCTGCTGCTTATACCTCAGCTATTCT 3796
QY 5276 GTAAAAATTTTAAAGATATATGCAATACCTGATTCCTGCTGCTTCTTTGAGATGAAGA 5335
Db 3795 GTAAAAATTTTAAAGATATATGCAATACCTGATTCCTGCTGCTTCTTTGAGATGAAGA 3736
QY 5336 GAAATTAATCTGAATAAGAAATCTTCCTGTTACCTGCTGCTTCTTCTCCATGCACCT 5395
Db 3735 GAAATTAATCTGAATAAGAAATCTTCCTGTTACCTGCTGCTTCTTCTCCATGCACCT 3676
QY 5396 GAGCATCTGCTTTTGAAGGCCCTGGGTTAGTAGTGGAGATGCTAAGGTAAGCCAGACT 5455
Db 3675 GAGCATCTGCTTTTGAAGGCCCTGGGTTAGTAGTGGAGATGCTAAGGTAAGCCAGACT 3616
QY 5456 CATACCCACCCATAGGCTGTAGAGTCTAGGAGTGCAGTCACTGATTCGAGGTGGCAAG 5515
```

```
|||||
Db 3615 CATACCCACCCATAGGCTGTAGAGTCTAGGAGTGCAGTACACGTAATCGAGGTGGCAAG 3556
QY 5516 ATGTCTCTCTAAAGATCTAGGAAAAAGTGAAGAGGGGTGAGGGTGGGGTCCCGGTGA 5575
Db 3555 ATGTCTCTCTAAAGATCTAGGAAAAAGTGAAGAGGGGTGAGGGTGGGGTCCCGGTGA 3496
QY 5576 GAGTGGTGAAGTCAATGCCCTGAGCTGGGCAATTTGGGCTTTGGGAAACTGCAGTTC 5635
Db 3495 GAGTGGTGAAGTCAATGCCCTGAGCTGGGCAATTTGGGCTTTGGGAAACTGCAGTTC 3436
QY 5636 CTTCTGGGGAGCTGATTGTAATGATCTTGGGTGGATCC 5674
Db 3435 CTTCTGGGGAGCTGATTGTAATGATCTTGGGTGGATCC 3397

RESULT 6
AF134576 49375 bp DNA PRI 06-APR-1999
LOCUS Homo sapiens MAGE10 and undefined MAGE genes, complete sequence.
DEFINITION AF134576
ACCESSION AF134576
VERSION AF134576.1 GI:4567140
KEYWORDS HTG..
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 49375)
AUTHORS Gloeckner, G. and Rosenthal, A.
TITLE Sequence of three cosmids of human Xq28 (16c3, 3q5, 3h5) containing
JOURNAL MAGE genes
REFERENCE 2 (bases 1 to 49375)
AUTHORS Gloeckner, G., Rosenthal, A. and Schattevoy, R.
TITLE Direct Submission
JOURNAL Submitted (12-MAR-1999) Genome Analysis, Institute for Molecular
Biotechnology, Beutenbergstrasse 11, Jena 07745, Germany
FEATURES
source
1..49375
/organism="Homo sapiens"
/db_xref="taxon:9606"
/map="Xq28"
/chromosome="X"
/clone="cosmids 16c3; 3q5; 3h5"
1..10000
/note="incomplete at 3' end"
/region="Region: Cosmid 16c3"
complement(10..202)
/rpt_family="MER93"
/evidence=not_experimental
289..372
/rpt_family="L1M1"
/evidence=not_experimental
446..726
/rpt_family="L1M1"
/evidence=not_experimental
528..43599
/region="Region: Cosmid 3q5"
731..4392
/rpt_family="L1MC3"
/evidence=not_experimental
complement(4393..4696)
/rpt_family="MER2"
/evidence=not_experimental
complement(4697..4755)
/rpt_family="L1MA2"
/evidence=not_experimental
complement(4756..4803)
/rpt_family="MER2"
/evidence=not_experimental
4805..4847
/rpt_family="L1MC3"
/evidence=not_experimental
```


Db	28315		CCGAGTCCCCCACCGCTTAAGCCGAGGGGA	-----CTCAGGAG	28335
Qy	1040	TCAGAGGTTGCTGTGACACAGGCGRAGGACTGTTTAGGAGAGGCGACAGGCTCTGCC	1099		
Db	28354	ACAGAGCTTGGTATGACACAGGCGCAGGACTGGTTAGGAGAGGACAGCTCCCAAGGCTCTGCC	28413		
Qy	1100	AGGCATCAAGATACAGCACCCCAAGAGGGAGGCGCTGTGGGCCCCCAAGAGCTGCATCCCAATC	1159		
Db	28414	AGGAACAACGTCAGGAACCTAAGGGAAGAGCTGAGGCTACCCC	28456		
Qy	1160	CCCACTCCCAACCCCATCGCATTCGCCATTCGCCACCCCAACCCCATCTCTCTCTCA	1219		
Db	28457	-----	-----CAC	28459	
Qy	1220	CTCCACCCCATCCCTACTCTACTTCCGTCACCTGACCAACCAACCCCTCAGAGCCCGAGCACC	1279		
Db	28460	CCCAACTCTATCTCTGTCCTACTCTCGTCCCCACCTACACCCCCCATTC	28514		
Qy	1280	AGCCCAACCCCTTTCGCACCTCACCCTACTGCCCCCAACCCCAACCTCATCTCTCTCA	1338		
Db	28515	CACCCATCCCTACCGGCACCTCTATCCCATCCGCCA	28553		
Qy	1340	TGTGCCCACTCCCATCGCCTCCCCATCTTGGCAGAAATCCGGTT-TGCCCGCTGCTCTCA	1398		
Db	28554	-----CCCTATCTTGGCAGAAATCCGATTCTGCCCGCTGATTCTCA	28592		
Qy	1399	ACCCAGGGAAGCCCTGTGAGCCCGAGTGTGAACCACTGACTTGAACCTCAGACTCTGA	1458		
Db	28593	ACCCAGGGAAGCCCTTAGGGGCGGAGTGTGATGTCTGTGACTTGTGCATTCGGGCTCAGA	28652		
Qy	1459	GAGAAAGCAGGTTCTATTTAATGGTTCTGAGGGGGGCTTGAGATCCACTGAGGGGAGTGG	1518		
Db	28653	GAGAAATCAAG-----GCATGGTTCTCAGAAAGCCGACTGAGATCAGCAGAGGGGAATGG	28706		
Qy	1519	TTTTAGGCTCTGTGAGGAGCAAGGTGAGA-TGCTGAGGGAGGACTGAGGAGGCACAC	1577		
Db	28707	GCCGGGCTCTGTGAGGAGCAAGGTGAGCCCGCAGAGAAATGAGGAAGCCCTCAC	28766		
Qy	1578	CCAGGTAGATGGCCCCAAAATGATCCAGTACCAACCCCTGTGCCAGCCCTTGGACCAACC	1637		
Db	28767	CCA--GATAGAGAACCCCAATAATCCAGTACTACTTGTGTGCCAGCCCTTGGACCA--	28822		
Qy	1638	GGCCAGGACAGATGCTCAGCTGGACCAACCCCGTCCCACTGCCACTGCCACTTAACCCA	1697		
Db	28823	--CAGGCGAGCTTCTCAGGCTGACCTTCCC--CCCTCCCACTGCCACTTAAGCCA	28877		
Qy	1698	CAGGCAATCTGTAGTCAATAGCTT-ATGTGACCGGGGAGGTTGGTCAGGAGGCGAGG	1756		
Db	28878	CAAGGAGCTCTGGAGTCAGACCTTGGTGTGACCAAGGAAGGCGCGTTCAGAGAG--	28933		
Qy	1757	GCCCAAGGCATCAAGTTCAGATCCGCGCGCATTTAGGCTCAGGACCCCTGGAGGGAAC	1816		
Db	28934	-----GCAGGGCCAGGCTCTGTTCAGGCATCAAAATCAGGACCCTGAGAGAAAT	28984		
Qy	1817	GAGGTTTCCCAACCAACCTGTCTCTCTATCTCCACGCCCAACCCACTCAGATCCCAT	1876		
Db	28985	GAGGCGCCCAACCCCAACCCCTATACCCATCCCTAAACCCCATCCCACTTACTTTGCA	29044		
Qy	1877	ACCTACCCCTACCCCA--ACCTCATCTGTTCAGAA-----TGCCCTGCTCTC	1922		
Db	29045	CCCAGCCCATCCCAACACCCCTACCCCATCTTGGCAGAAATCTGTTCTTCTCCCTCAG	29104		
Qy	1923	RAACCAGAGCCACGGGAATGGGGGCGCAGGACTCGGATCTTGACGTCGCCATCCAGG	1982		
Db	29105	RAACCACAGAGCCCGAGGAATGACAGACAGGCACACCAATCTTGACGTCACATCCAGG	29164		
Qy	1983	GTCTCATGGGGGAAGGGCT-----TGAAAGGGCCTCAGGGAGCAGAGGGAGG--	2039		
Db	29165	GCTGAAGAGGGAAGGCTTAGTATCATGACGAGGGCTCAGGGAGTCTCTGCTCTCTC	29234		
Qy	2034	--GCCCTACTGCGAGATGAGGAGGCGCTCAGAGGACCCAGCACCCCTAGA-----C	2082		

Db	29225	AAGCCCTCTCTGGGAGTAAAGGAGAGCCCTCAGGGAACCCAGGTCTCTCAGGATAGGGGGTCC	29282
Qy	2083	ACCCACACCCTGTCTGAGACTGAG--GOTGCCACTTTCGGCCTCAAGAATCAGAACGATG	2140
Db	29285	ACTCCAAACCCCTGTCTGAGACTGAGGGCGCTCTCTTTTCATCTCTCGGGAATCAGAGGGATG	29344
Qy	2141	GGGACTCAGATTGCATGGGGTGGGACCCAGGCGCTCGAAGCCTTACGGGAGGAAGAGGA	2200
Db	29345	GAGACTCACGTACAGAGAGGTTGGGGCCCAACCCCTGCCAGGATCANGGAGGAAGAAGA	29404
Qy	2201	GGGAGGACTCAGGGACCTTGGAAATCCAGATCAGTGTGGACCTCGGCCCTCAGAGGTCCA	2260
Db	29405	GGGAGGACTCAGGGTACCTTTGAGTCCAGACAATGGGACCTTTCCTCGGAGGTCCA	29464
Qy	2261	GGGACAGGTGCCACATATGCCCCATATTTCTCGATCTTTGAGGTGAC-----AGGACAG	2316
Db	29465	GTGCACAGTGGCCACCTGTAGCCCATGCTCTCTGCACCTTCTGGGTGACAAAGAGGAGAG	29524
Qy	2317	AGCTGTGTGTCGAGAAGTGGGGCCTCAGGTCAAAGAGGGAGGAGTTTCCAGGATCCCATAT	2376
Db	29525	GGCTGTGTACAGCAGTGTGTACTCAGGTACAGAGGGAGGAGTCCCAGCATCTGCAG	29584
Qy	2377	GGCCCCAAGATGTGCCCTTTCATGAGGACTGGGGATATPCCCGGCTCAGAAAGAAGGGAC	2436
Db	29585	CCCCCAATGTGTGCCCATTTCAAGAAATTTGGGATA--CCTTGGCTCAGAAAGAAGGAC	29643
Qy	2437	TCCACACAGTCTGGCTGTCCTTTTAGTAGCTCTAGGGGACACAGATCAGGGATGGCGG	2496
Db	29644	CCCACAGATCTGGCTGTCCCTCGATTTTGCTCAGAGGGAGCCAAATCAAGATATGCCCT	29703
Qy	2497	TATGTTCCATTCTCAGTTGTACCCACAGCAGGAAGTTGGGGGGCCCTCAGGGAGATGGGG	2556
Db	29704	TATGTGCCAACCTCATTTGTGCCACAGAAAGAGTTGAAGAGCCCTCAGGGTGATGGGG	29763
Qy	2557	TCTTGGGTAAGGGGGATGCTACTCATCTCAGGGAATTTGGGGTTGAGGAACACAG	2616
Db	29764	TCTTGCAGTAAGGGGAGCTATCTGCTCATCTCAGGGGTTTTCAGTTGAGGAATGGCAG	29823
Qy	2617	CGCGTGGCAGGAATAAAGATGAGTGAGACACAAAGGCTATTGGAATCCACACCCACAGAA	2676
Db	29824	GCCCCATCAG--ATGAAGAGTAAACCCACAGAGGCCATAGAACACTCACCCACAGAA	29879
Qy	2677	CCAAAGGGGTGAGCCCTGGACACCTCA-----CCACGATGTGGCTTCTTTTTCAC	2727
Db	29880	CCAAAGGGGTGCATACCTGGACACCCCATGTGGGGGTGACAGGATGTAGC--TCCATCTCAT	29938
Qy	2728	TCCTGTTTCCAGATCTGGGGCAGGTGAGGACCTCATTTCTCAGAGGGTGACATCAGTCAAC	2787
Db	29933	TCCCTGTTTTCAGATCTGGGGAGGTGAGGAATCTGTTCTCCAGAGTACATCAGGTCAAC	29998
Qy	2788	GTAGGACCCCCATCTGTGCTTAAAGACAGAGCGGTCCACAGGATCTGCCATCGCTTCGGGT	2847
Db	29999	ACAGGGGCCCATCTGTGTGATAGACAGAGTGTGCCAGGATCTGTCAGTAGTTCGGGT	30058
Qy	2848	GAGGAACATGAGGAGGACTCAGGTACCCAGGACAGACACTGAGGGAGACTGCACA	2907
Db	30059	GAGGAACATGAGGACGATTCAGGGCACCTTTGGGCCAAGACAGATGAGGACCTTCAGC	30118
Qy	2908	GAATTCAGCCCTGCCCTCTGTCTCACCCAGAGAGCATGGGCTGGGGCGTCTGCCGAGGT	2967
Db	30119	GAATCTGCCCTGCTGTCTCACTCCAGAGAGCATGGCAGGGCTGTCTGCTGCAGT	30178
Qy	2968	CCTTCC--GTTATCTCTGGGATCATTTGATGTACAGGACGGGAGGCTTTGGTCTCAGAAAG	3025
Db	30179	CCCCCCCACCTTACCCCTGGGAATCTTGGTGTTCAGGATGGGAGGTCTTTGTTC--GAGGGGT	30237
Qy	3026	CTGCCTCAGGTCAGTAGAGGAGCGTCCCAGGCCCTGCCAGGAGTCAAGGTGAGGACCA	3085
Db	30238	CTGACTCAGTTCAGTAGAGGAGCGCTTTAGGCCCTGCCAGGACAGAGTATAGACGA	30297
Qy	3086	AGCGGCGACCTCACCCAGGACACATTAATCCAAATGAATTTTGATATCTCTTGTCTGCCCT	3145
Db	30298	AGCAGGTTCCCTCACCCAGGACACATGAATTCCAATGCAATTCACGATCTCTTCTCTGCTCT	30357

QY	3146	TCCCA-AGGACCTAGGACGCTGTGGCCAGATGTTTGCCCTCCTCTCTCTTCATTCCT	3204
DB	30358	TCCCAGAGGACCTGGGACGCTGTGGCCAGATGATGAGTCTCCTCATGTCCF--GTTCCC	30414
QY	3205	TATCATGATGTGAACCTCTTGAATTTGGATTCTCAGACCAAGAAAGGCGAGGATCCAGG	3264
DB	30415	TATCAGGATGTGAGCTCTTAATCTGAGTTCTCAGGCCACAAAGAGGTGGGATCCAGG	30474
QY	3265	CCCTCCAGGAATAATATAAGGGCCCTGCTGAGAACAGAGGGGTCAATCCATGCATGA	3324
DB	30475	CCCTCCAGGAGAAAGGTGAGGGCCCTGTGAGCACAGAGGGGACCAATTCACCCRAGA	30534
QY	3325	GAGTGGGATGTACAGAGTCCAGGCCACCCCTCCTGTGTAGCACTGAGAAAGCCAGGGCTGT	3384
DB	30535	GGTGGAGACCTACAGATTCCAGCCTACCTCCTGTTAGCACTGGGGCCTGAGGCTGT	30594
QY	3385	GCTTCGGCTGTCACCCCTGAGGGCCCTGTGATCTCTTCTTGAGCTCCAGGAAACAGG	3444
DB	30595	GCTTCGATGTGACCCCTGAGGGCCATGCAATCTCTTCCAGAGCTCCAGGAAACAGA	30654
QY	3445	CAGTGAGCCCTTGCTGAGACAGTATCTCAGGTACAGAGCAGAGGATGCACAG----	3500
DB	30655	CACCTAGGCTTGGTCTGAGGCCGTGTCCTCAGGTACAGAGCAGAGGAGATGCAGAGCT	30714
QY	3501	GTGTGCCAGAGTAAGTTTGCCCTGAATGCACACAGAGGCCCCACCTGCCACAGGA	3560
DB	30715	CTAGTGCCAGCAGTGAAGCTTTCCTTGAAATGCACATTAATGGCCCCATCGCCCCAGAA	30774
QY	3561	CACATAGGACTCCACAGAGTCTGGCCCA-CCTCCCTACTGTCAGTCTGTAGAAATGCAC	3619
DB	30775	CATATGGGACTCCAGAGCACCTGGCCTCACCCCTCTACTGTCACTGCTGCAGAAATCAGC	30834
QY	3620	CCTCTCTGGCGGCTGATACCTGAGTACCCCTCCTACTTTCCTTCAGTTCCTTCAGGGGA	3679
DB	30835	CTCTGCTTCTGTGTACCTGAGGTGCCCTCTCACTTTTCTTCAGTTCTCAGGGGA	30894
QY	3680	CAGGCCAACCCAGAGGAC-----AGGATCCCTGGAGGCCACAGAGGAGCAC	3726
DB	30895	CAGGCTGACCAAGATCAGCAGGAAGCTCCAGAGATCCCAAGAGGCCCTAGAGGAGCAC	30954
QY	3727	C-AAGGAGAAGATCTGAAGTAGGGCTTTGTTAGAGTCTCCAAGTTTCAGTTCTCAGCTG	3785
DB	30955	CAAAGGAGAAGATCTGAAGTAGCCCTTGTGTAGAGCTCCAGGTTTCAGTTTTCAGCTG	31014
QY	3786	AGGCTCTTCACACTCCCTCTCTCCCGAGCCCTGTGGGTCTTCATTGCCAGTCCCTGCG	3845
DB	31015	AGGCTCTTCACATGCTCCTCTCTCCAGGCCAGTGGGTCTCCATTGCCAGACTCCTGCG	31074
QY	3846	CCACACTCTGCTGCTGCTGAGCAGAGTCATCATGCTCTTTCAGCAGAGGAGTCTGCG	3905
DB	31075	CCACACTCTGCTGCTGCTGGGTGACCAAGTCTGCTCTCTTCCTTCAGGAGAGTCTGCG	31134
QY	3906	ACTGCAAGCCTGAGGAAGCCCTTGAGGCCCAACAGAGGCCCTGGGCGCTGTGTGTGTCG	3965
DB	31135	ACTGCAAGCCTGAGGAAGCCCTTGACACCCAGAGAGGCCCTGGGCGCTGTGTGTGTCG	31194
QY	3966	AGGCTGCCACC-----TCTCCTCTCTCTCTCTGCTCTCTGGGCA	4004
DB	31195	AGGCTGCCACTACTGAGGAGCAGGAGGCTGTGCTCTCTCTCTCTGCTGTGCCAGCA	31254
QY	4005	CCCTGGAGAGGTGCCCACTGCTGGGTCAACAGATCTCTCCCGCAGAGTCTCTCAGGAGGCT	4064
DB	31255	CCCTGGGAGGTGCTGCTGCTGGGTCAACAGTCTCTCTCAAGAGTCTCTCAGGAGGCT	31314
QY	4065	CGGCTCTTCCACATACCATCAACTCTACTGCAGAGAGGCAACCCAGTGAGGGTTCACAGA	4124
DB	31315	CGGCCATCCCACTGCCATCGATTTCATCTATGAGGCAATCCATTAAAGGCTCCAGCA	31374
QY	4125	GCCGTGAAGAGAGGGGGCCAGCACCTCTTGTATCTGGAGTCTCTGTTCGAGCAGATAA	4184
DB	31375	ACCAAGAGAGAGGGGGCCAGCACCTCCCTCTGACCCAGAGTCTGTGTTCGAGCAGCAC	31434


```

/notes="exon 1-6"
4906..4963
/notes="exon 1-7"
5519..5648
/notes="exon 1-8"
9377..9448
/number=2
9524..11091
/number=3
9589..10542
/genes="MAGE4a"
9589..10542
/genes="MAGE4a"
/codon_start=1
/product="MAGE-4a antigen"
/protein_id="AA68871.1"
/db_xref="GI:533515"
/translation="MSEQKSHCKPEEGVEAEALGLVGAQPTTTEQEAIVSSSS
PLVPGTLEEVPAEAPPOGPOGASALPTTFTCWROPNEGSSQEEGSTSPDA
ESLFRALSNKVDLAFLHLYKRAKELVTKAMLERLVKNYKRCFPVIFGKASESLK
MIRGIDKVEDPASNYTLVTCGLSYDGLIGNNOIFPKTGLLIIVLGTIAMEGDSAS
EELIWEELGVMGYDGRHTVYGEPRKLLTQDWQENLYLEYRVPVPSNPARYEFLLWP
KALAEISYKVLSEHVVVNARVRIATPSLREAAALLEEEGV"
polyA_signal
11072..11077
polyA_site
2530 a 3788 c 2924 g 2253 t
BASE COUNT
ORIGIN
Query Match 46.88; Score 2655; DB 10; Length 11495;
Best Local Similarity 73.66; Pred. No. 0;
Matches 4231; Conservative 0; Mismatches 1100; Indels 416; Gaps 50;
QY 21 CTTCCCTTACACCCCAATCCCTTACGCCACCCCACTACCTTATGTCCTCATCCCCCAAC 6028
Db 5969 CCAGCACCCCTATCTCCCAAAACCCCACTACCTTATGTCCTCATCCCCCAAC 6028
QY 81 ACCCCAGCCCAAGCAGGAGAGATCCGGTTCACCCCTGCTCTCAACCCAGGAGAC-C 139
Db 6029 ACCACTATCCCATCCAGGTTGAATCGATTCGGTTTCTGCTTCAACCCAGGAGACTC 6088
QY 140 CAGGTGCCAGATGTGAGCCGACACTGACTTGAAGCATTTAGTGGTTAGAGAGAGGAGGTTT 199
Db 6089 CAGGTTCTGTGATGTGATGCCAGTACTTGTGCATTTGGGGTTAGAGAGAGCTAGTTC 6148
QY 200 TCGTCTGAGGGGGGCTTGAGATCGGTGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 258
Db 6149 TCAGTCTCACAGGAGGAGTGGGATGGCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 6208
QY 259 CAAGGTGACATGCTGAGGAGGAGT---GAGGAGGAGTACCCCAATAGAGAGGAGGAGG 315
Db 6209 CATAGTGAAGAGCTGAGGAGGAGTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 6268
QY 316 AATAATCC-----CTTCATGCCAGTCTCTGAGGAGGAGGAGGAGGAGGAGGAGGAGG 366
Db 6269 AATAATCGGACACCCCTCTCTGAGTCTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 6328
QY 367 TGGGCGACCCCGCCGCTGCTGTAAACCACTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 426
Db 6329 TGGGAGCGCCACCCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 6388
QY 427 GTGATCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 486
Db 6389 GTGATCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 6436
QY 487 CAGGATTCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 546
Db 6437 CAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 6493
QY 547 TCCATGCTCACTCCGTTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 606
Db 6494 TCCATGCTCACTCC-----TACCCCATCTGTACCCCC 6527
```

```

QY 607 ATCCCCACCCCACTCCCTCAACCCCTGATGCCCATCCGCCAGCCATTCACCCCTCAGCCC 666
Db 6528 ATTCCCCACCCCTGTGCCCTTATCCTCCCAACCCCAACCCCAACCCCTATACCCCTCCCC 6589
QY 667 CACCCCAACCCCAACCCCACTCCCAACCCCAACCCCAACCCCAACCCCTGCTTCAATCCAG 725
Db 6588 CACCCCTACCTTCATCCCATCAGTCAGCATCCGGTTCCACCCCTGCTTCAATCCAGG 6647
QY 726 AAACATCCGGGTCCCGGATGTGACGCCACTGACTTGGCATTTGGGGCAGAGAGAGC 785
Db 6648 CAAGCCCTGGGTGGCGGATGTGATGCCACTGACTTGTGAATTTAGGGTTAGAGAGAAT 6707
QY 786 GAGTTTCCATTTCTGAGGAGGAGGAGTTCGGCCGAAGGAACCTGACCCAGGCTCTG 845
Db 6708 GAGTTTCTGGGCTGAGGGTGGC-TTGAGTCCGAGAGGAGGAGGAGGAGGAGGAGGTTG 6766
QY 846 TGAGGAGGCAAGGTGAGAGGCTGAGGAGGAGTGAAGACCCCGCCACTCCAAATAGAGAG 905
Db 6767 TGAAGAGGCAAGGTGAGAGCTCTGAGGAGGAGTTCAGAAACCCCTATCCTGATAGAGG 6826
QY 906 CCCAAATATTCAGCCCGCCCTTCTGCCAGCCCTGCCCCACCCCGGAGAGAGCTCT 965
Db 6827 TCCAGCCCTGGACTACCC-----CGCGAGGCTGACTTCT 6862
QY 966 CAGCTGGGTGCCCGCCAGACCCCTGCTCCAAAGCCTTGAGAGACACAGGTTCTTCTC 1025
Db 6863 CAGACTGGGTGCTCCCGCCACTCCGCCCTC-----TTGCAACGCTTTGTTTAAAGCCAC 6917
QY 1026 CCCAAGCTCTGGAATCAGAGGTTGCTGTACAGGAGGAGGAGGAGGAGGAGGAGGAGG 1085
Db 6918 AGGGGACTCTGGAGTCAAGAGTTGGTGTATCAGGAGGAGGAGGAGGAGGAGGAGGAGG 6976
QY 1086 GCACAGGCTCTGCGAGGATCAAGATCAGACCCCAAGAGGAGGAGGAGGAGGAGGAGGAG 1145
Db 6977 GCCAGGCTCTGCGAGGATCAAGATCAGAACTCAGAAAC-TGAGAGGAGGAGGAGGAGG 7035
QY 1145 ACTGACTTCAATCCCACTCCACCCCTTCCCATTCGCATTCCTCCCAACCCCAACCCCAT 1205
Db 7036 ATCCTAGTCTAACCCCACTCCCAAC----- 7062
QY 1206 CTCTCAGCTACACTCCCACTCCCACTCCCACTCCCACTCCCACTCCCACTCCCACTCC 1265
Db 7063 -----ATCCGCTGCCATTTCCGCTGCTCCATTTCCCATTCCTTCCCT 7104
QY 1266 CCAGCCCGCAGCAGCCCGCCCAACCCCTTTCGCCACCTTCCCTCAGTCCCAACCCCAAC 1325
Db 7105 CCACCCCTCACA----- 7116
QY 1326 CCTCATCTCTCTCATGTGCCCACTCCCACTCCCACTCCCACTCCCACTCCCACTCC 1385
Db 7117 -----GGCAGATCCAGTTC 7131
QY 1386 GCC-CCTGCTCTCAACCCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1444
Db 7132 CCCTTCTGCTATCAATCCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 7183
QY 1445 CCTCAGATCTCAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1504
Db 7184 -----TGGGGTCAAGAAATCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 7232
QY 1505 ACTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1564
Db 7233 GCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 7292
QY 1565 AGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1624
Db 7293 AGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 7351
QY 1625 CCCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1684
Db 7352 TCCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 7404
QY 1685 GGCATTTAACCCCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1744
```



```

JOURNAL Submitted (19-DEC-1996) Genome Analysis, Insitut for Molecular
Biotechnology, Beutenbergstrasse 11, Jena 07745, Germany
FEATURES
source
1..158898
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="X"
/map="Xq28"
misc_feature
1..39138
/note="Region: cosmid IF064"
repeat_region
1..106
/rpt_family="L1PA11"
/evidence=not_experimental
repeat_region
213..282
/rpt_family="L1MB3"
/evidence=not_experimental
complement(1180..1284)
/note="GRAIL, score = 43.000%, comment = marginal"
/exon
/evidence=not_experimental
complement(1683..1757)
/note="MZF, score = 60%"
/evidence=not_experimental
complement(2062..2120)
/note="FEXHB, score = 11.76%"
/exon
/evidence=not_experimental
complement(2637..2710)
/rpt_family="L1M22"
/evidence=not_experimental
complement(2859..3028)
/rpt_family="L1MB3A"
/evidence=not_experimental
complement(2911..2978)
/note="MZF, score = 79.7%"
/exon
4250..4431
/note="GRAIL, score = 52.000%, comment = good shadow"
/evidence=not_experimental
complement(4639..4866)
/rpt_family="L1MA2"
/evidence=not_experimental
complement(4893..5203)
/rpt_family="L1MA2"
/evidence=not_experimental
complement(4974..5117)
/note="GRAIL, score = 61.000%, comment = good"
/evidence=not_experimental
complement(5206..5561)
/rpt_family="L1MA2"
/evidence=not_experimental
complement(5562..5602)
/rpt_family="L1MA9"
/evidence=not_experimental
complement(5619..5655)
/rpt_family="L1MA5"
/evidence=not_experimental
complement(6084..6254)
/rpt_family="MLTID"
/evidence=not_experimental
complement(6262..6322)
/rpt_family="MLTID"
/evidence=not_experimental
complement(6384..6549)
/rpt_family="MLTID"
/evidence=not_experimental
6664..6771
/note="homology = 89.80%, score = 82, counts = 27"
/rpt_type=tandem
/rpt_unit=cctt
/evidence=not_experimental
6807..6884
/note="FEXHB, score = 10.83%"
/evidence=not_experimental
7337..7454
/repeat_region

```


AUTHORS De Plaen, E., Arden, K., Traversari, C., Gaforio, J. J., Szikora, J. P.,
De Smet, C., Brasseur, F., van der Bruggen, P., Lethé, B., Lurquin, C.,
Brasseur, R., Chomez, P., De Backer, O., Cavenee, W. and Boon, T.
TITLE Structure, chromosomal localization, and expression of 12 genes of
the MAGE family
JOURNAL Immunogenetics 40 (5), 360-369 (1994)
MEDLINE 95012457
REFERENCE 2 (bases 1 to 4895)
AUTHORS De Plaen, E.
TITLE Direct Submission
JOURNAL Submitted (14-JUN-1994) Etienne De Plaen, Ludwig Institute for
Cancer Research, 74 Avenue Hippocrate, Brussels, 1200, Belgium
Location/Qualifiers

FEATURES
Source
1..4895
/organism="Homo sapiens"
/isolate="patient MZ2"
/db_xref="taxon:9606"
/chromosome="X"
/sex="female"
/cell_type="lymphocyte"
/tissue_type="blood"
/dev_stage="adult"
2777..2848
/number=2
2924..4491
/number=3
2989..3942
/gene="MAGE4b"
2989..3942
/gene="MAGE4b"
/codon_start=1
/product="MAGE-4b antigen"
/protein_id="AA68872.1"
/db_xref="GI:533517"
/translation="MSSEKQKPEEGVEAEALGLVGAQPTTEEQEAASVSS
PLVPGLEVPAAEAGAPQSGASALPTTISFTCWPNESGSSSEEGPSPDA
ESIFREALSNKYDELAHFLRLKYRAKELVTKAEMLVTKNFKRFPVIFGKASLSL
MIFGIDKEVDTSNTYLVLTCLGSLYGLGNOLFPKTLIIVLIGTIAEAGDSAS
EEIWEELGVNGVYDREHTYGERKLLTQWQENYLEYRQVFGSPARVEFLWGP
RALAETSYKVLHVVRVNRVRIAPSLREALLLEEEGV"
polyA_signal
4472..4477
BASE COUNT 1134 a 1235 c 1433 g 1093 t
ORIGIN

Query Match 44.3%; Score 2513.6; DB 10; Length 4895;
Best Local Similarity 79.9%; Pred. No. 0;
Matches 3415; Conservative 0; Mismatches 694; Indels 165; Gaps 32;

Qy 1478 ATGGTTCTGAGGGCGCTTGAGATCCACAGGAGGAGTGGTTTATGGCTCTGTGAGGAG 1537
Db 607 ATAGCTTGAGGGGCCAGTTGAGATCGGCTGAGGGAGCGGGCCCGAGCTCTGTGCGGAG 666
Qy 1538 GCAAGGTGAGATGCTGAGGAGGAGCTGAGGAGGACACACACCCAGAGTATGATGCCCAAA 1597
Db 667 GCAAGGTGAGACTCTGAGGAGGAGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 725
Qy 1598 ATGATCAGTACACACCCCTGCTCCAGCCCTGGACACACCCCGGACGACAGAGTGTCTCAG 1657
Db 726 ATATTCAGGCCAGCTGCTGCTGCGACCTGCTGCGACCTGCGACCTGCGACCTGCGACCTG 781
Qy 1658 CTGACACACCCCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1717
Db 782 ---GGCTAGGCCATCCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 836
Qy 1718 GCTATGACCCGGGGGAGTGGTTCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1777
Db 837 -----AGAGCTTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 866
Qy 1778 ATCCGCGCGGATAGGCTCAGGACCTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1837
Db 867 CTCYGCCTGGCTCGGGGTGAGGACCTTGAGGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 936

Qy 1838 GTCTCTCATCTCCACCGCCACCCCACTACATTCATCCATACCTACCCCTACCCCAAC 1897
Db 927 CATCGGCAATC-----CACATGCCCGCCCATCCCACTCCGTTTTCAGAA 976
Qy 1898 TCATCTTGTTCAGATTCCTGTCTCAACCCACGGAAGCCAGGGAATGGCGGCGCAGGAC 1957
Db 977 TCCATTTT---TCCCTGTGAGTCAACCCCGGGAAGACCTTGGGAATGGT---CAGGAC 1029
Qy 1958 TCGGATCTTGACGCTCCCATCCAGGCTGTGATGGAGGAAGG---GCTTGAACAG 2010
Db 1030 TCGGATCTTGATCATCCATCGAGGCTGGAAGAGGAGGAGAGTGTGATCATGAGCAG 1089
Qy 2011 GGCCTCAGGGGAGCAGAGGAGGAG-----GGCCCTACTCCGAGATCAGGAGGCTCAGAG 2064
Db 1090 AGCCTCAGGGTAGCAGAGGAGGAGGAGCCCTGGCCCTCTGGGAGATCAGGAAGGCTCAGGA 1149
Qy 2065 GACCCAGCACCC-----TAGGACACCCGACCCCTGTCTGAGACTGAG--GCTGCCA 2113
Db 1150 GACCCAGCACCCCAAGGAGGAGGAGGAGCCACCCACCCCTGTCTGAGATGAGGTGCTCTCT 1209
Qy 2114 CTCTGGCTCAAGAATCAGAACGATGGGAGTCTCAGATTGATGGGGTGGGA---CCAG 2171
Db 1210 CCTTAGCTCAGGAATCCAGGGATGCAACTCAGGTCAGCAGAGGGGTGGTTCACAG 1269
Qy 2172 GCCTCAAGGCTTAGCGGAGGAGGAGGAGGAGTCTCAGGAGGAGGAGGAGGAGGAGGAGGAG 2231
Db 1270 CCGTTCAGGATCAAGAAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1329
Qy 2232 CAGTGTGACCTCGCCCTGAGAGGTCAGAGGTCAGAGGTCAGAGGTCAGAGGTCAGAGGTC 2291
Db 1330 CAGTGTGACCTCGCCCTGGAGGTCCTGGAGGTCCTGGCAAGGTAGCCACCTGAGCTCATCTTC 1389
Qy 2292 CTGCACTTTGAGT---GACAGGACAGAGCTGTGGTCTGAGAGTGGGCTCAGGTC 2347
Db 1390 CTGCACTCTCGAGGTCACAGAGGAGGAGGAGGAGTGTGGTCTGAGGGGTGGTACTTCAGGTC 1449
Qy 2348 AACAGGAGGAGGAGTTCAGAGTCCATATGGCCCAAGATGTGCC--CCCTTCATGAGGACT 2406
Db 1450 CCGAGAGGAGGAGTCCAGAGTCTACAGGACCCCAAGGTGTGCCACACTTACAGGAGAT 1509
Qy 2407 GGGGATATCCCGGCTCAGAAAGAGGAGTCCACACAGTCTGGGTGTCCTTCTTTAGTA 2466
Db 1510 GGGGATATCTGTGGCTCAGAAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1569
Qy 2467 GCTTAGGGGGACAGATCAGGAGTGGGCTATGTTCATCTCAGTGTACACAGGCA 2526
Db 1570 GCTTAGGGGGACAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1629
Qy 2527 GGAAGTTGGGGGGCCCTCAGGAGATGGGGTCTTGGGGTAAAGGGGGGATGCTTACTCAT 2589
Db 1630 GGAAGTTGGGGAACTTCCAGGAGATGAGGTTTGGAGTAAAGGGGCAATGTTTCTCAT 1689
Qy 2587 GTCAGGAATGGGGTTGAGGAGCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2646
Db 1690 CTCAGGGGGTTGGGGTTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1749
Qy 2647 GACAGGCTATTGGATCCACACCCAGAACCAAGGGGTACGCCCTGGACACCTCACCC 2706
Db 1749 CAGGAGGCTCAGAACCCCTCACCCAGAACCAAGGGGTACGCCCTGGGACCCACAC 1808
Qy 2707 AG-----GATGTGGCTCTTTTCTCCTGTTTCCAGATCTGGGCGAGTGGAGAC 2758
Db 1809 AGGGGTGACAGGATGTGGCTCTCTCTCATTTCTGATTCAGATCTCAGTGGAGTGGAGAC 1868
Qy 2759 CTCATCTCAGAGGCTGACTCAGGTACAGTACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2819
Db 1869 CTGTCTCAGAGGCTGACTCAGGTACAGGTCACACAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1928
Qy 2819 CGGTCCAGGATCTGCGATCGCTTGGGTGAGGAGACATGAGGAGGAGGAGGAGGAGGAGGAGGAG 2878
Db 1929 TGGTCCAGGATCTGCCAAGAGTCTGTTGGTGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1989
Qy 2879 AGGACCAAGACACTGAGGGAGAGTGCACAGAAATCAGCCCTGCCCCCTGCTGTGTCACCCAG 2938


```
QY 5064 ACACGAGTCACAGCTCTCTGTATATAGTATTAAAGGTAGAGCTCTGTGTTTTATTTCAG 5123
Db 4202 GTAGTTAACGTATATTCTCTTAATATAGTTTAGGATAGAGCTCTGTTTTATTTCAG 4261
QY 5124 ATTGGGAATCCATCTCTATTTTGTGAATGGG---ATAATAACAGAGTGGAAATAGTAC 5180
Db 4262 ATTGGGAATCCGTTCTATTTTGTGAATTTGGGACATAATAACAGAGTGGAGTAAGTAT 4321
QY 5181 TTAGAAATGTGAATAATGACGACGATATAATAGATAGATATAAGAAATTAAGAG 5240
Db 4322 TTAGAAATGTG---AATTCACCGCTGAATAGGTGAGAT-----AAATTAAGAG 4366
QY 5241 ATAGTCAATTTCTGCCCTTATACCTCAGTCTATCTGTCTGTAAATTTTAAAGATATATGCAT 5300
Db 4367 ATACTTAATTCGCGCCTTATGCCCTCAGTCTATCTGTAAATTTTAAATATATATATGCAT 4426
QY 5301 ACCGTGATTTCCCTTGGCTTTTGGAGAAATTAAGAGAAATTAATCTGTAATAAGAAATTC 5360
Db 4427 ACCTGGAATTTCCCTTGGCTTC---GTGAATGTAAAGAGAAATTAATCTGTAATAATTAATTC 4483
QY 5361 TTCTGTCTCACTGCTCTTTTCTTCTCCATGCACTGAGCATCTGCTTTTGGAGAGCCCT 5420
Db 4484 TTCTGTCTCACTGCTCTTTTCTTCTCTATGCACTGAGCATCTGCTGTGGAGAGCCCA 4543
QY 5421 GGGTTAGTAGGAGATGCTTAAGTAAGCAGACTCATACCCACCATAGGGTCGTAGAG 5480
Db 4544 GGATTAGTAGGAGATGCTTAGGTAAGCAGACACACACCTACCGATAGGGTATTAAGA 4603
QY 5481 TCTAGGAGCTGCAGTCAAGTAATCGAGGTGGCAAGATGCTCTCTAAAGATGTAGGGAATA 5540
Db 4604 GTCTAGGAGCGGCTCATATAATTAAGTGCACAAGATGCTCTTAAGATGTAGGGAATA 4663
QY 5541 GTGAGAGAGGGGTAGGGTGTGGGGTCCGGGTGAGAGTGGTGGAGTGTCAATGCCCTGA 5600
Db 4664 GT----AACGAGTGTGGGTATGGGGTCCAGGTGAGAGTGGTGGGTGTAATTCCTGT 4719
QY 5601 GCTGGGCATTTTGGGCTTTGGGAATCGAGTCTCTCTGCGGGAGCTGATGTGAATGA 5660
Db 4720 G-TGGGGCTTTTGGGCTTTGGGAATCGAGTCTCTCTCTGCGGGAGCTGATGTGAATGA 4778
QY 5661 TCTTGGGTGGATCC 5674
Db 4779 AGCTTGGTGGGTCC 4792

RESULT 10
HSU10690
LOCUS
DEFINITION Human MAGE-5b antigen (MAGE5b) gene, complete cds.
ACCESSION U10690
VERSION U10690.1 GI:533520
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 4736)
De Plaen, E., Arden, K., Traversari, C., Gaforio, J. J., Szikora, J. P.,
De Smet, C., Brasseur, F., van der Bruggen, P., Lethe, B., Lurquin, C.,
Brasseur, R., Chomez, P., De Backer, O., Cavenee, W. and Boon, T.
Structure, chromosomal localization, and expression of 12 genes of
the MAGE family
Immunogenetics 40 (5), 360-369 (1994)
95012457
REFERENCE
2 (bases 1 to 4736)
De Plaen, E.
Direct Submission
AUTHORS
Submitted (14-JUN-1994) Etienne De Plaen, Ludwig Institute for
Cancer Research, 74 Avenue Hippocrate, Brussels, 1200, Belgium
JOURNAL
Location/Qualifiers
FEATURES
1..4736
/organism="Homo sapiens"
```

```
/isolate="patient M22"
/db_xref="taxon:9606"
/chromosome="X"
/sex="female"
/cell_type="lymphocyte"
/tissue_type="blood"
/dev_stage="adult"
644..696
/number=1
2848..2934
/number=2
3010..>4555
/number=3
3075..3449
/gene="MAGE5b"
3075..3449
/gene="MAGE5b"
/codon_start=1
/product="MAGE-5b antigen"
/protein_id="AA86874.1"
/db_xref="GI:533521"
/translation="MSLEQKSHQKPEEGLDQBEALGLVGVQAATTEQRAVSSSP
LVPTGLGEVPAAGSPGLPKSPQASAIPTAIDFTLWRQSIKGSNQBEEGSPSTPDPE
SVFRAALSKKVADLIHFLLKY"
BASE COUNT 1114 a 1278 c 1304 g 1040 t
ORIGIN
Query Match 42.8%; Score 2429.6; DB 10; Length 4736;
Best Local Similarity 75.9%; Pred. No. 0;
Matches 3736; Conservative 0; Mismatches 869; Indels 315; Gaps 47;
QY 715 TTCGCCGACGAGAAACATCCGGTGTCCCGATGTGACGCCACTGACTGGCATTTGGGG 774
Db 15 TTCAACCCAGGAAATCCCTGGGTGACAGATGTGTGCACCTGTCTTGACATTTGAGGT 74
QY 775 CAGAGAGAGGAGGAGTTTCCATTCTGAGGGGCGGTAGAGTTCGCCGCAAGAAACCTGA 834
Db 75 CGAGAGAGAGGAGGAGTCTGCTCTCAGGGGAGC-TGGAGATCAGCTGAGGGCAGCTGG 133
QY 835 CCCAGGCTCTGTGAGAGGCAAGGTGAGAGGTGAGGAGGAGTCTGAGGACCCGCCACTC 894
Db 134 CCTGTGCTCTGTGAGGATGCAAGGTGAGATGCTGAGGGAGGACTAAGGAGTATCCACCC 193
QY 895 CAAATAGAGAGCCCAATATTCAG---CCCCGCCCTTGTGCCAGCCCTGCCCCACCC 951
Db 194 CTGGTAGTGGACCCCAATAATCCAGTCCCCTCTCTGCTGCTAGCTCTGACCATCC 253
QY 952 GCGGGAAGACGCTCTCAGGCTGGGCTGCCCGCCAGACCCCTGTCTCAAAAGCCTTGAGAGAC 1011
Db 254 AGGCGAGGAGTCTTGTAGGTGGGCCACCCCGAGTCCCGCCTTAAGCCCGAGGGA- 312
QY 1012 ACCAGGTTCTTCTCCCAAGCTCTGGAATCAGAGTTGTGTGACAGGGCAGGAGTGGT 1071
Db 313 -----CTCAGGAGACAGGTTGTGTATGACAGGGCAGGAGTGGT 352
QY 1072 TAGGAGAGGCGAGGGACAGGCTCTGCCAGGCATCAAGATCAGACCCAGAGAGGAGGC 1131
Db 353 TAGGAGAGGACAGCTCCCA-GCTCTGCCAGGAACAACGTCAGGAACCTTAAGGGAAGCT 411
QY 1132 TGTGGGCCCCAGAGACTGACATCCCAATCCCACTCCACCCCAATTCGCAATCCCATCC 1191
Db 412 GAGGCTACCCC----- 422
QY 1192 CACCCAAACCCCATCTCTCAGCTACACCTACACCCCAATCCCTACTCTACTCGTCCAC 1251
Db 423 -----CACCCCAAACTCTATTCTGTCTCCCTAGCTCCGTC 457
QY 1252 CTGACCAACACCTCCAGCCCGCAGCAGCCAGCCCAACCTCTGCGACCTCACCCTCACT 1311
Db 458 CCACCTACACCCCAATTC-----CCACCCCTTCCCTACCGGACCTCTATCCACA 512
QY 1312 GCCCCCAACCCCAACCTCTATCTCTCTCTGTGCCCACTCCCATCCCATCCCTCCCTCTGTG 1371
```


[illegible]

[illegible]

Db	4432	-TAAAGAAATTAAGAGATTAATTAATCTTGCTGTATACCTAGCTATTCGGGTAAATTTTT	4490
QY	5285	TTAAAGATATATGCATACCTGGATTCCTTGGCTTTTGTAGAATGTAAGAGAAATTAAA	5344
Db	4491	TTTAAAAAATGTGCATACCTGGATTCCTTGGCTTCTTTGAGAATGTAAGACAAATTAAA	4559
QY	5345	TCGTAATAAGAAATTCCTTGTTCACATGGCTCTTTCTTCCATGCACATGACATCTG	5404
Db	4551	TCGTAATAATCAATTCCTCTGTCACATGGCTATTTATTCCTATGACATGACATTTG	4610
QY	5405	CTTTTGGAAAGGCCCTGGGTTAGTAGTGGAGATGCTAAGGTAAGCCAGACATCATCCAC	5464
Db	4611	CTCTCTGGAGGCCCTGGTTAATAGTGSAGATGCTAAGGTAAGCCAGACATCATCCAC	4670
QY	5465	COATAGGTCGTAGAGCTAGAGCTGCAGTCACTAGTAATCGAGTGGCAAGATGTCCTCT	5524
Db	4671	COACAGGCTAGTAAAGTCTAGAGCAGCAGTCATATAATTAAGGTGGAGAGTCCCTCT	4730
QY	5525	AA 5526	
Db	4731	AA 4732	
RESULT 12			
I36922			
LOCUS 2419 bp DNA PAT 13-MAY-1997			
DEFINITION Sequence 7 from patent US 5612201.			
ACCESSION I36922			
VERSION I36922.1 GI:2084882			
KEYWORDS			
SOURCE Unknown.			
ORGANISM Unknown.			
REFERENCE 1 (bases 1 to 2419)			
AUTHORS De Plaen, E., Boon-Falleur, T., Lethe, B., Szikora, J., De Smet, C. and Chomez, P.			
TITLE Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor			
JOURNAL Patent: US 5612201-A 7 18-MAR-1997;			
FEATURES Location/Qualifiers			
source 1..2419			
BASE COUNT 562 a 581 c 677 g 599 t			
ORIGIN			
Query Match 42.6%; Score 2419; DB 5; Length 2419;			
Best Local Similarity 100.0%; Pred. No. 0;			
Matches 2419; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	3256	GGATCCAGGCCCTGCCAGGAAATATTAAGGCCCTCGGTGAGACACAGAGGGGTCAATCC	3315
Db	1	GGATCCAGGCCCTGCCAGGAAATATTAAGGCCCTCGGTGAGACACAGAGGGGTCAATCC	60
QY	3316	ACTGCATGAGAGTGGGATGTCACAGAGTCACAGCCACCCCTCGGTAGCACTGAGAAAGC	3375
Db	61	ACTGCATGAGAGTGGGATGTCACAGAGTCACAGCCACCCCTCGGTAGCACTGAGAAAGC	120
QY	3376	CAGGCTGTGCTTGGGTCGTGCACCTGAGGCCCGGTGGATTCCTCTGGAGCTCCA	3435
Db	121	CAGGCTGTGCTTGGGTCGTGCACCTGAGGCCCGGTGGATTCCTCTGGAGCTCCA	180
QY	3436	GAACACGACAGTGGGCTTGGTCTGAGACAGTATCTCTAGGTCACAGACAGAGGATG	3495
Db	181	GAACACGACAGTGGGCTTGGTCTGAGACAGTATCTCTAGGTCACAGACAGAGGATG	240
QY	3496	CACAGGCTGCCAGCAGTGAATGTTTGCCTGAAATGCACACACAGGCCCCACCTGCCA	3555
Db	241	CACAGGCTGCCAGCAGTGAATGTTTGCCTGAAATGCACACACAGGCCCCACCTGCCA	300
QY	3556	CAGGACACATAGAGCTCCACAGAGTCTGGCTCAGTCTCTAGTCTCTGTAGAAT	3615
Db	301	CAGGACACATAGAGCTCCACAGAGTCTGGCTCAGTCTCTAGTCTCTGTAGAAT	360

ACCESSION AR007331 GI:3966815
VERSION AR007331.1
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 2420)
Fikes, J.D., Livingston, B.D., Sette, A.D. and Sidney, J.C.
TITLE DNA encoding NAGE-1 C-terminal cytotoxic t lymphocyte immunogenic peptides
JOURNAL Patent: US 5750395-A 23 12-MAY-1998;
FEATURES Location/Qualifiers
source l. 2420
BASE COUNT 562 a 582 c 677 g 599 t
ORIGIN /organism="unknown"

Query Match 42.4%; Score 2408; DB 5; Length 2420;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2419; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 3256 GGATCCAGGCCCTCCAGGAAAAATATAAGGCGCCCTGAGAACAGAGGGGGTCATCC 3315
DB 1 GGATCCAGGCCCTCCAGGAAAAATATAAGGCGCCCTGAGAACAGAGGGGGTCATCC 60
QY 3316 ACTGCATGAGAGTGGGATGTACAGAGTCCAGGCCACCCCTCTGTAGCAGTGAAGC 3375
DB 61 ACTGCATGAGAGTGGGATGTACAGAGTCCAGGCCACCCCTCTGTAGCAGTGAAGC 120
QY 3376 CAGGGCTGTCTGCGGTCTGCACCTCTGAGGGCCGTGGATTCTCTCTGTGAGCTCCA 3435
DB 121 CAGGGCTGTCTGCGGTCTGCACCTCTGAGGGCCGTGGATTCTCTCTGTGAGCTCCA 180
QY 3436 GGAACAGGAGTGGCCCTTGTCTGAGACACTATCTCAGTCTACAGCAGAGGAGTG 3495
DB 181 GGAACAGGAGTGGCCCTTGTCTGAGACACTATCTCAGTCTACAGCAGAGGAGTG 240
QY 3496 CACAGGTGTGCCAGCAGTGAATGTTTGGCCCTGAATGCACCAAGGGCCCACTGCCA 3555
DB 241 CACAGGTGTGCCAGCAGTGAATGTTTGGCCCTGAATGCACCAAGGGCCCACTGCCA 300
QY 3556 CAGGACATAGGACTCCAGAGTCTGGCCCTCACCTCCCTACTGACGTCCTGTAGAT 3615
DB 301 CAGGACATAGGACTCCAGAGTCTGGCCCTCACCTCCCTACTGACGTCCTGTAGAT 360
QY 3616 CGACCTGTGCGGCTGTACCTGAGTACCTCTCACTTCTCTCTCAGGTTTCAG 3675
DB 361 CGACCTGTGCGGCTGTACCTGAGTACCTCTCACTTCTCTCTCAGGTTTCAG 420
QY 3676 GGGACAGCCCAACCCAGAGCAGGATTCCTTGGAGCCACAGAGGACCAAGAGGAA 3735
DB 421 GGGACAGCCCAACCCAGAGCAGGATTCCTTGGAGCCACAGAGGACCAAGAGGAA 480
QY 3736 GATCTGTAAGTAGCCCTTTGTAGAGTCCAGAGTTCAGTCTCAGCTGAGGCCCTCA 3795
DB 481 GATCTGTAAGTAGCCCTTTGTAGAGTCCAGAGTTCAGTCTCAGCTGAGGCCCTCA 540
QY 3796 CACACTCCCTCTCTCCCGAGCCCTGTGGGTCTTCATTGCCAGCTCCTGCCACACTCCT 3855
DB 541 CACACTCCCTCTCTCCCGAGCCCTGTGGGTCTTCATTGCCAGCTCCTGCCACACTCCT 600
QY 3856 GCTGTGTCCTCTCAGAGAGTCAATGCTCTGTAGCAGAGAGTCTGCAGTGCAGGCC 3915
DB 601 GCTGTGTCCTCTCAGAGAGTCAATGCTCTGTAGCAGAGAGTCTGCAGTGCAGGCC 660
QY 3916 TGAGGAAGCCCTTGAGGCCCAACAGAGGCCCTGGGCTGGTGTGTGAGGCTGCCAC 3975
DB 661 TGAGGAAGCCCTTGAGGCCCAACAGAGGCCCTGGGCTGGTGTGTGAGGCTGCCAC 720
QY 3976 CTCTCTCTCTCTCTGCTGTGGCACCCTGGAGGAGTCCCACTCTCTGGGTCAAC 4035
DB 721 CTCTCTCTCTCTCTGCTGTGGCACCCTGGAGGAGTCCCACTCTCTGGGTCAAC 780

ORGANISM

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1 (bases 1 to 178515)

AUTHORS

Birren,B., Linton,L., Nusbaum,C. and Lander,E.

TITLE

Homo sapiens chromosome 8, clone RP11-173J18

JOURNAL

Unpublished

REFERENCE

2 (bases 1 to 178515)

AUTHORS

Birren,B., Linton,L., Nusbaum,C., Lander,E., Allen,N., Anderson,M.,

Baker,J., Baldwin,J., Barna,N., Beckerly,R., Benn,J., Brown,A.,

Castle,A., Cerny,J., Collangelo,M., Collins,S., Collymore,A.,

Cooke,P., DeArelano,K., Depayre,E., Devon,K., Dewar,K.,

Donelan,L., Doyle,M., Ferreira,P., FitzHugh,W., Forrest,C.,

Funke,R., Gage,D., Galagan,J., Gardyna,S., Gilbert,D., Grant,G.,

Hagob,A., Hearford,A., Horton,L., Howland,J.C., Jones,C., Kann,L.,

Karatas,A., Lehoczy,J., Lieu,C., Locke,K., Macdonald,P.,

Mardis,N., McEwan,P., McGurk,A., McKernan,K., McLaughlin,J.,

Meldrum,J., Molla,M., Morris,W., Morrow,J., Mychaleckyj,J.,

Naylor,J., Niloff,M., O'Connor,T., O'Donnell,P., Pavlin,B.,

Peterson,K., Pollara,V., Riley,R., Roberts,D., Roy,A., Severy,P.,

Stange-Thomann,N., Stojanovic,N., Stone,C., Subramanian,A.,

Testaye,S., Torruella-Miller,I., Vassiliev,H., Vo,A., Wagner,A.,

Wheeler,J., Wu,X., Wyman,D., Ye,W.J. and Zody,M.

Direct Submission

Submitted (28-AUG-1999) Whitehead Institute/MIT Center for Genome

Research, 320 Charles Street, Cambridge, MA 02141, USA

On Apr 8, 2000 this sequence version replaced gi:6751797.

All repeats were identified using RepeatMasker:

Smit, A.F.A. & Green, P. (1996-1997)

http://ftp.genome.washington.edu/RM/RepeatMasker.html

----- Genome Center

Center: Whitehead Institute/ MIT Center for Genome Research

Center code: WIBR

Web site: http://www-seq.wi.mit.edu

Contact: sequence_submissions@genome.wi.mit.edu

----- Project Information

Center project name: L2077

Center clone name: 173-J-18

----- Summary Statistics

Sequencing vector: M13; M7815; 100% of reads

Chemistry: Dye-terminator Big Dye; 96% of reads

Assembly program: Phrap; version 0.960731

Consensus quality: 154528 bases at least Q40

Consensus quality: 164381 bases at least Q30

Consensus quality: 169670 bases at least Q20

Insert size: 180000; agarose-ef

Insert size: 175915; sum-of-contigs

Quality coverage: 3.9 in Q20 bases; agarose-ef

Quality coverage: 3.9 in Q20 bases.

NOTE: This is a 'working draft' sequence. It currently

consists of 28 contigs. The true order of the pieces

is not known and their order in this sequence record is

arbitrary. Gaps between the contigs are represented as

runs of N, but the exact sizes of the gaps are unknown.

This record will be updated with the finished sequence

as soon as it is available and the accession number will

be preserved.

1 1206: contig of 1206 bp in length

1207 1306: gap of 100 bp

1307 2316: contig of 1010 bp in length

2317 2416: gap of 100 bp

2417 3791: contig of 1375 bp in length

3792 3891: gap of 100 bp

3892 5035: contig of 1144 bp in length

5036 5135: gap of 100 bp

5136 6291: contig of 1156 bp in length

6292 6391: gap of 100 bp

6392 7820: contig of 1429 bp in length

7821 7920: gap of 100 bp

7921 9966: contig of 2046 bp in length

9967 10066: gap of 100 bp

10067 11414: contig of 1348 bp in length

```

* 11415 11514: gap of 100 bp
* 11515 11580: contig of 2066 bp in length
* 13581 13680: gap of 100 bp
* 13681 15919: contig of 2239 bp in length
* 15920 16019: gap of 100 bp
* 16020 18054: contig of 2035 bp in length
* 18055 18154: gap of 100 bp
* 18155 20599: contig of 2445 bp in length
* 20600 20699: gap of 100 bp
* 20700 25017: contig of 4318 bp in length
* 25018 25117: gap of 100 bp
* 25118 29998: contig of 4881 bp in length
* 29999 30098: gap of 100 bp
* 30099 34538: contig of 4440 bp in length
* 34539 34638: gap of 100 bp
* 34639 39508: contig of 4870 bp in length
* 39509 39608: gap of 100 bp
* 39609 46103: contig of 6495 bp in length
* 46104 46203: gap of 100 bp
* 46204 52117: contig of 5914 bp in length
* 52118 52217: gap of 100 bp
* 52218 58555: contig of 6338 bp in length
* 58556 58655: gap of 100 bp
* 58656 65212: contig of 6557 bp in length
* 65213 65312: gap of 100 bp
* 65313 72795: contig of 7483 bp in length
* 72796 72895: gap of 100 bp
* 72896 78614: contig of 5719 bp in length
* 78615 78714: gap of 100 bp
* 78715 89051: contig of 10337 bp in length
* 89052 89151: gap of 100 bp
* 89152 100736: contig of 11585 bp in length
* 100737 100836: gap of 100 bp
* 100837 117851: contig of 17015 bp in length
* 117852 117951: gap of 100 bp
* 117952 135700: contig of 17749 bp in length
* 135701 135800: gap of 100 bp
* 135801 153915: contig of 18115 bp in length
* 153916 154015: gap of 100 bp
* 154016 178515: contig of 24500 bp in length.

FEATURES             Location/Qualifiers
     source            1..178515
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="8"
                        /map="8"
                        /clone="RP11-173J18"
                        /clone_lib="RP11 Human Male BAC"
     misc_feature      1..1206
                        /note="assembly_fragment"
     misc_feature      1307..2316
                        /note="assembly_fragment"
     misc_feature      2417..3791
                        /note="assembly_fragment"
     misc_feature      3892..5035
                        /note="assembly_fragment"
     misc_feature      5136..6291
                        /note="assembly_fragment"
     misc_feature      6392..7820
                        /note="assembly_fragment"
     misc_feature      7921..9966
                        /note="assembly_fragment"
     misc_feature      10067..11414
                        /note="assembly_fragment"
     misc_feature      11515..13580
                        /note="assembly_fragment"
     misc_feature      13681..15919
                        /note="assembly_fragment"
     misc_feature      16020..18054
                        /note="assembly_fragment"
     misc_feature      18155..20599
                        /note="assembly_fragment"
     misc_feature      20700..25017

```

```
/note="assembly_fragment"
25118..29998
/note="assembly_fragment"
30099..34538
/note="assembly_fragment"
34639..39508
/note="assembly_fragment"
39609..46103
/note="assembly_fragment"
46204..52117
/note="assembly_fragment"
52218..58555
/note="assembly_fragment"
58556..65212
/note="assembly_fragment"
clone_end:SP6
vector_side:right
65313..72795
/note="assembly_fragment"
72896..78614
/note="assembly_fragment"
78715..89051
/note="assembly_fragment"
89152..100736
/note="assembly_fragment"
clone_end:T7
vector_side:right
100837..117851
/note="assembly_fragment"
117952..135700
/note="assembly_fragment"
135801..153915
/note="assembly_fragment"
154016..178515
/note="assembly_fragment"

BASE COUNT 54258 a 34971 c 35239 g 51342 t 2705 others
ORIGIN

Query Match 41.0%; Score 2328; DB 74; Length 178515;
Best Local Similarity 71.9%; Pred. No. 0;
Matches 3790; Conservative 0; Mismatches 1140; Indels 338; Gaps 50;

QY 1 CCCGGGACACATGCGATCCCTCCCGTACACCCCGCCATCCCTCCGTTTACGCCACCC 60
D 73670 CCATGAGAACCCCATCTCCCGAGGCCCTACTCTCATCCACCCACCCACCCCT 73729
QY 61 ATCCAAACATCTTACGCTACCCCGCCAGCCAGGAGAGATCGGTTCCACCCCTG 120
D 73730 CATCTACCTACCTACCCCCCTATCCCTACATCTGTTAGATCCGTTTCGCCCTG 73789
QY 121 CTCACACCCAGGAG-CCAGGTGCCAGATGTAGCGCCACTGACTTGAGCATTAAGTG 179
D 73790 CTTTCAACCGAGGAATCCCGGGTGCOCGATGTGACACCACTGACTTG-GCGTTGGG 73848
QY 180 GTTAGAGAGAGCAGGPTTTCGCTGAGGGCGGCTTGAGATCGGTGGAGGGAACGG 239
D 73849 GTCAAGAGAGAGAGGTTCTGCTGAGTGGCGGCTTGAGATGGTGGAGGAAATGG 73908
QY 240 GCCCA-GCTCTGTAAAGGAGGCAAGTGACATGCTGAGGAGGAGTGAAGACCCACTTACC 298
D 73909 GTCCAGGCTCTGTGAAGAGGCAAGTGAGACTCTAAGGGAGGAGTCAAGAGGCCCCACC 73968
QY 299 CCAGATAGAGACCCCAATATCC-----CTTCATGCCAGTCTCTGACCATCTGG 349
D 73969 CCAGATAGAGGCCCCCAATATCAGCACTACTCTCTGCTGCCAGCCCTAAACCACTGG 74028
QY 350 TGGTGGACTCTCAGGTGGGCCACCCCGCCCGCT-----TGCTGCTTAAACCA 400
D 74029 GGGCGGACTCTCAGTCTGGGCCACTCCCTGCACCTCGCCAGCCCTGTGCTTAACCG 74088
QY 401 CTGGGGACTC-GAAGTCAGAGCTCCGTGTGATCAGGGAAGGCTGTAGGAGGCGAG 459
D 75079 GAGATCAAGG-----GCATGGTCTTGAGAGCCCGGAGTACAGCAGAGGGAATGG 75079
```

```
Db 74089 CAAGGGACTCTGGAGTCTAGAGCTTCGTGTGACCAAGGCGGGCTGTAGGAGGGGAC 74148
QY 460 CGTCCAGGCTCTGCCAGACATCATGCTCAGGATTCTCAAGGAGGGCTGAGGCTCCCTAAG 519
D 74149 TGSCCAAGCTCTGCCAGGATCAACATCAGGACCCCTAAGTGGAGGCTGAGGCGCCCAAC 74208
QY 520 ACCC---CACTCCGTTGACCCACCCCACTCCATGCTCTACTCCCGTACCCCAACCC 576
D 74209 CCCATTCOCATCCCCACCCCATCCCATTTCCATCCCATCCCACTCCATCCCA 74268
QY 577 TCTTCATTTGTCATTCACACCCCACTCCCACTCCCACTCCCACTCCCACTCCCACTGATC 636
D 74269 CCAGAACCCCTATCCCCACCAAGAACCTATCTCCACATCCCACTCCCACTCCCACTCC 74328
QY 637 CATTCGCCAGCCATTCACCTCACCCTACCC-CAACCCCACTCCCACTCCCACTCCCACTCC 695
D 74329 TACTCCACCATTCCTCCTCCCACTCCCACTCCCACTCCCACTCCCACTCCCACTCC 74388
QY 696 CCACCCAGGAGGATCCG-----TTCCCGGCAAGAAACATCCCGGGTCCCG 742
D 74389 ACACCTGGCAGATTCGGTTCTGCTCTCTTTCAACCCAGGATCCCTGGGTACCA 74448
QY 743 GATGTAGCCCACTGACTTGGCATTGTTGGGCGAGAGAGAGGAGGTTTCAATTCTGAG 802
D 74449 GATGTGTGCCACTGTCTGCATTTGAGTTCGAGAGAGAGAGGAGGCTTCGCTCTCAG 74508
QY 803 GGACGGGTAGAGTTCGGCGAAGAACCTGACCCAGGCTCTGTGAGGAGGCAAGGTGAG 862
D 74509 GGGCAGC-TGGAGATCAGTGAAGGAGGCTGGCCCTGCTGTGAGGATGCAAGGTGAG 74567
QY 863 AGCTGAGGAGGACTGAGGACCCCGCCACTCCAAATAGAGAGCCCAATATTTCCAGCC 922
D 74568 ATGCTGAGGAGGACTAAGGAGTATCCACCCCTGTGTGAGGAGGAGGAGGAGGAGT 74627
QY 923 CCGCC---CTTGTCTGACCCCTGGCCACCCCGGCGAGAGACGCTCTCAGCTGGGTGCC 979
D 74628 CCACCTCTCTGCTGTAGCTCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 74687
QY 980 CCAGAGCCCTGCTCCAAAGCCTTGAGAGACACAGGTTCTTCTCCCAAGCTCTGGAA 1039
D 74688 CCCAGTCCCGCCACCGTTAAGCGCAGGGA-----CTCAGGAG 74726
QY 1040 TCAGAGTTCTCTGACCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1099
D 74727 ACAGAGTTGTTATGACCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 74786
QY 1100 AGCATCAAGATCAGCAGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1159
D 74787 AGGAAACAGCTCAGGAACTAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 74829
QY 1160 CCACCTCCCGCCATTCGCAATTCCTCCCACTCCCACTCCCACTCCCACTCCCACTCC 1219
D 74830 -----CAC 74832
QY 1220 CTCACCCCGCCATCCCTACTCTACTCTGTCACCTGACCCAGGAGGAGGAGGAGGAGGAGG 1279
D 74833 GCCAACTCTATTCCTGTCCTTACCTCCGTCGCGCCAGGAGGAGGAGGAGGAGGAGGAG 74887
QY 1280 AGCCCAACCTCTCTGCGACCTCAGCTCAGTCCCGCCAGGAGGAGGAGGAGGAGGAGGAG 1339
D 74888 CACCCCATCCCTACCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 74926
QY 1340 TGTGCGCCACTCCCATCCGCTCCCGCATTTGCGAGAAATCCGGTT-TGCCCCCTGCTCTCA 1398
D 74927 -----CCCTATCTGCGAGAAATCCGATTTGCGCCCTGATTTCA 74965
QY 1399 ACCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1458
D 74966 ACCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 75025
QY 1459 GAGAAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1518
D 75026 GAGAAATCAAG-----GCATGGTCTTGAGAGCCCGGAGTACAGCAGAGGGAATGG 75079
```


[illegible][illegible]

Search completed: September 13, 2000, 05:33:47
Job time: 13929 sec

(TM)

Result No.	Query			ID	Description	Pred. No.
	Score	Match	Length			
1	61	100.0	280	2	JC3358 tumor-associated anti	1.51e-04
2	54	88.5	234	2	J38657 MAGE-8 associated - huma	1.43e-02
3	54	88.5	315	2	J38668 MAGE-9 antigen - huma	1.43e-02
4	52	85.2	369	2	J38668 MAGE-10 antigen - hum	5.00e-02
5	51	83.6	319	2	J38660 MAGE-11 antigen - hum	9.24e-02
6	48	78.7	129	2	E72685 hypothetical protein	5.60e-01
7	48	78.7	269	2	A49334 Ras homolog Rad - hum	5.60e-01
8	48	78.7	925	1	A339216 plasma cell membrane	5.60e-01
9	47	77.0	497	1	S33938 penton protein (III)	1.01e-00
10	46	75.4	9	2	P41299 MAGE 5 protein - huma	1.79e-00
11	46	75.4	314	2	JC2360 tumor-associated anti	1.79e-00
12	45	73.8	1033	2	S02188 type I site-specific	3.17e-00
13	44	72.1	98	2	F70769 hypothetical protein	5.55e-00
14	44	72.1	128	2	B72600 hypothetical protein	5.55e-00
15	44	72.1	461	2	T09933 nucleotide pyrophosph	5.55e-00
16	44	72.1	488	1	S55874 sulfite oxidase [EC 1	5.55e-00
17	44	72.1	488	1	A53107 sulfite oxidase [EC 1	5.55e-00
18	44	72.1	725	2	A45033 myelin transcription	5.55e-00
19	43	70.5	197	2	A70832 hypothetical protein	9.63e-00
20	43	70.5	290	2	S84312 hypothetical protein	9.63e-00
21	43	70.5	314	2	JC2361 tumor-associated anti	9.63e-00
22	43	70.5	347	2	J38008 MAGE-Xp protein - hum	9.63e-00
23	43	70.5	669	2	J38023 matrix metalloprotein	9.63e-00

```

#cross-references MUID:95012457
#accession 138667 Preliminary; translated from GB/EMBL/DBDJ
#status #molecule_type DNA
#residues 1-234 #label RES
#cross-references EMBL:U10693; NID:g533525; PIDN:AAA68876.1;
PID:g533526

GENETICS
#gene GDB:MAGEA8; MAGE8
#cross-references GDB:331123
#map_position Xq28-Xq28
#introns #status absent
CLASSIFICATION #superfamily tumor associated protein MAGE
SUMMARY #length 234 #molecular-weight 25197 #checksum 311

Query Match 88.5%; Score 54; DB 2; Length 234;
Best Local Similarity 77.8%; Pred. No. 1.43e-02;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 171 EVDPTGHSY 179
QY 1 EADPTGHSY 9

RESULT 3
ENTRY I38668 #type complete
TITLE MAGE-9 antigen - human
ORGANISM #formal_name Homo sapiens #common_name man
DATE 07-Jun-1996 #sequence_revision 07-Jun-1996 #text_change
24-Sep-1999
ACCESSIONS I38668
REFERENCE I38659
#authors De Plaen, E.; Arden, K.; Traversari, C.; Gaforio, J.J.;
Szikora, J.P.; De Smet, C.; Brasseur, F.; van der Bruggen,
P.; Lethe, B.; Lurquin, C.; Brasser, R.; Chomez, P.; De
Backer, O.; Cavenee, W.; Boon, T.
#journal Immunogenetics (1994) 40:360-369
#title Structure, chromosomal localization, and expression of 12
#cross-references MUID:95012457
#accession I38668 Preliminary; translated from GB/EMBL/DBDJ
#status #molecule_type DNA
#residues 1-315 #label RES
#cross-references EMBL:U10694; NID:g533527; PIDN:AAA68877.1;
PID:g533528

GENETICS
#gene GDB:MAGEA9; MAGE9
#cross-references GDB:331125
#map_position Xp21.3-Xp21.3
#introns #status absent
CLASSIFICATION #superfamily tumor associated protein MAGE
SUMMARY #length 315 #molecular-weight 35088 #checksum 2468

Query Match 88.5%; Score 54; DB 2; Length 315;
Best Local Similarity 77.8%; Pred. No. 1.43e-02;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 167 EVDPTGHSY 175
QY 1 EADPTGHSY 9

RESULT 4
ENTRY I38659 #type complete
TITLE MAGE-10 antigen - human
ORGANISM #formal_name Homo sapiens #common_name man
DATE 07-Jun-1996 #sequence_revision 07-Jun-1996 #text_change
24-Sep-1999
ACCESSIONS I38659
REFERENCE I38659
#authors De Plaen, E.; Arden, K.; Traversari, C.; Gaforio, J.J.;
Szikora, J.P.; De Smet, C.; Brasseur, F.; van der Bruggen,
P.; Lethe, B.; Lurquin, C.; Brasser, R.; Chomez, P.; De
Backer, O.; Cavenee, W.; Boon, T.
#journal Immunogenetics (1994) 40:360-369
#title Structure, chromosomal localization, and expression of 12
#cross-references MUID:95012457
#accession I38659 Preliminary; translated from GB/EMBL/DBDJ
#status #molecule_type DNA
#residues 1-319 #label RES
#cross-references EMBL:U10886; NID:g533512; PIDN:AAA68870.1;
PID:g533513

GENETICS
#gene GDB:MAGEA11; MAGE11
#cross-references GDB:331128
#map_position Xq28-Xq28
#introns #status absent
CLASSIFICATION #superfamily tumor associated protein MAGE
SUMMARY #length 319 #molecular-weight 35536 #checksum 9402

Query Match 83.6%; Score 51; DB 2; Length 319;
Best Local Similarity 77.8%; Pred. No. 9.24e-02;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 171 EVDPTGHSY 179
QY 1 EADPTGHSY 9

RESULT 6
ENTRY E72685 #type complete
TITLE hypothetical protein APE0901 - Aeropyrum pernix (strain K1)
ORGANISM #formal_name Aeropyrum pernix
DATE 20-Aug-1999 #sequence_revision 20-Aug-1999 #text_change

```

```

P.; Lethe, B.; Lurquin, C.; Brasser, R.; Chomez, P.; De
Backer, O.; Cavenee, W.; Boon, T.
Immunogenetics (1994) 40:360-369
#title Structure, chromosomal localization, and expression of 12
genes of the MAGE family.
#cross-references MUID:95012457
#accession I38659 Preliminary; translated from GB/EMBL/DBDJ
#status #molecule_type DNA
#residues 1-369 #label RES
#cross-references EMBL:U10685; NID:g533510; PIDN:AAA68869.1;
PID:g533511

GENETICS
#gene GDB:MAGEA10; MAGE10
#cross-references GDB:331126
#map_position Xq28-Xq28
#introns #status absent
CLASSIFICATION #superfamily tumor associated protein MAGE
SUMMARY #length 369 #molecular-weight 40766 #checksum 586

Query Match 85.2%; Score 52; DB 2; Length 369;
Best Local Similarity 77.8%; Pred. No. 5.00e-02;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 193 EVDPTGHSY 201
QY 1 EADPTGHSY 9

RESULT 5
ENTRY I38660 #type complete
TITLE MAGE-11 antigen - human
ORGANISM #formal_name Homo sapiens #common_name man
DATE 07-Jun-1996 #sequence_revision 07-Jun-1996 #text_change
24-Sep-1999
ACCESSIONS I38660
REFERENCE I38659
#authors De Plaen, E.; Arden, K.; Traversari, C.; Gaforio, J.J.;
Szikora, J.P.; De Smet, C.; Brasseur, F.; van der Bruggen,
P.; Lethe, B.; Lurquin, C.; Brasser, R.; Chomez, P.; De
Backer, O.; Cavenee, W.; Boon, T.
#journal Immunogenetics (1994) 40:360-369
#title Structure, chromosomal localization, and expression of 12
genes of the MAGE family.
#cross-references MUID:95012457
#accession I38660 Preliminary; translated from GB/EMBL/DBDJ
#status #molecule_type DNA
#residues 1-319 #label RES
#cross-references EMBL:U10886; NID:g533512; PIDN:AAA68870.1;
PID:g533513

GENETICS
#gene GDB:MAGEA11; MAGE11
#cross-references GDB:331128
#map_position Xq28-Xq28
#introns #status absent
CLASSIFICATION #superfamily tumor associated protein MAGE
SUMMARY #length 319 #molecular-weight 35536 #checksum 9402

Query Match 83.6%; Score 51; DB 2; Length 319;
Best Local Similarity 77.8%; Pred. No. 9.24e-02;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 171 EVDPTGHSY 179
QY 1 EADPTGHSY 9

RESULT 6
ENTRY E72685 #type complete
TITLE hypothetical protein APE0901 - Aeropyrum pernix (strain K1)
ORGANISM #formal_name Aeropyrum pernix
DATE 20-Aug-1999 #sequence_revision 20-Aug-1999 #text_change

```

```

20-Aug-1999
E72885
A72450
Kawarabayashi, Y.; Hino, Y.; Horikawa, H.; Yamazaki, S.;
Haikawa, Y.; Jin-no, K.; Takahashi, M.; Sekine, M.; Baba,
S.; Anka, A.; Kosugi, H.; Hosoyama, A.; Fukui, S.; Nagai,
Y.; Nishijima, K.; Nakazawa, H.; Takamiya, M.; Masuda, S.;
Funahashi, T.; Tanaka, T.; Kudoh, Y.; Yamazaki, J.;
Kushida, N.; Oguchi, A.; Aoki, K.; Kubota, K.; Nakamura,
Y.; Nomura, N.; Sako, Y.; Kikuchi, H.
DNA Res. (1999) 6:83-101
Complete genome sequence of an aerobic hyper-thermophilic
Crenarchaeon, Aeropyrum pernix K1.
#cross-references MUID:99310339
#accession E72685 preliminary
##status preliminary
##molecule_type DNA
##residues 1-129 ##label KAW
##cross-references DDBJ:AP00060; NID:95104188; PIDN:BAA79885.1;
PID:G1043671; PID:95104570
##experimental_source strain K1
GENETICS
#gene APE0901
#length 129 #molecular-weight 14303 #checksum 2150
SUMMARY
Query Match 78.7%; Score 48; DB 2; Length 129;
Best Local Similarity 85.7%; Pred. No. 5.60e-01;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Db 115 DPAGHSY 121
||:||||
QY 3 DPTGHSY 9

RESULT 7
ENTRY A49334 #type complete
TITLE Ras homolog Rad - human
AUTHOR NAMES
Ras associated with diabetes (Rad)
ORGANISM #formal_name Homo sapiens #common_name man
DATE 07-Oct-1994 #sequence_revision 07-Oct-1994 #text_change
28-Aug-1998
A49334
#cross-references MUID:94069319
#accession A49334
##status preliminary
##molecule_type mRNA
##residues 1-269 ##label REY
#cross-references GB:I24564
KEYWORDS alternative initiators; GTP binding; P-loop
FEATURE
59-66 #region nucleotide-binding motif A (P-loop)\
164-167 #region GTP-binding NKXD motif
#length 269 #molecular-weight 29262 #checksum 9237
SUMMARY
Query Match 78.7%; Score 48; DB 2; Length 269;
Best Local Similarity 55.6%; Pred. No. 5.60e-01;
Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Db 80 EAFAGHTY 88
||:|||||
QY 1 EADPTGHSY 9

RESULT 8
ENTRY A39216 #type complete
TITLE plasma cell membrane glycoprotein PC-1 - human
CONTAINS nucleotide pyrophosphatase (EC 3.6.1.9); phosphodiesterase I
(EC 3.1.4.1)
#formal_name Homo sapiens #common_name man
10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change
ACCESSIONS A39216; S21706; S23587; S51030
REFERENCE #authors Buckley, M.F.; Loveland, K.A.; McKinstry, W.J.; Garson, O.M.;
Goding, J.W.
J. Biol. Chem. (1990) 265:17506-17511
#journal Plasma cell membrane glycoprotein PC-1. cDNA cloning of the
#title human cell membrane, amino acid sequence, and chromosomal
location.
#cross-references MUID:91009202
#accession A39216 preliminary
##status preliminary
##molecule_type mRNA
##residues 1-925 ##label BUC
##cross-references GB:J05654
REFERENCE S21706
#authors Funakoshi, I.; Kato, H.; Horie, K.; Yano, T.; Horii, Y.;
Kobayashi, H.; Inoue, T.; Suzuki, H.; Fukui, S.; Tsukahara,
M.; Kajii, T.; Yamashina, I.
#journal Arch. Biochem. Biophys. (1992) 295:180-187
#title Molecular cloning of cDNAs for human fibroblast nucleotide
pyrophosphatase.
#cross-references MUID:92246539
#accession S21706
##status not compared with conceptual translation
##molecule_type mRNA
##residues 1-925 ##label FUN1
#accession S23587
##molecule_type protein
##residues 116-121;247-271,'X',273-275;279-280,'X',282-283;303-315;
362-364;449-465;482-525;529-534,'X',536-551,'X',553,
'X',555-556;597-606,'X',727-730;775-782;840-846,'X',
849-852,'X',854-859 ##label FUN2
#note it is uncertain whether Met-1 or Met-53 is the initiator
REFERENCE S51030
#authors Belli, S.I.; Goding, J.W.
#journal Eur. J. Biochem. (1994) 226:433-443
#title Biochemical characterization of human PC-1, an enzyme
possessing alkaline phosphodiesterase I and nucleotide
pyrophosphatase activities.
#cross-references MUID:95094801
#accession S51030 preliminary
##status preliminary
##molecule_type mRNA
##residues 1-80 ##label BEL
GENETICS
#gene GDB:PDNPF1; M6S1; NPPS
#cross-references GDB:I32615; OMIM:173335
#map_position 6q22-6q23
CLASSIFICATION #superfamily nucleotide pyrophosphatase; somatostatin B
homology
KEYWORDS glycoprotein; phosphoprotein; phosphoric diester hydrolase;
transmembrane protein
FEATURE
77-97 #domain transmembrane #status predicted #label TMM\
104-144 #domain somatostatin B homology #label SBH\
145-188 #domain somatostatin B homology #label SBH\
179-285,341,477,
578,585,643,700,
731,748
#binding_site carbohydrate (Asn) (covalent) #status
predicted\
#binding_site AMP (Thr) (covalent) #status predicted
#length 925 #molecular-weight 104924 #checksum 7446
SUMMARY
Query Match 78.7%; Score 48; DB 1; Length 925;
Best Local Similarity 66.7%; Pred. No. 5.60e-01;
Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Db 374 EPDSSGHSY 382
||:|||||
QY 1 EADPTGHSY 9

```

```

RESULT 9
ENTRY   S33938      #type complete
TITLE   penton protein (III) - human adenovirus 12
ORGANISM #formal_name Mastadenovirus h12 #common_name human adenovirus
DATE    10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change
ACCESSIONS
REFERENCE S33938
#authors Sprengel, J.
#submission submitted to the EMBL Data Library, June 1993
#accession S33938
#status preliminary
#molecule_type DNA
#residues 1-497 #label SPR
#cross-references EMBL:X73487; NID:g313361; PIDN:CAA51887.1;
#checksum 2182
CLASSIFICATION #superfamily adenovirus penton protein
SUMMARY #length 497 #molecular_weight 56393 #checksum 2182
Query Match 77.0%; Score 47; DB 1; Length 497;
Best Local Similarity 66.7%; Pred. No. 1.01e+00;
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
Db 310 ETDPKGRSY 318
I:| | | | |
QY 1 EADPTGHSY 9

RESULT 10
ENTRY   PH1299      #type fragment
TITLE   MAGE 5 protein - human (fragment)
ALTERNATE_NAMES MAGE 51 protein
ORGANISM #formal_name Homo sapiens #common_name man
DATE    30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change
ACCESSIONS PH1299; PH1300
REFERENCE PH1294
#authors Traversari, C.; van der Bruggen, P.; Luescher, I.F.; Lurquin,
C.; Chomez, P.; Van Pel, A.; De Plaen, E.; Amar-Costesec,
A.; Boon, T.
#journal J. Exp. Med. (1992) 176:1453-1457
#title A nonapeptide encoded by human gene MAGE-1 is recognized on
HLA-A1 by cytolytic T lymphocytes directed against tumor
antigen MZ2-E.
#cross-references MUID:93018875
#accession PH1299
#molecule_type DNA
#residues 1-9 #label TRA
#status preliminary
#molecule_type DNA
#residues 1-9 #label TR2
#cross-references MUID:93018875
#accession PH1299
#molecule_type DNA
#residues 1-9 #label TRA
#accession PH1300
#molecule_type DNA
#residues 1-9 #label TR2
SUMMARY #length 9 #checksum 3650
Query Match 75.4%; Score 46; DB 2; Length 9;
Best Local Similarity 66.7%; Pred. No. 1.79e+00;
Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Db 1 EADPTSNTY 9
I:| | | | |
QY 1 EADPTGHSY 9

RESULT 11
ENTRY   JC2360      #type complete
TITLE   tumor-associated antigen, MAGE 6 - human
ALTERNATE_NAMES melanoma antigen 6; tumor-associated antigen, MAGE-3b
ORGANISM #formal_name Homo sapiens #common_name man
DATE    20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change
ACCESSIONS JC2360; PH1301; I38665; G01445

```

```

REFERENCE JC2358
#authors Ding, M.; Beck, R.J.; Keller, C.J.; Fenton, R.G.
#journal Biochem. Biophys. Res. Commun. (1994) 202:549-555
#title Cloning and analysis of MAGE-1-related genes.
#cross-references MUID:94311935
#accession JC2360
#molecule_type mRNA
#residues 1-314 #label DIN
#experimental_source melanoma cell line DM150
REFERENCE PH1294
#authors Traversari, C.; van der Bruggen, P.; Luescher, I.F.; Lurquin,
C.; Chomez, P.; Van Pel, A.; De Plaen, E.; Amar-Costesec,
A.; Boon, T.
#journal J. Exp. Med. (1992) 176:1453-1457
#title A nonapeptide encoded by human gene MAGE-1 is recognized on
HLA-A1 by cytolytic T lymphocytes directed against tumor
antigen MZ2-E.
#cross-references MUID:93018875
#accession PH1301
#molecule_type DNA
#residues 168-176 #label TRA
REFERENCE I38659
#authors De Plaen, E.; Arden, K.; Traversari, C.; Gaforio, J.J.;
Szikora, J.P.; De Smet, C.; Brasseur, F.; van der Bruggen,
P.; Lethe, B.; Lurquin, C.; Brasseur, R.; Chomez, P.; De
Backer, O.; Cavenee, W.; Boon, T.
#journal Immunogenetics (1994) 40:360-369
#title Structure, chromosomal localization, and expression of 12
genes of the MAGE family.
#cross-references MUID:95012457
#accession I38665
#status preliminary; translated from GB/EMBL/DBDJ
#molecule_type DNA
#residues 1-314 #label RES
#cross-references EMBL:U10691; NID:g533522; PIDN:AAA68875.1;
PID:g533523
REFERENCE G07126
#authors Fenton, R.G.
#submission submitted to the EMBL Data Library, June 1994
#accession G01445
#status preliminary; translated from GB/EMBL/DBDJ
#molecule_type mRNA
#residues 1-314 #label FEN
#cross-references EMBL:U10339; NID:g499121; PIDN:AAA19006.1;
PID:g499122
GENETICS
#gene GDB:MAGEA6; MAGE6
#cross-references GDB:331121
#map_position Xq28-Xq28
#introns #status absent
CLASSIFICATION #superfamily tumor associated protein MAGE
FEATURE 168-176 #region HLA-A1 binding #status predicted
SUMMARY #length 314 #molecular_weight 34891 #checksum 9870
Query Match 75.4%; Score 46; DB 2; Length 314;
Best Local Similarity 66.7%; Pred. No. 1.79e+00;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Db 168 EVDPIGHVY 176
I:| | | | |
QY 1 EADPTGHSY 9

RESULT 12
ENTRY   S02168      #type complete
TITLE   type I site-specific deoxyribonuclease (EC 3.1.21.3)
ALTERNATE_NAMES EcoR124/3 chain hsdR - Escherichia coli plasmid R124/3
ORGANISM type I restriction enzyme EcoR124/3 chain hsdR
#formal_name Escherichia coli
DATE    01-Dec-1989 #sequence_revision 01-Dec-1989 #text_change
09-Sep-1997
ACCESSIONS S02168

```

```

REFERENCE S02166
#authors Price, C.; Lingner, J.; Bickle, T.A.
#journal J. Mol. Biol. (1989) 205:115-125
#title Basis for changes in DNA recognition by the EcoRI24 and
#cross-references EMBL:89178628
#accession S02168
#molecule_type DNA
##residues 1-1033 #label PRI
##cross-references EMBL:X13145; NID:g388978; PID:g41750
GENETICS
#gene hsdR
#genome plasmid
KEYWORDS DNA binding; hydrolase
SUMMARY #length 1033 #molecular-weight 119656 #checksum 4436
Query Match 73.8%; Score 45; DB 2; Length 1033;
Best Local Similarity 75.0%; Pred. No. 3.17e+00;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Db 23 ABPTGDSY 30
QY 2 ADPTGHSY 9
RESULT 13
ENTRY #type complete
TITLE hypothetical protein Rv1322 - Mycobacterium tuberculosis
#formal_name Mycobacterium tuberculosis
#organism (strain H37Rv)
#accession F70769
#journal Nature (1998) 393:537-544
#title Deciphering the biology of Mycobacterium tuberculosis from
#cross-references MUID:98295987
#accession F70769
#status preliminary; nucleic acid sequence not shown;
#molecule_type DNA
##residues 1-98 #label COL
##cross-references GB:W73902; GB:AL123456; NID:g3261576; PID:g245016;
#experimental_source strain H37Rv
GENETICS
#gene Rv1322
SUMMARY #length 98 #molecular-weight 11334 #checksum 2740
Query Match 72.1%; Score 44; DB 2; Length 98;
Best Local Similarity 66.7%; Pred. No. 5.55e+00;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Db 24 EAGPDGHEX 32
QY 1 EADPTGHSY 9
RESULT 14
ENTRY #type complete
TITLE hypothetical protein APE1266 - Aeropyrum pernix (strain K1)
#formal_name Aeropyrum pernix

```

```

DATE 20-Aug-1999 #sequence_revision 20-Aug-1999 #text_change
20-Aug-1999
ACCESSIONS B72600
REFERENCE A72450
#authors Kawarabayasi, Y.; Hino, Y.; Horikawa, H.; Yamazaki, S.;
Haikawa, Y.; Jin-no, K.; Takahashi, M.; Sekine, M.; Baba,
S.; Ankai, A.; Kosugi, H.; Hosoyama, A.; Fukui, S.; Nagai,
Y.; Nishijima, K.; Nakazawa, H.; Takamiya, M.; Masuda, S.;
Funahashi, T.; Tanaka, T.; Kudoh, Y.; Yamazaki, J.;
Kushida, N.; Oguchi, A.; Aoki, K.; Kubota, K.; Nakamura,
Y.; Nomura, N.; Sako, Y.; Kikuchi, H.
#journal DNA Res. (1999) 6:83-101
#title Complete genome sequence of an aerobic hyper-thermophilic
#cross-references MUID:99310339
#accession B72600
#status preliminary
#molecule_type DNA
##residues 1-128 #label KAW
##cross-references DDBJ:AP000061; NID:g5104821; PID:BAA80256.1;
#experimental_source strain K1
GENETICS
#gene APE1266
SUMMARY #length 128 #molecular-weight 13655 #checksum 5871
Query Match 72.1%; Score 44; DB 2; Length 128;
Best Local Similarity 57.1%; Pred. No. 5.55e+00;
Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Db 86 EPAGHGXY 92
QY 3 DPTGHSY 9
RESULT 15
ENTRY #type complete
TITLE nucleotide pyrophosphatase-like protein - Arabidopsis
#formal_name Arabidopsis thaliana
#organism protein T16L4.210
#accession T09933
#status preliminary
#molecule_type DNA
##residues 1-461 #label BEV
##cross-references EMBL:AL079344; GSPDB:GN00062; ATSP:T16L4.210
#experimental_source cultivar Columbia; BAC clone T16L4
GENETICS
#gene ATSP:T16L4.210
SUMMARY #map_position 4
#length 461 #molecular-weight 51587 #checksum 161
Query Match 72.1%; Score 44; DB 2; Length 461;
Best Local Similarity 55.6%; Pred. No. 5.55e+00;
Matches 5; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
Db 219 EPDOSHNY 227
QY 1 EADPTGHSY 9
Search completed: Tue Sep 12 13:19:15 2000
Job time : 9 secs.

```

W O R L D

(TW)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPsrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Tue Sep 12 13:18:14 2000; MasPar time 3.68 seconds
Tabular output not generated. 75,785 Million cell updates/sec

Title: >US-08-819-669E-26
Description: (1-9) from US08819669E.pap
Perfect Score: 61
Sequence: 1 EADPTGHSY 9

Scoring table: PAM 150
Gap 15

Searched: 85661 seqs, 30989116 residues

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database: swiss-prot38
1:swissprot

Statistics: Mean 21.172; Variance 19.906; scale 1.064

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description	Pred. No.
1	61	100.0	309	1	MAG1_HUMAN	MELANOMA-ASSOCIATED AN 3.30e-05
2	54	88.5	234	1	MAG8_HUMAN	MELANOMA-ASSOCIATED AN 4.36e-03
3	54	88.5	315	1	MAG9_HUMAN	MELANOMA-ASSOCIATED AN 4.36e-03
4	52	85.2	369	1	MAGA_HUMAN	MELANOMA-ASSOCIATED AN 1.66e-02
5	51	83.6	319	1	MAGE_HUMAN	MELANOMA-ASSOCIATED AN 3.20e-02
6	48	78.7	268	1	RAD_RAT	GTP-BINDING PROTEIN RA 2.19e-01
7	48	78.7	269	1	RAD_HUMAN	GTP-BINDING PROTEIN RA 2.19e-01
8	48	78.7	269	1	PC1_HUMAN	PLASMA-CELL MEMBRANE G 2.19e-01
9	47	77.0	497	1	PEN3_ADEL2	PENTON PROTEIN (VIRION 4.10e-01
10	46	75.4	314	1	MAG6_HUMAN	MELANOMA-ASSOCIATED AN 7.58e-01
11	46	75.4	346	1	MG84_HUMAN	MELANOMA-ASSOCIATED AN 7.58e-01
12	45	73.8	503	1	VP57_BDV	57 KDA PROTEIN (P57). 1.39e+00
13	45	73.8	1033	1	TIR1_ECOLI	TYPE I RESTRICTION ENZ 1.39e+00
14	44	72.1	98	1	YD22_MYCTU	HYPOTHETICAL 11.3 KDA 2.53e+00
15	44	72.1	488	1	SUOX_HUMAN	SULFITE OXIDASE PRECUR 2.53e+00
16	44	72.1	488	1	SUOX_RAT	SULFITE OXIDASE PRECUR 2.53e+00
17	44	72.1	488	1	MYT1_HUMAN	MYELIN TRANSCRIPTION F 2.53e+00
18	43	70.5	290	1	YGID_YEAST	HYPOTHETICAL 31.7 KDA 4.54e+00
19	43	70.5	314	1	MAG3_HUMAN	MELANOMA-ASSOCIATED AN 4.54e+00
20	43	70.5	347	1	MG81_HUMAN	MELANOMA-ASSOCIATED AN 4.54e+00
21	43	70.5	506	1	ZIGU_HUMAN	ZINC FINGER PROTEIN 15 4.54e+00
22	43	70.5	669	1	COSU_HUMAN	MATRIX METALLOPROTEIN 4.54e+00
23	43	70.5	878	1	YB9X_YEAST	HYPOTHETICAL 98.1 KDA 4.54e+00

24	42	58.9	145	1	ANG3_MOUSE	ANGIOGENIN-3 PRECURSOR	8.07e+00
25	42	58.9	156	1	YLSX_BACSU	HYPOTHETICAL 17.6 KDA	8.07e+00
26	42	58.9	283	1	FOLD_BACSU	FOLD BIFUNCTIONAL PROT	8.07e+00
27	42	58.9	317	1	MAG4_HUMAN	MELANOMA-ASSOCIATED AN	8.07e+00
28	42	58.9	326	1	YXX2_CAEEL	HYPOTHETICAL 34.6 KDA	8.07e+00
29	42	58.9	347	1	PYRC_SALTY	DIHYDROOROTASE (EC 3.5	8.07e+00
30	42	58.9	392	1	CGL_CAEEL	PUTATIVE CYSTATHIONINE	8.07e+00
31	42	58.9	555	1	WETA_EMEI	REGULATORY PROTEIN WET	8.07e+00
32	42	58.9	747	1	GUND_CELFI	ENDOGLUCANASE D PRECUR	8.07e+00
33	42	58.9	3396	1	POLG_DENIS	GENOME POLYPROTEIN [CO	8.07e+00
34	41	67.2	319	1	MG32_HUMAN	MELANOMA-ASSOCIATED AN	1.42e+01
35	41	67.2	366	1	CD44_BOVIN	CD44 ANTIGEN PRECURSOR	1.42e+01
36	41	67.2	459	1	2PR1_HUMAN	ZINC-FINGER PROTEIN ZP	1.42e+01
37	41	67.2	459	1	2PR1_MOUSE	ZINC-FINGER PROTEIN ZP	1.42e+01
38	41	67.2	566	1	GUNG_CLOTM	ENDOGLUCANASE G PRECUR	1.42e+01
39	41	67.2	581	1	PBP2_NEIME	PENICILLIN-BINDING PRO	1.42e+01
40	41	67.2	581	1	PBP2_NEIGO	PENICILLIN-BINDING PRO	1.42e+01
41	41	67.2	1025	1	ITAB_HUMAN	INTEGRIN ALPHA-8.	1.42e+01
42	41	67.2	2411	1	DAB_DROME	GENOME POLYPROTEIN.	1.42e+01
43	41	67.2	3898	1	POLG_BVDVS	GENOME POLYPROTEIN.	1.42e+01
44	40	65.6	429	1	ACEA_RHOFA	ISOCITRATE LYASE (EC 4	2.47e+01
45	40	65.6	919	1	YKQ5_YEAST	HYPOTHETICAL 105.7 KDA	2.47e+01

ALIGNMENTS

RESULT	1	STANDARD;	PRT;	309 AA.
AC	P43355; 000346;			
DT	01-NOV-1995 (Rel. 32, Created)			
DT	01-NOV-1995 (Rel. 32, Last sequence update)			
DT	15-FEB-2000 (Rel. 39, Last annotation update)			
DE	MELANOMA-ASSOCIATED ANTIGEN 1 (MAGE-1 ANTIGEN) (ANTIGEN MZ2-E).			
GN	MAGE1 OR MAGE1 OR MAGE1A.			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RX	MEDLINE; 92086861.			
RA	van der Bruggen P., Traversari C., Chomez P., Lurquin C., de Plaen E.,			
RA	van den Eynde B., Knuth A., Boon T.;			
RT	"A gene encoding an antigen recognized by cytolytic T lymphocytes on			
RT	a human melanoma."			
RL	Science 254:1643-1647(1991).			
RN	[2]			
RP	SEQUENCE FROM N.A.			
RC	TISSUE=SKIN;			
RX	MEDLINE; 94311935.			
RA	Ding M., Beck R.J., Keller C.J., Fenton R.G.;			
RT	"Cloning and analysis of MAGE-1-related genes."			
RL	Biochem. Biophys. Res. Commun. 202:549-555(1994).			
RN	[3]			
RP	SEQUENCE FROM N.A.			
RA	Gloeckner G., Rump A., Nordsiek G., Hinzmann B., Kioschis P.,			
RA	Heiss N., Poustka A., Bauer D., Drescher B., Knob A., Rosenthal A.;			
RT	Submitted (MAY-1997) to the EMBL/GenBank/DBJ databases.			
RN	[4]			
RP	MUTAGENESIS.			
RC	TISSUE=BLLOOD.			
RX	MEDLINE; 94157413.			
RA	Gaugler B., van den Eynde B., van der Bruggen P., Romero P.,			
RA	Garcia J.J., de Plaen E., Lethe B., Brasseur F., Boon T.;			
RT	"Human gene MAGE-3 codes for an antigen recognized on a melanoma by			
RT	autologous cytolytic T lymphocytes."			
RL	J. Exp. Med. 179:921-930(1994).			
RN	[5]			
RP	SUBCELLULAR LOCATION.			
RX	MEDLINE; 95012905.			
RA	Schultz-Thater E., Juretic A., Dellabona P., Luscher U., Siegrist W.,			
RA	Harder F., Heberer M., Zuber M., Spagnoli G.C.;			
RT	"MAGE-1 gene product is a cytoplasmic protein."			
RL	Int. J. Cancer 59:435-439(1994).			

CC -!- FUNCTION: NOT KNOWN, THOUGH MAY PLAY A ROLE IN EMBRYONAL
 CC DEVELOPMENT AND TUMOR TRANSFORMATION OR ASPECTS OF TUMOR
 CC PROGRESSION. ANTIGEN RECOGNIZED ON A MELANOMA BY AUTOLOGOUS
 CC CYTOLYTIC T LYMPHOCYTES.
 CC -!- SUBCELLULAR LOCATION: CYTOPLASMIC.
 CC -!- TISSUE SPECIFICITY: EXPRESSED IN MANY TUMORS OF SEVERAL TYPES,
 CC SUCH AS MELANOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA, LUNG,
 CC CARCINOMA AND BREAST CARCINOMA, BUT NOT IN NORMAL TISSUES EXCEPT
 CC FOR TESTES. NEVER EXPRESSED IN KIDNEY TUMORS, LEUKEMIAS AND
 CC LYMPHOMAS.
 CC -!- POLYMORPHISM: THE VARIANT AT POSITION 32 LIKELY REPRESENTS A
 CC POLYMORPHISM OF THE MAG-1 GENE.
 CC -!- SIMILARITY: BELONGS TO THE MAGE FAMILY.
 CC
 CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL: M77481; AAA03229.1; -;
 CC EMBL: U82872; AAB54061.1; -;
 CC MIM: 300016; -;
 CC PFAM: PF01454; MAGE; 1.
 CC Antigen: Multigene family; Polymorphism: Tumor antigen.
 CC VARIANT 32 T->A.
 CC DOMAIN 33 36 POLY-SER.
 CC FT MUTAGEN 163 163 D->A: ABOLISHES HLA-A1 BINDING.
 CC FT MUTAGEN 169 169 Y->A: ABOLISHES HLA-A1 BINDING.
 CC FT CONFLICT 72 72 R -> Q (IN REF. 3).
 CC SEQUENCE 309 AA; 34342 MW; 544EBB1F9F4E9D33 CRC64;
 CC
 CC Query Match 100.0%; Score 61; DB 1: Length 309;
 CC Best Local Similarity 100.0%; Pred. No. 3,30e-05;
 CC Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC
 CC Db 161 EADPTGHSY 169
 CC | | | | | | | | | |
 CC QY 1 EADPTGHSY 9
 CC
 CC RESULT 2
 CC ID MAG8_HUMAN STANDARD; PRG: 234 AA.
 CC AC P43361;
 CC DT 01-NOV-1995 (Rel. 32, Created)
 CC DT 01-NOV-1995 (Rel. 32, Last sequence update)
 CC DT 01-NOV-1997 (Rel. 35, Last annotation update)
 CC DE MELANOMA-ASSOCIATED ANTIGEN 8 (MAGE-8 ANTIGEN).
 CC GN MAGE8 OR MAGE8.
 CC OS Homo sapiens (Human).
 CC OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 CC OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
 CC [1]
 CC RP SEQUENCE FROM N.A.
 CC RX MEDLINE; 95012457.
 CC RA de Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.-P.,
 CC de Smet C., Brasseur F., van der Bruggen P., Lethe B., Lurquin C.,
 CC Brasseur R., Chomez P., de Backer O., Cavenee W., Boon T.;
 CC "Structure, chromosomal localization, and expression of 12 genes of
 CC the MAGE family.";
 CC RL Immunogenetics 40:360-369(1994).
 CC [2]
 CC RP SEQUENCE FROM N.A.
 CC RA Timms K.M., Bondeson M.L., Ansari-Lari M.A., Lagerstedt K.,
 CC Nelson D.L., Pettersson U., Gibbs R.A.;
 CC Submitted (SEP-1996) to the EMBL/GenBank/DBJ databases.
 CC -!- FUNCTION: NOT KNOWN, THOUGH MAY PLAY A ROLE IN EMBRYONAL
 CC DEVELOPMENT AND TUMOR TRANSFORMATION OR ASPECTS OF TUMOR
 CC PROGRESSION.
 CC -!- TISSUE SPECIFICITY: EXPRESSED IN MANY TUMORS OF SEVERAL TYPES,
 CC SUCH AS MELANOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA, LUNG,
 CC CARCINOMA AND BREAST CARCINOMA, BUT NOT IN NORMAL TISSUES EXCEPT
 CC FOR TESTES AND PLACENTA.
 CC -!- SIMILARITY: BELONGS TO THE MAGE FAMILY.
 CC
 CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL: U10694; AAA68877.1; -;
 CC EMBL: U66083; AAB67888.1; -;
 CC PFAM: PF01454; MAGE; 1.
 CC Antigen: Multigene family; Tumor antigen.
 CC DOMAIN 34 37 POLY-GLU.
 CC FT DOMAIN 87 90 POLY-GLU.
 CC SEQUENCE 315 AA; 35088 MW; 7FD2ED10D680D928 CRC64;
 CC

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL: U10693; AAA68876.1; -;
 CC PFAM: PF01454; MAGE; 1.
 CC Antigen: Multigene family; Tumor antigen.
 CC FT DOMAIN 40 43 POLY-SER.
 CC SEQUENCE 234 AA; 25197 MW; 058A92EE6003A982 CRC64;
 CC
 CC Query Match 88.5%; Score 54; DB 1: Length 234;
 CC Best Local Similarity 77.8%; Pred. No. 4,36e-03;
 CC Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 CC
 CC Db 171 EVDPAHGSY 179
 CC | | | | | | | | | |
 CC QY 1 EADPTGHSY 9
 CC
 CC RESULT 3
 CC ID MAG9_HUMAN STANDARD; PRG: 315 AA.
 CC AC P43362; Q92910;
 CC DT 01-NOV-1995 (Rel. 32, Created)
 CC DT 01-NOV-1995 (Rel. 32, Last sequence update)
 CC DT 01-NOV-1997 (Rel. 35, Last annotation update)
 CC DE MELANOMA-ASSOCIATED ANTIGEN 9 (MAGE-9 ANTIGEN).
 CC GN MAGE9 OR MAGE9.
 CC OS Homo sapiens (Human).
 CC OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 CC OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
 CC [1]
 CC RP SEQUENCE FROM N.A.
 CC RX MEDLINE; 95012457.
 CC RA de Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.-P.,
 CC de Smet C., Brasseur F., van der Bruggen P., Lethe B., Lurquin C.,
 CC Brasseur R., Chomez P., de Backer O., Cavenee W., Boon T.;
 CC "Structure, chromosomal localization, and expression of 12 genes of
 CC the MAGE family.";
 CC RL Immunogenetics 40:360-369(1994).
 CC [2]
 CC RP SEQUENCE FROM N.A.
 CC RA Timms K.M., Bondeson M.L., Ansari-Lari M.A., Lagerstedt K.,
 CC Nelson D.L., Pettersson U., Gibbs R.A.;
 CC Submitted (SEP-1996) to the EMBL/GenBank/DBJ databases.
 CC -!- FUNCTION: NOT KNOWN, THOUGH MAY PLAY A ROLE IN EMBRYONAL
 CC DEVELOPMENT AND TUMOR TRANSFORMATION OR ASPECTS OF TUMOR
 CC PROGRESSION.
 CC -!- TISSUE SPECIFICITY: EXPRESSED IN MANY TUMORS OF SEVERAL TYPES,
 CC SUCH AS MELANOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA, LUNG,
 CC CARCINOMA AND BREAST CARCINOMA, BUT NOT IN NORMAL TISSUES EXCEPT
 CC FOR TESTES AND PLACENTA.
 CC -!- SIMILARITY: BELONGS TO THE MAGE FAMILY.
 CC
 CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL: U10694; AAA68877.1; -;
 CC EMBL: U66083; AAB67888.1; -;
 CC PFAM: PF01454; MAGE; 1.
 CC Antigen: Multigene family; Tumor antigen.
 CC DOMAIN 34 37 POLY-GLU.
 CC FT DOMAIN 87 90 POLY-GLU.
 CC SEQUENCE 315 AA; 35088 MW; 7FD2ED10D680D928 CRC64;
 CC

```

Query Match      88.5%; Score 54; DB 1; Length 315;
Best Local Similarity 77.8%; Pred. No. 4.36e-03;
Matches          7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 167 EVDPTGHSY 175
QY 1 EADPTGHSY 9

RESULT 4
ID MAGA_HUMAN STANDARD; PRT; 369 AA.
AC P43363;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32; Last sequence update)
DE 01-NOV-1997 (Rel. 35; Last annotation update)
DE MELANOMA-ASSOCIATED ANTIGEN 10 (MAGE-10 ANTIGEN).
GN MAGEP10 OR MAGE10.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE; 95012457.
RA de Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.-P.,
RA de Smet C., Brasseur P., van der Bruggen P., Lethe B., Lurquin C.,
RA Brasseur R., Chomez P., de Backer O., Cavenee W., Boon T.;
RT "Structure, chromosomal localization, and expression of 12 genes of
RT the MAGE family";
RL Immunogenetics 40:360-369(1994).
CC -1- FUNCTION: NOT KNOWN, THOUGH MAY PLAY A ROLE IN EMBRYONAL
CC DEVELOPMENT AND TUMOR TRANSFORMATION OR ASPECTS OF TUMOR
CC PROGRESSION.
CC -1- TISSUE SPECIFICITY: EXPRESSED IN MANY TUMORS OF SEVERAL TYPES,
CC SUCH AS MELANOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA, LUNG
CC CARCINOMA AND BREAST CARCINOMA, BUT NOT IN NORMAL TISSUES EXCEPT
CC FOR TESTES AND PLACENTA.
CC -1- SIMILARITY: BELONGS TO THE MAGE FAMILY.
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC EMBL; U10685; AAA68869.1; -
CC PFAM; PF01454; MAGE; 1.
CC Antigen: Multigene family; Tumor antigen.
KW Antigen; Multigene family; Tumor antigen.
SQ SEQUENCE 369 AA; 40766 MW; 16FA3301CAB716A6 CRC64;

Query Match      85.2%; Score 52; DB 1; Length 369;
Best Local Similarity 77.8%; Pred. No. 1.66e-02;
Matches          7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 193 EVDPTGHSY 201
QY 1 EADPTGHSY 9

RESULT 5
ID MAGB_HUMAN STANDARD; PRT; 319 AA.
AC P43364;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32; Last sequence update)
DE 01-NOV-1997 (Rel. 35; Last annotation update)
DE MELANOMA-ASSOCIATED ANTIGEN 11 (MAGE-11 ANTIGEN).
GN MAGEP11 OR MAGE11.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE; 95012457.
RA de Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.-P.,
RA de Smet C., Brasseur P., van der Bruggen P., Lethe B., Lurquin C.,
RA Brasseur R., Chomez P., de Backer O., Cavenee W., Boon T.;
RT "Structure, chromosomal localization, and expression of 12 genes of
RT the MAGE family";
RL Immunogenetics 40:360-369(1994).
CC -1- FUNCTION: NOT KNOWN, THOUGH MAY PLAY A ROLE IN EMBRYONAL
CC DEVELOPMENT AND TUMOR TRANSFORMATION OR ASPECTS OF TUMOR
CC PROGRESSION.
CC -1- TISSUE SPECIFICITY: EXPRESSED IN MANY TUMORS OF SEVERAL TYPES,
CC SUCH AS MELANOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA, LUNG
CC CARCINOMA AND BREAST CARCINOMA, BUT NOT IN NORMAL TISSUES EXCEPT
CC FOR TESTES AND PLACENTA.
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC EMBL; U10685; AAA68869.1; -
CC PFAM; PF01454; MAGE; 1.
CC Antigen: Multigene family; Tumor antigen.
KW Antigen; Multigene family; Tumor antigen.
FT DOMAIN 54 62
FT POLY-SER 54 62
SQ SEQUENCE 369 AA; 40766 MW; 16FA3301CAB716A6 CRC64;

```

```

RX MEDLINE; 95012457.
RA de Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.-P.,
RA de Smet C., Brasseur P., van der Bruggen P., Lethe B., Lurquin C.,
RA Brasseur R., Chomez P., de Backer O., Cavenee W., Boon T.;
RT "Structure, chromosomal localization, and expression of 12 genes of
RT the MAGE family";
RL Immunogenetics 40:360-369(1994).
CC -1- FUNCTION: NOT KNOWN, THOUGH MAY PLAY A ROLE IN EMBRYONAL
CC DEVELOPMENT AND TUMOR TRANSFORMATION OR ASPECTS OF TUMOR
CC PROGRESSION.
CC -1- TISSUE SPECIFICITY: EXPRESSED IN MANY TUMORS OF SEVERAL TYPES,
CC SUCH AS MELANOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA, LUNG
CC CARCINOMA AND BREAST CARCINOMA, BUT NOT IN NORMAL TISSUES EXCEPT
CC FOR TESTES AND PLACENTA.
CC -1- SIMILARITY: BELONGS TO THE MAGE FAMILY.
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC EMBL; U10686; AAA68870.1; -
CC PFAM; PF01454; MAGE; 1.
CC Antigen: Multigene family; Tumor antigen.
KW Antigen; Multigene family; Tumor antigen.
SQ SEQUENCE 319 AA; 35536 MW; F51A0B4140277BE3 CRC64;

Query Match      83.6%; Score 51; DB 1; Length 319;
Best Local Similarity 77.8%; Pred. No. 3.20e-02;
Matches          7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 171 EVDPTSHSY 179
QY 1 EADPTGHSY 9

RESULT 6
ID RAD_RAT STANDARD; PRT; 268 AA.
AC P55043;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34; Last sequence update)
DT 01-OCT-1996 (Rel. 34; Last annotation update)
DE GTP-BINDING PROTEIN RAD (RAS ASSOCIATED WITH DIABETES) (RAD1).
GN RRAD OR RAD.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Rattus.
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=LUNG;
RA Rishi A.K., Gulamhussein A., Steele M.P.;
RL Submitted (DEC 1994) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: BELONGS TO THE RAD/GEM FAMILY OF GTP-BINDING
CC PROTEINS.
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC EMBL; U12187; AAA56719.1; -
CC HSSP; P10114; 2RAP.
CC PFAM; PF00071; ras; 1.
KW GTP-binding. 59 65 GTP (BY SIMILARITY).
FT NP_BIND 108 112 GTP (BY SIMILARITY).
FT NP_BIND 163 166 GTP (BY SIMILARITY).
SQ SEQUENCE 268 AA; 29053 MW; BF102CA24D8090F CRC64;

```

Query Match 78.7%; Score 48; DB 1; Length 269;
 Best Local Similarity 55.6%; Pred. No. 2.19e-01;
 Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Db 80 EAEAGHTY 88
 QY 1 EADPTGHSY 9

RESULT 7
 ID RAD_HUMAN STANDARD; PRT; 269 AA.
 AC P55042;
 DT 01-OCT-1996 (Rel. 34, Created)
 DT 01-OCT-1996 (Rel. 34, Last sequence update)
 DT 01-NOV-1997 (Rel. 35, Last annotation update)
 DE GTP-BINDING PROTEIN RAD (RAS ASSOCIATED WITH DIABETES) (RAD1).
 GN RRAD OR RAD.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE-SKELETAL MUSCLE;
 RA MEDLINE; 94089319.
 RA "Rad: a member of the Ras family overexpressed in muscle of type II diabetic humans."
 RT diabetics humans."
 RL Science 262:1441-1444(1993).
 CC -!- TISSUE SPECIFICITY: SKELETAL AND CARDIAC MUSCLE, LUNG, LESSER AMOUNTS IN PLACENTA AND KIDNEY. DETECTED IN ADIPOSE TISSUE.
 CC OVEREXPRESSED IN MUSCLE OF TYPE II DIABETIC HUMANS.
 CC -!- SIMILARITY: BELONGS TO THE RAD/GEM FAMILY OF GTP-BINDING PROTEINS.

 CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL Outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see <http://www.isb-sib.ch/announcement/> or send an email to license@isb-sib.ch).

DR EMBL; L24564; AAA36540.1; -
 DR HSSP; P10114; 2RAP.
 DR MIM; 179503; -
 DR PFAM; PF00071; ras; 1.
 KW GTP-binding.
 FT NP_BIND 59 66 GTP (BY SIMILARITY).
 FT NP_BIND 108 112 GTP (BY SIMILARITY).
 FT NP_BIND 164 167 GTP (BY SIMILARITY).
 SQ SEQUENCE 269 AA; 29262 MW; 1802AEBE738A98BE CRC64;

Query Match 78.7%; Score 48; DB 1; Length 269;
 Best Local Similarity 55.6%; Pred. No. 2.19e-01;
 Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Db 80 EAEAGHTY 88
 QY 1 EADPTGHSY 9

RESULT 8
 ID PCL_HUMAN STANDARD; PRT; 873 AA.
 AC P22413;
 DT 01-AUG-1991 (Rel. 19, Created)
 DT 01-AUG-1991 (Rel. 19, Last sequence update)
 DT 15-FEB-2000 (Rel. 39, Last annotation update)
 DE PLASMA-CELL MEMBRANE GLYCOPROTEIN PC-1 [INCLUDES: ALKALINE PHOSPHODIESTERASE I (EC 3.1.1.1); NUCLEOTIDE PYROPHOSPHATASE DE (EC 3.6.1.9) (NPPASE)].
 GN PDNPI OR PC1 OR NPPS.
 OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE; 91009202.
 RA Buckley M.F., Loveland K.A., McKinstry W.J., Garson O.M., Goding J.W.;
 RT "Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, amino acid sequence, and chromosomal location.";
 RL J. Biol. Chem. 265:17506-17511(1990).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE; 92246539.
 RA Funakoshi I., Kato H., Horie K., Yano T., Hori Y., Kobayashi H.,
 RA Inoue T., Suzuki H., Tsukahara M., Kajii T.,
 RA Yamashina I.;
 RT "Molecular cloning of cDNAs for human fibroblast nucleotide pyrophosphatase.";
 RL Arch. Biochem. Biophys. 295:180-187(1992).
 CC -!- FUNCTION: MAY HAVE A ROLE IN THE REGULATION OF N-GLYCOSYLATION.
 CC -!- CATALYTIC ACTIVITY: HYDROLYTICALLY REMOVES 5'-NUCLEOTIDES SUCCESSIVELY FROM THE 3'-HYDROXY TERMINI OF 3'-HYDROXY-TERMINATED OLIGO-NUCLEOTIDES.
 CC -!- CATALYTIC ACTIVITY: A DINUCLEOTIDE + H(2)O = 2 MONONUCLEOTIDE.
 CC -!- SUBUNIT: HOMODIMER, DISULFIDE-LINKED.
 CC -!- SUBCELLULAR LOCATION: TYPE II MEMBRANE PROTEIN.
 CC -!- TISSUE SPECIFICITY: EXPRESSED IN PLASMA CELLS AND ALSO IN A NUMBER OF NON-LYMPHOID TISSUES, INCLUDING THE DISTAL CONVOLUTED TUBULE OF THE KIDNEY, CHONDROCYTES, AND EPIDIDYMIS.
 CC -!- SIMILARITY: CONTAINS 2 SOMATOMEDIN-B TYPE DOMAINS.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL Outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see <http://www.isb-sib.ch/announcement/> or send an email to license@isb-sib.ch).

 DR EMBL; M57736; AAA63237.1; -
 DR EMBL; D12485; BAA02054.1; -
 DR EMBL; D12485; BAA02053.1; ALT_INIT.
 DR PIR; A39216; A39216.
 DR MIM; 173335; -
 DR PFAM; PF01663; Phosphodiesterase; 1.
 DR PFAM; PF01033; Somatomedin_B; 2.
 DR PRINTS; PR00022; SOMATOMEDIN.
 DR PROSITE; PS00524; SOMATOMEDIN_B; 2.
 KW Glycoprotein; Transmembrane; Duplication; Signal-anchor; Hydrolase.
 FT DOMAIN 1 24 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 25 45 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN).
 FT DOMAIN 46 873 EXTRACELLULAR (POTENTIAL).
 FT DOMAIN 52 92 SOMATOMEDIN-B LIKE.
 FT DOMAIN 93 136 SOMATOMEDIN-B LIKE.
 FT CARBOHYD 127 127 POTENTIAL.
 FT CARBOHYD 233 233 POTENTIAL.
 FT CARBOHYD 289 289 POTENTIAL.
 FT CARBOHYD 425 425 POTENTIAL.
 FT CARBOHYD 533 533 POTENTIAL.
 FT CARBOHYD 591 591 POTENTIAL.
 FT CARBOHYD 648 648 POTENTIAL.
 FT CARBOHYD 679 679 POTENTIAL.
 FT CARBOHYD 696 696 POTENTIAL.
 SQ SEQUENCE 873 AA; 99929 MW; 872608C20B048070 CRC64;

Query Match 78.7%; Score 48; DB 1; Length 873;
 Best Local Similarity 66.7%; Pred. No. 2.19e-01;
 Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Db 322 EPDSSGHSY 330
 QY 1 EADPTGHSY 9

RESULT 9
 ID PEN3_ADE12 STANDARD; PRT; 497 AA.
 AC P36716;
 DT 01-JUN-1994 (Rel. 29, Created)
 DT 01-JUN-1994 (Rel. 29, Last sequence update)
 DT 01-NOV-1997 (Rel. 35, Last annotation update)
 DE PENTON PROTEIN (VIRION COMPONENT III) (PENTON BASE PROTEIN).
 GN PIII.
 OS Human adenovirus type 12.
 OC Viruses; dsDNA viruses, no RNA stage; Adenoviridae; Mastadenovirus.
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE; 94076430.
 RA Sprengel J., Schmitz B., Heuss-Neitzel D., Zock C., Doerfler W.;
 RT "Nucleotide sequence of human adenovirus type 12 DNA: comparative
 functional analysis.";
 RL J. Virol. 68:379-389(1994).
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC EMBL; X73487; CAA51887.1; -;
 DR PIR; S33938; S33938.
 DR PFAM; PF01686; Adeno_Penton_B; 1.
 KW Late protein.
 SQ SEQUENCE 497 AA; 56393 MW; 0524D989F5A9ED13 CRC64;

Query Match 77.0%; Score 47; DB 1; Length 497;
 Best Local Similarity 66.7%; Pred. No. 4.10e-01;
 Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Db 310 ETDPKGRSY 318
 : : : : :
 QY 1 EADPTGHSY 9

RESULT 10
 ID MAG6_HUMAN STANDARD; PRT; 314 AA.
 AC F43360;
 DT 01-NOV-1995 (Rel. 32, Created)
 DT 01-NOV-1995 (Rel. 32, Last sequence update)
 DT 15-JUL-1999 (Rel. 38, Last annotation update)
 DE MELANOMA-ASSOCIATED ANTIGEN 6 (MAGE-6 ANTIGEN) (MAGE3B).
 GN MAGEA6 OR MAGE6.
 OS Homo sapiens (human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE; 95012457.
 RA de Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.-P.,
 RA Brasseur R., Chomez P., van der Bruggen P., Lethé B., Lurquin C.,
 RA "Structure, chromosomal localization, and expression of 12 genes of
 the MAGE family.";
 RT Immunogenetics 40:360-369(1994).
 RL [2]
 RN SEQUENCE FROM N.A.
 RP TISSUE-SKIN.
 RX MEDLINE; 94311935.
 RA Ding M., Beck R.J., Keller C.J., Penton R.G.;
 RT "Cloning and analysis of MAGE-1-related genes.";
 RL Biochem. Biophys. Res. Commun. 202:549-555(1994).
 RN [3]
 RP SEQUENCE FROM N.A.
 RX MEDLINE; 95369706.
 RA Imai Y., Shichijo S., Yamada A., Katayama T., Yano H., Itoh K.;
 RT "Sequence analysis of the MAGE gene family encoding human tumor-

rejection antigens.";
 RL Gene 160:287-290(1995).
 CC -!- FUNCTION: NOT KNOWN, THOUGH MAY PLAY A ROLE IN TUMOR
 CC OR ASPECTS OF TUMOR PROGRESSION.
 CC -!- TISSUE SPECIFICITY: EXPRESSED IN MANY TUMORS OF SEVERAL TYPES,
 CC SUCH AS MELANOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA, LUNG
 CC CARCINOMA AND BREAST CARCINOMA, BUT NOT IN NORMAL TISSUES EXCEPT
 CC FOR TESTES.
 CC -!- SIMILARITY: BELONGS TO THE MAGE FAMILY. STRONG SIMILARITY TO
 CC MAGE-3.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC EMBL; U10691; AAA68875.1; -;
 DR EMBL; U10339; AAA19006.1; -;
 DR EMBL; D32076; BAA06842.1; -;
 DR MIN; 300176; -;
 DR PFAM; PF01454; MAGE; 1.
 KW Antigen; Multigene family; Tumor antigen.
 FT DOKAIN 40
 43 POLY-SER
 SQ SEQUENCE 314 AA; 34891 MW; 29B83C7FA6E50263 CRC64;

Query Match 75.4%; Score 46; DB 1; Length 314;
 Best Local Similarity 66.7%; Pred. No. 7.58e-01;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Db 168 EVDPIGHVY 176
 : : : : :
 QY 1 EADPTGHSY 9

RESULT 11
 ID MGB4_HUMAN STANDARD; PRT; 346 AA.
 AC O15481;
 DT 15-DEC-1998 (Rel. 37, Created)
 DT 15-DEC-1998 (Rel. 37, Last sequence update)
 DT 15-DEC-1998 (Rel. 37, Last annotation update)
 DE MELANOMA-ASSOCIATED ANTIGEN B4 (MAGE-B4 ANTIGEN).
 GN MAGE-B4.
 OS Homo sapiens (human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE; 98110575.
 RA Lurquin C., de Smet C., Brasseur F., Muscatelli F., Martelange V.,
 RA de Plaen E., Brasseur R., Monaco A.F., Boon T.;
 RA "Two members of the human MAGEB gene family located in Xp21.3 are
 expressed in tumors of various histological origins.";
 RT Genomics 46:397-408(1997).
 RL [2]
 RN SEQUENCE FROM N.A.
 RP MAGEB.
 RA Chacko J., Chen J., Di W., Ding Y., Dugan S., Durbin J., Forcum J.,
 RA Ganesh R., Garcia C., Goodman M., Gorrell J.H., Haywood M.,
 RA Hernandez J., Jackson L., Jin S., Kampal R., Karpathy S., Kovar C.,
 RA Leal B., Li Y., Lichtarge O., Liu W., Logan O., Lu J., Ly T.,
 RA Martinez C., Oswal G., Perez L., Rashid N.D., Rowland K., Savage L.,
 RA Scherer S.E., Shen H., Simon M., Stovall K., Timms K.M., Todd J.,
 RA Vo Q., Williamson A., Worley K.C., Yu W., Chinault C., Nelson D.,
 RA Gibbs R.A.;
 RL Submitted (OCT-1998) to the EMBL/GenBank/DBJ databases.
 CC -!- TISSUE SPECIFICITY: EXPRESSED IN TESTIS.
 CC -!- SIMILARITY: BELONGS TO THE MAGE FAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

DR EMBL; U931163; AAC23619.1; -
 DR EMBL; AC005185; AAD10637.1; -

DR MIM; 300153; -
 DR PFW; PF01454; MAGE; 1;

KW Antigen; Multigene family.

SQ SEQUENCE 346 AA; 38923 MW; 804F260BD50F036A CRC64;

Query Match 75.4%; Score 46; DB 1; Length 346;

Best Local Similarity 66.7%; Pred. No. 7.58e-01;

Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Db 168 EVNPTTHSY 176

QY 1 EADPTGHSY 9

RESULT 12

ID VP57_BDV STANDARD; PRT; 503 AA.

AC P52638;

DT 01-OCT-1996 (Rel. 34, Created)

DT 01-OCT-1996 (Rel. 34, Last sequence update)

DT 01-NOV-1997 (Rel. 35, Last annotation update)

DE 57 KDA PROTEIN (P57).

OS Borna disease virus (BDV).

OC Viruses; ssRNA negative-strand viruses; Mononegavirales.

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=V;

RX MEDLINE; 94240137.

RA Briese T., Schneemann A., Lewis A.J., Park Y.-S., Kim S.,

RA Ludwig H., Lipkin W.I.

RT "Genomic organization of Borna disease virus";

RL Proc. Natl. Acad. Sci. U.S.A. 91:4382-4366(1994).

CC -!- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN (POTENTIAL).

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

DR EMBL; U04608; AAA20227.1; -

KW Glycoprotein; Transmembrane.

FT TRANSMEM 5 25 POTENTIAL.

FT TRANSMEM 274 294 POTENTIAL.

FT TRANSMEM 468 488 POTENTIAL.

FT CARBOHYD 63 63 POTENTIAL.

FT CARBOHYD 109 109 POTENTIAL.

FT CARBOHYD 139 139 POTENTIAL.

FT CARBOHYD 192 192 POTENTIAL.

FT CARBOHYD 196 196 POTENTIAL.

FT CARBOHYD 202 202 POTENTIAL.

FT CARBOHYD 221 221 POTENTIAL.

FT CARBOHYD 230 230 POTENTIAL.

FT CARBOHYD 235 235 POTENTIAL.

FT CARBOHYD 321 321 POTENTIAL.

FT CARBOHYD 328 328 POTENTIAL.

FT CARBOHYD 388 388 POTENTIAL.

FT CARBOHYD 438 438 POTENTIAL.

SQ SEQUENCE 503 AA; 56652 MW; 081B55347DF01A08 CRC64;

Query Match 73.8%; Score 45; DB 1; Length 503;

Best Local Similarity 55.6%; Pred. No. 1.39e+00;

Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Db 416 ETDPINHAY 424

QY 1 EADPTGHSY 9

RESULT 13

ID TIR1_ECOLI STANDARD; PRT; 1033 AA.

AC P10486;

DT 01-JUL-1989 (Rel. 11, Created)

DT 01-JUL-1989 (Rel. 11, Last sequence update)

DT 15-DEC-1998 (Rel. 37, Last annotation update)

DE TYPE I RESTRICTION ENZYME ECOR124II R PROTEIN (EC 3.1.21.3).

OS Escherichia coli.

OG Plasmid IncFIV R124/3.

OC Bacteria; Proteobacteria; gamma subdivision; Enterobacteriaceae;

OC Escherichia.

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE; 89178628.

RA Price C., Lingner J., Bickle J., Firman T.A., Glover S.W.;

RT "Basis for changes in DNA recognition by the Ecor124 and Ecor124/3

RT type I DNA restriction and modification enzymes.";

RL J. Mol. Biol. 205:115-125(1989).

CC -!- FUNCTION: THE Ecor124/3 I ENZYME RECOGNIZES 5'GAA(N7)ATC.

CC -!- ACTIVITY: SUBUNIT R IS REQUIRED FOR BOTH NUCLEASE AND ATPASE.

CC -!- SUBUNIT: THE TYPE I RESTRICTION & MODIFICATION SYSTEM IS COMPOSED

CC OF THREE POLYPEPTIDES R,M AND S.

CC -!- MISCELLANEOUS: TYPE I RESTRICTION AND MODIFICATION ENZYMES ARE

CC COMPLEX, MULTIFUNCTIONAL SYSTEMS WHICH REQUIRE ATP, S-ADENOSYL

CC METHIONINE AND MG(2+) AS CO-FACTORS AND, IN ADDITION TO THEIR

CC ENDONUCLEOTIC AND METHYLASE ACTIVITIES, ARE POTENT DNA-DEPENDENT

CC ATPASES.

CC -!- SIMILARITY: WITH ATPASES.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

DR EMBL; X13145; CAA31543.1; -

DR PIR; S02168; S02168.

DR REBASE; RB00989; Ecor124II.

KW Plasmid; Restriction system; Hydrolase; DNA-binding; ATP-binding.

SQ SEQUENCE 1033 AA; 119656 MW; B55F3991356C1506 CRC64;

Query Match 73.8%; Score 45; DB 1; Length 1033;

Best Local Similarity 75.0%; Pred. No. 1.39e+00;

Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 23 AEPTGDSY 30

QY 2 ADPTGHSY 9

RESULT 14

ID YD22_MYCTU STANDARD; PRT; 98 AA.

AC Q10635;

DT 01-OCT-1996 (Rel. 34, Created)

DT 01-OCT-1996 (Rel. 34, Last sequence update)

DT 15-FEB-2000 (Rel. 39, Last annotation update)

DE HYPOTHETICAL 11.3 KDA PROTEIN RV1322.

GN RV1322 OR MFCY130.07.

OS Mycobacterium tuberculosis.

OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;

OC Actinomycetales; Corynebacterineae; Mycobacteriaceae; Mycobacter

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=H37RV;

RA MEDLINE: 98295987.
 RA Cole S.T., Brosch K., Parkhill J., Garnier T., Churcher C., Harris D.,
 RA Gordon S.V., Eiglmeier K., Gas S., Barry C.E. III, Tekala F.,
 RA Badcock K., Basham D., Brown D., Chillingworth T., Connor R.,
 RA Davies R., Devlin K., Feltwell T., Gentles S., Hamlin N., Holroyd S.,
 RA Hornsby T., Jagels K., Krogg A., McLean J., Moule S., Murphy L.,
 RA Oliver S., Osborne J., Quail M.A., Rajandream M.A., Rogers J.,
 RA Rutter S., Seeger K., Skelton S., Squares S., Squires R., Sulston J.E.,
 RA Taylor K., Whitehead S., Barrell B.G.;
 RT "Deciphering the biology of Mycobacterium tuberculosis from the
 RL Nature 393:537-544(1998)."
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: Z73902; CAA98085.1;
 DR TUBERCULIST; Rv1322;
 KW Hypothetical protein.
 SQ SEQUENCE 98 AA; 11334 MW; 72DF33A68405AE4B CRC64;

Query Match 72.1%; Score 44; DB 1; Length 98;
 Best Local Similarity 66.7%; Pred. No. 2.53e+00;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Db 24 EAGPDGHEY 32
 ||| |||
 QY 1 EADPTGHSY 9

RESULT 15
 ID SUOX_HUMAN STANDARD; PRT; 488 AA.
 AC P31687;
 DT 01-OCT-1996 (Rel. 34, Created)
 DT 01-OCT-1996 (Rel. 34, Last sequence update)
 DT 15-JUL-1998 (Rel. 36, Last annotation update)
 DE SULFITE OXIDASE PRECURSOR (EC 1.8.3.1).
 GN SUOX.
 OS Homo sapiens (Human).
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=LIVER;
 RX MEDLINE: 95322455.
 RA Garrett R.M., Bellissimo D.B., Rajagopalan K.V.;
 RT "Molecular cloning of human liver sulfite oxidase."
 RL Biochim. Biophys. Acta 1262:147-149(1995).
 RN [2]
 RP VARIANTS GLN-150; ASP-208; TYR-370 AND ASP-473.
 RX MEDLINE: 98088796.
 RA Kisker C., Schindelin H., Pacheco A., Webb W.A., Garrett R.M.,
 RA Rajagopalan K.V., Enemark J.H., Rees D.C.;
 RT "Molecular basis of sulfite oxidase deficiency from the structure of
 RT sulfite oxidase."
 RL Cell 91:973-983(1997).
 RN [3]
 RP VARIANT GLN-150.
 RX MEDLINE: 98263367.
 RA Garrett R.M., Johnson J.L., Graf T.N., Feigenbaum A.,
 RA Rajagopalan K.V.;
 RT "Human sulfite oxidase R150Q: identification of the mutation in a
 RT sulfite oxidase-deficient patient and expression and characterization
 RT of the mutant enzyme."
 RL Proc. Natl. Acad. Sci. U.S.A. 95:6394-6398(1998).
 CC -1- CATALYTIC ACTIVITY: SULFITE + O(2) + H(2)O = SULFATE + H(2)O(2).
 CC -1- COFACTOR: MOLYBDENUM (MOLYBDOPTERIN) AND ONE PROTOHEME GROUP.
 CC -1- PATHWAY: TERMINAL REACTION IN THE OXIDATIVE DEGRADATION OF SULFUR-

CC CONTAINING AMINO ACIDS. IT USES CYTOCHROME C AS AN ELECTRON
 CC ACCEPTOR.
 CC -1- SUBUNIT: HOMODIMER (BY SIMILARITY).
 CC -1- SUBCELLULAR LOCATION: MITOCHONDRIAL INTER MEMBRANE SPACE.
 CC -1- DISEASE: DEFECTS IN SUOX ARE A CAUSE OF SULFITE OXIDASE
 CC DEFICIENCY; CHARACTERIZED BY NEUROLOGICAL ABNORMALITIES. OFTEN
 CC LEADS TO DEATH AT AN EARLY AGE.
 CC -1- SIMILARITY: WITH CYTOCHROME B5 AND NITRATE REDUCTASE.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: L31573; AAA74886.1;
 DR HSP; P07850; 1SOX.
 DR MIM: 272300;
 DR PFAM: PF00173; heme_1; 1.
 DR PFAM: PF00174; Oxidored_molyb; 1.
 DR PRINTS: PR00407; EUMOPTERIN.
 DR PROSITE: PS00191; CYTOCHROME_B5_1; 1.
 DR PROSITE: PS00559; MOLYBDOPTERIN_EUK; 1.
 KW Oxidoreductase; Mitochondrion; Heme; Molybdenum; Transit peptide;
 KW Disease mutation.
 FT TRANSIT 1 22 MITOCHONDRION (BY SIMILARITY).
 FT CHAIN 23 488 SULFITE OXIDASE.
 FT DOMAIN 23 107 CYTOCHROME DOMAIN (BY SIMILARITY).
 FT DOMAIN 108 124 HINGE (BY SIMILARITY).
 FT DOMAIN 125 488 MOLYBDENUM-PTERIN DOMAIN (BY SIMILARITY).
 FT BINDING 61 61 HEME LIGAND (BY SIMILARITY).
 FT BINDING 86 86 HEME LIGAND (BY SIMILARITY).
 FT METAL 207 207 MOLYBDENUM-PTERIN (BY SIMILARITY).
 FT METAL 260 260 MOLYBDENUM-PTERIN (BY SIMILARITY).
 FT VARIANT 160 160 R -> Q (IN SUOX DEFICIENCY; 2% OF
 FT ACTIVITY).
 FT /FTID-VAR_002200.
 FT A -> D (IN SUOX DEFICIENCY).
 FT /FTIG-VAR_002201.
 FT S -> Y (IN SUOX DEFICIENCY).
 FT /FTID-VAR_002202.
 FT G -> D (IN SUOX DEFICIENCY).
 FT /FTID-VAR_002203.
 SQ SEQUENCE 488 AA; 53884 MW; 41EFA367FAB766DA CRC64;

Query Match 72.1%; Score 44; DB 1; Length 488;
 Best Local Similarity 55.6%; Pred. No. 2.53e+00;
 Matches 5; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Db 265 DSDPTGTAY 273
 :|:|:|:
 QY 1 EADPTGHSY 9

Search completed: Tue Sep 12 13:18:21 2000
 Job time : 7 secs.

WIREH

(TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPSrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Tue Sep 12 13:18:37 2000; MasPar time 8.87 Seconds

Tabular output not generated.
70.368 Million cell updates/sec

Title: >US-08-819-669E-26

Description: (1-9) from US08819669E.pep

Perfect Score: 61

Sequence: 1 EADPTGHSY 9

Scoring table: PAM 150

Gap 15

Searched: 225878 seqs, 59334122 residues

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database: spiremb112

1:sp_archaea 2:sp_bacteria 3:sp_fungi 4:sp_human
5:sp_invertebrate 6:sp_mammal 7:sp_mhc 8:sp_organelle
9:sp_phase 10:sp_plant 11:sp_rodent 12:sp_unclassified
13:sp_vertebrate 14:sp_virus

Statistics: Mean 20.592; Variance 19.613; scale 1.050

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description	Pred. No.
1	49	80.3	347	4	DAM10=DSS-AHC CRITICAL	2.04e-01
2	49	80.3	347	4	MAGE-B1.	2.04e-01
3	48	78.7	129	1	Q9YDL2	3.86e-01
4	48	78.7	308	11	RAS-LIKE GTP-BINDING P	3.86e-01
5	48	78.7	308	4	RAD GTPASE.	3.86e-01
6	47	77.0	3942	11	BASSOON.	7.24e-01
7	46	75.4	1187	2	Q9S278	2.48e+00
8	45	73.8	131	2	ENDOXILANASE (EC 3.2.1	1.35e+00
9	45	73.8	330	11	HYPOTHETICAL 14.2 KD P	2.48e+00
10	45	73.8	330	11	MELANOMA ANTIGEN, RELA	2.48e+00
11	45	73.8	353	14	ORFV.	2.48e+00
12	45	73.8	503	14	GLYCOPROTEIN GP94.	2.48e+00
13	45	73.8	503	14	P57 (FRAGMENT).	2.48e+00
14	45	73.8	503	14	P57 (FRAGMENT).	2.48e+00
15	45	73.8	503	14	P57 (FRAGMENT).	2.48e+00
16	45	73.8	503	14	GLYCOPROTEIN.	2.48e+00
17	45	73.8	503	14	P57 (FRAGMENT).	2.48e+00
18	45	73.8	503	14	GLYCOPROTEIN.	2.48e+00
19	45	73.8	503	14	P57 (FRAGMENT).	2.48e+00
20	45	73.8	1032	11	INTEGRIN ALPHA-4 SUBUN	2.48e+00

21	44	72.1	128	1	Q9YCJ1	128AA LONG HYPOTHETICA	4.54e+00
22	44	72.1	320	11	O89006	MAGEA6 PROTEIN.	4.54e+00
23	44	72.1	325	11	O89010	MYELIN TRANSCRIPTION F	4.54e+00
24	44	72.1	1078	11	O08995	KIAA0835 PROTEIN.	4.54e+00
25	44	72.1	1121	4	O94922	TEGUMENT PROTEIN.	4.54e+00
26	44	72.1	2457	14	O41965	BASSOON.	4.54e+00
27	44	72.1	3938	11	O88778	MT2-MMP PROTEIN (FRAGM	8.20e+00
28	43	70.5	126	6	Q9XS18	ALPHA-AMYLASE 2 (EC 3.	8.20e+00
29	43	70.5	156	5	Q23961	HYPOTHETICAL 21.4 KD P	8.20e+00
30	43	70.5	197	2	O53701	LECITHIN-CHOLESTEROL A	8.20e+00
31	43	70.5	272	11	O35830	MAGEA5 PROTEIN.	8.20e+00
32	43	70.5	320	11	O89009	CYSTEINE PROTEINASE.	8.20e+00
33	43	70.5	341	5	O25028	KIAA0679 PROTEIN.	8.20e+00
34	43	70.5	453	4	Q9Y6X5	MATRIX METALLOPROTEINA	8.20e+00
35	43	70.5	564	4	O14111	MATRIX METALLOPROTEINA	8.20e+00
36	43	70.5	657	11	O54732	B0019.1 PROTEIN.	8.20e+00
37	43	70.5	668	5	Q9XXU5	HYPOTHETICAL 81.0 KD P	8.20e+00
38	43	70.5	745	2	O86648	YONG.	8.20e+00
39	43	70.5	875	9	O64044	YONG PROTEIN.	8.20e+00
40	43	70.5	875	2	O31978	ENDO-1,4-BETA-XYLANASE	8.20e+00
41	43	70.5	1085	2	O69230	BASSOON PROTEIN (KIAA0	8.20e+00
42	43	70.5	3851	4	O43161	HYPOTHETICAL 54.2 KD P	1.47e+01
43	42	68.9	503	2	O33360	HYPOTHETICAL 54.1 KD P	1.47e+01
44	42	68.9	503	2	O33266	T12M4.10 PROTEIN.	1.47e+01
45	42	68.9	568	10	O80487		

ALIGNMENTS

RESULT	ID	000601	1	PRELIMINARY;	PRT;	347	AA.
AC	O06001;						
DT	01-JUL-1997	(TEMBLrel. 04, Created)					
DT	01-JUL-1997	(TEMBLrel. 04, Last sequence update)					
DT	01-MAY-1999	(TEMBLrel. 10, Last annotation update)					
DE	DAM10=DSS-AHC CRITICAL INTERVAL	MAGE SUPERFAMILY PROTEIN.					
GN	DAM10.						
OS	Homo sapiens (Human).						
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;						
OC	Eutheria; Primates; Catarrhini; Hominidae; Homo.						
RN	[1]						
RP	SEQUENCE FROM N.A.						
RC	TISSUE=TESTIS;						
RX	MEDLINE: 96081328.						
RA	DABOVIC B., ZANARIA E., BARDONI B., BORDIGNON C., RUSSO V.,						
RA	MATESSI C., TRAVERSARI C., CAMERINO G.;						
RT	"A family of rapidly evolving genes from the sex reversal critical						
RT	region in Xp21."						
RL	Mamm. Genome 6:571-580(1995).						
DR	EMBL: S80936; AAC97145.1;						
DR	PFAM: PF01454; MAGE; 1.						
SQ	SEQUENCE	347	AA;	35049	MW;	AB96D5BB	CRC32;

Query Match 80.3%; Score 49; DB 4; Length 347;
Best Local Similarity 55.6%; Pred. No. 2.04e-01;
Matches 5; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Db 167 EDNPSGHTY 175

QY 1 EADPTGHSY 9

RESULT	ID	075862	2	PRELIMINARY;	PRT;	347	AA.
AC	O75862;						
DT	01-NOV-1998	(TEMBLrel. 08, Created)					
DT	01-NOV-1998	(TEMBLrel. 08, Last sequence update)					
DT	01-MAY-1999	(TEMBLrel. 10, Last annotation update)					
DE	MAGE-B1.						
GN	MAGE-B1.						
OS	Homo sapiens (Human).						
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;						
OC	Eutheria; Primates; Catarrhini; Hominidae; Homo.						

```

RN  SEQUENCE FROM N.A.
RP  MUZNY D., ARENSON A.D., ADAMS C., BRUNDAGE E., BUNAC C., CARVELLI K.,
RA  CHACKO J., CHEN J., DI W., DING Y., DUGAN S., DURBIN J., FORCUM J.,
RA  GANESH R., GARCIA C., GOODMAN M., GORRELL J.H., HAYWOOD M.,
RA  HERNANDEZ J., JACKSON L., JIN S., KAMPAL R., KARPATHY S., KOVAR C.,
RA  LEAL B., LI Y., LICHTARGE O., LIU W., LOGAN O., LU J., LY T.,
RA  MARTINEZ C., OSWAL G., PEREZ L., RASHID N.D., ROWLAND K., SAVAGE L.,
RA  SCHERER S.E., SHEN H., SIMON M., STOVALL K., TIMMS K.M., TODD J.,
RA  VO Q., WILLIAMSON A., WORLEY K.C., YU W., CHINAULT C., NELSON D.,
RA  GIBBS R.A.:
RT  "Direct Submission";
RL  Submitted (01-1998) to the EMBL/GenBank/DBJ databases.
DR  EMBL; AC005185; AADI0634.1; -.
DR  PFAM; PF01454; MAGE; 1.
SQ  SEQUENCE 347 AA; 39037 MW; 4BA34904 CRC32;

Query Match 80.3%; Score 49; DB 4; Length 347;
Best Local Similarity 55.6%; Pred. No. 2.04e-01;
Matches 5; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Db 167 EDNPSGHPT 175
QY 1 EADPTGHSY 9

RESULT 3
ID Q9YDL2 PRELIMINARY; PRT; 129 AA.
AC Q9YDL2;
DT 01-NOV-1999 (TrEMBLrel. 12, Created)
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DE 01-NOV-1999 (TrEMBLrel. 12, Last annotation update)
DE 129AA LONG HYPOTHETICAL PROTEIN.
GN APE0901.
OS Aeropyrum pernix.
OC Archaea; Crenarchaeota; Aeropyrum.
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN-K1;
RX MEDLINE; 99310339.
RA KAWARABAYASI Y., HINO Y., HORIKAWA H., YAMAZAKI S., HATKAWA Y.,
RA JIN-NO K., TAKAHASHI M., SEKINE M., BABA S., ANKAI A., KOSUGI H.,
RA HOSOIYAMA A., FUKUI S., NAGAI Y., NISHIJIMA K., NAKAZAWA H.,
RA TAKAMIYA M., MASUDA S., FUNAHASHI T., TANAKA T., KUDOH Y.,
RA YAMAZAKI J., KUSHIDA N., OGUCHI A., AOKI K., KUBOTA K., NAKAMURA Y.,
RA NOMURA N., SAKO Y., KIKUCHI H.;
RT "Complete genome sequence of an aerobic hyper-thermophilic
RT crenarchaeon, Aeropyrum pernix K1.";
RL DNA Res. 6:83-101(1999).
DR EMBL; AP000060; BAA79885.1; -.
SQ SEQUENCE 129 AA; 14303 MW; A2EB2774 CRC32;

Query Match 78.7%; Score 48; DB 1; Length 129;
Best Local Similarity 85.7%; Pred. No. 3.86e-01;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db 115 DPAGHSY 121
QY 3 DPTGHSY 9

RESULT 4
ID O88667 PRELIMINARY; PRT; 308 AA.
AC O88667;
DT 01-NOV-1998 (TrEMBLrel. 08, Created)
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)
DT 01-NOV-1999 (TrEMBLrel. 12, Last annotation update)
DE RAS-LIKE GTP-BINDING PROTEIN RAD.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
OC Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN-129 SVJ;
RX MEDLINE; 98345363.
RA DIECK S., SANMARTI-VILA L., LANGENASE K., RICHTER K., KINDLER S.,
RA SOYKE A., WEX H., SMALLA K.H., KAMPF U., FRANZER J.T., STUMM M.,
RA GARNER C.C., GUNDELFINGER E.D.;

```

```

RA FINLIN B.S., ANDRES D.A.;
RT "Cloning of the mouse Rad gene.";
RL Submitted (AUG-1998) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF084466; AAC3133.1; -.
DR HSSP; P10114; 2RAP. 1.
DR PFAM; PF00071; ras; 1.
SQ SEQUENCE 308 AA; 33279 MW; 10AE9F3C CRC32;

Query Match 78.7%; Score 48; DB 11; Length 308;
Best Local Similarity 55.6%; Pred. No. 3.86e-01;
Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Db 119 EAEAGHTY 127
QY 1 EADPTGHSY 9

RESULT 5
ID Q92788 PRELIMINARY; PRT; 308 AA.
AC Q92788;
DT 01-FEB-1997 (TrEMBLrel. 02, Created)
DT 01-FEB-1997 (TrEMBLrel. 02, Last sequence update)
DT 01-NOV-1999 (TrEMBLrel. 12, Last annotation update)
DE RAD GTPASE.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
OC Eutheria; Primates; Catarrhini; Homiidae; Homo.
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE; 94069319.
RA REYNET C., KAHN C.R.;
RT "Rad; a member of the Ras family overexpressed in muscle of type II
RT diabetic humans.";
RL Science 262:1441-1444(1993).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE; 96375161.
RA CALDWELL J.S., MOYERS J.S., DORIA A., REYNET C., KAHN R.C.;
RT "Molecular cloning of the human rad gene: gene structure and complete
RT nucleotide sequence.";
RL Biochim Biophys Acta 1316:145-148(1996).
DR EMBL; U46165; AAB17064.1; -.
DR HSSP; P10114; 2RAP. 1.
DR PFAM; PF00071; ras; 1.
SQ SEQUENCE 308 AA; 33220 MW; 4B7A3673 CRC32;

Query Match 78.7%; Score 48; DB 4; Length 308;
Best Local Similarity 55.6%; Pred. No. 3.86e-01;
Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Db 119 EAEAGHTY 127
QY 1 EADPTGHSY 9

RESULT 6
ID O88737 PRELIMINARY; PRT; 3942 AA.
AC O88737;
DT 01-NOV-1998 (TrEMBLrel. 08, Created)
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)
DT 01-NOV-1999 (TrEMBLrel. 08, Last annotation update)
DE BASSOON.
GN BASSOON.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
OC Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN-129 SVJ;
RX MEDLINE; 98345363.
RA DIECK S., SANMARTI-VILA L., LANGENASE K., RICHTER K., KINDLER S.,
RA SOYKE A., WEX H., SMALLA K.H., KAMPF U., FRANZER J.T., STUMM M.,
RA GARNER C.C., GUNDELFINGER E.D.;

```

RT "Bassoon, a novel zinc-finger CAG/glutamine-repeat protein selectively
 RT localized at the active zone of presynaptic nerve terminals.";
 RL J. Cell Biol. 142:499-509(1998).
 DR EMBL; Y17034; CAA76598.1; -.
 DR EMBL; Y17035; CAA76598.1; JOINED.
 DR EMBL; Y17036; CAA76598.1; JOINED.
 DR EMBL; Y17037; CAA76598.1; JOINED.
 DR EMBL; Y17038; CAA76598.1; JOINED.
 DR EMBL; Y17039; CAA76598.1; JOINED.
 SQ SEQUENCE 3942 AA; 418739 MW; 9D6C5BC6 CRC32;

Query Match 77.0%; Score 47; DB 11; Length 3942;
 Best Local Similarity 55.6%; Pred. No. 7.24e+01;
 Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Db 1589 DSOPTSHSY 1597
 :|||:|
 QY 1 EADPTGHSY 9

RESULT 7 PRELIMINARY; PRT; 1187 AA.
 ID Q59278 AC Q59278;
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
 DT 01-NOV-1999 (TrEMBLrel. 12, Last annotation update)
 DE ENDOXYLANASE (EC 3.2.1.8) (ENDO-1,4-BETA-XYLANASE)
 DE (1,4-BETA-D-XYLAN XYLANOXYLASE).
 GN XYNL.
 OS Cellulomonas fimi.
 OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;
 OC Actinomycetales; Micrococineae; Cellulomonadaceae; Cellulomonas.
 [1]
 RP SEQUENCE OF 1-352 FROM N.A.
 RX MEDLINE; 96245431.
 RA CLARKE J.H.; DAVIDSON K.; GILBERT H.J.; FONTES C.M.; HAZLEWOOD G.P.;
 RT "A modular xylanase from mesophilic Cellulomonas fimi contains the
 RT same cellulose-binding and thermostabilizing domains as xylanases from
 RT thermophilic bacteria.";
 RL FEMS Microbiol. Lett. 139:27-35(1996).
 [2]
 RP SEQUENCE FROM N.A.
 RA CLARKE J.H.;
 RL Submitted (AUG-1995) to the EMBL/GenBank/DBJ databases.
 CC -1- CATALYTIC ACTIVITY: ENDOHYDROLYSIS OF 1,4-BETA-D-XYLOSIDIC
 CC LINKAGES IN XYLANS.
 DR EMBL; Z50866; CAA90745.1; -.
 DR HSP; P14768; ICLX.
 DR PFAM; PF00331; Glyco_hydro_10; 1.
 DR PFAM; PF01522; Polysac_deacet; 1.
 DR PRINTS; PR00134; GLHYDLASE10.
 KW Xylan degradation; Hydrolase; Glycosidase.
 SQ SEQUENCE 1187 AA; 125378 MW; 92B3994A CRC32;

Query Match 75.4%; Score 46; DB 2; Length 1187;
 Best Local Similarity 75.0%; Pred. No. 1.35e+00;
 Matches 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Db 1046 TDPTGRSY 1053
 :|||:|
 QY 2 ADPTGHSY 9

RESULT 8 PRELIMINARY; PRT; 131 AA.
 ID O85701 AC O85701;
 DT 01-NOV-1998 (TrEMBLrel. 08, Created)
 DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)
 DE HYPOHETICAL 14.2 KD PROTEIN.
 OS Streptomyces lividans.
 CC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;
 CC Actinomycetales; Streptomycineae; Streptomycetaceae; Streptomyces.
 [1]

RP SEQUENCE FROM N.A.
 RC STRAIN=1326; AJ100;
 RA ALTENBUCHNER J.;
 RT "Amplifiable element AUD4 from Streptomyces lividans 66.";
 RL Submitted (JUN-1998) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AF072709; AAC25770.1; -.
 KW Hypothetical protein.
 SQ SEQUENCE 131 AA; 14187 MW; 8321BCE1 CRC32;

Query Match 73.8%; Score 45; DB 2; Length 131;
 Best Local Similarity 62.5%; Pred. No. 2.48e+00;
 Matches 5; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Db 110 SDPAGHSF 117
 :|||:|
 QY 2 ADPTGHSY 9

RESULT 9 PRELIMINARY; PRT; 330 AA.
 ID G60763 AC G60763;
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
 DT 01-NOV-1999 (TrEMBLrel. 12, Last annotation update)
 DE MELANOMA ANTIGEN, RELATED SEQUENCE 2 (SMAGE-3 PROTEIN).
 GN MAGE-RS3.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 OC Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=DBA/2; TISSUE=KIDNEY;
 RX MEDLINE; 96070435.
 RA DE BACKER O.; VERHEYDEN A.M.; MARTIN B.; GODELAINE D.; DE PLAEN E.;
 RA BRASSEUR R.; AVNER P.; BOON T.;
 RT "Structure, chromosomal location, and expression pattern of three
 RT mouse genes homologous to the human MAGE genes.";
 RL Genomics 28:74-83(1995).
 DR EMBL; U19033; AAA86098.1; -.
 DR PFAM; PF01454; MAGE; 1.
 SQ SEQUENCE 330 AA; 35985 MW; 83AD4246 CRC32;

Query Match 73.8%; Score 45; DB 11; Length 330;
 Best Local Similarity 66.7%; Pred. No. 2.48e+00;
 Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Db 161 EIDPSTHSY 169
 :|||:|
 QY 1 EADPTGHSY 9

RESULT 10 PRELIMINARY; PRT; 330 AA.
 ID G60761 AC G60761;
 DT 01-NOV-1998 (TrEMBLrel. 08, Created)
 DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)
 DT 01-NOV-1999 (TrEMBLrel. 12, Last annotation update)
 DE MELANOMA ANTIGEN RELATED SEQUENCES 1 AND 2
 DE (SMAGE-1 PROTEIN / SMAGE-2 PROTEIN).
 GN MAGE2 OR (MAGE-RS1 OR SMAGE1) AND (MAGE-RS2 OR SMAGE2).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 OC Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 [1]

RP SEQUENCE FROM N.A.
 RC STRAIN=DBA/2; TISSUE=KIDNEY;
 RX MEDLINE; 96070435.
 RA DE BACKER O.; VERHEYDEN A.M.; MARTIN B.; GODELAINE D.; DE PLAEN E.;
 RA BRASSEUR R.; AVNER P.; BOON T.;
 RT "Structure, chromosomal location, and expression pattern of three
 RT mouse genes homologous to the human MAGE genes.";
 RL Genomics 28:74-83(1995).
 CC -1- TISSUE SPECIFICITY: EXPRESSED IN TUMOURS OF VARIOUS HISTOLOGICAL

CC TYPES BUT NOT IN NORMAL TISSUES EXCEPT TESTIS.
 CC -I- SIMILARITY: BELONGS TO THE MAGE FAMILY.

DR EMBL; U19031; AAA86096.1; ALT_INIT.

DR EMBL; U19032; AAA86097.1; -.

DR MGD; MGI:105117; Maged2.

DR PFAM; PF01454; MAGE; 1.

KW Antigen; Tumor antigen.

SQ SEQUENCE 330 AA; 35936 MW; 36D760C5 CRC32;

Query Match 73.8%; Score 45; DB 11; Length 330;

Best Local Similarity 66.7%; Pred. No. 2.48e+00;

Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Db 161 EIDPSTHSY 169

Y 1 EADPTGHSY 9

RESULT 11

ID Q88626 PRELIMINARY; PRT; 353 AA.

AC Q88626; 1996 (TREMBLrel. 01, Created)

DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)

DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)

DT 01-NOV-1998 (TREMBLrel. 08, Last annotation update)

DE ORFV.

OS Borna disease virus (BDV).

OC Viruses; ssRNA negative-strand viruses; Mononegavirales.

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE; 94149825.

RT CUBITT B., OLDSTONE C., LA TORRE J.;

"Sequence and genome organization of Borna disease virus.";

RL J. Virol. 68:1382-1396(1994).

DR EMBL; L27077; AAA20666.1; -.

SQ SEQUENCE 353 AA; 39959 MW; 555715F0 CRC32;

Query Match 73.8%; Score 45; DB 14; Length 353;

Best Local Similarity 55.6%; Pred. No. 2.48e+00;

Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Db 266 ETDPINHAY 274

Y 1 EADPTGHSY 9

RESULT 12

ID Q9WNAO PRELIMINARY; PRT; 503 AA.

AC Q9WNAO;

DT 01-NOV-1999 (TREMBLrel. 12, Created)

DT 01-NOV-1999 (TREMBLrel. 12, Last sequence update)

DT 01-NOV-1999 (TREMBLrel. 12, Last annotation update)

DE GLYCOPROTEIN GP94.

OS Borna disease virus (BDV).

OC Viruses; ssRNA negative-strand viruses; Mononegavirales.

RN [1]

RP SEQUENCE FROM N.A.

RX STRAIN-RW98;

RA MEDLINE; 99329142.

RA PLANZ O., RENTZSCH C., BATRA A., BATRA A., WINKLER T., BUETTNER M.,

RZHA H.-J., STITZ L.;

"Pathogenesis of borna disease virus: granulocyte fractions of

psychiatric patients harbor infectious virus in the absence of

antiviral antibodies.";

RL J. Virol. 73:6251-6256(1999).

DR EMBL; AF158633; AA045291.1; -.

SQ SEQUENCE 503 AA; 56588 MW; EC993A56 CRC32;

Query Match 73.8%; Score 45; DB 14; Length 503;

Best Local Similarity 55.6%; Pred. No. 2.48e+00;

Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Db 416 ETDPINHAY 424

Y 1 EADPTGHSY 9

QY 1 EADPTGHSY 9

RESULT 13

ID O10403 PRELIMINARY; PRT; 503 AA.

AC O10403;

DT 01-JUL-1997 (TREMBLrel. 04, Created)

DT 01-JUL-1997 (TREMBLrel. 04, Last sequence update)

DT 01-AUG-1998 (TREMBLrel. 07, Last annotation update)

DE P57 (FRAGMENT).

OS Borna disease virus (BDV).

OC Viruses; ssRNA negative-strand viruses; Mononegavirales.

RN [1]

RP SEQUENCE FROM N.A.

RA ZIMMERMANN W., KOKORSCH J., DUERSWALD R., LUDWIG H.;

Submitted (MAR-1997) to the EMBL/GenBank/DBJ databases.

DR EMBL; U94862; AAB53731.1; -.

FT NON_TER 503

SQ SEQUENCE 503 AA; 56510 MW; E59DC9A6 CRC32;

Query Match 73.8%; Score 45; DB 14; Length 503;

Best Local Similarity 55.6%; Pred. No. 2.48e+00;

Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Db 416 ETDPINHAY 424

Y 1 EADPTGHSY 9

RESULT 14

ID O10399 PRELIMINARY; PRT; 503 AA.

AC O10399;

DT 01-JUL-1997 (TREMBLrel. 04, Created)

DT 01-JUL-1997 (TREMBLrel. 04, Last sequence update)

DT 01-AUG-1998 (TREMBLrel. 07, Last annotation update)

DE P57 (FRAGMENT).

OS Borna disease virus (BDV).

OC Viruses; ssRNA negative-strand viruses; Mononegavirales.

RN [1]

RP SEQUENCE FROM N.A.

RA ZIMMERMANN W., KOKORSCH J., DUERSWALD R., LUDWIG H.;

Submitted (MAR-1997) to the EMBL/GenBank/DBJ databases.

DR EMBL; U94874; AAB53723.1; -.

FT NON_TER 503

SQ SEQUENCE 503 AA; 56564 MW; 28555C1E CRC32;

Query Match 73.8%; Score 45; DB 14; Length 503;

Best Local Similarity 55.6%; Pred. No. 2.48e+00;

Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Db 416 ETDPINHAY 424

Y 1 EADPTGHSY 9

RESULT 15

ID O10394 PRELIMINARY; PRT; 503 AA.

AC O10394;

DT 01-JUL-1997 (TREMBLrel. 04, Created)

DT 01-JUL-1997 (TREMBLrel. 04, Last sequence update)

DT 01-AUG-1998 (TREMBLrel. 07, Last annotation update)

DE P57 (FRAGMENT).

OS Borna disease virus (BDV).

OC Viruses; ssRNA negative-strand viruses; Mononegavirales.

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=436;

RA ZIMMERMANN W., KOKORSCH J., LUNDGREN A.L., LUDWIG H.;

Submitted (MAR-1997) to the EMBL/GenBank/DBJ databases.

DR EMBL; U94866; AAB53715.1; -.

FT NON_TER 503

SQ SEQUENCE 503 AA; 56578 MW; B543AFC4 CRC32;

Query Match 73.8%; Score 45; DB 14; Length 503;
Best Local Similarity 55.6%; Pred. No. 2.48e+00;
Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
Db 416 ETDPINHAY 424
QY 1 EADPTGHSY 9

Search completed: Tue Sep 12 13:18:50 2000
Job time : 13 secs.

 M P S R E H
 (TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
 Copyright (c) 1993-1998 University of Edinburgh, U.K.
 Distribution rights by Oxford Molecular Ltd

MPSrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Wed Sep 13 07:14:17 2000; MasPar time 3.65 Seconds
 Tabular output not generated.
 58.333 Million cell updates/sec

Title: >US-08-819-669E-26
 Description: (1-9) from US08819669E.pap
 Perfect Score: 61
 Sequence: 1 EADPTGHSY 9

Scoring table: PAM 150
 Gap 15

Searched: 188963 seqs, 23686106 residues

Post-processing: Minimum Match 0%
 Listing first 45 summaries

Database: a-geneseq36
 1:geneseq

Statistics: Mean 15.425; Variance 35.597; scale 0.434

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description	Pred. No.
1	61	100.0	9	1 W98945	HLA-A1 binding peptide	2.32e-01
2	61	100.0	9	1 Y01727	Exemplary antigenic pe	2.32e-01
3	61	100.0	9	1 Y10633	Peptide antigen SEQ ID	2.32e-01
4	61	100.0	9	1 Y00685	Tumour antigen booster	2.32e-01
5	61	100.0	9	1 Y10424	HLA Class I motif pep	2.32e-01
6	61	100.0	9	1 Y10623	Peptide antigen SEQ ID	2.32e-01
7	61	100.0	9	1 W54622	Peptide from Mage-1 16	2.32e-01
8	61	100.0	9	1 R50281	MAGE-1 nonapeptide.	2.32e-01
9	61	100.0	9	1 R83932	MHC class I restricted	2.32e-01
10	61	100.0	9	1 R29769	Antigen E peptide.	2.32e-01
11	61	100.0	9	1 W68371	Human MAGE-1 peptide b	2.32e-01
12	61	100.0	9	1 W7125	gp75/TRP-1 synthetic p	2.32e-01
13	61	100.0	9	1 W75734	Peptidase-resistant pe	2.32e-01
14	61	100.0	9	1 W00897	Human melanoma MAGE1 t	2.32e-01
15	61	100.0	9	1 W75736	Peptidase-resistant pe	2.32e-01
16	61	100.0	9	1 R82988	P815 antigenic peptide	2.32e-01
17	61	100.0	9	1 R90592	Human leukocyte antige	2.32e-01
18	61	100.0	9	1 W56729	MAGE-1 antigenic parti	2.32e-01
19	61	100.0	9	1 R75954	Melanoma antigen (MAGE	2.32e-01
20	61	100.0	9	1 R93443	MAGE-1 nonapeptide.	2.32e-01
21	61	100.0	9	1 W78938	MAGE-1 protein fragmen	2.32e-01
22	61	100.0	9	1 R65112	MAGE-1 immunogenic pep	2.32e-01
23	61	100.0	9	1 R63675	Synthetic peptide deri	2.32e-01

24 61 100.0 9 1 R78824 MAGE-1 cytotoxic T lym
 25 61 100.0 9 1 R65135 MAGE-1 immunogenic pep
 26 61 100.0 9 1 R49224 HLA-A1 MAGE-1 antigen
 27 61 100.0 9 1 R47330 HLA-A1 MAGE-1 antigen
 28 61 100.0 10 1 W23038 MAGE-1/HLA-B44 tumour
 29 61 100.0 12 1 R80620 Immunogenic peptide of
 30 61 100.0 309 1 R70909 Human melanoma antigen
 31 61 100.0 309 1 W81548 Tumour rejection antig
 32 59 96.7 9 1 R99342 HLA binding nonapeptid
 33 58 95.1 9 1 R99339 HLA binding nonapeptid
 34 57 93.4 9 1 W75733 Peptidase-resistant pe
 35 57 93.4 9 1 W75735 Peptidase-resistant pe
 36 55 90.2 9 1 R93377 HLA binding nonapeptid
 37 55 90.2 9 1 R93340 HLA binding nonapeptid
 38 54 88.5 9 1 R99338 Peptide antigen SEQ ID
 39 52 85.2 9 1 Y10628 HLA binding nonapeptid
 40 49 80.3 9 1 R99341 HLA binding nonapeptid
 41 48 78.7 308 1 R45431 Diabetogene rad: A typ
 42 48 78.7 308 1 W13869 Rad protein.
 43 48 78.7 925 1 R79148 Human insulin receptor
 44 47 77.0 9 1 Y10629 Peptide antigen SEQ ID
 45 47 77.0 272 1 W44186 Maleate cis-trans isom

ALIGNMENTS

RESULT 1
 ID W98945 standard; peptide; 9 AA.
 AC W98945;
 DT 06-MAY-1999 (first entry)
 DE HLA-A1 binding peptide derived from MAGE-1.
 DE Human leukocyte antigen; HLA; HLA-A2 binding peptide; T cell;
 KW cytolytic T cell; CTL.
 OS Synthetic.
 OS Homo sapiens.
 PN W0988951-A1.
 PF 30-DEC-1998.
 PD 18-JUN-1998; U12879.
 PR 16-APR-1998; US-061388.
 PR 23-JUN-1997; US-880963.
 PA (LUDW-) LUDWIG INST CANCER RES.
 PI Carotini J, Romero P, Valmori D;
 DR WFI; 99-10509/09.
 PT New decamer peptides which bind to HLA molecules - useful to
 PT identify HLA-A2 positive cells and provoke T cells
 PS Example 7; Page 18; 45pp; English.
 CC The present invention describes peptides which bind to an HLA-A2
 CC molecule and have Val at the carboxy terminus, and either: (a) Ala, Tyr
 CC or Phe at the amino terminus, and Ala, Leu, or Met at positions 2 and 3, with the
 CC the amino terminus, and Ala, Leu, or Met at positions 2 and 3, with the
 CC proviso that Ala is not at both positions (P2). The peptides of the
 CC present invention are used to identify HLA-A2 positive cells, provoke
 CC T cells, and determine the presence of particular T cells including
 CC cytolytic T cells (CTLs). They provide a better target than the prior
 CC art CTL-stimulating peptide. The present sequence represents a peptide
 CC used in an example from the present invention.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9

RESULT 2
 ID Y01727 standard; Peptide; 9 AA.

AC Y01727;
 DT 25-JUN-1999 (first entry)
 DE Exemplary antigenic peptide derived from MAGE-1.
 KW MAGE-3; tumour associated gene; human leucocyte antigen Class II;

KW autologous CD4+ cell; MAGE-3 related disease; cancer; melanoma;
 KW osteosarcoma; leukemia; carcinoma.
 OS Homo sapiens.
 PN WO9914326-A1.
 PD 25-MAR-1999.

PF 04-SEP-1998; US18601.
 PR 12-SEP-1997; US-928615.
 PA (LUDW-) LUDWIG INST CANCER RES.
 PA (UVVR-) UNIV VRIJE BRUSSEL.
 PI Boon-Falleur T, Chaux P, Corthals J, Heirman C,
 PI Luiten R, Stroobant V, Thielemans K, Van Der Bruggen P;
 DR WPI; 99-244031/20.
 PT Isolated peptides that bind to human leucocyte antigen class II
 PT molecules

PS Disclosure; Page 27; 88pp; English.
 CC The present sequence represents an exemplary tumour associated peptide
 CC antigen. The specification describes a MAGE-3 tumour associated gene.
 CC peptides (Y01721-25) that bind human leucocyte antigen (HLA) Class II
 CC molecules can be derived from the MAGE-3 protein. These peptides and
 CC autologous CD4+ cells that bind to a complex of MAGE-3 peptide
 CC and HLA Class II, are used to treat MAGE-3 related diseases,
 CC particularly cancers (e.g. melanoma, osteosarcoma, leukemia and
 CC various forms of carcinoma). The peptides are also used to produce
 CC specific antibodies. Detection of the peptides, e.g. in binding
 CC assays, particularly with antibodies, is used for diagnosis of such
 CC diseases.
 CC Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9

RESULT 3
 ID Y10633 standard; Peptide; 9 AA.

AC Y10633;
 DT 12-MAY-1999 (first entry)
 DE Peptide antigen SEQ ID NO:563.
 KW Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;
 KW immunisation; tumour; infectious disease; immunotherapy; cancer;
 KW malignant melanoma; viral disease; hepatitis; AIDS.
 OS Synthetic.
 OS Homo sapiens.
 PN WO9902183-A2.
 PD 21-JAN-1999.
 PF 10-JUL-1998; U14289.
 PR 10-DEC-1997; US-988320.
 PR 10-JUL-1997; CA-209815.
 PA (CTL-) CTL IMMUNOTHERAPIES CORP.
 PI Kuendig TM, Simard JLL;
 DR WPI; 99-120514/10.

PT Inducing a cytotoxic T lymphocyte response - by maintaining a level
 PT of antigen in the lymphatic system of a mammal so as to provide a
 PT sustained CTL response, used to treat, e.g. AIDS
 PS Disclosure; Page 52; 199pp; English.
 CC The present invention describes a method of inducing and/or sustaining
 CC an immunological cytotoxic T lymphocyte (CTL) response in a mammal. The
 CC method comprises: (a) delivering an antigen to the mammal at a level to
 CC induce an immunological CTL response in the mammal; and (b) maintaining
 CC the level of the antigen in the mammal's lymphatic system to maintain
 CC the immunologic CTL response. The method can be used for the delivery of
 CC e.g. a differentiation antigen, a tumour-specific multilineage antigen,
 CC an embryonic antigen, an oncogene antigen, a mutated tumour-suppressor
 CC gene antigen, or a viral antigen. They can be used for the treatment of
 CC disease such as cancer, e.g. malignant melanoma or infectious disease,
 CC e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery
 CC to the lymphatic system provides for potent CTL stimulation that takes
 CC place in the milieu of the lymphoid organ, and it sustains stimulation
 CC that is necessary to keep CTL active, cytotoxic and recirculating

CC through the body. Y10071 to Y10639 represent examples of peptide
 CC antigens given in the present invention.

SQ Sequence 9 AA;
 Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9

RESULT 4

ID Y00685 standard; peptide; 9 AA.
 AC Y00685;
 DT 12-MAY-1999 (first entry)
 DE Tumour antigen booster peptide MAGE-1 HLA-A1.
 KW Tumour antigen; booster peptide; immune response modulation; allergy;
 KW immune response enhancer; tumour cell; tumour rejection antigen;
 KW leucocyte antigen-presenting molecule; autoimmune disease;
 KW allograft rejection.
 OS Homo sapiens.
 PN WO9858956-A2.
 PD 30-DEC-1998.
 PR 19-JUN-1998; U12894.
 PR 23-JUN-1997; US-880979.
 PA (LUDW-) LUDWIG INST CANCER RES.
 PI Boon-Falleur T, Oyttenhove C, Warnier G;
 DR WPI; 99-105612/09.
 PT Immunization methods using viruses expressing antigen for priming
 PT and booster immunizations - useful for modulating immune responses
 PT against antigen, e.g. enhancing immune response against tumour cells
 PT expressing tumour rejection antigens
 PS Claim 3; Page 9; 33pp; English.
 CC This sequence represents a tumour antigen booster peptide that can be
 CC used in the method of the invention. The method is for modulating an
 CC immune response in a mammal against an antigen, and comprises:
 CC (A) inducing an immune response by: (i) administering a virus containing
 CC a nucleic acid molecule encoding the antigen or its precursor to generate
 CC an immune response; and (ii) administering at least one booster dose
 CC comprising a peptide including the antigen, in an adjuvant, in a combined
 CC amount effective to enhance the initial immune response; or
 CC non-adjuvant with the peptide which includes the antigen, in an amount
 CC effective to reduce the initial immune response. Method (A) is used to
 CC enhance the immune response against tumour cells expressing tumour
 CC rejection antigens, and against pathogens in subjects having human
 CC leucocyte antigen-presenting molecules. Method (B) is used to reduce the
 CC immune response in allergy, autoimmune disease, and allograft rejection.
 CC Method (A) provides an immunisation method which, unlike prior art, is
 CC not limited by the host immune response against viral vectors.
 CC Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9

RESULT 5

ID Y10424 standard; Peptide; 9 AA.
 AC Y10424;
 DT 12-MAY-1999 (first entry)
 DE HLA Class I motif peptide SEQ ID NO:354.
 KW Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;
 KW immunisation; tumour; infectious disease; immunotherapy; cancer;
 KW malignant melanoma; viral disease; hepatitis; AIDS.
 OS Synthetic.
 OS Homo sapiens.

PN WO9902183-A2.
 PD 21-JAN-1999.
 PF 10-JUL-1998; U14289.
 PR 10-DEC-1997; US-988320.
 PR 10-JUL-1997; CA-209815.
 PA (CTLI-) CTL IMMUNOTHERAPIES CORP.
 PI Kuendig TM, Simard JUL;
 DR WPI: 99-120514/10.
 PT Inducing a cytotoxic T lymphocyte response - by maintaining a level
 PT of antigen in the lymphatic system of a mammal so as to provide a
 PI sustained CTL response, used to treat, e.g. AIDS
 PS Disclosure: Page 39; 1999p; English.
 CC The present invention describes a method of inducing and/or sustaining
 CC an immunological cytotoxic T lymphocyte (CTL) response in a mammal. The
 CC method comprises: (a) delivering an antigen to the mammal at a level to
 CC induce an immunological CTL response in the mammal; and (b) maintaining
 CC the level of the antigen in the mammal's lymphatic system to maintain
 CC the immunologic CTL response. The method can be used for the delivery of
 CC e.g. a differentiation antigen, a tumour-specific multilineage antigen,
 CC an embryonic antigen, an oncogene antigen, a mutated tumour-suppressor
 CC gene antigen, or a viral antigen. They can be used for the treatment of
 CC disease such as cancer, e.g. malignant melanoma or infectious disease,
 CC e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery
 CC to the lymphatic system provides for potent CTL stimulation that takes
 CC place in the milieu of the lymphoid organ, and it sustains stimulation
 CC that is necessary to keep CTL active, cytotoxic and recirculating
 CC through the body. Y10071 to Y10639 represent examples of peptide
 CC antigens given in the present invention.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9

RESULT 6

ID Y10623 standard; Peptide; 9 AA.
 AC Y10623;
 DT 12-MAY-1999 (first entry)
 DE Peptide antigen SEQ ID NO:553.
 KW Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;
 KW immunisation; tumour; infectious disease; immunotherapy; cancer;
 KW malignant melanoma; viral disease; hepatitis; AIDS.
 OS Synthetic.
 OS Homo sapiens.
 PN WO9902183-A2.
 PD 21-JAN-1999.
 PF 10-JUL-1998; U14289.
 PR 10-DEC-1997; US-988320.
 PR 10-JUL-1997; CA-209815.
 PA (CTLI-) CTL IMMUNOTHERAPIES CORP.
 PI Kuendig TM, Simard JUL;
 DR WPI: 99-120514/10.
 PT Inducing a cytotoxic T lymphocyte response - by maintaining a level
 PT of antigen in the lymphatic system of a mammal so as to provide a
 PI sustained CTL response, used to treat, e.g. AIDS
 PS Disclosure: Page 51; 1999p; English.
 CC The present invention describes a method of inducing and/or sustaining
 CC an immunological cytotoxic T lymphocyte (CTL) response in a mammal. The
 CC method comprises: (a) delivering an antigen to the mammal at a level to
 CC induce an immunological CTL response in the mammal; and (b) maintaining
 CC the level of the antigen in the mammal's lymphatic system to maintain
 CC the immunologic CTL response. The method can be used for the delivery of
 CC e.g. a differentiation antigen, a tumour-specific multilineage antigen,
 CC an embryonic antigen, an oncogene antigen, a mutated tumour-suppressor
 CC gene antigen, or a viral antigen. They can be used for the treatment of
 CC disease such as cancer, e.g. malignant melanoma or infectious disease,
 CC e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery
 CC to the lymphatic system provides for potent CTL stimulation that takes

CC place in the milieu of the lymphoid organ, and it sustains stimulation
 CC that is necessary to keep CTL active, cytotoxic and recirculating
 CC through the body. Y10071 to Y10639 represent examples of peptide
 CC antigens given in the present invention.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9

RESULT 7

ID W54622 standard; peptide; 9 AA.
 AC W54622;
 DT 25-SEP-1998 (first entry)
 DE Peptide from Mage-1 161-169.
 KW Mannose; antigen; antigen-presenting cell; mannosylated peptide; T cell;
 KW vaccine; treatment.
 OS Synthetic.
 PN WO9813378-A1.
 PD 02-APR-1998.
 PF 25-SEP-1997; NL0536.
 PR 26-SEP-1996; EP-202701.
 PA (UYLE-) RIJKSUNIV LEIDEN.
 PI Drijfhout JW, Koning F;
 DR WPI: 98-230631/20.
 PT Increasing uptake and presentation of antigen(s) - by adding mannose
 PT residue(s) to antigen for increasing T cell response, useful in,
 PT e.g. vaccines against viral infection(s)
 PS Disclosure: Page 28; 47pp; English.
 CC The peptides W5459-W5489 are examples of peptides to which at least 1
 CC (preferably 2) mannose can be attached to increase their uptake as
 CC antigens by antigen-presenting cells. Uptake of agonist mannosylated
 CC peptides will increase the T cell response, whereas uptake of antagonist
 CC peptides blocks the T cell response. Blocking binding of immunogenic
 CC autoantigens can be used in treatment of type I diabetes, rheumatoid
 CC arthritis, graft rejection etc.; also to induce T-cell non-
 CC responsiveness. Vaccines containing mannosylated antigen are used to
 CC prevent or treat infections by, e.g. bacteria, viruses, fungi, helminths
 CC and parasites.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9

RESULT 8

ID R50281 standard; Protein; 9 AA.
 AC R50281;
 DT 26-SEP-1994 (first entry)
 DE MAGE-1 nonapeptide.
 KW MAGE; nonapeptide; cancer; melanoma; breast cancer; HLA;
 KW histocompatibility; human leucocyte antigen; probe; treatment;
 KW therapy; vaccine.
 OS Synthetic.
 PN WO9405304-A.
 PD 17-MAR-1994.
 PF 30-AUG-1993; U08157.
 PR 31-AUG-1992; US-938334.
 PR 26-MAR-1993; US-037230.
 PR 07-JUN-1993; US-073103.
 PA (LUDW-) LUDWIG INST CANCER RES.
 PI Boon-faller T, De Plaen E, Lurquin C, Traversari C;
 PI Van Derbruggen P;

DR WPI: 94-100844/12.
 DR N-FSDB; Q44751.
 PT New nona:peptide derived from tumour rejection antigen precursor
 PT - presented by HLA-A1 cancer cells, for use in diagnosis or
 PT therapy of esp. melanoma and breast cancer.
 PS Disclosure; Page 19; 33pp; English.
 CC An isolated nonapeptide having the amino acid sequence Glu-Val-Asp-
 CC Pro-Ile-Gly-His-Leu-Tyr is derived from the tumour rejection antigen
 CC precursor encoded by the MAGE-3 gene and presented by HLA-A1. The
 CC nonapeptide can be used in a vaccine to treat a cancerous condition
 CC involving HLA-A1 subtype cancerous cells. The nucleic acid encoding
 CC the nonapeptide can be used as a probe to identify tumour cells.
 CC This sequence is homologous to the peptide described and is encoded
 CC by the MAGE-1 gene.
 SQ Sequence 9 AA;
 Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9
 RESULT 9
 ID R83932 standard; peptide; 9 AA.
 AC R83932;
 DT 05-JUN-1996 (first entry)
 DE MHC class I restricted antigenic peptide #2.
 KW MHC class I; antigen; MAGE; melanoma; breast cancer; bladder cancer;
 KW Titermax; cytotoxic T-lymphocyte; tumour; pathogenic disease; bacteria;
 KW parasite; human; animal.
 OS Synthetic.
 PN WO9528958-A1.
 PD 02-NOV-1995.
 PF 21-APR-1995; U04975.
 PR 22-APR-1994; US-233496.
 PA (SLOK) SLOAN KETTERING INST CANCER RES.
 PI Dyall R, Nikolic-Zugic J;
 WPI: 95-382848/49.
 DR Cytotoxic T-cell induction by MHC class I-restricted peptide in
 PT adjuvant - useful for treating tumours and bacterial or parasitic
 PT pathogenic diseases
 PS Claim 11; Page 38; 50pp; English.
 CC The sequences given in R83931-49 are MHC class I restricted 8-12
 CC amino acid antigenic peptides. This peptide is derived from MAGE
 CC and is present in melanoma, breast and bladder cancer. These
 CC peptides may be administered to a subject in combination with a
 CC suitable adjuvant, pref. Titermax (RTM), to induce cytotoxic T-
 CC lymphocytes. This method may be used in the treatment of a tumour
 CC or a pathogenic disease, esp. diseases of bacterial or parasitic
 CC origin, in humans and animals, e.g. monkeys, dogs, cows, horses, etc.
 SQ Sequence 9 AA;
 Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9
 RESULT 10
 ID R29769 standard; peptide; 9 AA.
 AC R29769;
 DT 22-APR-1993 (first entry)
 DE Antigen E peptide.
 KW Antigen; tumorigenic cell; A+ B+; T-cell; response; syngeneic;
 KW animal; mouse; tumour rejection antigen precursor; TRAP; PIA.
 OS Homo sapiens.
 PN WO9220356-A.

PD 26-NOV-1992.
 PF 22-MAY-1992; U04354.
 PR 23-MAY-1991; US-705702.
 PR 09-JUL-1991; US-728838.
 PR 23-SEP-1991; US-764364.
 PR 12-DEC-1991; US-807043.
 PA (LUDW-) LUDWIG INST CANCER RES.
 PI Boon T, Chomez P, De Plaen E, Lurquin C, Traversari C;
 PI Van Den Eynde B, Van Der Bruggen P, Van Pel A;
 DR WPI: 92-41560/50.
 PT Nucleic acid mol. encoding a human tumour rejection antigen
 PT precursor - useful as an immunostimulant in a vaccine for
 PT treating and preventing cancers, also useful in diagnosis
 PS Disclosure; Page 97; 142pp; English.
 CC This sequence represents the sequence of the antigen E. Antigens such
 CC as this one cause a T-cell response to be elicited which transplanted
 CC into a syngeneic animal, usually a mouse. This antigen is derived from
 CC the cell line MEL3.1. See also Q32351.
 SQ Sequence 9 AA;
 Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9
 RESULT 11
 ID W68371 standard; peptide; 9 AA.
 AC W68371;
 DT 14-OCT-1998 (first entry)
 DE Human MAGE-1 peptide binds HLA-A1.
 KW Antigen; major histocompatibility complex; MHC; lymphocyte; detection;
 KW immobilisation; cytotoxic T-cell; tumour; leukaemia; lymphoma;
 KW viral infection.
 OS Synthetic.
 OS Homo sapiens.
 PN WO9744657-A2.
 PD 27-NOV-1997.
 PF 21-MAY-1997; F00892.
 PR 21-MAY-1996; US-651925.
 PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.
 PA (INSP) INST PASTEUR.
 PI Abastado J, Kourilsky P, Langlade-Demoyen P, Lone Y;
 WPI: 98-018653/02.
 DR Detection, purification and elimination of antigen-specific
 DR lymphocytes - for producing cytotoxic T cells for immuno-therapy of
 PT cancers and viral infection
 PS Disclosure; Page 30; 222pp; French.
 CC Peptides W68301-W68384 are examples of antigens (Ag) which can be loaded
 CC onto recombinantly produced major histocompatibility complex (MHC)
 CC molecules in a method of detecting antigen-specific lymphocytes. The
 CC MHC-antigen complex is then immobilised on a solid support and a sample
 CC containing cells recognising the MHC-Ag complex may be isolated. This
 CC peptide is derived from the human MAGE-1 protein and binds the human
 CC leukocyte antigen A1 (HLA-A1). A similar method is used to isolate,
 CC purify or eliminate Ag-specific T-cells or to produce Ag-specific
 CC cytotoxic T-cells (CTC). The method is also used to detect and quantify
 CC tumour-specific T-cells and to generate CTC for specific killing of
 CC tumour cells (solid tumours, leukaemia or lymphoma) by injection into
 CC a human or animal, but also for treating viral infections.
 SQ Sequence 9 AA;
 Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9

```

RESULT 12
ID W7125 standard; peptide; 9 AA.
AC W7125;
DE 16-NOV-1998 (first entry)
DE gp75/TRP-1 synthetic peptide epitope 1.
KW Tyrosinase; tyrosinase cytotoxic lymphocyte response;
KW cytotoxic T lymphocyte; cysteine-depleted; melanoma.
OS Synthetic.
PN WO9833810-A2.
PD 06-AUG-1998.
PR 29-JAN-1998; U01592.
PR 30-JAN-1997; US-037781.
PA (UYVI-) UNIV VIRGINIA PATENT FOUND.
PI Engelhard VH, Hunt DF, Kittlesen D, Slingluff CL;
DR WPI; 98-437388/37.
PT Disease specific immunogen - comprises disease specific cytotoxic T
PT lymphocyte epitope used to elicit melanoma specific CTL response
PS Disclosure; Page 27; 93pp; English.
CC The peptide epitope W7119-W7138 were created for human tumour-specific
CC cytotoxic T lymphocyte response. These peptides are cysteine-
CC depleted mutants of a native disease-specific CTL epitope. The cysteine-
CC depleted CTL epitopes elicit a stronger or more specific CTL response
CC than the native epitope. The epitopes can be used in a disease-specific
CC immunogen to protect a mammal against disease in particular melanomas.
CC The peptides may also be used to screen a sample for the presence of
CC an antigen with the same epitope, or with a different cross-reactive
CC epitope.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. NO. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 13
ID W75734 standard; peptide; 9 AA.
AC W75734;
DE 19-Nov-1998 (first entry)
DE Peptidase-resistant peptide 2.
KW Tumour antigen M22-E; T-cell; immunotherapy; cytolytic T-cell; CTL;
KW therapeutic agent; peptidase; M22-E antigen peptide analogue; HLA;
KW human leucocyte antigen; MHC; lysis; vaccine.
OS Synthetic.
PN Location/Qualifiers
PI Key
FT Misc_difference 2 /note= "D-form residue"
FT Misc_difference 8 /note= "D-form residue"
FT WO9833511-A1.
PD 06-AUG-1998.
PR 19-NOV-1997; U21296.
PR 05-FEB-1997; US-795733.
PA (CNRS ) CENT NAT RECH SCI.
PA (LUDW-) LUDWIG INST CANCER RES.
PI Ayoub M, Gairin JE, Mazarguil H, Monsarrat B, Van Den Eynde B;
DR WPI; 98-437166/37.
PT Peptidase-resistant peptide(s) that bind to HLA molecules and
PT related antibodies - particularly for treatment of cancer by
PT inducing proliferation of cytotoxic T cells
PS Claim 20; Page 20; 32pp; English.
CC Sequences W75733-W75736 are peptidase-resistant peptides which are
CC analogues of the tumour antigen M22-E. This antigen is a potential
CC target for T-cell based immunotherapy and can also be used to stimulate
CC the antigen-specific CTL, however its use as a therapeutic agent is
CC limited due to its degradation by peptidase. The M22-E antigen peptide
CC analogues were modified at both peptidase sensitive portions, and were
CC all shown to exhibit a longer half-life relative to peptidase degradation
CC as well as the ability to bind a human leucocyte antigen (HLA). The

```

```

CC specific peptides W75733 and W75735 were established to have a comparable
CC affinity for the MHC as the tumour antigen, and W75735 was found to be
CC the ideal peptide analog to use due to it also being able to sensitise
CC the target cells to lysis by effector molecules at similar concentrations
CC to those of the antigen M22-E. These peptide analogues can be used in
CC vaccines to induce an immune response for treating conditions in which
CC abnormal HLA/peptide complexes are present on the surface of cells.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. NO. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 14
ID W00897 standard; Peptide; 9 AA.
AC W00897;
DT 23-MAY-1997 (first entry)
DE Human melanoma MAGE1 tumour associated antigen p161-169.
KW Adeno-associated virus; vector; liposome; transfection;
KW dendritic cell; melanoma; MAGE1; adoptive immunotherapy;
KW tumour associated antigen.
OS Homo sapiens.
PN WO9703703-A1.
PD 06-FEB-1997.
PF 19-JUL-1996; U12012.
PR 21-JUL-1995; US-001312.
PR 01-NOV-1995; US-007184.
PR 01-DEC-1995; US-566286.
PA (RHON ) RHONE POULENC RORER PHARM INC.
PI Lebkowski JS, Philip R;
DR WPI; 97-145208/13.
PT Adeno-associated virus:liposome complexes for transfecting dendritic
PT cells - for inducing immune response, useful for treating e.g.
PT neoplasia or infections
PS Example 5; Page 58; 134pp; English.
CC Tumour associated antigens (W13660-61, W00878-903) can be loaded
CC into dendritic cells and used to induce antitumour immunity.
CC Alternatively, the dendritic cells are transfected with adeno
CC associated virus plasmid DNA (which includes DNA encoding the
CC tumour associated antigen) complexed with cationic liposomes. The
CC antigen loaded or transfected dendritic cells can be used to
CC generate tumour antigen-specific cytotoxic T lymphocytes for use in
CC adoptive immunotherapy in a patient having the corresponding
CC tumour. A suitable antigen comprises amino acids 161-169 (W00897)
CC of human melanoma MAGE1.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. NO. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 15
ID W75736 standard; peptide; 9 AA.
AC W75736;
DT 19-NOV-1998 (first entry)
DE Peptidase-resistant peptide 4.
KW Tumour antigen M22-E; T-cell; immunotherapy; cytolytic T-cell; CTL;
KW therapeutic agent; peptidase; M22-E antigen peptide analogue; HLA;
KW human leucocyte antigen; MHC; lysis; vaccine.
OS Synthetic.
PN Location/Qualifiers
PI Key
FT Modified_site 2 /note= "N-Methyl-Alanine"
FT

```

FT Modified_site 8 /note= "N-Methyl-Serine"

PN W09833511-A1.

PD 06-AUG-1998.

PF 19-NOV-1997; U21296.

PR 05-FEB-1997; US-795733.

PS (CNRS) CENT NAT RECH SCI.

PA (LUDW-) LUDWIG INST CANCER RES.

PI Ayyoub M, Gairin JF, Mazarguil H, Monsarrat B, Van Den Eynde B;

DR WPI; 98-437166/37.

PT Peptidase-resistant peptide(s) that bind to HLA molecules and

PT related antibodies - particularly for treatment of cancer by

PT inducing proliferation of cytotoxic T cells

PS Claim 20; Page 20; 32pp; English.

CC Sequences W5733-W5736 are peptidase-resistant peptides which are

CC analogues of the tumour antigen M22-E. This antigen is a potential

CC target for T-cell based immunotherapy and can also be used to stimulate

CC the antigen-specific CTL, however its use as a therapeutic agent is

CC limited due to its degradation by peptidase. The M22-E antigen peptide

CC analogues were modified at both peptidase sensitive portions, and were

CC all shown to exhibit a longer half-life relative to peptidase degradation

CC as well as the ability to bind a human leukocyte antigen (HLA). The

CC specific peptides W5733 and W5735 were established to have a comparable

CC affinity for the MHC as the tumour antigen, and W5735 was found to be

CC the ideal peptide analog to use due to it also being able to sensitise

CC the target cells to lysis by effector molecules at similar concentrations

CC to those of the antigen M22-E. These peptide analogues can be used in

CC vaccines to induce an immune response for treating conditions in which

CC abnormal HLA/peptide complexes are present on the surface of cells.

CC Sequence 9 AA;

SQ

Query Match 100.0%; Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 2.32e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

QY 1 EADPTGHSY 9

RESULT 16

ID R2988 standard; Peptide; 9 AA.

AC R2988;

DT 26-FEB-1996 (first entry)

DE P815 antigenic peptide.

KW P815 antigen; P1A antigen; cancer; vaccine.

OS Synthetic.

PN W09523874-A1.

PD 08-SEP-1995; U02203.

PF 23-FEB-1995; US-204727.

PR 01-MAR-1994; US-209172.

PR 10-MAR-1994; US-209172.

PR 01-SEP-1994; US-298849.

PR 30-NOV-1994; US-346774.

PA (LUDW-) LUDWIG INST CANCER RES.

PI Boon-Falleur T, Brasseur F, Chomez P, De Plaen E;

PI De Smet C, Gaugler B, Lethe B, Marchand M, Pataud J;

PI Szikora J, Van Den Eynde B, Van Derbruggen P, Weynants P;

DR WPI; 95-320586/41.

PT Determn. of cancerous condition(s) - using a nucleic acid as a

PT primer to determine expression of a MAGE tumour rejection antigen

PT precursor

PS Example 13; Page 22; 121pp; English.

CC Using the sequence of the p815A antigen precursor gene P1A

CC (T01176), an antigenic peptide (R82988) which was A+B+ (i.e.

CC characteristic of cells which express both A and B antigens) was

CC produced. The peptide lysed PO.HTR cells in the presence of

CC cytolytic T lymphocyte cell lines, and may be useful as a vaccine

CC component.

CC Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 2.32e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

QY 1 EADPTGHSY 9

RESULT 17

ID R90692 standard; peptide; 9 AA.

AC R90692;

DT 31-JUL-1996 (first entry)

DE Human leukocyte antigen (HLA-A1) presented peptide M22-E.

KW Human leukocyte antigen; HLA-A1; MAGE-1 derived;

KW Human mononuclear cell; BMC; CD8-beta+ cell; cytolytic T cell;

KW CTL cell; treatment; tumour cell; diagnosis; assay;

KW presented peptide.

OS Synthetic.

PN W09535500-A1.

PD 28-DEC-1995; U07559.

PF 14-JUN-1994; US-261541.

PR 17-JUN-1994; US-261541.

PA (LUDW-) LUDWIG INST CANCER RES.

PI Boon-Falleur T, Coullie P, Van Der Bruggen P;

DR WPI; 96-058510/06.

PT Prodn. of specific cytolytic T cell sub-populations - by contacting

PT blood mononuclear cells with specific peptide(s) and a population of

PT CD8-beta(+) cells

PS Claim 5; Page 19; 25pp; English.

CC The present peptide is the human leukocyte antigen (HLA-A1), MAGE-1

CC derived presented peptide, M22-E. By contacting a sample of blood

CC mononuclear cells (BMC) with the peptide (which binds directly to

CC HLA-A1 mols. on the surface of the BMC) and CD8-beta+ cells (which

CC stimulate peptide/HLA-A1 complex specific cytolytic T (CTL) cell

CC peptide/HLA-A1 complex specific cytolytic T (CTL) cell

CC subpopulation can be obtd. . The CTL cells obtd. can be

CC administered to a patient to treat tumour cell related conditions,

CC and can be used in diagnostic methods, e.g. in assays for the

CC peptide/HLA-A1 complex.

SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 2.32e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

QY 1 EADPTGHSY 9

RESULT 18

ID W56729 standard; peptide; 9 AA.

AC W56729;

DT 31-JUL-1998 (first entry)

DE MAGE-1 antigenic partial peptide sequence (residues 161-169).

KW MAGE; replication defective; adenovirus; tumour; antigen; cancer;

KW immunotherapy; tumour rejection antigen precursor; TRAP; CTL;

KW human leukocyte antigen; HLA; cytolytic T lymphocyte.

OS Synthetic.

PN W09815638-A2.

PD 16-APR-1998; U17948.

PF 06-OCT-1996; US-027891.

PR (LUDW-) LUDWIG INST CANCER RES.

PI Cerrottini J, Jongeneel CV, Reed DS, Rimoldi D,

PI Romero P;

DR WPI; 98-240824/21.

PT New replication-defective adenoviruses - comprise insert encoding

PT tumour rejection antigen precursor(s), useful for, e.g. cancer

PT immuno-therapy

PS Examples; Page 42; 56pp; English.

CC This is a partial sequence of the MAGE-1 antigenic peptide used in the

CC methods of the invention. The specification provides a new nucleic acid

CC molecule comprising a replication-defective adenovirus genome containing

an insert encoding a tumour rejection antigen precursor (TRAP). The replication-defective adenovirus genome is useful as a vector for introducing a TRAP molecule into mammalian (especially human) cells. The recombinant adenovirus is preferably targeted to tumour cells, e.g. by binding a ligand to the virus coat. The TRAP peptides which are generated from the expressed TRAP are presented by human leukocyte antigen (HLA) molecules and as a result cytolytic T lymphocyte (CTL) production is increased (claimed). The CTLs then kill the TRAP-expressing tumour cells. Also, cells transfected by the recombinant adenovirus can be used for assessing the processing of TRAPs, including post-translational modifications. The adenovirus (genome) can be administered by injection, topical application or intracavitarily in 10⁶-10¹⁰ pfu doses. The range of TRAP peptides produced by replication-defective adenovirus means that patients with a range of HLA phenotypes can be treated. Also, host cell immune response to TRAPs is enhanced, e.g. by induction of tumour-specific cytolytic T lymphocytes.

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

Qy 1 EADPTGHSY 9

RESULT 19

ID R75954 standard; Peptide; 9 AA.
AC R75954;
DT 06-MAR-1996 (first entry)
DE Melanoma antigen (MAGE-1) epitope.
KW MAGE-3; melanoma antigen; vaccine; immune response; immunogenic peptide;
KW cytotoxic T lymphocyte response; CTL; melanoma; breast cancer; antibody.
OS Homo sapiens.
PN W09519783-A1.
PD 27-JUL-1995.
PF 25-JAN-1995; U01000.
PR 25-JAN-1994; US-186266.
FA (CYTE-) CYTEL CORP.
PI Celis E, Grey HM, Kubo RT, Sette A;
DR WPI: 95-269270/35.
PT Immunogenic peptide(s) that induce immune response to cancer cells
PT - that express a MAGE-3 protein peptide epitope used in vaccines or
PT adoptive immunotherapy to induce cytotoxic T lymphocytes
PS Example; Page 33; 44pp; English.
CC R75954 is derived from MAGE-1 protein. It was used to show the
CC specificity of CTL response to MAGE-3 peptides shown in R75942-53.
CC R75942 is derived from the sequence of the melanoma antigen (MAGE-3)
CC protein and can be used to elicit a primary cytotoxic T lymphocyte
CC response against cells expressing MAGE-3. Synthetic peptides R75945-53
CC can be used therapeutically to elicit CTL responses to melanoma, breast,
CC colon, prostate, or other cells which express proteins with this epitope.
CC The peptides have specific HLA-A1 binding capacity.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

Qy 1 EADPTGHSY 9

RESULT 20

ID R99343 standard; Protein; 9 AA.
AC R99343;
DT 22-APR-1997 (first entry)
DE MAGE-1 nonapeptide.
KW HLA binding peptide; cell lysis; cytolytic T cell; MAGE family; human;
KW tumour rejection antigen precursor; TRA; MAGE-1; tumour; cancer cell;
KW antibody; melanoma; universal effector cell; vaccine; breast cancer; CTL;

therapy.
KW Homo sapiens.
OS
PN W09626214-A1.
PD 29-AUG-1996.
PF 01-FEB-1996; U01489.
PR 23-FEB-1995; US-393273.
PA (LUDW-) LUDWIG INST CANCER RES.
PI Boon-Falleur T, De Plaen E, Gaugler B, Lurquin C;
PI Romero P, Traversari C, Van Den Eynde B, Van Der Bruggen P;
DR WPI: 96-402317/40.
DR N-PSDB; T35408.
PT New nona-peptide(s) that bind to HLA molecule(s) and induce lysis
PT by specific cytolytic T cells, for diagnosis and treatment of
PT tumours and to expand T cells in vitro.
PT Example 4; Fig 4; 41pp; English.
PS
CC R9943-R9950 represent MAGE nonapeptides, based on the tumour rejection
CC antigen region of the full length MAGE sequences. These peptides were
CC used to design the nonapeptides of the invention (see R99337-R99342),
CC which bind to a HLA molecule on a cell, and provoke lysis by cytolytic T
CC cells (CTLs) specific for a complex of the HLA molecule and nonapeptide.
CC The nonapeptides can be used diagnostically to identify tumours
CC expressing a particular HLA molecule, or to identify cancer cells. The
CC peptides can also be used therapeutically, to induce a CTL response to
CC tumours (where the peptides are optionally coupled to tumour-specific
CC antibodies), or to induce a response by CTLs that are otherwise inactive.
CC The peptide sequences may also be used to expand specific CTLs in vitro
CC for later return to the patient, such as for treating melanoma. Tumour
CC cells can be identified by using DNA encoding the nonapeptides as probes.
CC Non-human cells transformed with the HLA-A1 gene and a DNA sequence
CC encoding one of the peptides, can be used to generate CTLs, or to detect
CC the presence of CTLs in human samples. The non-human transformed cells,
CC when polytransformed, are universal effector cells, and can be used in
CC vaccines, or for treating melanoma or breast cancer.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 2.32e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

Qy 1 EADPTGHSY 9

RESULT 21

ID W78838 standard; peptide; 9 AA.
AC W78838;
DT 17-NOV-1998 (first entry)
DE MAGE-1 protein fragment 161-169.
KW Microparticle delivery; polymeric matrix; autoantigen; tumour antigen;
KW class II associated peptide; pathogen; gene therapy; genetic disease;
KW infection; downregulation; immune response.
OS Homo sapiens.
OS Synthetic.
PN W09831398-A1.
PD 23-JUL-1998.
PF 22-JAN-1998; U01499.
PR 06-JAN-1998; US-003253.
PR 22-JAN-1997; US-787547.
PA (PANG-) PANGAEA PHARM INC.
PI Curley JM, Hedley ML, Langer RS, Lunsford LB;
DR WPI: 98-427556/36.
PT New preparations of microparticles - comprising a synthetic polymer
PT matrix and nucleic acid comprising an expression vector for use in
PT gene therapy
PS Disclosure; Page 10; 101pp; English.
CC A microparticle preparation (MP) has been developed, consisting of
CC microparticles having a diameter of less than 100 nm. The MP comprises:
CC (a) a polymeric matrix (PM) consisting of one or more synthetic polymers
CC having a solubility in water of less than 1 mg/l; and (b) an expression
CC vector selected from RNA molecules (at least 50% of which are closed
CC circles) or circular plasmid DNA (at least 50% of which are supercoiled).
CC Also described is a MP of at most 20 microns in diameter, comprising: (a)

CC a PM; and (b) a NAM comprising an expression control sequence operatively
 CC linked to a coding sequence, where the coding sequence encodes an
 CC expression product selected from: (1) a polypeptide at least 7 amino
 CC acids in length, having a sequence identical to the sequence of (i) a
 CC fragment of a naturally-occurring mammalian protein; or (ii) a fragment
 CC of a naturally-occurring protein from an infectious agent which infects
 CC a mammal; (2) a peptide having a length and sequence which permits it to
 CC bind to an MHC class I or II molecule; and (3) the polypeptide or the
 CC peptide linked to a trafficking sequence, W69763 to W69765, and W69793
 CC to W78897 are peptide fragments for use in the present invention. The
 CC MPs are highly effective vehicles for the delivery of polynucleotides
 CC into phagocytic cells. They can be used for gene therapy, e.g. for
 CC treating genetic diseases, infections or tumours or for downregulating
 CC an immune response.
 CC Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 |||||
 QY 1 EADPTGHSY 9

RESULT 22

ID R65112 standard; peptide; 9 AA.
 AC R65112;
 DT 08-OCT-1995 (first entry)
 DE MAGE 1 immunogenic peptide 161-169.
 KW MAGE 1; immunogenic peptide 161-169; cytotoxic C cells;
 KW in vitro activation; cancer; AIDS; bacterial infections; malaria;
 KW fungal infections; tuberculosis; hepatitis.
 OS Homo sapiens.
 PN W09504817-A.
 PD 16-FEB-1995.
 PF 01-AUG-1994; U08672.
 PR 06-AUG-1993; US-103401.
 PA (CYTE-) CYTEL CORP.
 PI Celis E, Kubo R, Seria H, Tsai V, Wentworth P;
 DR WPI: 95-090895/12.
 PT In vitro activation of cytotoxic T cells for selected killing of
 PT target cells - for treating e.g. cancer, AIDS, hepatitis etc. by
 PT incubating them with antigen presenting cells loaded with
 PT appropriate immunogenic peptide
 PS Example 3; Page 35; 53pp; English.

CC R65109-R65145 are immunogenic peptides, they are used in a new
 CC method for the in vitro activation of cytotoxic T cells (CTC).
 CC This is achieved by incubating the CTCs with antigen presenting
 CC cells loaded with an appropriate immunogenic peptide (e.g. one
 CC of the above peptides). By selecting the peptides used the
 CC following diseases and infections can be treated; cancer, AIDS,
 CC hepatitis, other viral and bacterial infections, malaria and
 CC tuberculosis.
 CC Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 |||||
 QY 1 EADPTGHSY 9

RESULT 23

ID R63675 standard; Protein; 9 AA.
 AC R63675;
 DT 22-JUN-1995 (first entry)
 DE Synthetic peptide derived from exon 3.1 of MAGE 1.
 KW Melanoma antigen-1; MAGE-1; cytolytic T cells; antigen E; exon 3.1.
 OS Synthetic.
 PN W09423031-A.

PD 13-OCT-1994.
 PF 17-MAR-1994; U02877.
 PR 26-MAR-1993; US-037230.
 PA (LUDW-) LUDWIG INST CANCER RES.
 FI Boon-falleur I, Gaugier B, Van DEN EYNDE B, Van DER BRUGGEN P;
 DR WPI: 94-333192/41.
 PT New tumour rejection antigen precursor MAGE3 - useful in
 PT treatment and diagnosis of cancer
 PS Example 34; Page 36; 105pp; English.
 CC R63675 is a synthetic peptide derived from exon 3.1 of melanoma
 CC antigen-1 (MAGE-1) it was used to transfer antigen-E cytolytic T
 CC lymphocyte sensitivity to normally non-sensitive cells.
 CC Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 |||||
 QY 1 EADPTGHSY 9

RESULT 24

ID R78824 standard; peptide; 9 AA.
 AC R78824;
 DT 26-MAR-1996 (first entry)
 DE MAGE-1 cytotoxic T lymphocyte epitope.
 KW MAGE-1; cytotoxic T; CTL; epitope; helper T; HTL; lymphocyte;
 KW cell; viruses; parasites; tumours; antigens; disease prevention;
 KW treatment.
 OS Homo sapiens.
 PN W09522317-A1.
 PD 24-AUG-1995.
 PF 16-FEB-1995; U02121.
 PR 16-FEB-1994; US-197484.
 PA (CYTE-) CYTEL CORP.
 PI Celis E, Chesnut RW, Grey H, Sette AD, Vitello MA;
 DR WPI: 95-302545/39.
 PT Compn. inducing cytotoxic T lymphocyte response to pref. viral,
 PT bacterial, parasitic or tumour antigens - useful in the treatment
 PT and prevention of diseases associated with the antigen e.g.
 PT hepatitis B
 PS Disclosure; Page 17; 109pp; English.

CC A compn. which induces a cytotoxic T lymphocyte (CTL) response to
 CC an antigen (Ag) in a mammal comprises, a CTL Ag response inducing
 CC peptide (i.e. R78824-R78853) and a lipid conjugated helper T cell
 CC inducing peptide. The compn. induces a CTL response to bacterial,
 CC viral or tumour Ags, and is therefore useful in the treatment and
 CC prevention of diseases associated with the Ag.
 CC Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 |||||
 QY 1 EADPTGHSY 9

RESULT 25

ID R65135 standard; peptide; 9 AA.
 AC R65135;
 DT 09-OCT-1995 (first entry)
 DE MAGE 1 immunogenic peptide A01.
 KW MAGE 1; immunogenic peptide A01; cytotoxic C cells;
 KW in vitro activation; cancer; AIDS; bacterial infections; malaria;
 KW fungal infections; tuberculosis; hepatitis.
 OS Homo sapiens.
 PN W09504817-A.
 PD 16-FEB-1995.
 PF 01-AUG-1994; U08672.

```

PR 06-AUG-1993; US-103401.
PA (CYTE-) CYTEL CORP.
PI Celis E, Kubo R, Serra H, Tsai V, Wentworth P;
DR WPI: 95-090895/12.
PT In vitro activation of cytotoxic T cells for selected killing of
PT target cells - for treating e.g. cancer, AIDS, hepatitis etc.by
PT incubating them with antigen presenting cells loaded with
PT appropriate immunogenic peptide
PS Example 3; Page 38; 53pp; English.
CC R65109-R65145 are immunogenic peptides, they are used in a new
CC method for the in vitro activation of cytotoxic T cells (CTC).
CC This is achieved by incubating the CTCs with antigen presenting
CC cells loaded with an appropriate immunogenic peptide (e.g. one
CC of the above peptides). By selecting the peptides used the
CC following diseases and infections can be treated; cancer, AIDS,
CC hepatitis, other viral and bacterial infections, malaria and
CC tuberculosis.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2,32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 26
ID R49224 standard; Protein: 9 AA.
AC R49224;
DT 31-AUG-1994 (first entry)
DE HLA-A1 MAGE 1 antigen peptide fragment 958.01.
KW Immunogenic; HLA-A3.2; HLA-A1; binding motif; MHC molecule;
KW immune response; viral infection; cancer; prostate cancer; lymphoma;
KW hepatitis; AIDS; antibody; diagnosis; melanoma antigen.
OS Synthetic.
PN W09403205-A.
PD 17-FEB-1994.
PR 06-AUG-1993; US-926666.
PR 05-MAR-1993; US-027746.
PA (CYTE-) CYTEL CORP.
PI Celis E, Grey RM, Kubo RT, Sette A;
DR WPI: 94-065403/08.
PT Peptide which specifically binds selected MHC allele - used to
PT induce an immune response for treatment or prevention of viral
PT infection or cancer, or for diagnosis
PS Example 16; Page 116; 150pp; English.
CC The sequences given in R47304-33 and R49201-44 are immunogenic
CC peptides which have a HLA-A3.2, HLA-A1 or a HLA-A11 binding motif.
CC These peptides are capable of binding selected MHC molecules and
CC inducing an immune response. They can be used to treat and/or
CC prevent viral infection and cancer, eg. prostate cancer, lymphoma,
CC hepatitis or AIDS. They can also be used to produce antibodies for
CC use as diagnostic or therapeutic agents. The peptides can also be
CC used as diagnostic agents.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2,32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 27
ID R47330 standard; Protein: 9 AA.
AC R47330;
DT 31-AUG-1994 (first entry)

```

```

DE HLA-A1 MAGE 1 antigen peptide fragment 161-169.
KW Immunogenic; HLA-A3.2; HLA-A1; binding motif; MHC molecule;
KW immune response; viral infection; cancer; prostate cancer; lymphoma;
KW hepatitis; AIDS; antibody; diagnosis; melanoma antigen.
OS Synthetic.
PN W09403205-A.
PD 17-FEB-1994.
PR 06-AUG-1993; US-926666.
PR 05-MAR-1993; US-027746.
PA (CYTE-) CYTEL CORP.
PI Celis E, Grey RM, Kubo RT, Sette A;
DR WPI: 94-065403/08.
PT Peptide which specifically binds selected MHC allele - used to
PT induce an immune response for treatment or prevention of viral
PT infection or cancer, or for diagnosis
PS Example 8; Page 52; 150pp; English.
CC The sequences given in R47304-33 and R49201-44 are immunogenic
CC peptides which have a HLA-A3.2, HLA-A1 or a HLA-A11 binding motif.
CC These peptides are capable of binding selected MHC molecules and
CC inducing an immune response. They can be used to treat and/or
CC prevent viral infection and cancer, eg. prostate cancer, lymphoma,
CC hepatitis or AIDS. They can also be used to produce antibodies for
CC use as diagnostic or therapeutic agents. The peptides can also be
CC used as diagnostic agents.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2,32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 28
ID W23038 standard; Peptide: 10 AA.
AC W23038;
DT 25-FEB-1998 (first entry)
DE MAGE-1/HLA-B44 tumour rejection antigen.
KW MAGE-1; tumour rejection antigen precursor; TRAP; HLA-B44;
KW human leukocyte antigen B44; cytotoxic T lymphocyte; cancer;
KW melanoma; therapy; diagnosis; vaccine.
OS Homo sapiens.
PN W09731017-A1.
PD 28-AUG-1997.
PR 05-FEB-1997; U01915.
PR 20-FEB-1996; US-602506.
PA (LUDW-) LUDWIG INST CANCER RES.
PI Boon-Falleur T, Coullie P, Herman J, Luescher I;
DR WPI: 97-435086/40.
PT Tumour rejection antigens presented by human leukocyte antigen B44
PT molecules - useful to identify HLA-B44 positive cells for diagnosis
PT and therapy of cellular abnormalities
PS Claim 2; Page 49; 74pp; English.
CC This peptide is a tumour rejection antigen presented by a HLA-B44
CC molecule and derived from a MAGE-1 tumour rejection antigen
CC precursor (TRAP). Claimed tumour rejection antigens (W23038-43)
CC are able to bind to HLA-B44 positive cells, making them useful in
CC identifying cells which present HLA-B44 molecules on their
CC surfaces for use in the diagnosis and therapy of cellular
CC abnormalities. The complex of the tumour rejection antigen and HLA
CC molecule provokes a cytolytic T cell response. The tumour
CC rejection antigens, or complexes of tumour rejection antigens and
CC HLA-B44, can be used as vaccines to treat disorders characterised
CC by expression of the TRAP molecule such as cancer, especially
CC melanoma. Vaccines can also be prepared from cells which present
CC the tumour rejection antigen/HLA complexes on their surface, such
CC as non-proliferative cancer cells and non-proliferative
CC transfectants.

```



```

SQ Sequence 10 AA;
Query Match 100.0%; Score 61; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 2 EADPTGHSY 10
    |||||
QY 1 EADPTGHSY 9

RESULT 29
ID R80620 standard; Protein; 12 AA.
AC R80620;
DT 28-FEB-1996 (first entry)
DE Immunogenic peptide of tumour rejection antigen (MAGE-1).
KW Tumour rejection antigen; MAGE-1; monoclonal antibody; MAb;
KW diagnosis; immunoassay; cancer; immunogen; antiserum.
OS Homo sapiens.
PN W09520974-A1.
PD 10-AUG-1995.
PF 05-JAN-1995; U00095.
PR 01-FEB-1994; US-190411.
PA (LUDW-) LUDWIG INST CANCER RES.
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PA (SLOK) MEMORIAL SLOAN-KETTERING CANCER CENT.
PI Boon-falleur T, Chen Y, Garin-chesa P, Old LJ, Rettig WJ;
PI Stockert E, Van der bruggen P;
DR WPI; 95-283606/37.
PT New monoclonal antibody binding specifically to MAGE-1 - useful for
PT diagnosis and monitoring of cancer, also new hybridomas, recombinant
PT MAGE-1 and immunogenic peptide(s)
PT Claim 12; Page 20; 33pp; English.
PS A monoclonal antibody directed against the tumour rejection antigen
CC (MAGE-1) can be used to detect MAGE-1 in samples by standard
CC immunoassay methods for diagnosis and monitoring of cancer etc. The
CC monoclonal antibody is designated MA454 and is produced by the
CC hybridoma deposited as ATCC HB11540. The monoclonal antibody is
CC specific for MAGE-1 having no reactivity for MAGE-2 or MAGE-3.
CC Peptide fragments of MAGE-1 (See R80618-20) may be useful as
CC immunogens for production of the monoclonal antibody and antiserum.
SQ Sequence 12 AA;

Query Match 100.0%; Score 61; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 4 EADPTGHSY 12
    |||||
QY 1 EADPTGHSY 9

RESULT 30
ID R70909 standard; Protein; 309 AA.
AC R70909;
DT 09-OCT-1995 (first entry)
DE Human melanoma antigen MAGE-1.
KW Human melanoma antigen; MAGE-1; vaccines; MAGE associated tumours;
KW HLA-restricted cytotoxic T-lymphocyte activity.
OS Homo sapiens.
PN W09504342-A.
PD 16-FEB-1995.
PF 02-AUG-1994; U08721.
PR 06-AUG-1993; US-103623.
PA (CYTE-) CYTEL CORP.
PA Fikes JD, Livingston BD, Sette AD, Sidney JC;
DR WPI; 95-090681/12.
DR N-PSDB; Q85435.
PT Human melanoma antigen, MAGE-1, peptide(s) - useful for
PT stimulating immune response against melanoma
PS Example 1; Fig 1; 59pp; English.
CC Q85435 encodes R70909 human melanoma antigen MAGE-1, it was used
CC to produce the C-terminal MAGE-1 peptides described in R70915 to

```

```

CC R70969. These peptides are useful for defining epitopes that
CC engender a HLA-restricted cytotoxic lymphocyte activity against
CC MAGE-1 antigens. Compsns. containing these peptides can be
CC administered, as a vaccine to patients susceptible to MAGE
CC associated tumours, e.g. melanomas.
SQ Sequence 309 AA;

Query Match 100.0%; Score 61; DB 1; Length 309;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 161 EADPTGHSY 169
    |||||
QY 1 EADPTGHSY 9

RESULT 31
ID W81548 standard; Protein; 309 AA.
AC W81548;
DT 01-MAR-1999 (first entry)
DE Tumour rejection antigen precursor MAGE-A1.
KW MAGE-A1; human; tumour rejection antigen precursor; TRAP;
KW therapy; diagnosis.
OS Homo sapiens.
PN W09849184-A1.
PD 05-NOV-1998.
PF 24-APR-1998; U08493.
PR 25-APR-1997; US-845528.
PA (LUDW-) LUDWIG INST CANCER RES.
PI Boon-Falleur T, De Smet C, Lucas S;
DR WPI; 99-024041/02.
DR N-PSDB; V69719.
PT Tumour rejection antigen precursors - used for determining presence
PT of cytolytic T cells specific for complexes of a human leukocyte
PT antigen
PS Disclosure; Page 50-51; 84pp; English.
CC This is the amino acid sequence of human tumour rejection antigen
CC precursor (TRAP) MAGE-A1. MAGE-A1 cDNA (see V69719) shows homology
CC to novel human MAGE-C1 cDNA (see V69720). MAGE-C1 (see W81546) is a
CC novel member of the MAGE family that may be recognised by cytotoxic
CC T cells, leading to lysis of the tumour cells which express it. It
CC is expressed in a variety of tumours and in normal testis cells,
CC but not by other normal cells. The invention provides MAGE-C1 and
CC MAGE-C2 nucleic acids and polypeptides, useful e.g. in a claimed
CC method for determining the presence of cytolytic T cells specific
CC for complexes of a human leukocyte antigen (HLA).
SQ Sequence 309 AA;

Query Match 100.0%; Score 61; DB 1; Length 309;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 161 EADPTGHSY 169
    |||||
QY 1 EADPTGHSY 9

Search completed: Wed Sep 13 07:14:24 2000
Job time : 7 secs.

```

MAGE (TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPsrch_pp protein - protein database search, using Smith-Waterman algorithm
Run on: Tue Sep 12 13:23:01 2000; Maspar time 5.52 Seconds
76.943 Million cell updates/sec
Tabular output not generated.

Title: >US-08-819-669E-26
Description: (1-9) from US08819669E.pep
Perfect Score: 61
Sequence: 1 EADPTGHSY 9

Scoring table: PAM 150
Gap 15

Searched: 142080 seqs, 47172406 residues

Post-processing: Minimum Match 0%
Listing first 1000 summaries
Maximum DB seq length 9

Database: pir64
1:pir1 2:pir2 3:pir3 4:pir4
Statistics: Mean 20.662; Variance 21.178; scale 0.976

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB ID	Description	Pred. No.
1	46	75.4	9	2	PH1299 MAGE 5 protein - huma	1.79e+00

Note: Post-processor removed 999 summaries from list due to search parameters chosen.

ALIGNMENTS

RESULT 1
ENTRY PH1299 #type fragment
TITLE MAGE 5 protein - human (fragment)
ALTERNATE_NAMES MAGE 51 protein
ORGANISM #formal_name Homo sapiens #common_name man
DATE 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 03-Aug-1998
ACCESSIONS PH1299; PH1300
REFERENCE PH1294
#authors Traversari, C.; van der Bruggen, P.; Luescher, I.F.; Larquin, C.; Chomez, P.; Van Pel, A.; De Plaen, E.; Amar-Costesec, A.; Boon, T.
#journal J. Exp. Med. (1992) 176:1453-1457
#title A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor

antigen M22-E.
#cross-references MUID:93018875
#accession PH1299
#molecule_type DNA
#residues 1-9 #label TRA
#accession PH1300
#molecule_type DNA
#residues 1-9 #label TR2
SUMMARY #length 9 #checksum 3660
Query Match 75.4%; Score 46; DB 2; Length 9;
Best Local Similarity 66.7%; Pred. No. 1.79e+00;
Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Db 1 EADPTSNTY 9
| | | | | : | | |
QY 1 EADPTGHSY 9

Search completed: Tue Sep 12 13:23:48 2000
Job time : 47 secs.

W P E R L H (TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (C) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

Mpsrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Tue Sep 12 13:20:57 2000; MasPar time 3.60 Seconds
77.389 Million cell updates/sec

Tabular output not generated.

Title: >US-08-819-669E-26
Description: (1-9) from US08819669E.pep
Perfect Score: 61
Sequence: 1 EADPTGHSY 9

Scoring table: PAM 150
Gap 15

Searched: 85661 seqs, 30989116 residues

Post-processing: Minimum Match 0%
Listing first 1000 summaries
Maximum DB seq length 9

Database: swiss-prot38
1:swissprot

Statistics: Mean 21.172; Variance 19.906; scale 1.064

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	Query	%	No.	Score	Match	Length	DB	ID	Description	Pred. No.
--------	-------	---	-----	-------	-------	--------	----	----	-------------	-----------

No matches found.

Search completed: Tue Sep 12 13:21:37 2000
Job time : 40 secs.

MPSRCH (TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPSrch_pp protein - protein database search, using Smith-Waterman algorithm
Run on: Tue Sep 12 13:21:54 2000; MasPar time 8.64 Seconds
Tabular output not generated. 72.251 Million cell updates/sec

Title: >US-08-819-669E-26
Description: (1-9) from US08819669E.pep
Perfect Score: 61
Sequence: 1 EADPTGHSY 9

Scoring table: PAM 150
Gap 15

Searched: 225878 seqs, 69334122 residues

Post-processing: Minimum Match 0%
Listing first 1000 summaries
Maximum DB seq length 9

Database: sptrembl2
1:sp_archaea 2:sp_bacteria 3:sp_fungi 4:sp_human
5:sp_invertebrate 6:sp_mammal 7:sp_mhc 8:sp_organelle
9:sp_phage 10:sp_plant 11:sp_rodent 12:sp_unclassified
13:sp_vertebrate 14:sp_virus

Statistics: Mean 20.592; Variance 19.613; scale 1.050


Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	Query					
No.	Score	Match	Length	DB ID	Description	Pred. No.
-----	-----	-----	-----	-----	-----	-----

No matches found.

Search completed: Tue Sep 12 13:22:44 2000
Job time : 50 secs.



Release 3.1A John F. Collins, BioComputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MParch_pp protein - protein database search, using Smith-Waterman algorithm
Run on: Wed Sep 13 06:32:58 2000; MasPar time 3.59 Seconds
Tabular output not generated.
59.387 Million cell updates/sec

Title: >US-08-819-669E-26
Description: (1-9) from US08819669E.pep
Perfect Score: 61
Sequence: 1 EADPTGHSY 9

Scoring table:
PAM 150
Gap 15

Searched: 188963 seqs, 23686106 residues

Post-processing: Minimum Match 0%
Listing first 1000 summaries
Maximum DB seq length 9

Database: a-geneseq36
1:geneseqp

Statistics: Mean 15.425; Variance 35.537; scale 0.434

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description	Pred. No.
1	61	100.0	9	1 W98945	HLA-A1 binding peptide	2.32e-01
2	61	100.0	9	1 Y01727	Exemplary antigenic pe	2.32e-01
3	61	100.0	9	1 Y10633	Peptide antigen SEQ ID	2.32e-01
4	61	100.0	9	1 Y00885	Tumour antigen booster	2.32e-01
5	61	100.0	9	1 Y10424	HLA Class I motif pep	2.32e-01
6	61	100.0	9	1 Y10623	Peptide antigen SEQ ID	2.32e-01
7	61	100.0	9	1 W54622	Peptide from Mage-1 16	2.32e-01
8	61	100.0	9	1 R50281	MAGE-1 nonapeptide.	2.32e-01
9	61	100.0	9	1 R83932	MHC class I restricted	2.32e-01
10	61	100.0	9	1 R29769	Antigen E peptide	2.32e-01
11	61	100.0	9	1 W68371	Human MAGE-1 peptide b	2.32e-01
12	61	100.0	9	1 W7125	gp75/TRP-1 synthetic p	2.32e-01
13	61	100.0	9	1 W57534	Peptidase-resistant pe	2.32e-01
14	61	100.0	9	1 W00897	Human melanoma MAGE1 t	2.32e-01
15	61	100.0	9	1 W75736	Peptidase-resistant pe	2.32e-01
16	61	100.0	9	1 R82988	P615 antigenic peptide	2.32e-01
17	61	100.0	9	1 R90692	Human leukocyte antige	2.32e-01
18	61	100.0	9	1 W56729	MAGE-1 antigenic parti	2.32e-01
19	61	100.0	9	1 R75954	Melanoma antigen (MAGE	2.32e-01
20	61	100.0	9	1 R99343	MAGE-1 nonapeptide.	2.32e-01
21	61	100.0	9	1 W78838	MAGE-1 protein fragmen	2.32e-01
22	61	100.0	9	1 R65112	MAGE 1 Immunogenic pep	2.32e-01

23	61	100.0	9	1 R63675	Synthetic peptide deri	2.32e-01
24	61	100.0	9	1 R78824	MAGE-1 cytotoxic T lym	2.32e-01
25	61	100.0	9	1 R65135	MAGE 1 immunogenic pep	2.32e-01
26	61	100.0	9	1 R42224	HLA-A1 MAGE 1 antigen	2.32e-01
27	61	100.0	9	1 R47330	HLA-A1 MAGE 1 antigen	2.32e-01
28	59	96.7	9	1 R99342	HLA binding nonapeptid	4.62e-01
29	58	95.1	9	1 R99339	HLA binding nonapeptid	6.49e-01
30	57	93.4	9	1 W75733	Peptidase-resistant pe	9.12e-01
31	57	93.4	9	1 W75735	Peptidase-resistant pe	9.12e-01
32	55	90.2	9	1 R99337	HLA binding nonapeptid	1.79e-01
33	55	90.2	9	1 R99340	HLA binding nonapeptid	1.79e-01
34	54	88.5	9	1 R99338	HLA binding nonapeptid	2.50e-01
35	52	85.2	9	1 Y10628	Peptide antigen SEQ ID	4.86e-01
36	49	80.3	9	1 R99341	HLA binding nonapeptid	1.30e-01
37	47	77.0	9	1 Y10629	Peptide antigen SEQ ID	2.47e-01
38	46	75.4	9	1 Y10604	Peptide antigen SEQ ID	3.40e-01
39	46	75.4	9	1 R50288	MAGE-51 nonapeptide.	3.40e-01
40	46	75.4	9	1 Y10605	Peptide antigen SEQ ID	3.40e-01
41	46	75.4	9	1 R50287	MAGE-5 nonapeptide.	3.40e-01
42	46	75.4	9	1 R99349	MAGE-5/MAGE-51 nonapep	3.40e-01
43	46	75.4	9	1 R99350	MAGE-6 nonapeptide.	3.40e-01
44	46	75.4	9	1 R50289	MAGE-6 nonapeptide.	3.40e-01
45	43	70.5	9	1 Y00687	Tumour antigen booster	8.72e-01
46	43	70.5	9	1 Y01729	Exemplary antigenic pe	8.72e-01
47	43	70.5	9	1 Y10627	Peptide antigen SEQ ID	8.72e-01
48	43	70.5	9	1 R99346	MAGE-3 nonapeptide.	8.72e-01
49	43	70.5	9	1 R50284	MAGE-3 nonapeptide.	8.72e-01
50	43	70.5	9	1 W7127	MAGE-1 synthetic pepti	8.72e-01
51	43	70.5	9	1 R65118	MAGE 3 immunogenic pep	8.72e-01
52	43	70.5	9	1 W78840	MAGE-3 protein fragmen	8.72e-01
53	43	70.5	9	1 Y10427	HLA Class I motif pep	8.72e-01
54	43	70.5	9	1 W98942	MAGE-3 TRAP 168-176.	8.72e-01
55	43	70.5	9	1 Y10621	Peptide antigen SEQ ID	8.72e-01
56	43	70.5	9	1 R75942	Melanoma antigen (MAGE	8.72e-01
57	43	70.5	9	1 W68374	Human MAGE-3 peptide b	8.72e-01
58	43	70.5	9	1 R83931	MHC class I restricted	8.72e-01
59	43	70.5	9	1 W54606	Peptide 1 from Mage-3.	8.72e-01
60	43	70.5	9	1 R49222	HLA-A1 MAGE 3 antigen	8.72e-01
61	42	68.9	9	1 R99348	MAGE-41 nonapeptide.	1.19e-01
62	42	68.9	9	1 Y10603	Peptide antigen SEQ ID	1.19e-01
63	42	68.9	9	1 R50286	MAGE-41 nonapeptide.	1.19e-01
64	39	63.9	9	1 R99347	MAGE-4 nonapeptide.	2.95e-01
65	39	63.9	9	1 Y10602	Peptide antigen SEQ ID	2.95e-01
66	39	63.9	9	1 R50285	MAGE-4 nonapeptide.	2.95e-01
67	36	59.0	9	1 Y10625	Peptide antigen SEQ ID	7.11e-01
68	36	59.0	9	1 Y10626	Peptide antigen SEQ ID	7.11e-01

Note: Post-processor removed 932 summaries from list due to search parameters chosen.

ALIGNMENTS

RESULT 1	
ID W98945	standard; peptide; 9 AA.
AC W98945	
DT 06-MAY-1999	(first entry)
DE HLA-A1 binding peptide derived from MAGE-1.	
KW Human leukocyte antigen; HLA; HLA-A2 binding peptide; T cell;	
KW cytolytic T cell; CTL.	
OS Synthetic.	
OS Homo sapiens.	
PN W09858951-A1.	
PD 30-DEC-1998.	
PF 18-JUN-1998; U12879.	
PR 16-APR-1998; US-061388.	
PR 23-JUN-1997; US-880963.	
PA (LUDW-) LUDWIG INST CANCER RES.	
PI Cerottini J, Romero P, Valmori D;	
DR WPI, 93-105609/09.	
PT New decamer peptides which bind to HLA molecules - useful to	
PT identify HLA-A2 positive cells and provoke T cells	
PS Example 7; Page 18; 45pp; English.	
CC The present invention describes peptides which bind to an HLA-A2	

CC molecule and have Val at the carboxy terminus, and either: (a) Ala, Tyr
 CC or Phe at the amino terminus, and Ala at position 2 (P1); or (b) Glu at
 CC the amino terminus, and Ala, Leu, or Met at positions 2 and 3, with the
 CC proviso that Ala is not at both positions (P2). The peptides of the
 CC present invention are used to identify HLA-A2 positive cells, provoke
 CC T cells, and determine the presence of particular T cells including
 CC cytolytic T cells (CTLs). They provide a better target than the prior
 CC art CTL-stimulating peptide. The present sequence represents a peptide
 CC used in an example from the present invention.
 SQ Sequence 9 AA;

-Query Match 100.0%; Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. NO. 2.32e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

QY 1 EADPTGHSY 9

RESULT 2

ID Y01727 standard; Peptide; 9 AA.

AC Y01727;

DT 25-JUN-1999 (first entry)

DE Exemplary antigenic peptide derived from MAGE-1.

KW MAGE-3; tumour associated gene; human leucocyte antigen Class II;

KW autologous CD4+ cell; MAGE-3 related disease; cancer; melanoma;

KW osteosarcoma; leukemia; carcinoma.

OS Homo sapiens.

PN WO9914326-A1.

PD 25-MAR-1999.

PF 04-SEP-1998; U18601.

PR 12-SEP-1997; US-928615.

PA (LUDW-) LUDWIG INST CANCER RES.

PI (UYVR-) UNIV VRIJE BRUSSEL.

PI Boon-Falleur T, Chau P, Corthals J, Heirman C,

PI Luiten R, Stroobant V, Thielemans K, Van Der Bruggen P;

DR WPI: 99-244031/20.

PT Isolated peptides that bind to human leucocyte antigen class II

PT molecules

PS Disclosure; Page 27; 88pp; English.

CC The present sequence represents an exemplary tumour associated peptide

CC antigen. The specification describes a MAGE-3 tumour associated gene.

CC Peptides (Y01721-25) that bind human leucocyte antigen (HLA) Class II

CC molecules can be derived from the MAGE-3 protein. These peptides and

CC autologous CD4+ cells that bind to a complex of MAGE-3 peptide

CC and HLA Class II, are used to treat MAGE-3 related diseases,

CC particularly cancers (e.g. melanoma, osteosarcoma, leukemia and

CC various forms of carcinoma). The peptides are also used to produce

CC specific antibodies. Detection of the peptides, e.g. in binding

CC assays, particularly with antibodies, is used for diagnosis of such

CC diseases.

SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. NO. 2.32e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

QY 1 EADPTGHSY 9

RESULT 3

ID Y10633 standard; Peptide; 9 AA.

AC Y10633;

DT 12-MAY-1999 (first entry)

DE Peptide antigen SEQ ID NO:563.

KW Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;

KW immunisation; tumour; infectious disease; immunotherapy; cancer;

KW malignant melanoma; viral disease; hepatitis; AIDS.

OS Synthetic.

OS Homo sapiens.

PN WO9902183-A2.

PD 21-JAN-1999.

PF 10-JUL-1998; U14289.

PR 10-DEC-1997; US-988320.

PR 10-JUL-1997; CA-209815.

PA (CTLI-) CTL IMMUNOTHERAPIES CORP.

PI Kuendli TM, Simard JLL;

DR WPI: 99-120514/10.

PT Inducing a cytotoxic T lymphocyte response - by maintaining a level

PT of antigen in the lymphatic system of a mammal so as to provide a

PT sustained CTL response, used to treat, e.g. AIDS

PS Disclosure; Page 52; 199pp; English.

CC The present invention describes a method of inducing and/or sustaining

CC an immunological cytotoxic T lymphocyte (CTL) response in a mammal. The

CC method comprises: (a) delivering an antigen to the mammal at a level

CC induce an immunological CTL response in the mammal; and (b) maintaining

CC the level of the antigen in the mammal's lymphatic system to maintain

CC the immunologic CTL response. The method can be used for the delivery of

CC e.g. a differentiation antigen, a tumour-specific multiligand antigen,

CC an embryonic antigen, an oncogene antigen, a mutated tumour-suppresso

CC gene antigen, or a viral antigen. They can be used for the treatment of

CC disease such as cancer, e.g. malignant melanoma or infectious disease

CC e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery

CC to the lymphatic system provides for potent CTL stimulation that takes

CC place in the milieu of the lymphoid organ, and it sustains stimulating

CC that is necessary to keep CTL active, cytotoxic and recirculating

CC through the body. Y10071 to Y10639 represent examples of peptide

CC antigens given in the present invention.

SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. NO. 2.32e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

QY 1 EADPTGHSY 9

RESULT 4

ID Y00685 standard; peptide; 9 AA.

AC Y00685;

DT 12-MAY-1999 (first entry)

DE Tumour antigen booster peptide MAGE-1 HLA-A1.

KW Tumour antigen; booster peptide; immune response modulation; allergy;

KW immune response enhancer; tumour cell; tumour rejection antigen;

KW leukocyte antigen-presenting molecule; autoimmune disease;

KW allograft rejection.

OS Homo sapiens.

PN WO9858956-A2.

PD 30-DEC-1998.

PF 19-JUN-1998; U12894.

PR 23-JUN-1997; US-880979.

PA (LUDW-) LUDWIG INST CANCER RES.

PI Boon-Falleur T, Uyttenhove C, Warnier G;

DR WPI: 99-105612/09.

PT Immunization methods using viruses expressing antigen for priming

PT and booster immunizations - useful for modulating immune responses

PT against antigen, e.g. enhancing immune response against tumour cells

PT expressing tumour rejection antigens

PS Claim 3; Page 9; 33pp; English.

CC This sequence represents a tumour antigen booster peptide that can be

CC used in the method of the invention. The method is for modulating an

CC immune response in a mammal against an antigen, and comprises:

CC (A) inducing an immune response by: (i) administering a virus containing

CC a nucleic acid molecule encoding the antigen or its precursor to generate

CC an immune response; and (ii) administering at least one booster dose

CC comprising a peptide including the antigen, in an adjuvant, in a combined

CC amount effective to enhance the initial immune response; or

CC (B) reducing an immune response as defined for (A) but using a

CC non-adjuvant with the peptide which includes the antigen, in an amount

CC effective to reduce the initial immune response. Method (A) is used to

CC enhance the immune response against tumour cells expressing tumour

CC rejection antigens, and against pathogens in subjects having human
CC leukocyte antigen-presenting molecules. Method (B) is used to reduce the
CC immune response in allergy, autoimmune disease, and allograft rejection.
CC Method (A) provides an immunisation method which, unlike prior art, is
CC not limited by the host immune response against viral vectors.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 5

ID Y10424 standard; Peptide; 9 AA.
AC Y10424; 1999 (first entry)
DE HLA class I motif peptide SEQ ID NO:354.
DT Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;
KW Immunisation; tumour; infectious disease; immunotherapy; cancer;
KW malignant melanoma; viral disease; hepatitis; AIDS.
OS Synthetic.
OS Homo sapiens.
PN WO9902183-A2.
PD 21-JAN-1999.
PF 10-JUL-1998; U14289.
PR 10-DEC-1997; US-988320.
PR 10-JUL-1997; CA-209815.
PA (CTL-) CTL IMMUNOTHERAPIES CORP.
PI Kuendig TM, Simard JLL;
DR WPI; 99-120514/10.
PT Inducing a cytotoxic T lymphocyte response - by maintaining a level
PT of antigen in the lymphatic system of a mammal so as to provide a
PT sustained CTL response, used to treat, e.g. AIDS
PS Disclosure; Page 39; 1999p; English.
CC The present invention describes a method of inducing and/or sustaining
CC an immunological cytotoxic T lymphocyte (CTL) response in a mammal. The
CC method comprises: (a) delivering an antigen to the mammal at a level to
CC induce an immunological CTL response in the mammal; and (b) maintaining
CC the level of the antigen in the mammal's lymphatic system to maintain
CC the immunologic CTL response. The method can be used for the delivery of
CC e.g. a differentiation antigen, a tumour-specific multilineage antigen,
CC an embryonic antigen, an oncogene antigen, a mutated tumour-suppressor
CC gene antigen, or a viral antigen. They can be used for the treatment of
CC disease such as cancer, e.g. malignant melanoma or infectious disease,
CC e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery
CC to the lymphatic system provides for potent CTL stimulation that takes
CC place in the milieu of the lymphoid organ, and it sustains stimulation
CC that is necessary to keep CTL active, cytotoxic and recirculating
CC through the body. Y10071 to Y10639 represent examples of peptide
CC antigens given in the present invention.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 6

ID Y10623 standard; Peptide; 9 AA.
AC Y10623;
DE 12-MAY-1999 (first entry)
DT Peptide antigen SEQ ID NO:553.
KW Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;
KW Immunisation; tumour; infectious disease; immunotherapy; cancer;
KW malignant melanoma; viral disease; hepatitis; AIDS.

OS Synthetic.
OS Homo sapiens.
PN WO9902183-A2.
PD 21-JAN-1999.
PF 10-JUL-1998; U14289.
PR 10-DEC-1997; US-988320.
PR 10-JUL-1997; CA-209815.
PA (CTL-) CTL IMMUNOTHERAPIES CORP.
PI Kuendig TM, Simard JLL;
DR WPI; 99-120514/10.

PT Inducing a cytotoxic T lymphocyte response - by maintaining a level
PT of antigen in the lymphatic system of a mammal so as to provide a
PT sustained CTL response, used to treat, e.g. AIDS
PS Disclosure; Page 51; 1999p; English.
CC The present invention describes a method of inducing and/or sustaining
CC an immunological cytotoxic T lymphocyte (CTL) response in a mammal. The
CC method comprises: (a) delivering an antigen to the mammal at a level to
CC induce an immunological CTL response in the mammal; and (b) maintaining
CC the level of the antigen in the mammal's lymphatic system to maintain
CC the immunologic CTL response. The method can be used for the delivery of
CC e.g. a differentiation antigen, a tumour-specific multilineage antigen,
CC an embryonic antigen, an oncogene antigen, a mutated tumour-suppressor
CC gene antigen, or a viral antigen. They can be used for the treatment of
CC disease such as cancer, e.g. malignant melanoma or infectious disease,
CC e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery
CC to the lymphatic system provides for potent CTL stimulation that takes
CC place in the milieu of the lymphoid organ, and it sustains stimulation
CC that is necessary to keep CTL active, cytotoxic and recirculating
CC through the body. Y10071 to Y10639 represent examples of peptide
CC antigens given in the present invention.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 7

ID W54622 standard; peptide; 9 AA.
AC W54622;
DT 25-SEP-1998 (first entry)
DE Peptide from Mage-1 181-169.
KW Mannose; antigen; antigen-presenting cell; mannosylated peptide; T cell;
KW vaccine; treatment.
OS Synthetic.
PN WO9813378-A1.
PD 02-APR-1998.
PF 25-SEP-1997; N10536.
PF 26-SEP-1996; EP-202701.
PA (OYLE-) RIJRSUNIV LEIDEN.
PI Drijfhout JW, Konig F;
DR WPI; 98-230631/20.
PT Increasing uptake and presentation of antigen(s) - by adding mannose
PT residue(s) to antigen for increasing T cell response, useful in,
PT e.g. vaccines against viral infection(s)
PS Disclosure; Page 28; 47pp; English.

CC The peptides W5459-W54809 are examples of peptides to which at least
CC (preferably 2) mannose can be attached to increase their uptake as
CC antigens by antigen-presenting cells. Uptake of agonist mannosylated
CC peptides will increase the T cell response, whereas uptake of antagonist
CC peptides blocks the T cell response. Blocking binding of immunogenic
CC autoantigens can be used in treatment of type I diabetes, rheumatoid
CC arthritis, graft rejection etc., also to induce T-cell non-
CC responsiveness. Vaccines containing mannosylated antigen are used to
CC prevent or treat infections by, e.g. bacteria, viruses, fungi, helminths
CC and parasites.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 2.32e-01; Mismatches 0; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 |||||
 QY 1 EADPTGHSY 9

RESULT 8
 ID R50281 standard; Protein; 9 AA.
 AC R50281;
 DT 26-SEP-1994 (first entry)
 DE MAGE-1 nonapeptide.
 KW MAGE-1 nonapeptide; cancer; melanoma; breast cancer; HLA;
 KW histocompatibility; human leucocyte antigen; probe; treatment;
 KW therapy; vaccine.
 OS Synthetic.
 PN W09405304-A.
 PD 17-MAR-1994.
 PF 30-AUG-1993; U08157.
 PR 31-AUG-1993; US-938334.
 PR 26-MAR-1993; US-037230.
 PR 07-JUN-1993; US-073103.
 PA (LUDW-) LUDWIG INST CANCER RES.
 PI Boon-falleur T, De Plaen E, Lurquin C, Traversari C;
 PI Van Derbruggen P;
 DR WPI; 94-100844/12.
 DR N-PSDB; Q44751.
 PT - presented by HLA-A1 cancer cells, for use in diagnosis or
 PT therapy of esp. melanoma and breast cancer.
 PS Disclosure; Page 19; 35pp; English.
 CC An isolated nonapeptide having the amino acid sequence Glu-Val-Asp-
 CC Pro-Ile-Gly-His-Leu-Tyr is derived from the tumour rejection antigen
 CC precursor encoded by the MAGE-3 gene and presented by HLA-A1. The
 CC nonapeptide can be used in a vaccine to treat a cancerous condition
 CC involving HLA-A1 subtype cancerous cells. The nucleic acid encoding
 CC the nonapeptide can be used as a probe to identify tumour cells.
 CC This sequence is homologous to the peptide described and is encoded
 CC by the MAGE-1 gene.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 |||||
 QY 1 EADPTGHSY 9

RESULT 9
 ID R83932 standard; peptide; 9 AA.
 AC R83932;
 DT 05-JUN-1996 (first entry)
 DE MHC class I restricted antigenic peptide #2.
 KW MHC class I; antigen; MAGE; melanoma; breast cancer; bladder cancer;
 KW Titermax; cytotoxic T-lymphocyte; tumour; pathogenic disease; bacteria;
 KW parasite; human; animal.
 OS Synthetic.
 PN W09528958-A1.
 PD 02-NOV-1995.
 PF 21-APR-1995; U04975.
 PR 22-APR-1994; US-233496.
 PA (SLOK) SLOAN KETTERING INST CANCER RES.
 PI Dyll R, Nikolic-Zugic J;
 DR WPI; 95-382848/49.
 PT Cytotoxic T-cell induction by MHC class I-restricted peptide in
 PT adjuvant - useful for treating tumours and bacterial or parasitic
 PT pathogenic diseases
 PS Claim 11; Page 38; 50pp; English.
 CC The sequences given in R83931-49 are MHC class I restricted 8-12
 CC amino acid antigenic peptides. This peptide is derived from MAGE

CC and is present in melanoma, breast and bladder cancer. These
 CC peptides may be administered to a subject in combination with a
 CC suitable adjuvant, pref. Titermax (RTM), to induce cytotoxic T-
 CC lymphocytes. This method may be used in the treatment of a tumour
 CC or a pathogenic disease, esp. diseases of bacterial or parasitic
 CC origin, in humans and animals, e.g. monkeys, dogs, cows, horses, etc.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 |||||
 QY 1 EADPTGHSY 9

RESULT 10
 ID R29769 standard; Peptide; 9 AA.
 AC R29769;
 DT 22-APR-1993 (first entry)
 DE Antigen E peptide.
 KW Antigen; tumorigenic cell; A+ B+; T-cell; response; syngeneic;
 KW animal; mouse; tumour rejection antigen precursor; TRAP; PIA.
 OS Homo sapiens.
 PN W09220356-A.
 PD 26-NOV-1992.
 PF 22-MAY-1992; U04354.
 PR 23-MAY-1991; US-705702.
 PR 09-JUL-1991; US-728838.
 PR 23-SEP-1991; US-764364.
 PR 12-DEC-1991; US-807043.
 PA (LUDW-) LUDWIG INST CANCER RES.
 PI Boon T, Chomez P, De Plaen E, Lurquin C, Traversari C;
 PI Van Den Eynde B, Van Der Bruggen P, Van Pel A;
 DR WPI; 92-415460/50.
 PT Nucleic acid mol. encoding a human tumour rejection antigen
 PT precursor - useful as an immunostimulant in a vaccine for
 PT treating and preventing cancers, also useful in diagnosis
 PS Disclosure; Page 37; 142pp; English.
 CC This sequence represents the sequence of the antigen E. Antigens suc
 CC as this one cause a T-cell response to be elicited which transplanted
 CC into a syngeneic animal, usually a mouse. This antigen is derived fr
 CC the cell line MEL3.1. See also Q32351.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 |||||
 QY 1 EADPTGHSY 9

RESULT 11
 ID W68371 standard; peptide; 9 AA.
 AC W68371;
 DT 14-OCT-1998 (first entry)
 DE Human MAGE-1 peptide binds HLA-A1.
 KW Antigen; major histocompatibility complex; MHC; lymphocyte; detection
 KW immobilisation; cytotoxic T-cell; tumour; leukaemia; lymphoma;
 KW viral infection.
 OS Synthetic.
 OS Homo sapiens.
 PN W09744667-A2.
 PD 27-NOV-1997.
 PF 21-MAY-1997; F00892.
 PR 21-MAY-1996; US-651925.
 PA (INRM) INERM INST NAT SANTE & RECH MEDICALE.
 PA (INSP) INST PASTEUR.
 PI Abastado J, Kourilsky P, Langlade-Demoyen P, Lone Y;
 DR WPI; 98-018653/02.

PT Detection, purification and elimination of antigen-specific
 PT lymphocytes - for producing cytotoxic T cells for immuno-therapy of
 PT cancers and viral infection
 PS Disclosures: Page 30; 22pp; French.
 CC Peptides W68301-W68384 are examples of antigens (Ag) which can be loaded
 CC onto recombinantly produced major histocompatibility complex (MHC)
 CC molecules in a method of detecting antigen-specific lymphocytes. The
 CC MHC-antigen complex is then immobilised on a solid support and a sample
 CC containing cells recognising the MHC-Ag complex may be isolated. This
 CC peptide is derived from the human MAGE-1 protein and binds the human
 CC leucocyte antigen A1 (HLA-A1). A similar method is used to isolate,
 CC purify or eliminate Ag-specific T-cells or to produce Ag-specific
 CC cytotoxic T-cells (CTC). The method is also used to detect and quantify
 CC tumour-specific T-cells and to generate CTC for specific killing of
 CC tumour cells (solid tumours, leukaemia or lymphoma) by injection into
 CC a human or animal, but also for treating viral infections.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

QY 1 EADPTGHSY 9

RESULT 12

ID W77125 standard; peptide; 9 AA.

DT 16-NOV-1998 (first entry)

DE gp75/TRP-1 synthetic peptide epitope 1.

KW Tyrosinase; tyrosinase cytotoxic lymphocyte response;

KW cytotoxic T lymphocyte; cysteine-depleted; melanoma.

OS Synthetic.

PN W09833810-A2.

PD 06-AUG-1998.

PF 29-JAN-1998; U01592.

PR 30-JAN-1997; US-037781

PA (UUVI-) UNIV VIRGINIA PATENT FOUND.

PI Engelhard VH, Hunt DF, Kittlesen D, Slingluff CL;

DR WPI; 98-437388/37.

PT Disease specific immunogen - comprises disease specific cytotoxic T

PT lymphocyte epitope used to elicit melanoma specific CTL response

PS Disclosures: Page 27; 93pp; English.

CC Cytotoxic T lymphocyte response. These peptides are for human tumour-specific

CC depleted mutants of a native disease-specific CTL epitope. The cysteine-

CC depleted CTL epitopes elicit a stronger or more specific CTL response

CC than the native epitope. The epitopes can be used in a disease-specific

CC immunogen to protect a mammal against disease in particular melanomas.

CC The peptides may also be used to screen a sample for the presence of

CC an antigen with the same epitope, or with a different cross-reactive

CC epitope.

SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 2.32e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

QY 1 EADPTGHSY 9

RESULT 13

ID W75734 standard; peptide; 9 AA.

AC W75734;

DT 19-NOV-1998 (first entry)

DE Peptidase-resistant peptide 2.

KW Tumour antigen M22-E; T-cell; immuno-therapy; cytolytic T-cell; CTL;

KW therapeutic agent; peptidase; M22-E antigen peptide analogue; HLA;

KW human leucocyte antigen; MHC; lysis; vaccine.

OS Synthetic.

PH Key Location/Qualifiers

FT Misc_difference 2

FT /note= "D-form residue"

FT Misc_difference 8

FT /note= "D-form residue"

PN W09833511-A1.

PD 06-AUG-1998.

PF 19-NOV-1997; U1296.

PR 05-FEB-1997; US-795733.

PA (CNRS) CENT NAT RECH SCI.

PA (LUDW-) LUDWIG INST CANCER RES.

PI Ayyoub M, Gairin JE, Mazarguil H, Monsarrat B, Van Den Eynde B;

DR WPI; 98-437166/37.

PT Peptidase-resistant peptide(s) that bind to HLA molecules and

PT related antibodies, particularly for treatment of cancer by

PT inducing proliferation of cytotoxic T cells

PS Claim 20; Page 20; 32pp; English.

CC Sequences W75733-W75736 are peptidase-resistant peptides which are

CC analogues of the tumour antigen M22-E. This antigen is a potential

CC target for T-cell based immunotherapy and can also be used to stimulate

CC the antigen-specific CTL, however its use as a therapeutic agent is

CC limited due to its degradation by peptidase. The M22-E antigen peptide

CC analogues were modified at both peptidase sensitive portions, and were

CC all shown to exhibit a longer half-life relative to peptidase degradation

CC as well as the ability to bind a human leucocyte antigen (HLA). The

CC affinity for the MHC as the tumour antigen, and W75735 was found to be

CC the ideal peptide analog to use due to it also being able to sensitize

CC the target cells to lysis by effector molecules at similar concentrations

CC to those of the antigen M22-E. These peptide analogues can be used in

CC vaccines to induce an immune response for treating conditions in which

CC abnormal HLA/peptide complexes are present on the surface of cells.

SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 2.32e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

QY 1 EADPTGHSY 9

RESULT 14

ID W00897 standard; Peptide; 9 AA.

AC W00897;

DT 23-MAY-1997 (first entry)

DE Human melanoma MAGE1 tumour associated antigen p161-169.

KW Adeno-associated virus; vector; liposome; transfection;

KW dendritic cell; melanoma; MAGE1; adoptive immunotherapy;

KW tumour associated antigen.

OS Homo sapiens.

PN W09703703-A1.

PD 06-FEB-1997.

PF 19-JUL-1996; U12012.

PR 21-JUL-1995; US-001312.

PR 01-NOV-1995; US-007184.

PR 01-DEC-1995; US-566286.

PA (RHON) RHONE-POULENC RORER PHARM INC.

PI Lebkowski JS, Philip R;

DR WPI; 97-145208/13.

PT Adeno-associated virus:liposome complexes for transfecting dendritic

PT cells - for inducing immune response, useful for treating e.g.

PT neoplasia or infections

PS Example 5; Page 58; 134pp; English.

CC Tumour associated antigens (W13660-61, W00878-903) can be loaded

CC into dendritic cells and used to induce antitumour immunity.

CC Alternatively, the dendritic cells are transfected with adeno

CC associated virus plasmid DNA (which includes DNA encoding the

CC tumour associated antigen) complexed with cationic liposomes. The

CC antigen loaded or transfected dendritic cells can be used to

CC generate tumour antigen-specific cytotoxic T lymphocytes for use in

CC adoptive immunotherapy in a patient having the corresponding
 CC tumour. A suitable antigen comprises amino acids 161-169 (W00897)
 CC of human melanoma MAGE1.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

QY 1 EADPTGHSY 9

RESULT 15

ID W75736 standard; peptide; 9 AA.
 AC W75736;
 DT 19-NOV-1998 (first entry)
 DE Peptidase-resistant peptide 4.
 KW Tumour antigen M22-E; T-cell; immunotherapy; cytolytic T-cell; CTL;
 KW therapeutic agent; peptidase; M22-E antigen peptide analogue; HLA;
 KW human leukocyte antigen; MHC; lysis; vaccine.
 OS Synthetic.
 FH Key Location/Qualifiers
 FT Modified_site 2 /note= "N-Methyl-Alanine"
 FT Modified_site 8 /note= "N-Methyl-Serine"
 FT Modified_site 9 /note= "N-Methyl-Serine"
 FT W09833511-Al.
 PN 06-AUG-1998.
 PD 19-NOV-1997; U21296.
 PR 05-FEB-1997; US-795733.
 PA (CNRS) CENT NAT RECH SCI.
 PA (LUDW-) LUDWIG INST CANCER RES.
 PI Ayyoub M, Gairin JE, Mazarguil H, Monsarrat B, Van Den Eynde B;
 DR WPI; 98-43/166/37.
 DT Peptidase-resistant peptide(s) that bind to HLA molecules and
 PT related antibodies - particularly for treatment of cancer by
 PT inducing proliferation of cytotoxic T cells
 PS Claim 20; Page 20; 32pp; English.
 CC Sequences W75733-W75736 are peptidase-resistant peptides which are
 CC analogues of the tumour antigen M22-E. This antigen is a potential
 CC target for T-cell based immunotherapy and can also be used to stimulate
 CC the antigen-specific CTL, however its use as a therapeutic agent is
 CC limited due to its degradation by peptidase. The M22-E antigen peptide
 CC analogues were modified at both peptidase sensitive portions, and were
 CC all shown to exhibit a longer half-life relative to peptidase degradation
 CC as well as the ability to bind a human leukocyte antigen (HLA). The
 CC specific peptides W75733 and W75735 were established to have a comparable
 CC affinity for the MHC as the tumour antigen, and W75735 was found to be
 CC the ideal peptide analog to use due to it also being able to sensitise
 CC the target cells to lysis by effector molecules at similar concentrations
 CC to those of the antigen M22-E. These peptide analogues can be used in
 CC vaccines to induce an immune response for treating conditions in which
 CC abnormal HLA/peptide complexes are present on the surface of cells.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

QY 1 EADPTGHSY 9

RESULT 16

ID R82988 standard; peptide; 9 AA.
 AC R82988;
 DT 26-FEB-1996 (first entry)
 DE P815 antigenic peptide.
 KW P815 antigen; P1A antigen; cancer; vaccine.
 OS Synthetic.

PN W09523874-Al.

PD 08-SEP-1995.

PF 23-FEB-1995; U02203.

PR 01-MAR-1994; US-204727.

PR 10-MAR-1994; US-209172.

PR 01-SEP-1994; US-239849.

PR 30-NOV-1994; US-346774.

PA (LUDW-) LUDWIG INST CANCER RES.

PI Boon-Falleur T, Brasseur F, Chomez P, De Plaen E;

PI De Smet C, Gaugler B, Lethe B, Marchand M, Pataard J;

PI Szikora J, Van Den Eynde B, Van Derbruggen P, Weynants P;

DR WPI; 95-320586/41.

PT Determin. of cancerous condition(s) - using a nucleic acid as a

PT primer to determine expression of a MAGE tumour rejection antigen

PT precursor

PS Example 13; Page 22; 121pp; English.

CC Using the sequence of the pR15A antigen precursor gene P1A

CC (T01176), an antigenic peptide (R82988) which was A+B+ (i.e.

CC characteristic of cells which express both A and B antigens) was

CC produced. The peptide lysed PO.HTR cells in the presence of

CC cytolytic T lymphocyte cell lines, and may be useful as a vaccine

CC component. 9 AA;

SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 2.32e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

QY 1 EADPTGHSY 9

RESULT 17

ID R00692 standard; peptide; 9 AA.

AC R00692;

DT 31-JUL-1996 (first entry)

DE Human leukocyte antigen (HLA-Al) presented peptide M22-E.

KW Human leukocyte antigen; HLA-Al; MAGE-1 derived;

KW blood mononuclear cell; BMC; CD8-beta+ cell; cytolytic T cell;

KW CTL cell; treatment; tumour cell; diagnosis; assay;

KW presented peptide.

OS Synthetic.

PN W09533500-Al.

PD 28-DEC-1995.

PR 14-JUN-1995; U07559.

PR 17-JUN-1994; US-261541.

PA (LUDW-) LUDWIG INST CANCER RES.

PI Boon-Falleur T, Coullie P, Van Der Bruggen P;

DR WPI; 96-058510/06.

DT Prod. of specific cytolytic T cell sub-populations - by contacting of

PT blood mononuclear cells with specific peptide(s) and a population of

PT CD8-beta(+) cells

PS Claim 5; Page 19; 25pp; English.

CC The present peptide is the human leukocyte antigen (HLA-Al), MAGE-1

CC derived presented peptide, M22-E. By contacting a sample of blood

CC mononuclear cells (BMC) with the peptide (which binds directly to

CC HLA-Al mols. on the surface of the BMC) and CD8-beta+ cells (which

CC stimulate peptide/HLA-Al complex specific cytolytic T (CTL) cell

CC peptide/HLA-Al complex specific cytolytic T (CTL) cell

CC subpopulation can be obt. . The CTL cells obtd. can be

CC administered to a patient to treat tumour cell related conditions,

CC and can be used in diagnostic methods, e.g. in assays for the

CC peptide/HLA-Al complex.

SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 2.32e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

QY 1 EADPTGHSY 9

RESULT 18
 ID W56729 standard; peptide; 9 AA.
 AC W56729;
 DE MAGE-1 antigenic partial peptide sequence (residues 161-169).
 KW MAGE; replication defective; adenovirus; tumour; antigen; cancer;
 KW immunotherapy; tumour rejection antigen precursor; TRAP; CTL;
 KW human leukocyte antigen; HLA; cytolytic T lymphocyte.
 OS Synthetic.
 PN WO9815638-A2.
 PD 16-APR-1998.
 PF 06-OCT-1997; U17948.
 PR 06-OCT-1996; US-027891.
 PA (LUDW-) LUDWIG INST CANCER RES.
 PI Cerrottiini J, Jongeneel CV, Reed DS, Rimoldi D,
 PI Romero P;
 DR WPI: 98-240824/21.
 PT New replication-defective adenoviruses - comprise insert encoding
 PT tumour rejection antigen precursor(s), useful for, e.g. cancer
 PT immuno-therapy
 PS Examples; Page 42; 56pp; English.
 CC This is a partial sequence of the MAGE-1 antigenic peptide used in the
 CC methods of the invention. The specification provides a new nucleic acid
 CC molecule comprising a replication-defective adenovirus genome containing
 CC an insert encoding a tumour rejection antigen precursor (TRAP). The
 CC replication-defective adenovirus genome is useful as a vector for
 CC introducing a TRAP molecule into mammalian (especially human) cells. The
 CC recombinant adenovirus is preferably targeted to tumour cells, e.g. by
 CC binding a ligand to the virus coat. The TRAP peptides which are generated
 CC from the expressed TRAP are presented by human leukocyte antigen (HLA)
 CC molecules and as a result cytolytic T lymphocyte (CTL) production is
 CC increased (claimed). The CTL's then kill the TRAP-expressing tumour
 CC cells. Also, cells transfected by the recombinant adenovirus can be used
 CC for assessing the processing of TRAPs, including post-translational
 CC modifications. The adenovirus (genome) can be administered by injection,
 CC topical application or intracavitarily in 106-1010 pfu doses. The range
 CC of TRAP peptides produced by replication-defective adenovirus means that
 CC patients with a range of HLA phenotypes can be treated. Also, host cell
 CC immune response to TRAP's is enhanced, e.g. by induction of tumour-
 CC specific cytolytic T lymphocytes.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9
 |||||

RESULT 19
 ID R75954 standard; Peptide; 9 AA.
 AC R75954;
 DE Melanoma antigen (MAGE-1) epitope.
 KW MAGE-3; melanoma antigen; vaccine; immune response; immunogenic peptide;
 KW cytotoxic T lymphocyte response; CTL; melanoma; breast cancer; antibody.
 OS Homo sapiens.
 PN WO9519783-A1.
 PD 27-JUL-1995.
 PF 25-JAN-1995; U01000.
 PR 25-JAN-1994; US-186266.
 PA (CYTE-) CYTEL CORP.
 PI Celis E, Grey HM, Kubo RT, Sette A;
 DR WPI: 95-269270/35.
 PT Immunogenic peptide(s) that induce immune response to cancer cells
 PT - that express a MAGE-3 protein peptide epitope used in vaccines or
 PT adoptive immuno-therapy to induce cytotoxic T lymphocytes
 PS Example; Page 33; 44pp; English.
 CC R75954 is derived from MAGE-1 protein. It was used to show the

CC specificity of CTL response to MAGE-3 peptides shown in R75942-53.
 CC R75942 is derived from the sequence of the melanoma antigen (MAGE-3)
 CC protein and can be used to elicit a primary cytotoxic T lymphocyte
 CC response against cells expressing MAGE-3. Synthetic peptides R75945-5
 CC can be used therapeutically to elicit CTL responses to melanoma, breast
 CC colon, prostate, or other cells which express proteins with this epitope.
 CC The peptides have specific HLA-A1 binding capacity.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9
 |||||

RESULT 20
 ID R99343 standard; Protein; 9 AA.
 AC R99343;
 DT 22-APR-1997 (first entry)
 DE MAGE-1 nonapeptide.
 KW HLA binding peptide; cell lysis; cytolytic T cell; MAGE family; human
 KW tumour rejection antigen precursor; TRA; MAGE-1; tumour; cancer cell;
 KW antibody; melanoma; universal effector cell; vaccine; breast cancer;
 KW therapy.
 OS Homo sapiens.
 PN WO9626214-A1.
 PD 29-AUG-1996.
 PR 01-FEB-1996; U01489.
 PR 23-FEB-1995; US-393273.
 PA (LUDW-) LUDWIG INST CANCER RES.
 PI Boon-Falleur T, De Plaen E, Gaugler B, Lurquin C;
 PI Romero P, Traversari C, Van Den Eynde B, Van Der Bruggen P;
 DR WPI: 96-402317/40.
 DR N-PSDB: T35408.
 PT New nona-peptide(s) that bind to HLA molecule(s) and induce lysis
 PT by specific cytolytic T cells, for diagnosis and treatment of
 PT tumours and to expand T cells in vitro.
 PS Example 4; Fig 4; 41pp; English.
 CC R99343-R99350 represent MAGE nonapeptides, based on the tumour rejection
 CC antigen region of the full length MAGE sequences. These peptides were
 CC used to design the nonapeptides of the invention (see R99337-R99342).
 CC which bind to a HLA molecule on a cell, and provoke lysis by cytolytic
 CC cells (CTLs) specific for a complex of the HLA molecule and nonapeptide.
 CC The nonapeptides can be used diagnostically to identify tumours
 CC expressing a particular HLA molecule, or to identify cancer cells. The
 CC peptides can also be used therapeutically, to induce a CTL response to
 CC tumours (where the peptides are optionally coupled to tumour-specific
 CC antibodies), or to induce a response by CTLs that are otherwise inactive.
 CC The peptide sequences may also be used to expand specific CTLs in vitro
 CC for later return to the patient, such as for treating melanoma. Tumour
 CC cells can be identified by using DNA encoding the nonapeptides as probes.
 CC Non-human cells transformed with the HLA-A1 gene and a DNA sequence
 CC encoding one of the peptides, can be used to generate CTLs, or to detect
 CC the presence of CTLs in human samples. The non-human transformed cells,
 CC when polytransformed, are universal effector cells, and can be used in
 CC vaccines, or for treating melanoma or breast cancer.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9
 |||||

RESULT 21
 ID W78838 standard; peptide; 9 AA.
 AC W78838;

DT 17-NOV-1998 (first entry)
DE MAGE-1 protein fragment 161-169.
KW Microparticle; delivery; polymeric matrix; autoantigen; tumour antigen;
KW class II associated peptide; pathogen; gene therapy; genetic disease;
KW infection; downregulation; immune response.
OS Homo sapiens.
OS Synthetic.
PN WO9831398-A1.
PD 23-JUL-1998.
PF 22-JAN-1998; U01499.
PR 06-JAN-1998; US-003253.
PR 22-JAN-1997; US-787547.
PA (PANG-) PANGAEA PHARM INC.
PI Curley JM, Hedley ML, Langer RS, Lunsford LB;
DR WPI; 98-427556/36.
PT New preparations of microparticles - comprising a synthetic polymer
PT matrix and nucleic acid comprising an expression vector for use in
PT gene therapy
PS Disclosure: Page 10; 101pp; English.
CC A microparticle preparation (MP) has been developed, consisting of
CC microparticles having a diameter of less than 100 mu m. The MP comprises:
CC (a) a polymeric matrix (PM) consisting of one or more synthetic polymers
CC having a solubility in water of less than 1 mg/l; and (b) an expression
CC vector selected from RNA molecules (at least 50% of which are closed
CC circles) or circular plasmid DNA (at least 50% of which are supercoiled).
CC Also described is a MP of at most 20 microns in diameter, comprising: (a)
CC a PM; and (b) a NAM comprising an expression control sequence operatively
CC linked to a coding sequence, where the coding sequence encodes an
CC expression product selected from: (i) a polypeptide at least 7 amino
CC acids in length, having a sequence identical to the sequence of: (i) a
CC fragment of a naturally-occurring mammalian protein; or (ii) a fragment
CC of a naturally-occurring protein from an infectious agent which infects
CC a mammal; (2) a peptide having a length and sequence which permits it to
CC bind to an MHC class I or II molecule; and (3) the polypeptide or the
CC peptide linked to a trafficking sequence. W69763 to W69765, and W78793
CC to W78897 are peptide fragments for use in the present invention. The
CC MPs are highly effective vehicles for the delivery of polynucleotides
CC into phagocytic cells. They can be used for gene therapy, e.g. for
CC treating genetic diseases, infections or tumours or for downregulating
CC an immune response.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9
|||||

RESULT 22
ID R65112 standard; peptide; 9 AA.
AC R65112;
DT 06-OCT-1995 (first entry)
DE MAGE 1; immunogenic peptide 161-169.
KW MAGE 1; immunogenic peptide 161-169; cytotoxic C cells;
KW in vitro activation; cancer; AIDS; bacterial infections; malaria;
KW fungal infections; tuberculosis; hepatitis.
OS Homo sapiens.
PN WO9504817-A.
PD 16-FEB-1995.
PF 01-AUG-1994; U08672.
PR 06-AUG-1993; US-103401.
PA (CYTE-) CYTEL CORP.
PI Cells E, Kubo R, Serra H, Tsai V, Wentworth P;
DR WPI; 95-090895/12.
PT In vitro activation of cytotoxic T cells for selected killing of
PT target cells - for treating e.g. cancer, AIDS, hepatitis etc. by
PT incubating them with antigen presenting cells loaded with
PT appropriate immunogenic peptide
PS Example 3; Page 35; 53pp; English.
CC R65109-R65145 are immunogenic peptides, they are used in a new

CC method for the in vitro activation of cytotoxic T cells (CTC).
CC This is achieved by incubating the CTCs with antigen presenting
CC cells loaded with an appropriate immunogenic peptide (e.g. one
CC of the above peptides). By selecting the peptides used the
CC following diseases and infections can be treated; cancer, AIDS,
CC hepatitis, other viral and bacterial infections, malaria and
CC tuberculosis.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9
|||||

RESULT 23
ID R63675 standard; Protein; 9 AA.
AC R63675;
DT 22-JUN-1995 (first entry)
DE Synthetic peptide derived from exon 3.1 of MAGE 1.
KW Melanoma antigen-1; MAGE-1; cytolytic T cells; antigen E; exon 3.1.
OS Synthetic.
PN WO9423031-A.
PD 13-OCT-1994.
PF 17-MAR-1994; U02877.
PR 26-MAR-1993; US-037230.
PA (LUDW-) LUDWIG INST CANCER RES.
PI Boon-Ralleur T, Gaugler B, Van DEN EYNDE B, Van DER BRUGGEN P;
DR WPI; 94-33192/41.
PT New tumour rejection antigen precursor MAGE3 - useful in
PT treatment and diagnosis of cancer
PS Example 34; Page 36; 105pp; English.
CC R63675 is a synthetic peptide derived from exon 3.1 of melanoma
CC antigen-1 (MAGE-1), it was used to transfer antigen-E cytolytic T
CC lymphocyte sensitivity to normally non-sensitive cells.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9
|||||

RESULT 24
ID R78824 standard; peptide; 9 AA.
AC R78824; 1996 (first entry)
DE MAGE-1 cytotoxic T lymphocyte epitope.
KW MAGE-1; cytotoxic T; CTL; epitope; helper T; HTL; lymphocyte;
KW cell; viruses; parasites; tumours; antigens; disease prevention;
KW treatment.
OS Homo sapiens.
PN WO9522317-A1.
PD 24-AUG-1995.
PF 16-FEB-1995; U02121.
PR 16-FEB-1994; US-197484.
PA (CYTE-) CYTEL CORP.
PI Cells E, Chesnut RW, Grey H, Sette AD, Vitello MA;
DR WPI; 95-302545/39.
PT Compn. inducing cytotoxic T lymphocyte response to pref. viral,
PT bacterial, parasitic or tumour antigens - useful in the treatment
PT and prevention of diseases associated with the antigen e.g.
PT hepatitis B
PS Disclosure; Page 17; 109pp; English.
CC A compsn. which induces a cytotoxic T lymphocyte (CTL) response to
CC an antigen (Ag) in a mammal comprises, a CTL Ag response inducing
CC peptide (i.e. R78824-R78853) and a lipid conjugated helper T cell

CC inducing peptide. The compsn. induces a CTL response to bacterial,
 CC viral or tumour Ags, and is therefore useful in the treatment and
 CC prevention of diseases associated with the Ag.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1 EADPTGHSY 9
 |||||
 Qy 1 EADPTGHSY 9

RESULT 25
 ID R65135 standard; peptide: 9 AA.
 AC R65135;
 DT 09-OCT-1995 (first entry)
 DE MAGE 1; immunogenic peptide A01.
 KW MAGE 1; immunogenic peptide A01; cytotoxic C cells;
 KW in vitro activation; cancer; AIDS; bacterial infections; malaria;
 KW fungal infections; tuberculosis; hepatitis.
 OS Homo sapiens.
 PN W09504817-A.
 PD 16-FEB-1993.
 PF 01-AUG-1994; U08672.
 PR 06-AUG-1993; US-103401.
 PA (CYTE-) CYTEL CORP.
 PI Celis E, Kubo R, Serra H, Tsai V, Wentworth P;
 DR WPI; 95-090895/12.
 PT In vitro activation of cytotoxic T cells for selected killing of
 PT target cells - for treating e.g. cancer, AIDS, hepatitis etc. by
 PT incubating them with antigen presenting cells loaded with
 PT appropriate immunogenic peptide
 PT Example 3; Page 36; 33pp; English.
 CC R65109-R65145 are immunogenic peptides, they are used in a new
 CC method for the in vitro activation of cytotoxic T cells (CTC).
 CC This is achieved by incubating the CTCs with antigen presenting
 CC cells loaded with an appropriate immunogenic peptide (e.g. one
 CC of the above peptides). By selecting the peptides used the
 CC following diseases and infections can be treated; cancer, AIDS,
 CC hepatitis, other viral and bacterial infections, malaria and
 CC tuberculosis.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1 EADPTGHSY 9
 |||||
 Qy 1 EADPTGHSY 9

RESULT 26
 ID R49224 standard; Protein: 9 AA.
 AC R49224;
 DT 31-AUG-1994 (first entry)
 DE HLA-A1 MAGE 1 antigen peptide fragment 958.01.
 KW Immunogenic; HLA-A3.2; HLA-A1; binding motif; MHC molecule;
 KW immune response; viral infection; cancer; prostate cancer; lymphoma;
 KW hepatitis; AIDS; antibody; diagnosis; melanoma antigen.
 OS Synthetic.
 PN W09403205-A.
 PD 17-FEB-1994.
 PF 06-AUG-1993; U07421.
 PR 07-AUG-1992; US-926666.
 PR 05-MAR-1993; US-027746.
 PA (CYTE-) CYTEL CORP.
 PI Celis E, Grey HM, Kubo RT, Sette A;
 DR WPI; 94-065403/08.
 PT Peptide which specifically binds selected MHC allele - used to
 PT induce an immune response for treatment or prevention of viral

PT infection or cancer, or for diagnosis
 PS Example 16; Page 116; 150pp; English.
 CC The sequences given in R47304-33 and R49201-44 are immunogenic
 CC peptides which have a HLA-A3.2, HLA-A1 or a HLA-A11 binding motif.
 CC These peptides may be used in the composition of the invention.
 CC These peptides are capable of binding selected MHC molecules and
 CC inducing an immune response. They can be used to treat and/or
 CC prevent viral infection and cancer, eg. prostate cancer, lymphoma,
 CC hepatitis or AIDS. They can also be used to produce antibodies for
 CC use as diagnostic or therapeutic agents. The peptides can also be
 CC used as diagnostic agents.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1 EADPTGHSY 9
 |||||
 Qy 1 EADPTGHSY 9

RESULT 27
 ID R47330 standard; Protein: 9 AA.
 AC R47330;
 DT 31-AUG-1994 (first entry)
 DE HLA-A1 MAGE 1 antigen peptide fragment 161-169.
 KW Immunogenic; HLA-A3.2; HLA-A1; binding motif; MHC molecule;
 KW immune response; viral infection; cancer; prostate cancer; lymphoma;
 KW hepatitis; AIDS; antibody; diagnosis; melanoma antigen.
 OS Synthetic.
 PN W09403205-A.
 PD 17-FEB-1994.
 PF 06-AUG-1993; U07421.
 PR 07-AUG-1992; US-926666.
 PR 05-MAR-1993; US-027746.
 PA (CYTE-) CYTEL CORP.
 PI Celis E, Grey HM, Kubo RT, Sette A;
 DR WPI; 94-065403/08.
 PT Peptide which specifically binds selected MHC allele - used to
 PT induce an immune response for treatment or prevention of viral
 PT infection or cancer, or for diagnosis
 PS Example 8; Page 52; 150pp; English.
 CC The sequences given in R47304-33 and R49201-44 are immunogenic
 CC peptides which have a HLA-A3.2, HLA-A1 or a HLA-A11 binding motif.
 CC These peptides may be used in the composition of the invention.
 CC These peptides are capable of binding selected MHC molecules and
 CC inducing an immune response. They can be used to treat and/or
 CC prevent viral infection and cancer, eg. prostate cancer, lymphoma,
 CC hepatitis or AIDS. They can also be used to produce antibodies for
 CC use as diagnostic or therapeutic agents. The peptides can also be
 CC used as diagnostic agents.
 SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1 EADPTGHSY 9
 |||||
 Qy 1 EADPTGHSY 9

Search completed: Wed Sep 13 06:33:38 2000
 Job time : 40 secs.